---
document_datetime: 2023-09-21 21:44:08
document_pages: 176
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/imjudo-epar-public-assessment-report_en.pdf
document_name: imjudo-epar-public-assessment-report_en.pdf
version: success
processing_time: 279.3706721
conversion_datetime: 2026-01-01 22:22:45.81329
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

15 December 2022 EMA/CHMP/17771/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Imjudo

International non-proprietary name: tremelimumab

Procedure No. EMEA/H/C/006016/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:                  | Imjudo                                                                                                                                                  |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                      | AstraZeneca AB 151 85 Sodertalje SWEDEN                                                                                                                 |
| Active substance:                               | Tremelimumab                                                                                                                                            |
| International Non-proprietary Name/Common Name: | tremelimumab                                                                                                                                            |
| Pharmaco-therapeutic group (ATC Code):          | monoclonal antibodies and antibody drug conjugates, other monoclonal antibodies and antibody drug conjugates L01FX20                                    |
| Therapeutic indication(s):                      | Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). |
| Pharmaceutical form(s):                         | Concentrate for solution for infusion                                                                                                                   |
| Strength(s):                                    | 20 mg/ml                                                                                                                                                |
| Route(s) of administration:                     | Intravenous use                                                                                                                                         |
| Packaging:                                      | vial (glass)                                                                                                                                            |
| Package size(s):                                | 1 vial                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                   | ..............................................8                                                          |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................8        |                                                                                                          |
| 1.2. Legal basis, dossier content...................................................................................8        |                                                                                                          |
| 1.3. Information on Paediatric requirements...................................................................8              |                                                                                                          |
| 1.4. Information relating to orphan market exclusivity.....................................................8                 |                                                                                                          |
| 1.4.1. Similarity..........................................................................................................8 |                                                                                                          |
| 1.4.2. New active Substance status...............................................................................8           |                                                                                                          |
| 1.5. Scientific Advice...................................................................................................9   |                                                                                                          |
| 1.6. Steps taken for the assessment of the product.........................................................9                 |                                                                                                          |
| 2. Scientific discussion                                                                                                     | ..............................................................................11                         |
| 2.1. Problem statement                                                                                                       | .............................................................................................11          |
| 2.1.1. Disease or condition.........................................................................................11       |                                                                                                          |
| 2.1.2. Epidemiology and risk factors............................................................................11           |                                                                                                          |
| 2.1.3. Biologic features..............................................................................................11     |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                  | ............................................12                                                           |
| 2.1.5. Management...................................................................................................12       |                                                                                                          |
| 2.2. About the product                                                                                                       | ..............................................................................................13         |
| 2.3. Type of Application and aspects on development....................................................14                    |                                                                                                          |
| 2.4. Quality aspects                                                                                                         | ..................................................................................................14     |
| 2.4.1. Introduction....................................................................................................14    |                                                                                                          |
| 2.4.2. Active substance                                                                                                      | .............................................................................................14          |
| 2.4.3. Finished medicinal product................................................................................21          |                                                                                                          |
| 2.4.4. Discussion on chemical, and pharmaceutical aspects............................................27                      |                                                                                                          |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ......................27                                                                                 |
| 2.4.6. Recommendation(s) for future quality development.............................................27                       |                                                                                                          |
| 2.5. Non-clinical aspects                                                                                                    | ............................................................................................28           |
| 2.5.1. Introduction....................................................................................................28    |                                                                                                          |
| 2.5.2. Pharmacology                                                                                                          | .................................................................................................28      |
| 2.5.3. Pharmacokinetics.............................................................................................33       |                                                                                                          |
| 2.5.4. Toxicology                                                                                                            | ......................................................................................................37 |
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                             | .........................................................42                                              |
| 2.5.6. Discussion on non-clinical aspects......................................................................42            |                                                                                                          |
| 2.5.7. Conclusion on the non-clinical aspects................................................................45              |                                                                                                          |
| 2.6. Clinical aspects                                                                                                        | ..................................................................................................45     |
| 2.6.1. Introduction....................................................................................................45    |                                                                                                          |
| 2.6.2. Clinical pharmacology                                                                                                 | ......................................................................................52                 |
| 2.6.3. Discussion on clinical pharmacology...................................................................79              |                                                                                                          |
| 2.6.4. Conclusions on clinical pharmacology.................................................................81               |                                                                                                          |
| 2.6.5. Clinical efficacy                                                                                                     | ...............................................................................................81        |
| 2.6.6. Discussion on clinical efficacy..........................................................................             | 134                                                                                                      |
| 2.6.7. Conclusions on the clinical efficacy...................................................................               | 138                                                                                                      |
| 2.6.8. Clinical safety................................................................................................       | 138                                                                                                      |

<div style=\"page-break-after: always\"></div>

2.6.10. Conclusions on the clinical safety  ...................................................................  169

2.7. Risk Management Plan ......................................................................................  169

2.7.1. Safety concerns  .............................................................................................  169

2.7.2. Pharmacovigilance plan  ..................................................................................  169

2.7.3. Risk minimisation measures  ............................................................................  169

2.7.4. Conclusion  ....................................................................................................  169

2.8. Pharmacovigilance  ............................................................................................  170

2.8.1. Pharmacovigilance system  ..............................................................................  170

2.8.2. Periodic Safety Update Reports submission requirements ................................... 170

2.9. Product information ..........................................................................................  170

2.9.1. User consultation  ...........................................................................................  170

2.9.2. Labelling exemptions .....................................................................................  170

2.9.3. Additional monitoring  .....................................................................................  170

3. Benefit-Risk Balance............................................................................  171

3.1. Therapeutic Context .........................................................................................  171

3.1.1. Disease or condition  .......................................................................................  171

3.1.2. Available therapies and unmet medical need  ..................................................... 171

3.1.3. Main clinical studies .......................................................................................  171

3.2. Favourable effects ............................................................................................  172

3.3. Uncertainties and limitations about favourable effects  ........................................... 172

3.4. Unfavourable effects  .........................................................................................  172

3.5. Uncertainties and limitations about unfavourable effects ....................................... 173

3.6. Effects Table  ....................................................................................................  173

3.7. Benefit-risk assessment and discussion  ............................................................... 174

3.7.1. Importance of favourable and unfavourable effects  ............................................ 174

3.7.2. Balance of benefits and risks  ...........................................................................  174

3.7.3. Additional considerations on the benefit-risk balance ......................................... 174

3.8. Conclusions .....................................................................................................  175

4. Recommendations ...............................................................................  175

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation or special term   | Explanation                                                      |
|--------------------------------|------------------------------------------------------------------|
| ADA                            | Anti-drug antibody                                               |
| ADCC                           | Antibody-dependent cellular cytotoxicity                         |
| ADR                            | Adverse drug reaction                                            |
| AE                             | Adverse event                                                    |
| AESI                           | Adverse event of special interest                                |
| AEX                            | Anion exchange chromatography                                    |
| AFP                            | Alpha-fetoprotein                                                |
| ALBI                           | Albumin-bilirubin                                                |
| ALT                            | Alanine aminotransferase                                         |
| AST                            | Aspartate aminotransferase                                       |
| AUC                            | Area under the serum concentration-time curve                    |
| AUC                            | Analytical ultracentrifugation                                   |
| AUC 0-inf                      | Area under the serum concentration-time curve from 0 to infinity |
| BCLC                           | Barcelona clinic liver cancer                                    |
| BICR                           | Blinded independent central review                               |
| BIP                            | Boehringer Ingelheim Pharma Gmbh & Co. KG                        |
| BLA                            | Biologics license application                                    |
| BOR                            | Best objective response                                          |
| BRAT                           | Benefit-risk assessment tool                                     |
| BSA                            | Bovine serum albumin                                             |
| BSE                            | Bovine spongiform encephalopathy                                 |
| CCI                            | Container closure integrity                                      |
| CD                             | Cluster of differentiation                                       |
| CD                             | Circular dichroism                                               |
| CDC                            | Complement-dependent cytotoxicity                                |
| CDR                            | Complementarity determining region                               |
| CEP                            | Certificate of suitability                                       |
| CEX                            | Cation exchange chromatography                                   |
| CFU                            | Colony-forming unit                                              |
| CGE                            | capillary gel electrophoresis                                    |
| CI                             | Confidence interval                                              |
| cIEF CIP                       | Capillary isoelectric focusing Cleaned-in-place                  |
| C max                          | Maximum serum concentration                                      |
| C min                          | Minimum serum concentration                                      |
| C min,1                        | Minimum serum concentration after the first dose                 |
| CPP                            | Critical process parameter                                       |
| CQA                            | Critical quality attribute                                       |
| CR                             | Complete response                                                |
| CRF CSP                        | Case report form Clinical study                                  |
| CSR                            | protocol Clinical study report                                   |
| CTCAE                          | Common terminology criteria for adverse events (version 4.03)    |
| CTLA-4                         | Cytotoxic T lymphocyte-associated antigen 4                      |
|                                | mg (20 mg/kg) Q4W                                                |
| D                              | Durvalumab 1500                                                  |
| DCO                            | Data cut-off                                                     |
| DCR DCR-16w                    | Disease control rate Disease control rate at                     |
| DCR-24w                        | 16 weeks Disease control rate at 24 weeks                        |
| DF                             | Diafiltration                                                    |
| dFBS                           | Dialysed fetal bovine serum                                      |
| DNA DoR                        | Deoxyribonucleic acid Duration of response                       |
| DSC                            | Differential scanning calorimetry                                |
|                                | Eastern Cooperative Oncology Group                               |
| ECOG                           | European Directorate For The Quality Of Medicines & Healthcare   |
| EDQM EHS                       | Extrahepatic spread                                              |
| ELISA                          | Enzyme-linked                                                    |
|                                | immunosorbent assay                                              |

<div style=\"page-break-after: always\"></div>

| Abbreviation or special term   | Explanation                                                                                         |
|--------------------------------|-----------------------------------------------------------------------------------------------------|
| EMA                            | European Medicines Agency                                                                           |
| EORTC                          | European Organization for Research and Treatment of Cancer                                          |
| ESMO                           | European Society for Medical Oncology                                                               |
| ES-SCLC                        | Extensive-stage small cell lung cancer                                                              |
| EU                             | Endotoxin unit                                                                                      |
| EVA                            | Ethylene vinyl acetate                                                                              |
| FA                             | Final analysis                                                                                      |
| FAS                            | Full analysis set                                                                                   |
| FBS                            | fetal bovine serum                                                                                  |
| Fc region                      | Fragment crystallizable region                                                                      |
| FDA                            | United States Food and Drug Administration                                                          |
| GMP                            | Good manufacturing practices                                                                        |
| HBV                            | Hepatitis B virus                                                                                   |
| HC                             | Heavy chain                                                                                         |
| HCC                            | Hepatocellular carcinoma                                                                            |
| HCP                            | Host cell protein                                                                                   |
| HCV                            | Hepatitis C virus                                                                                   |
| HNSCC                          | Head and neck squamous cell carcinoma                                                               |
| HPLC                           | high performance liquid chromatography                                                              |
| HPSEC                          | high pressure size exclusion chromatography                                                         |
| HR                             | Hazard ratio                                                                                        |
| HRQoL                          | Health-related quality of life                                                                      |
| IA                             | Interim analysis                                                                                    |
| ICH                            | International Council For Harmonization Of Technical Requirements For Pharmaceuticals For Human Use |
| ICI                            | Immune checkpoint inhibitor                                                                         |
| IDMC                           | Independent Data Monitoring Committee                                                               |
| IEC                            | Ion exchange chromatography                                                                         |
| IEMT                           | Information Exploration Management Team (acronym used to identify supplementary data outputs)       |
| IgG                            | Immunoglobulin G                                                                                    |
| imAE                           | Immune-mediated adverse event                                                                       |
| IO IPC                         | Immuno-oncology In-process control                                                                  |
| IPT                            | In-process test                                                                                     |
| ISI                            | integrated summary of immunogenicity                                                                |
| ISS                            | integrated summary of safety                                                                        |
| IV                             | Intravenous                                                                                         |
| JP                             | Japanese Pharmacopoeia                                                                              |
| KPP                            | Key process parameter                                                                               |
| LC                             | Light chain                                                                                         |
| LIVCA                          | Limit of in vitro cell age                                                                          |
| LRV                            | Log reduction value                                                                                 |
| mAb                            | Monoclonal antibody Master cell bank                                                                |
| MCB                            |                                                                                                     |
| MTP                            | Multiple testing procedure                                                                          |
| MVI                            | Macrovascular invasion                                                                              |
| MVM                            | Minute virus of mice                                                                                |
| nAb                            | Neutralizing antibody                                                                               |
| NCCN                           | National comprehensive cancer network                                                               |
| NCPP                           | Non-critical process parameter States)                                                              |
| NF                             | National Formulary (United                                                                          |
| NI                             | Noninferiority                                                                                      |
| NK cell                        | Natural killer cell                                                                                 |
| NKPP NOR                       | Non-key process parameter Normal operating range                                                    |
| NSCLC                          | Non-small cell lung cancer                                                                          |
| ORR                            | Objective response rate                                                                             |
| OS                             | Overall survival                                                                                    |
|                                | Post-approval change protocol                                                                       |
| PACMP                          | management                                                                                          |

<div style=\"page-break-after: always\"></div>

| Abbreviation or special term   | Explanation                                                                                   |
|--------------------------------|-----------------------------------------------------------------------------------------------|
| PAR                            | Proven acceptable range                                                                       |
| PD                             | Progressive disease                                                                           |
| PD-1                           | Programmed cell death-1                                                                       |
| PDE                            | Permitted daily exposure                                                                      |
| PD-L1                          | Programmed cell death ligand-1                                                                |
| PD-L2                          | Programmed cell death ligand-2                                                                |
| PFS                            | Progression-free survival                                                                     |
| Ph. Eur.                       | European Pharmacopoeia                                                                        |
| PK                             | Pharmacokinetic(s)                                                                            |
| PO                             | Polyolefin                                                                                    |
| PopPK                          | Population pharmacokinetics                                                                   |
| PP                             | Process parameter                                                                             |
| PPQ                            | Process performance qualification                                                             |
| PR                             | Partial response                                                                              |
| PRO                            | Patient reported outcome                                                                      |
| PRS                            | Primary eeference atandard                                                                    |
| PRV                            | Pseudorabies virus                                                                            |
| PS                             | Performance status                                                                            |
| PT                             | Preferred term                                                                                |
| PV                             | Process validation                                                                            |
| PVC                            | Polyvinyl chloride                                                                            |
| QLQ-C30                        | 30-item core quality of life questionnaire                                                    |
| QLQ-HCC18                      | 18-item hepatocellular cancer health-related quality of life questionnaire                    |
| QoL                            | Quality of life                                                                               |
| QxW RECIST 1.1                 | Every x weeks Response Evaluation Criteria in Solid Tumors, version 1.1                       |
| Reo-3                          | Reovirus type 3                                                                               |
| RLP                            | Retrovirus-like particle                                                                      |
| RT-qPCR                        | Reverse transcription quantitative real-time polymerase chain reaction                        |
| S                              | Sorafenib 400 mg twice daily                                                                  |
| SAE                            | Serious adverse event                                                                         |
| SAP                            | Statistical analysis plan                                                                     |
| SD                             | Stable disease                                                                                |
| SIP                            | Steamed-in-place                                                                              |
| SMQ                            | Standardized MedDRA query                                                                     |
| SoC                            | Standard of care                                                                              |
| SPR                            | Surface plasmon resonance                                                                     |
| T                              | Tremelimumab 750 mg (10 mg/kg) Q4W Ã— 7 doses followed by Q12W                                 |
| T300+D                         | Tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W |
| TEM                            | mg (20 mg/kg) Q4W Transmission electron microscopy                                            |
| TKI                            | Tyrosine kinase inhibitor                                                                     |
| TSE                            | Transmissible spongiform encephalopathy                                                       |
| TTC                            | Threshold of toxicological concern                                                            |
| TTP                            | Time to progression                                                                           |
| TTR                            | Time to onset of objective response                                                           |
| UC                             | Urothelial carcinoma                                                                          |
| UF                             | Ultrafiltration                                                                               |
| UPB                            | Unprocessed bulk                                                                              |
| US                             | United States                                                                                 |
| USP                            | United States Pharmacopoeia                                                                   |
| UV                             | Ultraviolet                                                                                   |
| VEGF                           | Vascular endothelial growth factor                                                            |
| VEGFR                          | Vascular endothelial growth factor receptor                                                   |
| WCB                            | Working cell bank Working reference standard                                                  |
| WRS                            |                                                                                               |
| XMuLV                          | Xenotropic murine leukaemia virus                                                             |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant AstraZeneca AB submitted on 4 March 2022 an application for marketing authorisation to the European Medicines Agency (EMA) for Imjudo, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 14 October 2021.

The applicant applied for the following indication:

IMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0107/2021 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0107/2021 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.4.2. New active substance status

The applicant requested the active substance tremelimumab contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 1.5. Scientific advice

The applicant did seek Scientific Advice from the CHMP.

## Summary of questions raised/ issues discussed in the scientific advice

The applicant received scientific advice on the development of durvalumab, tremelimumab for the treatment of hepatocellular carcinoma from the CHMP on the 18 May 2017

(EMA/CHMP/SAWP/286452/2017). The scientific advice pertained to the following clinical aspects:

- AstraZeneca intends to conduct a Phase 3 randomised study to evaluate durvalumab and durvalumab in combination with tremelimumab for the treatment of patients with unresectable HCC who are not eligible for loco-regional therapy.
- The proposed Phase 3 study design is appropriate to support registration of durvalumab and durvalumab in combination with tremelimumab at the proposed dosing regimens. In particular: the patient population has been appropriately defined in this study to support registration in HCC patients who are not eligible for loco-regional therapy; the proposed geographical recruitment and trial stratification criteria are appropriate and in turn, will support registration in this region; the sorafenib is the most appropriate active comparator for this study; the proposed endpoints and targeted magnitude of benefit; the proposed statistical analysis approach to evaluate the efficacy endpoints, as well as the multiple testing procedure to control the overall Type 1 error rate.
- The data from the Phase 1/2 Study 22 will provide sufficient evidence of contribution of components for durvalumab and for tremelimumab to support registration of durvalumab in combination with tremelimumab in patients with HCC not eligible for loco-regional therapy.
- The registrational utility of surrogate endpoints in this disease setting. Specifically, does the Agency agree that Time to Progression (TTP) (defined as time to progression or HCC-related death [i.e. non-HCC-related deaths will be censored]), if included as another primary endpoint, with appropriate control of the overall type I error rate (for example the alpha could be split between overall survival and TTP), could form the basis of regulatory approval in advance of the overall survival result being available.
- AstraZeneca's proposed biomarker development strategy.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Aaron Sosa Mejia  Co-Rapporteur:  Selma Arapovic Dzakula

| The application was received by the EMA on                                                      | 4 March 2022   |
|-------------------------------------------------------------------------------------------------|----------------|
| The procedure started on                                                                        | 24 March 2022  |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on    | 13 June 2022   |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on | 23 June 2022   |

<div style=\"page-break-after: always\"></div>

| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                   | 27 June 2022      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                        | 21 July 2022      |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                            | 09 September 2022 |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                | 14 October 2022   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                       | 27 October 2022   |
| The CHMP agreed on a list of outstanding issues to be sent to the applicant on                                                                                                 | 10 November 2022  |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                | 22 November 2022  |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on       | 30 November 2022  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive for granting a marketing authorisation to Imjudo on | 15 December 2022  |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product                                         | 15 December 2022  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Primary liver cancer (Hepatocellular carcinoma, HCC) accounts for approximately 906,000 new cases and 830,000 deaths per year globally. In Europe, there are approximately 87,000 new cases a year and around 78,000 deaths (WHO 2020). Hepatocellular carcinoma represents about 90% of primary liver cancers (EASL 2018).

The initially claimed therapeutic indication was:

TRADENAME in combination with durvalumab is indicated for the treatment of adults with unresectable hepatocellular carcinoma (uHCC).

## 2.1.2. Epidemiology and risk factors

The incidence of HCC increases progressively with advancing age in all populations, reaching a peak at 70 years (El-Serag 2012, White et al 2017). Rates of both incidence and mortality are 2 to 3 times higher among men than among women in most regions (Sung et al 2021).

The main risk factors for HCC are chronic infection with HBV or HCV, aflatoxin-contaminated foods, heavy alcohol intake, excess body weight, type 2 diabetes, and smoking. The major risk factors vary from region to region, which is reflected in the incidence of HCC across geographic regions (Sung et al 2021). The highest incidence rates are seen in East Asia and Sub-Saharan Africa, while lower rates are seen in Europe and North America (WHO 2019).

Worldwide, HBV causes an estimated 75% to 80% of HCC cases, while HCV causes 10% to 20% of cases (Perz et al 2006). HCV infection (particularly in the US, Japan, and Egypt [Mak et al 2018, McGlynn et al 2015]), excessive alcohol consumption, and non-alcoholic fatty liver disease (linked to the growing prevalence of obesity and type 2 diabetes) represent the main risk factors for HCC (Vogel et al 2019).

## 2.1.3. Biologic features

Normal liver tolerogenic mechanisms are likely responsible for chronic liver inflammation or carcinogenesis. Chronic presentation of pathological antigens in the liver can actively suppress immune responses, thus inducing a state of immune tolerance to the pathogen or tumour. Hepatocellular carcinoma takes advantage of peripheral tolerance to evade cell mediated immune responses, which allows the tumour to grow. Chronic hepatic inflammatory responses are the number one risk factor for liver tumour development (Makarova-Rusher et al 2015).

Moreover, increased expression of immunosuppressive cell populations, such as regulatory T cells and myeloid derived suppressor cells, and inhibitory signalling molecules, such as CTLA 4 and PD 1, have been observed in HCC (Gao et al 2009, Hato et al 2014, Pardee and Butterfield 2012) and is additionally associated with HBV and HCV infection. This upregulation contributes to the immunosuppressive environment for HCC and highlights the importance of the PD-(L)1 and CTLA-4 pathways in HCC (Golden-Mason et al 2007, Pardee and Butterfield 2012, Peng et al 2008).

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

The HCC prognosis and treatment depend on factors such as tumour burden, degree of liver dysfunction, and clinical performance status (PS) (Marrero et al 2018, Vogel et al 2019). Hepatocellular carcinoma classically develops and grows in silent fashion, making its discovery challenging prior to the development of later stage disease (Bialecki and Di Bisceglie 2005), which usually leads to a late diagnosis, with a median survival following diagnosis of approximately 6 to 20 months (McGlynn et al 2015). Hepatocellular carcinoma is a medically complex and difficult to treat disease as the majority of patients have underlying cirrhosis requiring management of both the malignancy and underlying liver disease. Hence, the 5-year survival rate for HCC is less than 20% (Sarveazad et al 2019, Villanueva 2019). Unresectable HCC remains a difficult to treat disease, and the majority of patients will ultimately die of either HCC or complications of liver disease.

## 2.1.5. Management

Sorafenib, an oral TKI targeting multiple kinases, including VEGFR-1, -2, and -3 and BRAF, has been the standard of care (SOC) for advanced HCC in the first-line setting since its approval in 2007, which was based on improvement compared to placebo, establishing a median OS of 10.7 months (vs 7.9 months for placebo [Llovet et al 2008]). Subsequent studies have demonstrated a median OS ranging from 10.7 to 13.4 months (Finn et al 2021, Llovet et al 2008, Yamashita et al 2020). In 2018, lenvatinib, another multiple kinase inhibitor against VEGFR-1, -2, and -3 and fibroblast growth factor receptor-1, -2, -3, and -4, was approved as first-line treatment for advanced HCC in patients without main portal vein invasion and ECOG PS 0 to 1. Lenvatinib demonstrated non-inferiority to sorafenib in a Phase III study, with a median OS of 13.6 months vs 12.3 months with sorafenib (Kudo et al 2018). Atezolizumab (a PD-L1 inhibitor) in combination with bevacizumab (an angiogenesis inhibitor targeting vascular endothelial growth factor A) has also been approved in the first-line setting, after the Phase III IMbrave150 study showed improvements in OS and PFS compared to sorafenib (Finn et al 2020b, Finn et al 2021). The NCCN, ESMO, and Japanese Society of Hepatology guidelines were updated in 2020 to recommend atezolizumab in combination with bevacizumab as the preferred option to treat first-line HCC (NCCN Guidelines 2021, JSH 2021; Vogel and Martinelli 2021 [ie, ESMO Guidelines 2021]).

Regorafenib and cabozantinib (both multitargeted TKIs) have been approved for patients with advanced HCC, who have tolerated and progressed on sorafenib (Abou-Alfa et al 2018, Bruix et al 2017). Another approved second-line therapy is ramucirumab (a monoclonal antibody against VEGFR 2), which has improved survival in patients with serum AFP â‰¥ 400 ng/mL and previous treatment with sorafenib (Zhu et al 2019). In addition, nivolumab (an anti-PD-1 mAb) in combination with ipilimumab (an anti CTLA-4 mAb) has recently received accelerated approval from the FDA for patients previously treated with sorafenib, due to results from the CheckMate 040 study, a Phase II study in which nivolumab (1 mg/kg, Q3W) plus ipilimumab (3 mg/kg Q3W Ã— 4) (N=50; 28/50 [56%] with HBV) achieved a 32% ORR (Yau et al 2020).

## Unmet medical need

Despite recent advances in treatment options, patients with uHCC continue to have a low life expectancy and the underlying liver disease and portal vein hypertension increase the risk of gastrointestinal bleeding in patients with advanced HCC, which can be potentially life-threatening. Currently available therapies provide only a modest improvement in survival with safety profiles that require management due to adverse events such as diarrhoea, hypertension, and palmar-plantar erythrodysaesthesia (PPE). Treatment with atezolizumab plus bevacizumab also carries a higher incidence of bleeding, including fatal bleeding, despite attempts to exclude patients at risk for

<div style=\"page-break-after: always\"></div>

gastrointestinal bleeding from the pivotal study. Moreover, the underlying liver cirrhosis may result in moderate liver dysfunction, which may exacerbate the toxicity of systemic therapies such as TKIs. Hence, additional therapeutic options are needed, including options for patients with uHCC who are at higher risk of bleeding events, so there exist an unmet medical need for better and tolerable treatment options for patients with uHCC.

## 2.2. About the product

Tremelimumab binds to CTLA-4 that is primarily expressed on the surface of activated T lymphocytes. Binding of CTLA-4 to its target ligands (CD80 and CD86) provides a negative regulatory signal, which limits T-cell activation and blocks the interaction of the co-stimulatory receptor CD28 with CD80 and CD86, thus limiting CD28-mediated T cell co-stimulation. Tremelimumab antagonises binding of CTLA4 to its ligands and enhances human T-cell activation as demonstrated by increased cytokine (IL-2, IFNÎ³) production in vitro in whole blood or PBMC cultures. In addition, blockade of CD80/86 binding to CTLA-4 by anti CTLA-4 antibodies results in markedly enhanced T-cell activation and anti-tumour activity in animal models, including killing of established murine solid tumours and induction of protective anti-tumour immunity. Therefore, it is expected that treatment with tremelimumab will lead to activation of the human immune system, increasing anti-tumour immunity in subjects with solid tumours.

Durvalumab binds to programmed cell death ligand-1 (PD-L1) (but not programmed cell death ligand2) and thus blocks its interaction with programmed cell death 1 (PD-1) on T-lymphocytes (T-cells) and cluster of differentiation (CD) 80 (B7.1) on immune cells (ICs) and is engineered to reduce antibodydependent cell-mediated cytotoxicity (ADCC). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses and may result in tumour regressions including objective responses based on tumour cell reduction as well as in stable disease due to tumour growth control. This mechanism of action may elicit eventually delay of progression and extension of survival.

The CHMP adopted a positive opinion for the following indication:

IMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

Posology: The recommended dose of Imjudo is 300 mg as a single dose (intravenous infusion over 1 hour) administered in combination with durvalumab 1500 mg at Cycle 1/Day 1, followed by durvalumab monotherapy every 4 weeks, until disease progression or unacceptable toxicity. Dose escalation or reduction is not recommended during treatment with Imjudo in combination with durvalumab. Treatment withholding or discontinuation may be required based on individual safety and tolerability.

<div style=\"page-break-after: always\"></div>

## 2.3. Type of application and aspects on development

Table 1: Summary of EMA regulatory interactions and correspondence specific to the HIMALAYA study

| Date                        | Type of interaction             | Summary of outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17 March 2017 - 22 May 2017 | Pre-Phase III Scientific Advice | EMA agreed with the principles of the statistical analysis and commented that the proposed interim analysis may lack power and/or maturity when investigating all subgroups (including patients with low expression of PD-L1 in whom prognosis may be better and treatment efficacy less pronounced). The design of Study 22 is appropriate, but contribution of components is dependent on results and could be driven by PD-L1 expression.                                                                                                                                                                                                                                                                                                                                                          |
| 19 Jan 2022                 | Joint Pre- submission Meeting   | AstraZeneca held a joint pre-submission meeting with the Rapporteur and Co-Rapporteur to review the planned submission of tremelimumab in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma. The Rapporteur acknowledged that HIMALAYA was well-designed to evaluate contribution of components. It was noted, however, that the added benefit of tremelimumab relative to the safety profile of the combination would be a key consideration in the review. Additionally, study integrity will be a key consideration for the Agency during their review. The Rapporteur sought assurance to support that study integrity was maintained, as the non- inferiority margin was adopted without prior agency feedback during the conduct of the study. |

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as concentrate for solution for infusion containing 20 mg/mL of tremelimumab as active substance.

Other ingredients are: histidine, histidine hydrochloride monohydrate, trehalose dihydrate, disodium edetate dihydrate, polysorbate 80 and water for injections.

The product is available in a 2 mL type I glass vial with an elastomeric stopper and a violet flip-off aluminum seal for the 25 mg presentation and in a 20 mL type I glass vial with an elastomeric stopper and a dark blue flip-off aluminum seal vial for the 300 mg presentation.

## 2.4.2. Active substance

## 2.4.2.1. General information

Tremelimumab (INN) active substance is a human monoclonal antibody from the immunoglobulin (Ig) G2a subclass comprising of 2 heavy chains (HC) and 2 light chains (LC) covalently linked with 6 interchain disulfide bonds. There is one N-linked glycosylation site at Asn-301 on each HC (Fc region). The molecular weight of tremelimumab is 149,145 Da. The theoretical and experimentally confirmed extinction coefficient is 1.43 (mg/mL) -1 cm -1  and the pI is in the range of 8.5-9.0.

<div style=\"page-break-after: always\"></div>

The mechanism of action is blocking of the interaction between CTLA-4, a cell surface receptor expressed on activated T cells, and the natural B7 ligands (CD80 and CD86) on antigen-presenting cells resulting in enhanced T cell-mediated immune response such as T cell activation, proliferation, and lymphocyte infiltration into tumours leading to tumour cell death.

## 2.4.2.2. Manufacture, process controls and characterisation

Manufacturing and testing of the active substance is performed by Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorfer Strasse 65, Biberach an der Riss 88397, Germany. The active substance is manufactured, packaged, stability tested and quality-control tested in accordance with Good Manufacturing Practice (GMP).

## Description of manufacturing process and process controls

The active substance manufacturing process has been adequately described and is considered acceptable. It comprises of upstream process (cell culture steps) and downstream process (purification steps).

The upstream process comprises of vial thaw, inoculum expansion, seed bioreactors, production bioreactor and harvest. Cell culture process is initiated with the thaw of cells from one working cell bank (WCB) vial. One production bioreactor results in one batch of active substance (parent batch), for which a unique batch number is assigned. Subsequently, this parent batch may be subject to splitting/pooling (sub-lotting) and stored under refrigerated or frozen conditions. The applicant defined the material inputs, critical process parameters (CPPs) and non-critical process parameters (NCPPs), and process outputs (in-process controls, microbial controls, and performance attributes) for each manufacturing step and are considered acceptable. The harvest is initiated by lowering the bioreactor temperature and followed by continuous centrifugation and filtrations (depth filtration and membrane filtration). The pre-harvest samples are taken from the production bioreactor on the harvest day to perform unprocessed bulk (UPB) testing. Harvest product is tested for bioburden and endotoxins.

The protein is then purified using a series of packed bed chromatographic and membrane filtration techniques. All purification steps were sufficiently described. The used buffers and solutions, chromatography media, filters and other product contact disposables were presented. CPPs, NCPPs, inprocess controls (IPCs), microbial controls and performance attributes with the proposed limits (proven acceptable range - PARs, acceptance criteria or action limits) were adequately defined for each purification step.

The purification process is followed by a formulation step, which consists of product concentration, diafiltration and dilution to formulate the bulk active substance at a concentration of 20 g/L. The formulated bulk is then filtered into a stainless-steel mobile vessel. The filtered bulk is then 0.2 Âµm filtered into the active substance containers (Ethyl Vinyl Acetate - EVA - bags) for long-term storage at 2-8Â°C. Shipment to the finished product manufacturing site is carried out using EVA bags.

There is one optional step 'controlled freeze, frozen storage and controlled thaw of the active substance' during the manufacturing process, to facilitate frozen storage of the active substance. The formulated bulk active substance is transferred through a filter into cryovessels and subjected to controlled freezing. The frozen bulk can be stored in stainless-steel cryovessels for up 48 months at 40Â±10Â°C. The frozen active substance can be thawed and filtered into a stainless-steel mobile vessel. After the indicated hold times in mobile stainless-steel vessels at specified temperatures, the thawed active substance is again filtered into the EVA bags which are then shipped to the finished product manufacturing site to initiate the manufacturing process of the finished product. The applicant justified its strategy to include this optional manufacturing step as it is required for commercial supply and

<div style=\"page-break-after: always\"></div>

inventory management. The applicant clarified that the release testing of the active substance is performed on the bulk active substance under GMP part II (i.e. freezing, thawing, filtrations, storage and transfer between storage containers). This approach is considered unusual, however, all manufacturing steps between the bulk active substance and the active substance filled in EVA bags were appropriately validated and it was shown that after these additional processing steps, all quality attributes comply with the active substance specification. Further, bioburden and endotoxin testing are routinely performed at each filtration step to ensure the microbial quality of the active substance. Stability data under frozen and refrigerated storage conditions were provided and indicated that no significant change in product quality attributes was observed over the proposed storage hold times in the individual containers (stainless steels and EVA bags). In conclusion, the proposed strategy is not considered in conflict with GMP principles. Nonetheless, it is recommended that the proposed active substance manufacturing process and control strategy should be under intensive surveillance of the GMP supervisory authority during future inspections.

Reprocessing steps have been adequately described by the applicant.

The primary packaging component for the liquid active substance stored at 2-8Â°C is a disposable, single-use EVA bag, constructed from a multilayer film, with the product contact layer composed of ethylene vinyl acetate (EVA) copolymer and a gas barrier film composed of ethyl vinyl alcohol. The materials of construction of the individual components were provided and a representative certificate of release from the supplier was provided. Acceptance of the EVA bags for use is based on confirmation from the supplier's CoA that all acceptance criteria were met. The bags are pre-sterilised by the vendor using validated gamma irradiation (25 kGy minimum) and a representative certificate of irradiation from the approved sub-contractor was also provided in the dossier. Compatibility of the active substance with EVA bags was demonstrated through stability studies. Extractables and leachables assessment for EVA bags was performed and the EVA bags were found to be of low risk for leachables upon review of data from the process qualification study.

The mobile vessel and the cryovessel are both made of 316L stainless-steel (manufactured from noncorroding chromium-nickel-molybdenum), cleaned-in-place (CIP), steamed-in-place (SIP) and integrity-tested via a pressure hold test prior to use. Both are equipped with a 0.2 Âµm liquid filter, so the active substance is filtered prior to entry into these containers. Compatibility of the active substance with stainless-steel cryovessels and mobile vessels was demonstrated through stability studies. The stainless-steel tanks are considered low risk for extractables and leachables. A risk assessment for the presence of elemental impurities has been performed by the applicant, in line with ICH Q3D, and the conclusion that no specific control of elemental impurities at the active substance level is endorsed.

## Control of materials

Sufficient information regarding the raw materials used in the active substance manufacturing process has been submitted. Compendial raw materials are tested in accordance with the corresponding monograph, while specifications (including test methods) for non-compendial raw materials are presented.

The preparation of cell culture media and nutrient feed was adequately described in the dossier. Storage temperature and storage duration were provided for both cell culture media and nutrient feed. Information related to the origin of the cell culture medium and specifications for the material were provided. No animal sourced ingredients or animal derived reagents are used in their manufacture.

Materials of animal origin were used during cell line development and also in the banking of the master cell bank (MCB) and adequate information regarding these materials was included in the dossier.

<div style=\"page-break-after: always\"></div>

The tremelimumab antibody was initially generated in a hybridoma cell line. The genes encoding tremelimumab were isolated from hybridoma cells and were used for generation of the expression plasmid.

The host cell line (NS0 mouse myeloma cell line) was used for the preparation of the production cell line by electroporation of NS0 cells with the expression plasmid. These cells were subsequently used to prepare a pre-MCB stock, which was tested for sterility and mycoplasma.

A two-tiered cell banking system is used for tremelimumab manufacturing. Preparation of the MCB and WCB is adequately presented in the dossier. In line with ICH Q5D, 2 independent WCB storage sites are used to ensure continuous, uninterrupted production of pharmaceuticals in case of catastrophic events. The cell banks were tested for identity, purity, cell substrate stability including sterility, mycoplasma, adventitious viruses and genetic stability. MCB and limit of in vitro cell age (LIVCA) bank were also tested for infectious retroviruses. The range of used tests is considered sufficient in accordance with ICH Q5A requirements and all tests met the acceptance criteria. The results confirmed the identity, cell banks viability and that the cell banks are free of bacteria, fungi, mycoplasma and adventitious viruses. Phenotypic stability was demonstrated by assessing growth, productivity, and product quality for a certain number of days from the WCB thaw. The genetic stability of the expression plasmid and integrated genes for tremelimumab was characterised based on testing of the MCB, WCB, and the LIVCA bank. Based on cell line stability data and viral safety data from LIVCA, the limit of in vitro cell age is considered adequately justified.

The applicant has provided a stability protocol for MCB and WCB, indicating the stability tests and the acceptance criteria. The stability programme with respect to growth and viability (recoverability) of the MCB and WCB was introduced with 5 years measure intervals.

In conclusion, sufficient information is provided regarding testing of MCB and WCB and release of future WCBs.

## Control of critical steps and intermediates

A comprehensive overview of the critical IPCs and critical in-process tests (IPTs) applied throughout the active substance manufacturing process is given. Acceptable information has been provided on the control system in place to monitor and control the active substance manufacturing process with regards to critical, as well as non-critical operational parameters and IPTs. Actions taken if limits are exceeded are specified.

## Process validation

A three-stage strategy is followed to define and validate the active substance manufacturing process throughout the process lifecycle. Stage 1 (process design) included the process characterisation and determination of CPPs. Stage 2 (process qualification stage) included the evaluation of the process design to determine if the process is capable of reproducible commercial manufacturing. Stage 3 (continued process verification) is considered as ongoing assurance gained during routine production that the process remains in a state of control.

The overall approach is in line with ICH Q7 Guideline and it is considered acceptable. Process validation was completed using consecutive active substance lots at the proposed commercial manufacturing scale at the proposed manufacturer (Boehringer Ingelheim Pharma GmbH &amp; Co. KG - BIP). Continued process verification identified 2 new critical quality attributes (CQAs) which resulted in the reclassification of some process parameters and hold times. Additional concurrent validation data demonstrated that results for the process parameters and process outputs for the recently produced lots are consistent with the outcomes of the prospective validation study.

<div style=\"page-break-after: always\"></div>

All manufacturing steps were covered during the process validation studies and the process parameters selected included all the CPPs and selected NCPPs, the latter being further classified as Key Process Parameters (KPPs) and Non-Key Process Parameters (NKPPs), based on their potential impact on process performance. Regarding the process outputs, results for IPCs, microbial controls (MCs) and performance attributes (PAs) were monitored in the process validation study. The validation acceptance criteria for monitored process parameters were established within the PARs which were determined based on process characterisation study. All acceptance criteria for the critical operational parameters and likewise acceptance criteria for the IPTs are fulfilled, demonstrating that the purification process consistently produces active substance of reproducible quality that complies with the predetermined specification and in-process acceptance criteria. Deviations observed in the process validation study were investigated and it was concluded that no impact on the process validation study could be expected.

Process intermediates and active substance hold times were validated through a small-scale study evaluating biochemical hold stability and are supported by equipment qualification hold time studies, demonstrating effective microbial control. Resin lifetime and carryover studies were also conducted at small-scale to establish the maximum number of product-contacting cycles for each chromatography resin used in the purification process and to demonstrate that the cleaning procedures for the chromatography resins are sufficient to reduce carryover of protein and host cell DNA to acceptable levels. Overall, the validation lifetime and carryover studies met the acceptance criteria and therefore the proposed maximum number of product-contacting cycles for the affinity resin and maximum cycles for both ion exchange resins are considered acceptable.

Filtration membrane studies were conducted at commercial scale to validate membrane carryover cleaning, reuse and storage for the filtration steps in the purification process. The target maximum number of membranes uses is adequately defined by the applicant. Validation of reprocessing steps was performed using small-scale studies. In line with the Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission (EMA/CHMP/BWP/187338/2014), the verification protocols to be applied in case of the need for reprocessing at large scale were provided and are considered adequate. The applicant demonstrated the suitability of all components that come into contact with the active substance formulation during the manufacture. Materials evaluated for leachables and details regarding the risk assessment were provided.

In conclusion, the active substance manufacturing process has been adequately validated.

## Manufacturing process development

Different manufacturing processes have been described. Process A to E batches were used in nonclinical and clinical studies. All clinical studies in this application were conducted by AstraZeneca utilizing Process E (the intended commercial process) active substance lots. During the development, several formulations and manufacturing sites were used. The applicant adequately described changes that were made throughout the development of the manufacturing process, as well as the comparability assessments that were conducted.

The applicant provided detailed results of analytical testing for the active substance lots manufactured from processes C, D and E. Furthermore, batch analysis data for process B and C and a summary of min-max ranges for early development Process A batches (used for early toxicology studies and nonclinical PK study) were provided. Overall, the lots met the specifications in place at the time of release. Side-by-side testing of the characterisation tests for each comparability assessment was summarised in tabular format. The results demonstrate that the active substance lots manufactured using Process C, D and E are highly comparable in terms of product quality, physicochemical and biological properties.

<div style=\"page-break-after: always\"></div>

## Characterisation

A comprehensive physicochemical and biological characterisation of the tremelimumab molecule was presented. The characterisation of tremelimumab involved primary structure, higher order structure, carbohydrate structure, charge and size heterogeneity, and biological properties.

In conclusion, the active substance has been sufficiently characterised, revealing that tremelimumab has the expected structure of a human IgG2a subclass antibody. The analytical results are consistent with the proposed structure.

Product-related impurities have been well characterised and studied. These attributes are considered CQA and the impact of these attributes on biological activity was adequately discussed. Adequate characterisation of product-related impurities has been presented, and therefore, the controls strategy for such impurities can be endorsed.

Process-related impurities comprise of impurities which arise from the cell substrates, cell culture and purification processing. Clearance and control of process-related impurities have been sufficiently discussed.

In summary, the characterisation is considered appropriate for this type of molecule.

## 2.4.2.3. Specification

Tremelimumab active substance specification has been defined in accordance with ICH Q6B and includes: general tests (clarity, colour, pH), oligosaccharide analysis, total protein content, identity, product-related impurities, process-related impurities), potency and safety attributes tests (bioburden, endotoxin).

Results from the statistical analysis of both release and stability data were used to support the justification of the proposed specifications. Justification for the omission of certain tests has been adequately presented by the applicant. During the assessment, acceptance criteria for several quality attributes (i.e. purity, product-related impurities and potency) were tightened upon request. In conclusion, the proposed tests panel is considered appropriate and acceptance criteria clinically justified.

The analytical methods and acceptance criteria applied during stability studies are identical to the active substance release specifications, except for certain tests conducted only at release. The stability acceptance criteria are set wider than the release acceptance criteria for several parameters, which is in principle acceptable. As the number of available batches for setting the acceptance criteria was limited, the applicant should further revise the active substance stability specification acceptance criteria for these parameters, when data from additional batches are available (REC) .

## Analytical methods

Analytical procedures performed in accordance with Ph. Eur. are appearance (color, clarity), pH, bioburden and endotoxin. Non-compendial methods are generally described with a sufficient level of detail (including equipment, reagents, system suitability and sample acceptance criteria) and are appropriately validated in accordance with ICH guidelines. The biological activity (potency) of the active substance is determined using a cell-based potency assay.

## Batch analysis

The applicant provided detailed results of analytical testing for the active substance lots manufactured from processes C, D and E. The results are within the specifications in place at the time of release and confirm consistency of the manufacturing process.

<div style=\"page-break-after: always\"></div>

In addition, batch analyses data for Process B and Process C active substance lots were provided and min-max ranges for Process A lots were summarised.

## Reference materials

The history of the used reference materials was provided. Several reference standards were used during development, however only the current primary reference standard (PRS) was used to test clinical material for this application. A two-tiered system of reference standards (PRS and working reference standard - WRS) is established and a portion of PRS was used as the first lot of WRS. Both PRS and WRS are representative of the production process and clinical performance and meet the release specifications. The preparation, storage and qualification of future standards was described in the dossier and is considered acceptable.

## 2.4.2.4. Stability

The applicant proposed that the active substance shelf-life is up to 48 months storage at -50Â°C to 30Â°C in stainless-steel vessels, followed by up to 24 months storage in EVA bags at 2Â°C to 8Â°C. The total storage duration should not exceed 72 months.

The applicant provided stability data to support storage of frozen bulk active substance in stainlesssteel containers at -50Â°C to -30Â°C (long-term storage conditions), and 2-8Â°C and 23-27Â°C/55-65% RH (accelerated storage conditions).

Stability studies for the frozen bulk active substance were performed using reduced-scale stainlesssteel containers (considered representative of the full-scale vessels) and lots manufactured at the commercial site (BIP) using the commercial manufacturing process (Process E). Long-term stability studies (48 months) are completed for 4 representative lots and for one lot data for 36 out of 48 months have been provided. No meaningful change was observed under frozen storage conditions. The results demonstrate stability of the frozen bulk active substance at -50Â°C to -30Â°C in stainless-steel vessels for up to 48 months.

Additionally, 12 months stability data have been provided for 5 bulk active substance lots stored at accelerated storage conditions (2-8Â°C and 23-27Â°C/55-65% RH). All stability lots met the acceptance criteria, however some trends in the studied parameters were observed which were more significant under storage at 23-27Â°C/55-65% RH. The applicant sufficiently discussed all these trends. Based on these results, the short-term storage of liquid active substance in stainless-steel containers is considered justified.

The stability of the active substance when stored in EVA bags has been demonstrated for 36 months at 5Â±3Â°C. Stability studies were performed using reduced-scale EVA bags and lots manufactured at the commercial site (BIP) using the commercial manufacturing process (Process E).

Data from long-term (2-8Â°C, for 36 months) and accelerated (23-27Â°C/55-65% RH, for 6 months) stability studies were provided. Long-term studies are completed for 3 representative lots and for one lot data for 6 out of 36 months have been provided.

Additionally, the applicant provided a summary of active substance photostability studies, conducted in accordance with ICH Q1B guideline. Based on the conclusions of these studies, the active substance should be protected from light during storage.

A sequential stability study supporting the proposed cumulative shelf-life (48 months storage at -50Â°C to -30Â°C in stainless-steel vessels followed by up to 24 months storage in EVA bags at 2Â°C to 8Â°C) has not been performed. However, 3 active substance stability batches which were included in the stability study for the active substance filled in EVA bags for 36 months at 2Â°C to 8Â°C followed the 12 months

<div style=\"page-break-after: always\"></div>

storage in stainless steel tanks at -50Â°C to -30Â°C. Therefore, based on the overall presented stability data, the proposed cumulative shelf-life for the active substance is considered acceptable. The applicant committed to perform a sequential stability study utilizing at least one active substance batch stored in accordance with the above-mentioned conditions (REC) .

A post-approval stability protocol and stability commitment have been given. For ongoing studies any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA.

## 2.4.3. Finished medicinal product

## 2.4.3.1. Description of the product and pharmaceutical development

Tremelimumab finished product is a sterile, preservative-free, liquid dosage form intended for intravenous infusion after dilution. The finished product is provided in 2 single-dose presentations: a 25 mg/1.25 mL vial presentation and a 300 mg/15 mL vial presentation.

Both presentations contain 20 mg/mL tremelimumab in 20 mM histidine/histidine-HCl monohydrate, 222 mM trehalose dihydrate, 0.27 mM disodium edetate dihydrate and 0.02% (w/v) polysorbate 80.

The finished product is filled with a volume in excess of the label-claim volume to meet the USP/Ph. Eur./JP test requirements. The proposed overfill volumes are 0.26 mL and 1 mL for 25 mg and 300 mg presentations respectively, resulting in target fill volumes of 1.51 mL and 16 mL. The proposed overfill was adequately justified based on development data. The finished product does not contain any overages.

The primary packaging components consist of a type I borosilicate glass vial (2R or 20R) and grey butyl elastomer stopper (13 mm or 20 mm) capped with an aluminium seal. The vials comply with Ph. Eur. 3.2.1 for Type I borosilicate glass. The butyl elastomer stopper complies with Ph. Eur. 3.2.9. Stoppers are silicone coated and the compliance with Ph. Eur. Monograph 3.1.8 was confirmed. Extractables and leachables from primary container components were evaluated based on a 3-stage risk-based strategy. All results were either below the Threshold of Toxicological Concern (TTC), not detected over time or found below the established and toxicologically justified Permitted Daily Exposure (PDE) level. The choice of the container closure system has been validated by finished product stability data and is adequate for the intended use of the product.

The active substance is delivered ready-to-fill and no formulation or dilution steps are performed during the finished product manufacturing process. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. No novel excipients or no excipients of human or animal origin are used in the finished product formulation. Compatibility of tremelimumab with these excipients was demonstrated in long-term stability studies.

## Pharmaceutical development

The formulation composition was developed based on experience with the solubility, structural integrity and stability of the product. A summary of the formulation development studies was provided and the rationale for introduced changes to develop the intended commercial formulation was thoroughly discussed. A characterisation study was executed to evaluate the robustness of the intended commercial formulation, to identify any critical formulation parameters and to understand the impact of those critical parameters on the finished product CQAs. In conclusion, the suitability of the intended formulation has been demonstrated based on development studies.

<div style=\"page-break-after: always\"></div>

The applicant presented 4 versions of the manufacturing process used throughout the clinical development. Process 4 for the commercial 25 mg and 300 mg finished product vials uses Process E active substance. Overall, the finished product manufacturing process development was clearly described. The rationale of the performed changes throughout the development was discussed accordingly and did not raise concerns.

Three studies were presented to demonstrate the comparability between lots produced in different stages of development. The performed comparability studies are considered well designed and in accordance with ICH Q5E guideline. The provided results demonstrate the comparability of the lots produced by different finished product manufacturing processes and sites.

Process characterisation studies were performed. Individual unit operations were evaluated regarding impact on CQAs and process performance parameters. Based on the results from the process characterisation studies, parameters that impact CQAs are classified as CPPs, while process parameters that do not impact any CQA are classified as NCPPs. Based on the tested ranges for process parameters, their respective PARs were defined. It was demonstrated that in the defined PARs there is no impact on the quality attributes of the product. As part of the characterisation study, the impact of manufacturing environment was evaluated. Leachables from in-process product contact materials were evaluated based on risk assessment. Potential leachables were found at concentrations well below the TTC limit. Therefore, the provided conclusion that the risk to patient safety is low is considered acceptable.

## In-use compatibility

The finished product must be diluted into 0.9% (w/v) saline or 5% (w/v) dextrose solutions prior to dose administration. Compatibility of the finished product was assessed in 250 mL polyolefin (PO) and polyvinyl chloride (PVC) intravenous (IV) bags. Compatibility with PVC administration sets and 0.2 Âµm polyethersulfone in-line filters was also tested.

In summary, the physical-chemical and microbiological in-use stability of the diluted product in IV bags has been demonstrated for up to 28 days at 2Â°C to 8Â°C and for up to 48 hours at room temperature (up to 30Â°C) from the time of preparation. The provided results support the proposed instructions for use and handling of the finished product stated in the SmPC (i.e., if not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be normally longer than 24 hours at 2Â°C to 8Â°C or 12 hours at room temperature (up to 25Â°C), unless dilution has taken place in controlled and validated aseptic conditions).

## 2.4.3.2. Manufacture of the product and process controls

The finished product is manufactured, filled, packaged, inspected and tested in accordance with GMP at qualified vendors. The finished product is released in the EEA by AstraZeneca AB, GÃ¤rtunavÃ¤gen, SE151 85 SÃ¶dertÃ¤lje, Sweden. A process flow diagram for the manufacture of the finished product is provided in the dossier. Detailed descriptions of the manufacturing steps are presented. Batch formula has been provided for the intended commercial batch size ranges: for the 25 mg finished product (1.51 mL target fill volume) and for the 300 mg finished product (16 mL target fill volume).

<div style=\"page-break-after: always\"></div>

The finished product manufacturing process consists of pre-filtration and pooling, mixing, and sterile filtration of the active substance, followed by aseptic vial filling and stoppering with sterile container closure components. There are no reprocessing steps in the finished product manufacturing process.

Process control strategy is sufficiently detailed and considered acceptable. In line with the process characterisation study, CPPs and NCPPs are defined in the manufacturing process and controlled with appropriate limits. Elements of microbial control strategy were described in detail. Process parameters are monitored and maintained within established PARs. Overall, the manufacturing process and the equipment used are considered adequately described.

The manufacturing process validation study was performed following a traditional approach. The manufacturing process was validated with consecutive lots for each vial presentation at the proposed commercial manufacturing site. Production scale process validation data were presented. All process parameters (CPPs, KPPs and NKPPS) were maintained within the specified operating ranges, based on PARs established in the characterisation study. To confirm process consistency, additional IPTs (process outputs) were monitored in the process validation study and all results fell within the predefined acceptance criteria.

The pre-filtration and pooling process is designed to enable pooling of multiple active substance bags. The provided results demonstrate that homogeneity of the bulk active substance prior to filling is achieved and therefore, pooling and mixing of active substance is considered validated.

The microbial control strategy includes process design and controls, material controls, facility controls, and testing. In the process validation study, all process steps were performed as expected and the results demonstrate adequate microbial control and sterility assurance.

Sterilisation of primary container components is performed at the manufacturing site under GMP surveillance. The performed validation studies are in line with the Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container

(EMA/CHMP/CVMP/QWP/850374/2015) and the provided data demonstrated the suitability of the selected sterilisation processes.

Aseptic filling process is validated using media fill runs. The matrix approach alternates the smallest and largest vial format for media fill simulations. It is therefore ensured that the commercial batches are filled within the qualified aseptic filing time.

Shipping qualification studies for the bulk vials and shipping validation for finished product packaging were performed. Details regarding the validation protocols and analytical testing results were provided in dossier and are considered acceptable.

In conclusion, the validation study demonstrated consistency and robustness of the manufacturing process for both product presentations.

## 2.4.3.3. Product specification, analytical procedures, batch analysis

The proposed release specifications for the finished product were defined in accordance with ICH Q6B.

<div style=\"page-break-after: always\"></div>

The finished product specification for both 25 mg and 300 mg presentation is generally based on the active substance release specification and includes general testing (appearance, osmolarity, pH, subvisible particles, extractable volume), quantity testing, identity testing, purity testing, charge heterogeneity testing, potency testing and safety attributes testing (sterility and endotoxin). Most of the quality attributes are also tested during stability with wider acceptance criteria.

Overall, the selection of tests is endorsed and the proposed acceptance criteria are generally acceptable. Acceptance criteria for product-related impurities and variants were revised during the procedure to better reflect the clinically qualified ranges. However, as number of available batches for setting the acceptance criteria was limited, the applicant should revise the finished product release and stability specification acceptance criteria when data from an additional 30 batches are available (REC) .

No additional impurities are introduced in the finished product manufacturing process. Product-related impurities are tested as part of release specification and monitored in stability studies. Process-related impurities are controlled in finished product release and stability specifications.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed, considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided it is accepted that no risk was identified on the possible presence of nitrosamine impurities in the active substance or the related finished product. Therefore, no additional control measures are deemed necessary.

Detailed assessment of elemental impurities in accordance with ICH Q3D guideline was provided. It is concluded that the overall risk of a potential release of elemental impurities into the finished product is low and no specific control is considered necessary. This conclusion is agreed.

## Analytical methods

The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with ICH guidelines. Most of the analytical methods used for the finished product testing are identical to the ones used for testing of the active substance. Transfer of analytical methods between testing sites has been successfully completed.

## Batch analysis

Summary of individual batch release results for Process 3 (clinical, stability) and Process 4 (validation, commercial, clinical, stability) lots was included in the dossier. Results for finished product lots manufactured by Process 3 and finished product 25 mg lots and 300 mg lots manufactured by Process 4 were provided. Only a summary of historic ranges of quality attributes were provided for Process 1 and Process 2 finished product lots, which is acceptable. The results are within the specifications set in place at the time of release and confirm consistency of the finished product manufacturing process.

## Reference materials

See active substance section on Reference materials.

<div style=\"page-break-after: always\"></div>

## 2.4.3.4. Stability of the product

The finished product stability studies were performed at long-term storage conditions (2-8Â°C), accelerated conditions (23-27Â°C/55-65% RH) and stressed conditions (38-42Â°C/70-80% RH), in accordance with ICH guidelines. In addition, photostability studies were conducted in accordance with ICH Q1B guideline. The stability studies are performed using the proposed commercial primary container and closure systems.

Tremelimumab 25 mg and 300 mg commercial presentations (Process 4) and 400 mg presentation (Process 3, used during finished product development) were included in stability studies. Concerning the 25 mg finished product presentation, stability data are provided, with three process validation (PV) lots designated the primary stability lots. Stability testing is ongoing for additional lots manufactured post-PV. For the 400 mg strength, stability data are provided for multiple production scale lots (PV and post-PV lots). These data are included as primary data for the 300 mg finished product presentation and supporting data for the 25 mg presentation. For the 300 mg finished product presentation, stability data are provided for 3 PV lots. Results for elemental impurities from leachable studies for up to 48 months are available for the 25 mg presentation and only initial values were provided for the 300 mg presentation. The elemental impurities stability testing and the formal stability study for the 300 mg vial presentation are still ongoing and the applicant committed to submit the results for Agency review when available (REC) .

The claimed finished product shelf-life of 48 months at 2-8Â°C for both 25 mg and 300 mg presentations was established based on real-time data (up to 48 months) for the 25 mg presentation at long-term storage conditions. Data for 300 mg presentation are currently very limited (up to 6 months), however, up to 48 months of stability data were provided for the 400 mg presentation used during finished product development. The applicant proposes that a combination of stability data from the 400 mg vial presentation and 25 mg vial presentation could be considered in the assignment of shelf-life for the 300 mg vial presentation. Suitability of this approach was thoroughly discussed. An identical primary container is used for both 400 mg and 300 mg presentations. All finished product presentations have the same formulation, are produced using active substance from the commercial process and the comparability between finished product Process 3 and Process 4 materials was demonstrated. Taken together, all these considerations and the comparison of stress stability study data demonstrating the highly comparable degradation profiles between the 25 mg and the 300 mg presentations, it is agreed that the data for 25 mg and 400 mg finished product presentations may be extrapolated to support the proposed shelf-life claim for the 300 mg finished product presentation.

The provided stability data at accelerated stability conditions support the proposed finished product total time out of refrigerator of 30 days, as detectable changes are observed only after 2-6 months at 23-27Â°C/55-65% RH, with no significant degradation trend.

Thermal stress stability studies (38-42Â°C/70-80% RH) were performed to reveal the finished product degradation profile. Up to 6 months of stability data for the 400 mg and 25 mg presentations and 3 months for the 300 mg presentation are available. Clear degradation trends were observed for purity, methionine oxidation and charge heterogeneity. Slight decrease in potency was observed. It was demonstrated that changes in quality profile under stress conditions are detectable by suitable analytical methods and attributes like purity, charge heterogeneity and potency are considered stability indicating.

Finished product lots exposed to light showed an increase in acidic variants, higher methionine oxidation rate, and a slight decrease in purity. No significant differences were observed for other quality attributes, including potency. It is therefore agreed that the finished product should be stored protected from light.

<div style=\"page-break-after: always\"></div>

In conclusion, based on the provided stability data, the proposed shelf-life for the finished product of 48 months and storage conditions as stated in the SmPC ( Store in a refrigerator (2 Â° C - 8 Â° C) . Do not freeze. Store in the original package in order to protect from light ) are acceptable. Reconstitution and in-use instructions in the SmPC are consistent with the reported stability findings of the in-use studies, as previously discussed.

A post-approval stability protocol and stability commitment have been given. For ongoing studies any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA. The ongoing stability programme will be followed up by the annual incorporation of at least one additional commercial-scale batch as stated in a stability commitment.

## 2.4.3.5. Adventitious agents

Materials of animal origin were used only during cell line development as well as during preparation of specified cell banks and used also during cryopreservation of the specified cell banks. Certificates of analysis including information regarding the origin and certificates of suitability (CEPs) issued by the European Directorate for the Quality of Medicines &amp; HealthCare (EDQM) were provided for all these materials. A TSE/BSE (Transmissible/Bovine Spongiform Encephalopathy) risk assessment for all these materials was performed with the conclusion that the risk of transmission of TSE/BSE from these materials is extremely low, which is endorsed. The applicant also provided the certificate of origin for the cell culture medium. This material is considered sufficiently documented, with negligible TSE/BSE risk of transmission.

A comprehensive programme, in accordance with ICH Q5A, is employed to test, evaluate and eliminate the potential risks of adventitious and endogenous viral agents. The programme includes control of raw materials used in the manufacturing, viral testing and characterisation of the cell banks (MCB, WCB, LIVCA) used in the GMP process, virus testing of UPB and viral clearance and inactivation assessment of the purification process.

Viral clearance capability of the active substance purification process was evaluated in scale-down experiments using 4 model viruses. The viral clearance experiments were performed matching predefined acceptance ranges for process parameters and performance outputs. The level of purification of the scaled-down version was shown to be representative of the production procedure.

All viral clearance experiments were performed in duplicate. The lower log10 reduction value (LRV) from the duplicate experiments was used to calculate cumulative LRV. The viral clearance experiments demonstrated that the purification process provides a cumulative LRV of â‰¥ 21.16, â‰¥ 18.28, â‰¥ 17.05, and â‰¥ 16.49, respectively, for the 4 model viruses. For the chromatography steps, the used chromatography resin provided LRVs either comparable to (within 0.5 log10) or better than the new chromatography resin, demonstrating that resin reuse has no negative impact on the viral clearance capacity of the chromatography steps. The resin sanitisation and storage studies demonstrated that the solutions used for the sanitisation and storage of the resins meet acceptable levels of antimicrobial efficacy and that the risk of cross contamination is minimal.

Endogenous retrovirus-like particles (RLPs) may be present in the cell line used to produce the tremelimumab active substance. These particles are measured by TEM analysis of the UPB. A safety factor for the removal of RLPs was calculated, resulting in a factor of greater than 9.0 log10 for the removal of endogenous virus, which is equivalent to less than 1 retrovirus-like particle for every 1.0 Ã— 10 9  doses of tremelimumab. The results are considered adequate.

<div style=\"page-break-after: always\"></div>

## 2.4.3.6. GMO

Not applicable.

## 2.4.3.7. Post-approval change management protocol(s)

The applicant introduced a Post-Approval Change Management Protocol (PACMP) to support the use of alternative single-use disposable filters across a number of steps in the active substance manufacturing process. Details regarding the planned technical assessment, assessment of extractables and leachables, small-scale studies and at-scale verification studies for the purpose of demonstration of comparability were provided. The upcoming changes will not have an impact on the composition, active substance and finished product specifications, active substance manufacturing process, critical steps, in-process controls or hold times and at-scale active substance batches will be placed on stability. Overall, the proposed PACMP is considered acceptable.

## 2.4.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the benefit/risk ratio of the product, which pertain to lack of data for cumulative active substance stability study, revision and potentially tightening of the active substance stability specification and finished product release/shelf-life specification acceptance criteria for product-related impurities and variants when additional data become available and submission of elemental impurity stability testing and formal stability study results for the 300 mg finished product presentation. These points are put forward and agreed as recommendations for future quality development.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.4.6. Recommendation(s) for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

1. The applicant should review and, if found appropriate, revise the active substance stability specification and finished product release/shelf-life specification acceptance criteria when data from an additional 30 batches are available.
2. The applicant should perform a sequential stability study according to the post-approval sequential stability protocol and provide the results supporting a shelf-life for the active substance of 48 months storage at -40Â°C Â± 10Â°C in stainless-steel vessels, followed by up to 24 months storage in EVA bags at 5Â°C Â± 3Â°C (for a total of up to 72 months).

<div style=\"page-break-after: always\"></div>

3. The elemental impurities stability testing and the formal stability study for the 300 mg finished product presentation are still ongoing. The results should be submitted for Agency's review when available.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

A comprehensive package of in vitro and in vivo studies was designed to characterise the pharmacological properties of tremelimumab with respect to mechanism of action and antitumour activity, pharmacokinetics (PK), pharmacodynamics (PD), and toxicological profile.

Based on the selective binding to human and cynomolgus monkey CTLA-4, the cynomolgus monkey was considered to be the only pharmacologically relevant species for assessment of nonclinical safety of tremelimumab. Tremelimumab binds to recombinant cynoCTLA-4 (rcynoCTLA-4) with slightly lower binding affinity comparable to that for the binding to recombinant human CTLA-4.

The nonclinical safety testing strategy for tremelimumab appears to meet the requirements as outlined in relevant ICH guidance, including ICH S6(R1), 'Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals', and ICH S9, 'Nonclinical Evaluation for Anticancer Pharmaceuticals'. All pivotal nonclinical safety studies were conducted in an Organization for Economic Co-operation and Development (OECD) member country in accordance with OECD GLP guidance. The IV route of administration was used for nonclinical toxicity studies as this is the intended clinical route of administration.

## 2.5.2. Pharmacology

Tremelimumab (previously CP-675,206) is a fully human immunoglobulin gamma-2 (IgG2) monoclonal antibody (mAb) engineered to bind to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD152), a cell surface receptor expressed on activated T cells. Upon T-cell activation, CTLA-4 expression is upregulated and acts to dampen immune responses, modulating and eventually switching off T-cell activation. The natural ligands for CTLA-4 are CD80 [B7.1] and CD86 [B7.2], which are present on antigen-presenting cells (APCs). Binding of CTLA-4 to CD80/CD86 functions to limit T-cell activation, primarily by competing with CD28 for access to CD80/CD86 (Walker and Sansom 2015).

In vitro , tremelimumab enhances T-cell function, measured by increased release of interleukin 2 (IL2), interferon gamma (IFNÎ³), and other cytokines (Tarhini and Kirkwood 2008).

In animal models of cancer, blockade of CTLA-4 function using anti-mouse CTLA-4 antibodies results in enhanced T cell function and antitumour activity that is enhanced by concomitant PD-L1 blockade (Wu et al 2012).

## 2.5.2.1. Primary pharmacodynamic studies

## In vitro pharmacology

Selectivity of tremelimumab was demonstrated by comparing binding to rhCTLA-4-Ig and 3 related proteins (hCD28-Ig, hB7.2, and hIgG1) at 1 (n=5), 10 (n=5), 100 (n=2) and 300 (n=2) Âµg/mL using ELISA to quantify the binding. Selectivity was &gt;500 in most instances except one at 1 Âµg/mL in which the selectivity was only 14 towards B7.2.

<div style=\"page-break-after: always\"></div>

In a more functional assay of binding, activated T cells was used to demonstrate that tremelimumab (CP-675,206 at 10 Âµg/mL) only bind to human and monkey CTLA-4. No binding to activated T cells from rat, mouse, hamster, or rabbit could be detected (Report 15-CP-675,206). For the mouse a positive control was included. It was stated in the report that tremelimumab in excess generally displayed ~ 3-fold higher total binding (surface plus intracellular) to stimulated human CD3+ cells than to rhesus or cynomolgus CD3+ cells as judged by median fluorescence intensities. Moreover, the affinity of tremelimumab to rhCTLA-4 and rcynoCTLA-4 was quantified using the BIAcore 2000 technology showing a slight difference in KD values for binding of tremelimumab to rhCTLA-4 and rcynoCTLA-4. KD values were 0.28 and 0.98 nM, respectively (Report 14-CP-675,206).

It was demonstrated that tremelimumab inhibited CD80 and CD86 binding in a competitive ELISA assay with sub-nanomolar EC50s (0.78 and 0.46 nM respectively, Report 03-CP-675,206).

In a functional assay of activated primary human T cells cocultured with Raji cells expressing CD80 and CD 86 an increase in secretion of IL2 (510%) and INFÎ³ (54%) was observed when treated with tremelimumab at 30 Âµg/mL as compared to the negative isotype control anti-KLH (Report 02-CP675,206). This concentration corresponds to one third (1/3) of Cmax (~ 100 Âµg/mL, Table 6, Summary of Clinical Pharmacology) and therefore can be considered clinically relevant.

The involvement of CD80 and CD86 was further demonstrated in a superantigen assay (Report 08-CP675,206) according to which, the following was concluded: Effects of B7 blockade on IL-2 production and enhancement of IL-2 by tremelimumab at 30 Âµg/mL were tested in staphylococcal enterotoxin A (SEA)-stimulated human PBMC and blood cultures from 3 healthy donors. Anti-B7.1 and anti-B7.2 antibodies (CD80 and CD86) and CTLA4-Ig (all at 30 Âµg/mL) were used to block B7 signalling. In PBMC cultures, blockade of B7.2 or B7.1 plus B7.2 reduced IL-2 baseline levels and also enhancement of IL-2 produced by tremelimumab by 89% to 100%. Blockade of B7.1 (CD80) was less effective, inhibiting both baseline IL-2 and IL-2 enhancement by tremelimumab by ~ 50%. In general, blockade of B7 in human blood cultures produced results that were similar to PBMC cultures with slightly less reduction of baseline IL-2 or enhancement of IL-2 induced by tremelimumab. These studies clearly demonstrate that SEA superantigen stimulation is highly B7 dependent (Report 08-CP-675,206).

In study 01-CP-675,206 PBMC and blood from further 15 healthy donors was used in the SEA assay to demonstrate that tremelimumab enhanced the production of IL-2 as compared to anti-KLH isotype control.

The final study using the SAE assay on human biomaterial included PBMC and blood from further 15 healthy donors and from &gt;80 cancer patients as well (Report 13-CP-675-206). Tumour types included prostate (minimal and advanced disease), renal, rectal, colon, ovarian, melanoma, non- Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma, but not HCC. Although the numerical IL-2 response was variable and PBMCs and blood from a few patients did not respond to tremelimumab, the increase in IL-2 response at 30 Âµg/mL tremelimumab can be considered consistent as observed across the range of tumour types in this study. Moreover, the response was also demonstrated to be concentration dependent with enhancement of IL-2 production from 10 Âµg/mL and to increase further at 30 and 100 Âµg/mL.

Similarly, cultures of whole blood from 5 cynomolgus monkeys confirmed that tremelimumab enhanced IL-2 production in the SEA assay at 30 Âµg/mL (Report 04-CP-675,206). Hence, the cynomolgus monkey is considered pharmacologically relevant.

As stated by Ohue, 2019, regulatory T cells (T-regs) suppress the activation of other T-cell populations and that Tegs are recruited into the microenvironment inside cancer tumours to enhance tumour immunity.

<div style=\"page-break-after: always\"></div>

Study 11-cp-675-206 was aimed at determining if blockade of CTLA4 by tremelimumab affects the ability of peripheral blood human Treg cells (CD4+CD25+) to inhibit IFNÎ³ production or  3 H-thymidine incorporation of anti-CD3/anti-CD28 activated T responder cells (CD4+CD25-) in an in vitro co-culture system. Treg cells were isolated from peripheral blood mononuclear cells. FACS analyses indicated that 84% Â± 5% of the isolated CD4+ Tregs were CD25+ and Foxp3+.

Under the assay conditions, a 2:1 ratio of peripheral blood Treg cells cultured with T responder cells markedly inhibited IFNÎ³ production and 3 H-thymidine incorporation compared to cultures without Treg cells. Moreover, these studies indicated that tremelimumab does not reverse the ability of human peripheral Tregs to suppress IFNÎ³ production or thymidine incorporation of stimulated human peripheral T responder cells at 30 or 100 Âµg/mL.

Studies in mice suggested that anti-CTLA-4 mAbs may also selectively deplete intratumoral FOXP3+ regulatory T cells via an Fc-dependent mechanism. In a key publication by Sharma et al, 2019, it is shown that ipilimumab and tremelimumab are not depleting intratumoral FOXP3+Tregs in human cancers and that this represents an opportunity for future improvement of these types of cancer treatments. Hence, for tremelimumab, increased activation of effector T-cells is the more likely mechanism of action.

## In vivo pharmacology

A mouse surrogate antibody (hamster anti-mouse CTLA-4 mAb named 9H10) of tremelimumab showed relevant efficacy in a mouse tumour model (12-cp-675-206). Syngeneic SA1N fibrosarcoma cells were injected subcutaneously into A/J mice (5/group). Treatment with 9H10 at 200 Âµg on day 0, 3 and 6 resulted in a 90% reduction in average tumour size on Day 28 compared to treatment with an isotypecontrol Ab. Plasmaconcentrations of 9H10 24 hours after administration was 102 Î¼g/mL and decreased to 34 Î¼g/mL 3 days later, hence were clinical ly relevant (Cmax ~ 100 Âµg/mL, Table 6, Summary of Clinical Pharmacology). Further studies showed a dose dependent tumour reduction at 200, 100 and 50 Âµg, although with no effect at 25 Âµg. Hence, a mouse surrogate of tremelimumab demonstrated efficacy as monotherapy in a mouse tumour model, when treatment was initiated at the same day as the inoculation.

All previous studies were conducted at Pfizer Groton. A new proof of concept study was sponsored by AstraZeneca (experimental work in 2017 and 2018, report signed 2021) demonstrating pharmacological activity of murine surrogates for tremelimumab and durvalumab in mouse syngeneic tumour models (ONC1123-0001).

In this study, treatment was initiated when the tumours reached 100 to 150 mm 3  and can therefore be considered more clinically relevant than study 12-CP-675,206 in which treatment was initiated at the time of inoculation.

The anti-mouse CTLA-4 mIgG1 tremelimumab surrogate mAb demonstrated modest antitumour activity as monotherapy, but good effect in combination with anti-PD-L1 in the EMT6 breast and CT26 colon syngeneic mouse tumour models (tumour growth and survival).

<div style=\"page-break-after: always\"></div>

Figure 1: Survival curves for CT26 antitumour efficacy study - Experiment 1

<!-- image -->

Likewise, the tremelimumab surrogate showed combination activity with anti-PD-L1 therapy in the MCA205 fibrosarcoma model, but no relevant effect as monotherapy. However, the effects were not fully comparable, while the addition of tremelimumab to durvalumab monotherapy increase the efficacy in colon model, in breast model, the combination effect is mainly due to durvalumab, thus in this case, addition of tremelimumab do not provide an increase in efficacy compared to durvalumab monotherapy. Due to this heterogenic data and since an uHCC mouse model has not been studied, the effect in the proposed indication cannot be anticipated. Monotherapy and combination with anti-PD-L1 also induced in-tumour CD4+ or CD8+ T cell proliferation in these 3 mouse tumour models, demonstrating the pharmacodynamic activity of the tremelimumab surrogate with respect to T-cell activation. As shown previously in vitro for tremelimumab, that peripheral Tregs was not depleted (11CP-675,206), the tremelimumab surrogate did not deplete peripheral Tregs in vivo , establishing the mAb as a relevant surrogate to explore the pharmacodynamic and antitumour activity in these mouse syngeneic tumour models.

A study entitled 'Profiling of Biomarkers Relevant to Immunotherapies in Paediatric Solid Tumours' was included in the submission. Immunohistochemistry data for PD-L1 and CD8 were generated for 76 and 77 paediatric tumours, respectively. Only one sample was positive for PDL1 staining, defined as â‰¥ 1% of TC expression of PD-L1. The level of CD8 T-cell infiltration within the paediatric tumours was relatively low as compared to adult tumours. Overall, these IHC data suggest a limited immune response against these paediatric tumours.

It was further concluded that these data were illustrative of a group of samples with relatively low levels of mutation and with a limited degree of immunogenicity and immune activation. These characteristics suggest that checkpoint blockade, using molecules such as durvalumab and tremelimumab, would be unlikely to result in significant activity in paediatric tumours, and is in keeping with the relatively low levels of activity observed to date for similar molecules in this setting.

## 2.5.2.2. Secondary pharmacodynamic studies

Study 07-CP-675,206 showed that plate-bound tremelimumab did not inhibit T cell activation in the SEA assay (0.01-100 Âµg/mL) as the IL-2 response was not changing in any direction at any platingconcentration. This is presented as a surrogate measure of non-specific surface bound or aggregated tremelimumab in vivo in which then tremelimumab is not expected to have any effect.

In study 05-CP-675,206 tremelimumab was added to unstimulated human whole blood from healthy volunteers at concentrations of 10 or 100 Î¼g/mL and did not induce levels o f TNFÎ±, IL -6, or IL1Î² in

<div style=\"page-break-after: always\"></div>

vitro that would be predictive of cytokine release syndrome in vivo . The positive control anti-CD3 induced cytokine release as expected in this assay. Hence, tremelimumab is not expected to induce spontaneous cytokine release in vivo , which is confirmed in clinical trials.

Study 10-CP-675,206 evaluated whole blood incubated with tremelimumab and a positive control antibody CP-642,570. Only the positive control reduced platelet number in the incubations. Tremelimumab and the negative control antibody anti-KLH did not reduce platelet numbers over the 24 -hour period the experiment lasted. It should be noted that the testing concentration was only 30 Âµg/mL and is therefore not covering Cmax, i.e. no safety margin is established. Immune thrombocytopenia has been observed in clinical trials with tremelimumab, however not in the HCC pool.

A human IgG1 antibody has much higher affinity for most human FcÎ³ receptors compared to a human IgG2 antibody such as tremelimumab. A study (16-CP-675,206) of competitive binding between a low concentration of  125 I-labeled antibody compared to when added 500-fold excess of unlabelled antibody to blood leucocytes, showed that an average of 53%, 43%, and 62% of the binding of hIgG1 antibody was inhibited by addition of excess unlabelled IgG1 antibody to human healthy donor, human prostate cancer patient, or cynomolgus monkey peripheral blood leukocytes. An average of 0%, 15%, and 2% of the binding of tremelimumab was inhibited by addition of excess unlabelled tremelimumab to human healthy donor, human prostate cancer patient, or cynomolgus monkey peripheral blood leukocytes. These results indicate that tremelimumab shows minimal specific binding to Fc receptor-bearing leukocytes, whether originating from humans or cynomolgus monkeys or cancer patients. Hence, Fc binding is not anticipated to be part of the mechanism of action of tremelimumab. Moreover, the tremelimumab binding to FcÎ³RI, FcÎ³RIIa, FcÎ³RIIb and FcÎ³RIII was evaluated using SPR assays and the KD obtained are not expected to be reached in the clinical setting.

In a study of antibody-dependent cell-mediated cytotoxicity (ADCC) against naÃ¯ve and activated human T cells using a FACS-based assay (09-cp-675-206), it was demonstrated that tremelimumab (100 Î¼g/mL) added to naÃ¯ve or anti -CD3/CD28 activated human T cells Â± IL-2- activated NK cells (up to an effector-to-target ratio of 25:1) produced no increases in ADCC compared to the no-treatment controls. The positive control anti-CD3 (Mu-IgG2a) did induce T-cell toxicity in both naÃ¯ve and activated T cells in this assay. Hence, ADCC is not anticipated to be part of the mechanism of action of tremelimumab.

CDC risk was evaluated using doses below clinical concentration (5 Âµg/ml). CDC activity was not seen in cells incubated with tremelimumab under this condition.  However, given the lack of effects on T cell depletion in the non-clinical in vivo studies and clinical studies, it is likely that the occurrence of CDC in vivo does not occur at biological relevant levels.

## 2.5.2.3. Safety pharmacology programme

No stand-alone safety pharmacology studies were conducted for tremelimumab. This is acceptable and according to guideline, especially when non-human primate is the only relevant species.

ECG, heart rate, blood pressure and vital signs (respiration rate and body temperature) was evaluated twice pre-dose and 5 min post dose in the GLP single dose study (tmax) and on several occasions during the dosing and recovery phase in the two repeat-dose studies. No dose-related changes from normal were observed in any study or on any occasion.

No dedicated CNS safety study was conducted. Instead, daily observations of the behaviour of the animals during the studies served this purpose. This is also acceptable as it is not expected that tremelimumab will cross the blood brain barrier. Any CNS effects is expected to be secondary to the

<div style=\"page-break-after: always\"></div>

pharmacological effect of increased systemic inflammation. Histopathology revealed mononuclear cell infiltration of choroid plexus of the brain and pituitary in the 6 months repeat-dose study. Dose-related mononuclear cell inflammation was present in kidney. Clinical signs of diarrhoea in the 50 mg/kg/week group generally correlated with inflammation in the cecum and colon.

## 2.5.2.4. Pharmacodynamic drug interactions

No pharmacodynamic drug interaction studies of tremelimumab were submitted.

## 2.5.3. Pharmacokinetics

## Methods of analysis

## Bioanalysis

An ELISA bioanalytical method was developed and revised over the time providing versions each of which was validated according to GLP and used for the three pivotal studies in monkeys. For the 6month toxicity and the EFD study an ELISA method validated as described in report DM2004-675206014 was used. These studies were conducted in 2005 and 2007, prior to issuing of the current bioanalytical guidelines. Hence, incurred sample reproducibility was not demonstrated. Nevertheless, the bioanalytical method appears to have been in good control and to be validated in GLP compliance according to common practice at the time of conduct including e.g. dilutional integrity up to 2000-fold, hook effect and specificity.

In the assay, the ELISA plate was coated with a capture antigen (human CD152/CTLA-4). The samples were aliquoted in duplicate and allowed to incubate. The drug-antigen complex was then detected using a biotin-mouse anti-human IgG2 conjugate and a streptavidin HRP conjugate. A colorimetric signal is produced using a commercial TMB substrate solution. The intensity of colour generated is directly proportional to the concentration of tremelimumab in the sample. Sample concentrations were determined by interpolation from a standard curve which was fit using a four-parameter curve fit. The minimum required dilution (MRD) for all samples was 1:20 and the required sample volume was 0.050 mL in duplicate. The quantitation range was 156 to 3000 ng/mL. Samples were stored at a nominal temperature of 80ËšC prior to analysis. Using this method, stability at -80Ëš C was demonstrated in monkey plasma for 174 days.

## ADA analysis

GLP compliant ADA analysis was used in the 1 month and 6 months toxicity studies (validation report DM2007-675206-022 from 2001). Samples were collected in the EFD study, but not analysed, since pharmacokinetics implied that this was not necessary. This is accepted.

The ADA method was a qualitative sandwich ELISA assay in which the plate was coated with F(ab')2 fragments prepared from tremelimumab. Anti-tremelimumab antibodies in plasma was then captured by the immobilised tremelimumab F(ab')2- fragment, washed and then detected and visualised by Protein G conjugated to horseradish peroxidase (HRP) and tetramethylbenzidine (TMB). A normal cynomolgus sodium heparin plasma pool and a reference standard plasma (diluted 1:500, 1:1500, and 1:4500) were included on each plate as negative and positive controls, respectively. Results were reported as the net signal at the 1:500 dilution if not â‰¥ 3.0, then the 1:1500 was reported.

The reference standard plasma was pooled plasma from eighteen monkeys that received a single dose of tremelimumab. The plasma was collected following clearance of tremelimumab as measured by ELISA. This reference standard served as a quality control sample in all subsequent assays.

<div style=\"page-break-after: always\"></div>

This is not the state of the art, however it appears to be a feasible way of determining ADA.

Reference range, dilution effects, stability, lot to lot variation of the negative control and intra/inter assay variability (robustness) was included in the validation. Long term stability was not presented. ADA could not be detected in the presence of tremelimumab above LLOQ of the bioanalytical method. A new method was developed for clinical samples with good assay drug tolerance.

## NAb assay

Positive samples identified in the ADA assay were subjected to a nAb assay, which was also validated (validation report DM2007-675206-023).

A non-functional qualitative sandwich enzyme immunoassay technique was utilised to determine antitremelimumab neutralizing antibodies to tremelimumab F(ab')2 in cynomolgus sodium heparin plasma. with specificity and sufficient affinity to disrupt the binding of tremelimumab to its ligand (CTLA4) in cynomolgus sodium heparin plasma.

Samples were diluted with CTLA4/Ig and incubated with F(ab')2 fragments prepared from tremelimumab which had been immobilised on an ELISA plate. After incubation, unbound material was washed away and CTLA4/Ig was detected using goat anti-mouse Ig-HRP and visualised with TMB. A normal cynomolgus sodium heparin plasma pool and a reference standard plasma (diluted 1:10, 1:50, and 1:100) were included on each plate as negative and positive controls. The presence of nAb is indicated by a reduction in signal intensity as compared to normal cynomolgus monkey plasma (naive to tremelimumab). Study samples were run at 1:10 and 1:50 dilution, and the results were reported as the percentage of normal plasma signal generated by a dilution of test plasma in a given concentration of CTLA4IIg (10 ng/mL). This is considered an acceptable strategy for a nAb assay. It should be mentioned that the nAb assay was not functional in the presence of tremelimumab above LLOQ of the bioanalytical assay.

## Absorption

Absorption was evaluated for the subcutaneous route at 5 mg/kg. Bioavailability was 54% when comparing clearance/F for SC administration with mean clearance from two studies of 0.75 mg/kg IV. It should be noted that tremelimumab is for intravenous administration together with durvalumab in a hospital setting. Hence this study is of minor clinical relevance. Pharmacokinetics after intravenous administration is discussed in section Other pharmacokinetic studies below.

## Distribution

As expected for a monoclonal antibody, volume of distribution is mostly confined to the vascular space as the volume of distribution in monkey demonstrate (Vss = 54 mL/kg).

## Metabolism

There is no evidence of nonlinearity of the pharmacokinetics of tremelimumab over the dose range of 0.75 to 100 mg/kg single dose. Therefore, it can be assumed that tremelimumab is not cleared via target mediated disposition but only through proteolytic degradation and catabolism.

## Excretion

Excretion was not studied for tremelimumab. This is acceptable due to nature of the molecule and that it is expected to be cleared as small peptides or aminoacids or incorporated in the endogenous aminoacid pool.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic drug interactions

Pharmacokinetic drug interactions were not studied. This is acceptable as PK drug interactions are not expected.

## Other pharmacokinetic studies

## Single dose IV pharmacokinetics

Pharmacokinetics of clonally and non-clonally derived tremelimumab was evaluated after IV administration of 0.75 mg/kg to cynomolgus monkey. This is a very low dose compared to the highest doses used in the toxicity studies (50 and 30 mg/kg/week). Minor differences in Vss (0.0705 and 0.0538 L/kg), clearance (0.00339 and 0.00300 mL/min/kg) and resulting half-life (11 and 9.1 days), for clonally and non-clonally derived tremelimumab were observed.

A single dose toxicity study was performed in cynomolgus monkeys at dose levels of 10, 30 and 100 mg/kg. The toxicokinetic report was very brief providing only Cmax, Tmax and AUC and no pharmacokinetic profiles. A trend towards lower increments in systemic levels at lower dose ranges in all pharmacokinetic and toxicokinetic studies were observed. For example, when comparing AUC0-tlast for 0.75 and 10 mg/kg, the increase in dose of 13.3-fold (from 0.75 to 10 mg/kg) only increased AUC by 7.8 and 6.8, the increase in dose of 3-fold (from 10 to 30 mg/kg) increased AUC by 2.3 and the increase in dose of 3.3-fold (from 30 to 100 mg/kg) increased AUC by 3.1. In addition, in the 1-mont and 6-month toxicity studies, accumulation on Day 29 was more pronounced at the lowest dose (AUC024h D29/ AUC0-24h D1 were 1.8 and 1.6 at 5 mg/kg, 1.1 at 15 mg/kg and 1.4 at 50 mg/kg).

New submitted PK data support that the higher accumulation observed at the lowest dose might be due to lower CL, although the high variability in exposure hinders understanding the PK profile of tremelimumab in animals. Despite the observed variability in exposure might be due to the impact of ADA on clearance of tremelimumab, it should be noted that the ADA analysis was limited to samples that showed pre-dose exposure below LLOQ (8/30 and 7/28 animals in the 1-month and 6 months toxicity studies, respectively) and thus, are limited to conclude the impact of ADA in exposure variability.

It should be noted that the dose of 0.75 mg/kg is clinically relevant. The dose in patients is a flat single dose of 300 mg providing geometric mean Cmax of 100 Âµg/mL. This is in close range to Cmax in the monkeys administered a single dose of 0.75 mg/kg of 25-30 Âµg/mL.

## Repeat-dose IV Pharmacokinetics

Repeat-dose toxicokinetics was evaluated in the 1-month toxicology study in which tremelimumab was administered IV once weekly at 5, 15 and 50 mg/kg (DM2001-675206-006). A few animals showed concentrations of tremelimumab above LLOQ at Day 1. However, so low as this is not anticipated to impact the conclusions of the study.

No gender-related differences in exposure was observed, why data was pooled across gender. AUC increased according to increase in dose on day 1, however slightly more than dose-proportional on Day 29.

Slight accumulation was observed as a result of pre-dose plasma concentration being 30-50% of Cmax over the following doses. The accumulation was most pronounced at the highest dose. This could be due to neutralising antidrug antibodies at the lower dose levels, see below.

Antidrug antibodies were detected in 8/12 monkey in the recovery phase. As expected, variability in plasma concentrations tended to increase from Day 22 and onwards. On Day 29 at the mid dose of 15 mg/kg, 5/8 animals showed lower plasma concentrations indicating antibody mediated increased

<div style=\"page-break-after: always\"></div>

clearance in selected animals. At the low dose only 2/8 and at the high dose only 1/8 showed lower plasma concentrations demonstrating that the animals were, in general, exposed as intended.

Repeat-dose toxicokinetics was evaluated in the 6-month toxicology study in which tremelimumab was administered IV once weekly at 5 and 15 mg/kg/week, n=4 (DM2001-675206-006) for 26 weeks. The high dose group of 50 mg/kg/week was terminated on Day 78 due to excess toxicity (last dose on day 43). Two male and two females continued in to a 100-day recovery phase (Study day 177). There were no recovery animals allocated for the low and the mid dose. Pre-dose samples were below LLOQ (0.156 Âµg/mL) on Day 1 and so were all samples collected from control animals. The observed slight gender differences in exposure were ascribed to variability due to neutralising antibodies and resulting waning exposure later in the study in some animals. Hence, the pharmacokinetic data were pooled across gender.

As expected, slight accumulation was observed between day 1 and 29. A slight decrease was evident on Day 176 probably due to increased clearance in some animals. Only one animal (34F, 15 mg/kg dose) developed antidrug antibodies already on day 22 were the predose sample was below LLOQ. From day 43, 3 more animals (28F, 12M and 14M) showed up with exposure at or below LLOQ and from Day 141 one more (12F). When pre-dose samples showed exposure below LLOQ, these were subjected to ADA assays. Anti-tremelimumab antibodies were detected in animal 12M, 14M and 34F in predose samples from Day 44, 44 and 23, respectively correlating with waning exposure in predose samples.

The systemic exposure to tremelimumab appeared to increase with increase in dose in a linear manner on Day 1. On day 29, the increase was slightly lower than the increase in dose. This was even more obvious on Day 176 due to the increase in neutralising antidrug antibodies and waning exposure in some animals. However, on Day 176, a 3-fold increase in dose still increased the exposure 2-fold. All monkeys at 5 and 15 mg/kg dose groups had measurable plasma concentrations of tremelimumab throughout the 6-month treatment period following each dose except one, which reached LLOQ on Day 141. Hence, the animals were subjected to adequate dose-related exposure during the dosing phase and the validity of the study.

Since exposure was relatively stable during the study, the AUCday1-30 can be acceptable as a rough estimate of for calculating exposure margins. No NOAEL could be established in this 6-months study as the monkeys also at the low dose experienced diarrhoea requiring supportive care and skin rash. The low dose provided exposure from Day 1 to 30 of 94700 Âµg/mL*h ((=94700/30)/(19104/28)) = 3157/682 ~ 5 times higher than clinical exposure.

Exposure was also followed in the EFD study. Pregnant female monkeys (n=12 or 14) per group were dosed 5, 15 or 30 mg/kg/week IV from GD20 to GD49 (5 doses). Systemic exposure (Cmax and AUCGD20-49) appeared to increase with increase in dose in a linear manner. Slight increase in exposure was observed between GD20 and GD 49 as expected for a product with a half-life longer than the dosing interval. ADA samples were obtained in the study, but since only very few animals showed increased clearance during the study as evident from low plasma concentrations in pre-dose samples on day 48 (12884 in the low dose group, 12702 and 13004 in the mid dose group and animal 12836 in the high dose group), these samples were not subjected to ADA analysis.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

Two single dose toxicity studies were presented for tremelimumab. The first one was with only a 10 mg/kg dose in one female and one male monkey and 12 weeks treatment-free observation period (Study 00-1985-06, non-GLP). This dose was well tolerated with no clinical signs, only a slight increase in lymphocyte counts was considered related to the pharmacological effect of tremelimumab. Exposure (AUC0-tlast) was documented to be similar to the same dose level in next study (Study 99-1985-01) and the female monkey was found positive for ADA.

The second study was GLP compliant and included 3 monkeys of each sex in each group (control, 10, 30 and 100 mg/kg) and a 15-week treatment free observation period (Study 99-1985-01).

This study included core end points such as mortality, clinical signs (daily), body weight, food consumption, physical examinations, haematology, clinical chemistry, inspection of administration site, gross pathology, microscopic pathology. Only the control and high dose group was subjected to necropsy on Day 106. The others were returned to colony. Moreover, this study included evaluation of some safety pharmacology parameters (ECG, heart rate, respiration rate and blood pressure 5 min post dosing).

AUC0-tlast was proportional to the increase in dose and all 9 animals were found positive for ADA.

All animals survived until the end of the study. The most prominent clinical sign was diarrhoea/loose stool which was dose related in incidence and severity. However, this did not result in change in food intake or body weight.

Haematology revealed a general drug-related increase in lymphocyte counts, which occurred in both males and females at â‰¥30 mg/kg. Moreover, a general drug-related increase in eosinophil counts was observed in females at all dose levels and males at 100 mg/kg. These effects are considered a result of the pharmacological effect of tremelimumab. The increase in circulating lymphocytes was not associated with corresponding microscopic changes in the organs examined. Other changes in haematology were consistent with stress leucogram profile as they were also observed in the control group or were characteristic for an inflammatory response against a foreign protein (human CTLA4 antibody; tremelimumab).

All microscopic findings were comparable between drug-treated and control animals and consistent with those commonly or sporadically found in non-human primates.

Safety pharmacology evaluation was included in this study by assessing vital signs (heart rate, respiration rate and body temperature) and ECG/blood pressure twice pre-study and 5 minutes (Tmax) after dosing. Hence, only acute effects were monitored. No acute drug-related changes were observed. This is endorsed.

## 2.5.4.2. Repeat dose toxicity

## 1-month i.v toxicity study with 2 months post-dose observation in cynomolgus monkey (Study 00-1985-04, GLP)

The 1 month repeat-dose toxicity study was performed in compliance with GLP as a multi-site study with Pfizer, Groton, CT, USA as the primary site. Only the immunophenotyping and serology was not performed to GLP.

<div style=\"page-break-after: always\"></div>

Animals (5/sex/group) were administered tremelimumab at 5, 15 or 50 mg/kg via once-weekly IV bolus injection on Day 1, 8, 15, 22 and 29. Control animals (5/sex) received vehicle according to the same dosing schedule. Scheduled necropsies were conducted on Day 30 (3/sex/group), and following a 2-month treatment-free period (Day 105; 2/sex/group). I.e. there were recovery animals in all four groups.

Weekly IV bolus administration of tremelimumab over a period of 1 month was associated with intermittent diarrhoea or loose stool in individual animals across all treated groups during the dosing phase. In the 2-month treatment-free period, this effect was only observed in the high dose group. As expected from the primary pharmacodynamics of tremelimumab, reversible increases in the absolute number and/or percent of peripheral blood lymphocytes that correlated with increases in circulating T cells and/or B cells at 15 and 50 mg/kg/week was observed. Histopathology revealed periportal mononuclear cell infiltrates in the liver at 15 and 50 mg/kg/week, which reversed in females but not in males after a 2-month treatment-free period. Additional histopathology findings included lymphoid hyperplasia in the spleen and mesenteric lymph node, which was observed at all dose levels. Again, these changes were considered consistent with the primary pharmacodynamics of tremelimumab and reversed or showed a trend towards reversal after a 2-month treatment-free period. Based on the above findings, the 5 mg/kg/week dose was considered to be the NOAEL and the 50 mg/kg/week dose was considered to be the highest non-severely toxic dose (HNSTD) for tremelimumab in this study.

## 6-month i.v toxicity study in cynomolgus monkey (study 2004-0150, GLP)

The 6 month repeat-dose toxicity study was performed in compliance with GLP as a multi-site study with Pfizer, Kalamazoo, MI, USA as the primary site. Test formulation and analysis was performed at Pfizer, Chesterfield, MO. Plasma analysis at Pfizer, Richmond, VA, ADA analysis and TK, immunephenotyping were performed at Pfizer Groton, CT and finally the ECG analysis by an associate professor at Michigan University, East Lansing, MI, USA. The quality assurance statement includes dates of audits/inspections which cover from draft protocol across in-life phases to ECG, necropsy and study reporting. Individual quality assurance statement was provided for bioanalysis, toxicokinetics, immunophenotyping and ADA reports. No quality assurance statement was associated with the report of analysis of the dosing solutions.

The plasma concentration of tremelimumab collected from the control group animals at 0.5-hour postdose on treatment Days 1, 29 and 176 and recovery Day 99 were less than the LLOQ (0.156 Î¼g/mL).

Cynomolgus monkeys were administered a solution of tremelimumab in vehicle intravenously at doses of 5, 15, and 50 mg/kg/week for 6 months (the same dose levels as in the 1-month study).

Six monkeys/sex were assigned to the 0 (control) and 50 mg/kg/week groups (with 4 monkeys/sex designated as main study monkeys and 2 monkeys/sex designated as recovery-phase monkeys). Four monkeys/sex were assigned to the 5 and 15 mg/kg/week groups (no recovery-phase monkeys).

Dosing had to be suspended in the high dose group already after 6 or 7 weeks due to persistent diarrhoea and what seems to be rather severe adverse skin conditions. Several of the animals failed to improve after suspension of dosing and had to be euthanised despite supportive treatment of fluids, snacks, benadryl and prednisolone. On Day 79, the remaining 50 mg/kg/week monkeys (2/sex) and the control monkeys originally designated as recovery monkeys (2/sex) were placed in a newly designated 99-day recovery phase. Mortality was observed in the low dose group, which were not associated with treatment (broken forearm and peracute diarrhoea due to acute infection).

As expected from the pharmacodynamic effects of tremelimumab, changes were observed in hematological, immunophenotyping and clinical chemistry endpoints, such as increased numbers of white blood cells and lymphocytes and slightly decreased A/G ratio.

<div style=\"page-break-after: always\"></div>

A decrease in thyroid hormones (T3 and T4) in combination with increased TSH was observed in one male and 1 female in each of the mid and high dose. These changes correlated with moderate to marked thyroid atrophy as observed microscopically at day 170 at the mid dose and at Day 42 at the high dose. Immune mediated hypothyroidism was observed in clinical trials. In section 4.4 in SmPC a recommendation of monitoring for abnormal thyroid function. Hypothyroidism is classified as a very common adverse effect (13.3%) in section 4.8 of SmPC.

Tremelimumab-related histologic findings were generally consistent with the intended pharmacology of increased immune reactivity. All treated groups had a dose-related increase in the incidence of mononuclear cell infiltration and mononuclear cell inflammation in numerous organs apart from skin and intestinal system in which adverse effects were obvious by clinical signs.

Dose-related mononuclear cell infiltration was present in the cecum, colon, skin, brain (choroid plexus), oesophagus, eye (conjunctiva), heart, liver (periportal area), kidney, skeletal muscle, pancreas (acinar), parathyroid, pituitary, prostate, salivary gland, thyroid, tongue and uterus of the 5, 15, and 50 mg/kg/week groups.

Histological evaluation of the recovery animals showed minimal inflammation of salivary gland (1/4 animals) and skin (3/4 animals).

NOAEL was not determined based on clinical observations that required supportive care (prednisolone, benadryl, IV or gavage fluids, snacks) in the 5 mg/kg/week and 50 mg/kg/week groups and mononuclear cell inflammation in the kidney, skin and salivary gland of all tremelimumab-treated groups. Exposure to tremelimumab, assessed by mean Cmax and AUC values, was largely maintained throughout the dosing phase despite antidrug antibodies in individual animals and there were no consistent gender differences in mean exposure. The maximum tolerated dose was considered to be 15 mg/kg/week. At 15 mg/kg/week on Day 176 the combined-sex Cmax and AUCDay1-30 means were 444 Î¼g/mL and 212000 Î¼gÂ·h/mL, respectively. This is much higher than Cmax of 100 Âµg/ml and AUC0-28days of 19104 Âµg/mL*h in patients after a single dose of 300 mg. Exposure at 5 mg/kg/week was also 5 times higher than in patients indicating that the dose setting in this study was too high. Mean AUC130days was 94700 Âµg/mL*h in the monkey. AUC0-28days in patients was 19104 Âµg/mL*h. Hence, exposure margin to the lowest dose was (94700/30)/(19104/28) = ~ 5. Nevertheless, the majority of the findings appeared to be clinically relevant, even the palliative treatment of corticosteroids in the most affected animals.

## 2.5.4.3. Genotoxicity

No genotoxicity studies were conducted with tremelimumab.

## 2.5.4.4. Carcinogenicity

No carcinogenicity studies were conducted with tremelimumab.

## 2.5.4.5. Reproductive and developmental toxicity

Tremelimumab potential for influencing fertility and early embryonic development was not evaluated.

In the 6 months toxicity study (Study 2004-0150; GLP), mammary gland, uterus, vagina, oviduct, cervix, ovary, epididymides, prostate, seminal vesicle and testes were included in the list of organs subjected to histopathology on Day 177, where the low and mid dose animals had been dosed weekly up until sacrifice and the high dose animals had been off dosing for 99 days.

<div style=\"page-break-after: always\"></div>

As for the male reproductive organs, mononuclear cell inflammation/infiltration was observed as minimal or mild in seminal vesicle (1/4 in High dose), testes (1/4 in Low dose and Mid dose with 1/4 with mild inflammation in the high dose), epididymides (1/4 in control, 1/4 in Low dose, 1/4 in Mid dose and 2/4 in High dose). Prostate was more affected in incidence and severity compared to the other male reproductive organs, as one of the four high dose animals also showed moderate mononuclear cell inflammation.

As for the female reproductive organs, mononuclear cell inflammation/infiltration was observed as minimal or mild in uterus (0/4 in control, 3/4 in low dose, 1/4 in mid dose and 3/4 in high dose). In vagina, this finding was dose related in incidence and severity and was found to be moderate in 1/4 in mid dose and 2/4 in the high dose. In mammary gland, mononuclear infiltration was mild in 1/4 in low and mid dose and mononuclear inflammation was present in the 3/4 of the high dose animals with one classified as moderate. Other findings were only present in one animal and is considered incidental.

The embryofoetal development study of tremelimumab was a multisite study performed with Covance, MÃ¼nster, Germany as the primary site with a comprehensive audit programme covering most phases of the study (2501-001). Analysis of a stock solution took place at Covance using UV absorbance. Bioanalysis (GLP) was conducted at Nerviano Medical Sciences, Italy and toxicokinetics (GLP) at Pfizer, Groton, CT. ADA analysis was decided not to be performed, since the pharmacokinetics appeared to be minimally affected by possible neutralising antibodies towards tremelimumab. Moreover, exposure was dose-related and similar to the repeat-dose toxicity studies.

In this study, the animals were dosed once weekly with tremelimumab from day 20 to 50 of gestation (e.g. on days 20, 27, 34, 41, and 48 of gestation) at dose levels of 0, 5, 15 or 30 mg/kg/week.

Toxicokinetic samples were collected: days 20 and 48 of gestation: predose, and at approximately 0.5, 8, and 24 hours post-dose and days 27, 34, and 41, of gestation: predose and at approximately 0.5 hours post-dose, hence exposure was well-covered throughout the study.

All animals were observed once daily for behaviour and appearance. A second examination was performed on all animals later in the day as a cage side observation, including another faeces evaluation. Additionally, a detailed fur examination was performed at weekly intervals for each individual animal.

The only clinical signs assigned to treatment was slight dose-related increase in the incidence of days with diarrhoea.

Foetuses were delivered via Caesarean section and euthanised on day 100 Â± 1 of gestation, followed by examination for weight, external, visceral, and skeletal abnormalities, and weights of selected organs. Placentae were examined for weight and gross appearance.

There was no effect of treatment on the incidence of prenatal loss. There were no treatment-related changes in foetal body or organ weights, foetal body measurements, or placental weights among the live foetuses. External and visceral examination revealed several minor findings in foetuses of all groups including the control group. Type, frequency and pattern of those findings did not show any dose-relationship.

Hence, there were no signs of tremelimumab having adverse effects on the outcome of pregnancy and embryofoetal development at doses up to 30 mg/kg/week during pregnancy (GD20 to GD48) in the monkey providing sufficient margin of exposure.

A pre- and postnatal development study (PPND) study was not performed.

Studies in juvenile animals were not performed.

<div style=\"page-break-after: always\"></div>

## 2.5.4.6. Toxicokinetic data

Table 2: Key findings in toxicity studies with tremelimumab in cynomolgus monkeys

| Dose (mg/kg)                                                                      | Key Findings                                                                                                                                                                                                                                                                                                                                                                         | C'mara (Î¼g/mL)                                                                    | AUCa (Î¼g:hr/mL)                                                                   |
|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Single-dose with 3-month observation period after dosing (3 animals/sex)          | Single-dose with 3-month observation period after dosing (3 animals/sex)                                                                                                                                                                                                                                                                                                             | Single-dose with 3-month observation period after dosing (3 animals/sex)          | Single-dose with 3-month observation period after dosing (3 animals/sex)          |
| 10                                                                                | â†‘ eosinophil counts; ADA detected                                                                                                                                                                                                                                                                                                                                                    | 251                                                                               | 29000                                                                             |
| 30                                                                                | â†‘ eosinophil counts loose stools;â†‘ lymphocyte counts; ADA detected                                                                                                                                                                                                                                                                                                                   | 688                                                                               | 66900                                                                             |
| 100                                                                               | â†‘ eosinophil counts loose stools;â†‘ lymphocyte counts; ADA detected No gross or microscopic findings after 3-month observation period                                                                                                                                                                                                                                                 | 2970                                                                              | 209000                                                                            |
| 1-month repeat-dose with 2-month observation period after dosing (5 animals/sex)b | 1-month repeat-dose with 2-month observation period after dosing (5 animals/sex)b                                                                                                                                                                                                                                                                                                    | 1-month repeat-dose with 2-month observation period after dosing (5 animals/sex)b | 1-month repeat-dose with 2-month observation period after dosing (5 animals/sex)b |
| 5 (NOAEL)                                                                         | Loose stools; lymphoid hyperplasia in the spleen and mesenteric lymph nodes; ADA detected                                                                                                                                                                                                                                                                                            | 107 164                                                                           | 69500 88600                                                                       |
| 15                                                                                | Loose stools; lymphoid hyperplasia in the spleen; â†‘ peripheral blood CD3+CD4+ T cells; periportal infiltration of mononuclear cells ADA detected                                                                                                                                                                                                                                     | 357 433                                                                           | 186000 210000                                                                     |
| 50 (HNSTD)                                                                        | Loose stools with supportive care; lymphoid hyperplasia in the spleen;T peripheral blood lymphocytes; â†‘ peripheral blood CD3+CD4+ T cells, CD3+ T cells, and/or CD20+ B cells; â†“ RBC, hemoglobin, and hematocrit                                                                                                                                                                     | 1,090 1,480                                                                       | 590000 775000                                                                     |
| 6-month repeat-dose (4 or 6 animals/sex)*                                         | 6-month repeat-dose (4 or 6 animals/sex)*                                                                                                                                                                                                                                                                                                                                            | 6-month repeat-dose (4 or 6 animals/sex)*                                         | 6-month repeat-dose (4 or 6 animals/sex)*                                         |
|                                                                                   | Diarrhoea requiring supportive care; skin rash; lymphoid hyperplasia; â†‘incidence and severity ofmononuclear cell infiltration and/or inflammation in skin and tissues that have a spontaneous background incidence of mononuclear cell aggregates; ADA detected                                                                                                                      | 145 234 192                                                                       | 94700                                                                             |
| 15 (HNSTD)                                                                        | Diarrhoea; skin rash (requiring supportive care in 1 male); lymphoid hyperplasia; â†‘ incidence and severity of mononuclear cell infiltration and/or inflammation in skin and tissues that have a spontaneous background incidence of mononuclear cell aggregates; â†‘ CD3+CD4+ peripheral blood lymphocytes; inflammation of cecum and colon; thyroid atrophy; ADA detected             | 418 505 444                                                                       | 212000                                                                            |
| 50                                                                                | Diarrhoea; skin rash; lymphoid hyperplasia; â†‘ incidence and severity ofmononuclear cellinfiltrationand/orinflammationinskinand tissues that have a spontaneous background incidence of lymphocytes; inflammation of duodenum, cecum, and colon; acinar pancreatic and thyroid atrophy; ADA detected; early euthanasia due to progressive skin condition, diarrhea, and â†“ body weight | 1400 2030 NC                                                                      | 776000                                                                            |

| Embryo-Fetal Development (l6 females/group)d   | Embryo-Fetal Development (l6 females/group)d   |          |        |
|------------------------------------------------|------------------------------------------------|----------|--------|
| 5                                              | Slight increase in diarrhoea                   | 154 187  |  76800 |
| 15                                             | Slight increase in diarrhoea                   | 498 707  | 208000 |
| 30 (NOAEL)                                     | Slight increase in diarrhoea                   | 954 1230 | 454000 |

â†‘ = increased; â†“ = decreased; ADA = antidrug antibody; AuC = area under the plasma concentration-timecurve; AUCo-Tlst = area under the plasma concentration-time curve from time O to last measurable concentration; AUCDaysl-30 = area under the plasma concentration-time curve from Day 1 to Day 30; AUCDay 20-49= area under the concentration-time curve from GD 20 to GD 49; Cmax = maximum observed concentration; GD = gestation day; NC = not calculated; NOAEL = no-observed-adverse-effect level; HNSTD = highest non-severely toxic dose; RBC =redblood cell.

- In the single-dose study, AUC is AUCo-Tlast from Day 1 through Day 105. In the 1-month repeat-dose study, Cmax values are on Day 1 and Day 29 and AUC values are AUCDaysl-30 and AUCo-Thst, where Tust is from Day 1 through the end of the observation period (Day 105). In the 6 month repeat-dose study, Cmax values afe from Days 1, 29 and 176 and AUC values are AUCDaysl-30. In the EFD study, Cmax Values are from GD 20 and 48 and AUC values are AUCGD20-49
- b Tremelimumab was administered on Days 1, 8, 15,22, and 29.
- Tremelimumab at dose 1evels of 5 and 15 mg/kg was administered once weekly for 26 consecutive weeks, and at dose 1evel of 50 mg/kg once weekly for 7 consecutive weeks.
- d Tremelimumab was administered on GD 20, 27, 34, 41, and 48.

<div style=\"page-break-after: always\"></div>

## 2.5.4.7. Local Tolerance

Local tolerance was assessed in both single and repeat-dose toxicity studies. When changes were observed, these were considered procedurally related and similar in incidence and severity between control and tremelimumab dosed animals.

## 2.5.4.8. Other toxicity studies

## Tissue cross reactivity

Tissue cross reactivity studies of tissue binding of a fluorosceinated version of tremelimumab to cynomolgus monkey and human tissues was presented in reports IM645 and IM676. The studies were conducted according to GLP at Pathology Associates, a Charles River Company, Maryland, USA. The range of tissue was sufficiently broad and covered tissues of vital organs such organs of reproduction, heart and lung apart from expected target organs of gastrointestinal system, thymus, pancreas and lymph system. Human lymphocytes and human cerebellum tissue were used as positive and negative control, respectively.

The tissue binding profile of the two species was remarkably similar. The tissues binding tremelimumab were tonsils, lymphocytes in stomach, colon, spleen, lymph nodes and thymus in monkey. In human tissues it was tonsils, lymph nodes, thymus, lymphocytes in spleen, colon and small intestine with low binding in 1 out of three donors of thyroid. Tissue binding correlates with expected pharmacological effect and adverse findings in the monkey and adverse effects in patients.

## Antigenicity

Tremelimumab did give rise to antidrug antibodies in the monkeys, however with limited impact on exposure. Only few animals showed decreasing exposure over time due to neutralising antidrug antibodies. This seems to be the case in patients as well, where 12.1% tested positive for ADAs and 10.0% for neutralising ADAs. The presence of ADAs did not impact tremelimumab pharmacokinetics, and there was no apparent effect on efficacy and safety (SmPC).

## Immunotoxicity

Tremelimumab is a product, which enhance the reactivity of the immune system by inhibiting one of the down-regulating functions (CTLA4). This gives rise to general inflammation (in essence autoimmune reactions) in a range of organs - most severely in the intestinal system and skin as observed from clinical signs in the monkey. The increase in general inflammation seems to be well documented in the studies in cynomolgus monkeys also on the cellular level but may be less obvious in the patient population in which leucopenia and neutropenia are very common adverse effects.

## 2.5.5. Ecotoxicity/environmental risk assessment

Tremelimumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), tremelimumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment.

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

<div style=\"page-break-after: always\"></div>

It is acknowledged that tremelimumab inhibits CTLA4 and thereby activate T cells. A range of both in vitro , in vivo pharmacology and repeat-dose toxicity studies documents this effect, which in vivo translates into severe systemic inflammation and mortality after repeat-dosing. However, the lack of effects on Tregs ability to dampen IFNÎ³ production by activated T cells is a concern. According to e.g. Ohue, 2019, Tregs may be part of cancer tumours microenvironment to enhance tumour immunity providing a possibility for evading the activated T cells.

To further explain this trait of tremelimumab not targeting the intratumoral Tregs limiting its efficacy in cancer treatment, a scientific discussion was provided. Depletion of Tregs is dependent on ADCC of which tremelimumab is not capable mainly due to lack of FcR affinity. Selby et al. demonstrated that in mouse tumour models surrogate antibodies with higher affinity for FcR showed both the ability of depleting Tregs and enhanced antitumour activity.

There is a difference in affinity of IgG isotypes for FcR between mouse and human. IgG2a is a mouse isotype, with relatively potent Fc binding properties and is broadly equivalent to human IgG1. Additionally, human IgG2 (such as tremelimumab) has very minimal Fc binding properties and is broadly equivalent to mouse IgG1 (as used in the in vivo studies described below) (Stewart et al 2014).

This discrepancy between nonclinical and clinical findings could be summarised as translational challenges associated with: 1) differences between IgG isotypes across species; 2) type of effector cells infiltrated in tumour and expression of different FcÎ³Rs on the surface between mouse and human; 3) varying CTLA-4 expression level on Tregs.

To conclude, tremelimumab is not capable of performing ADCC and therefore does not reduce Tregs number. In the context of immune related adverse events, that property is desirable, but intratumoral Tregs might be potential target for more efficient therapy because reducing Tregs inside tumours is associated with superior antitumour activity. Tremelimumab achieves its effect by targeting CTLA-4 on activated effector T cells and should be administered in combination with anti-PD-L1 antibody. Results from nonclinical studies showed that combination is superior to monotherapy with tremelimumab in cancer treatment, but similar to anti-PD-L1 monotherapy. Totality of data suggest that not affecting Tregs might be the reason for weaker efficacy of tremelimumab.

Key in vitro and in vivo studies highlight applicantÂ´s statement that tremelimumab is not capable of affecting Tregs, however, the absence might be associated with weaker clinical outcomes and questionable contribution of tremelimumab in antitumour efficacy.

This deficiency might also explain the modest effect in the in vivo mouse cancer models.

Despite the principle of abrogating the T-cell inhibition was studied in vitro as well as in vivo , different results have been obtained from different animal disease models. A proof of principle specific for the tumour type included in the indication was not demonstrated. Thus, the relevance for the current proposed indication, uHCC, was not provided. According to e.g. Chulpanova et al 2020, the syngeneic mouse tumour models lack the complexity of the tumour microenvironment observed in patients, hence the translational value of the mouse model is questionable.

## Pharmacokinetics

As expected for a monoclonal antibody, volume of distribution is mostly confined to the vascular space as the volume of distribution in monkey demonstrate (Vss = 54 mL/kg). The major elimination pathway of tremelimumab is expected to be through protein catabolism. Pharmacokinetic drug-drug interactions of tremelimumab with other therapeutics are not anticipated.

<div style=\"page-break-after: always\"></div>

The pharmacokinetics of tremelimumab appear to be independent of dose and providing a linear relation between exposure and dose within the dose range tested (0.75 to 100 mg/kg), which also is the case in humans over the dose range of 1 to 20 mg/kg.

Antidrug antibodies (ADAs) were observed in several animals during the repeat-dose toxicology studies and in some cases appeared to increase clearance. However, the overall exposure was deemed sufficient securing the validity of the studies.

## Toxicology

Repeat-dose toxicity studies were conducted in monkeys of 1- or 6- months duration. In the 1-mont study  findings  were  consistent  with  tremelimumab  pharmacology  by  inducing  inflammation  but  not severe.

In the chronic 6-month study in cynomolgus monkeys, treatment with tremelimumab was associated with dose-related incidence in persistent diarrhoea and skin rash, scabs and open sores, which were dose-limiting. These clinical signs were also associated with decreased appetite and body weight and swollen peripheral lymph nodes. Histopathological findings correlating with the observed clinical signs included reversible chronic inflammation in the cecum and colon, and mononuclear cell infiltration in the skin and hyperplasia in lymphoid tissues. A dose-dependent increase in the incidence and severity of mononuclear cell infiltration with or without mononuclear cell inflammation was observed in the salivary gland, pancreas (acinar), thyroid, parathyroid, adrenal, heart, oesophagus, tongue, periportal liver area, skeletal muscle, prostate, uterus, pituitary, eye (conjunctiva, extra ocular muscles), and choroid plexus of the brain. No NOAEL was found in this study with animals treated with the lowest dose of 5 mg/kg/week requiring supportive care. This dose provided an exposure-based safety margin of 1-2 to clinically relevant exposure (taking species difference in potency into account).

Mononuclear cell infiltration in prostate and uterus was observed in repeat dose toxicity studies. Since animal fertility studies have not been conducted with tremelimumab, the clinical relevance of these findings for fertility is unknown. In reproduction studies, administration of tremelimumab to pregnant Cynomolgus monkeys during the period of organogenesis was not associated with maternal toxicity or effects pregnancy losses, foetal weights, or external, visceral, skeletal abnormalities or weights of selected foetal organs.

Tremelimumab potential for influencing fertility and early embryonic development was not evaluated or discussed by the applicant. According to ICH S9, effects on reproductive organs from the repeat-dose toxicity studies can make the basis for this evaluation.

Pre- and postnatal development studies were not performed, and this is acceptable and in line with ICH S9.

No studies in juvenile animals were performed, and this is acceptable since the sought indication is only including adult patents.

Tremelimumab  was  not  evaluated  for  genotoxic  potential,  and  this  is  acceptable  for  a  monoclonal antibody. Carcinogenic potential of tremelimumab was not evaluated, and this is acceptable given the indication sought in the treatment of unresectable hepatocellular carcinoma (uHCC).

## RMP

The findings observed in the pivotal repeat-dose general toxicity studies of inflammation in cecum, colon and skin were also observed in patients. Moreover, clinical chemistry findings in patients and monkeys related to liver toxicity correlated to histological changes. As for toxicity to reproduction, it is acknowledged that the EFD study in monkeys did not give rise to concerns. However, inflammatory

<div style=\"page-break-after: always\"></div>

markers were present in organs of reproduction of both male and female animals even after 99 days of recovery.

## 2.5.7. Conclusion on the non-clinical aspects

The non-clinical data submitted support the marketing authorisation of tremelimumab.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Study                                                                                                                                                                                                                                              | Phase              | Objectives of study                                                                                            | Study design and type of control     | Route of administration and dosage regimen             | Route of administration and dosage regimen                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal study                                                                                                                                                                                                                                      | Pivotal study      | Pivotal study                                                                                                  | Pivotal study                        | Pivotal study                                          | Pivotal study                                                                                                                                                                                         |
| HIMALAYA (D419CC00002) Randomised, Open- label, Multicentre Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)                                                   | III                | Efficacy and safety of durvalumab and tremelimumab in combination versus durvalumab alone and sorafenib as SoC | Randomised, open-label               | Durvalumab 1500 mg Q4W                                 | Durvalumab 1500 mg Q4W                                                                                                                                                                                |
| HIMALAYA (D419CC00002) Randomised, Open- label, Multicentre Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)                                                   | III                | Efficacy and safety of durvalumab and tremelimumab in combination versus durvalumab alone and sorafenib as SoC | Randomised, open-label               | Durvalumab 1500 mg Q4W Tremelimumab 300 mg single dose | Durvalumab 1500 mg Q4W Tremelimumab 300 mg single dose                                                                                                                                                |
| HIMALAYA (D419CC00002) Randomised, Open- label, Multicentre Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)                                                   | III                | Efficacy and safety of durvalumab and tremelimumab in combination versus durvalumab alone and sorafenib as SoC | Randomised, open-label               | Durvalumab 1500 mg Q4W Tremelimumab 75 mg 4 doses      | Durvalumab 1500 mg Q4W Tremelimumab 75 mg 4 doses                                                                                                                                                     |
| HIMALAYA (D419CC00002) Randomised, Open- label, Multicentre Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)                                                   | III                | Efficacy and safety of durvalumab and tremelimumab in combination versus durvalumab alone and sorafenib as SoC | Randomised, open-label               | Sorafenib (SoC) 400 mg BID                             | Sorafenib (SoC) 400 mg BID                                                                                                                                                                            |
| Supporting studies                                                                                                                                                                                                                                 | Supporting studies | Supporting studies                                                                                             | Supporting studies                   | Supporting studies                                     | Supporting studies                                                                                                                                                                                    |
| Study 22 (D4190C00022) A study of safety, tolerability, and clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC | I/II               | Safety, tolerability, efficacy, PK, and immunogenicity                                                         | Open-label, multiple-arm, randomised | Part 1                                                 | Tremelimumab 75 mg (1 mg/kg) Ã— 4 doses Durvalumab 1500 mg (20 mg/kg) Q4W                                                                                                                              |
| Study 22 (D4190C00022) A study of safety, tolerability, and clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC | I/II               | Safety, tolerability, efficacy, PK, and immunogenicity                                                         | Open-label, multiple-arm, randomised | Part 2A & China Cohort                                 | Durvalumab monotherapy 1500 mg (20 mg/kg) Q4W Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W Ã— 7 doses followed by Q12W Tremelimumab 75 mg (1 mg/kg) Ã— 4 doses + Durvalumab IV 1500 mg (20 mg/kg) Q4W |
| Study 22 (D4190C00022) A study of safety, tolerability, and clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC | I/II               | Safety, tolerability, efficacy, PK, and immunogenicity                                                         | Open-label, multiple-arm, randomised | Part 2B                                                | Tremelimumab IV 300 mg (4 mg/kg) Ã— 1 dose + Durvalumab IV 1500 mg (20 mg/kg) Q4W                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                 |    |                                                                                            |                             | Part 3                                                                   | Durvalumab monotherapy 1500 mg (20 mg/kg) Q4W Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W Ã— 7 doses followed by Q12W Tremelimumab 75 mg (1 mg/kg) Ã— 4 doses + Durvalumab 1500 mg (20 mg/kg) Q4W Tremelimumab 300 mg (4 mg/kg) Ã— 1 dose + Durvalumab 1500 mg (20 mg/kg) Q4W   | Durvalumab monotherapy 1500 mg (20 mg/kg) Q4W Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W Ã— 7 doses followed by Q12W Tremelimumab 75 mg (1 mg/kg) Ã— 4 doses + Durvalumab 1500 mg (20 mg/kg) Q4W Tremelimumab 300 mg (4 mg/kg) Ã— 1 dose + Durvalumab 1500 mg (20 mg/kg) Q4W   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|--------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                 |    |                                                                                            |                             | Part 4                                                                   | Durvalumab 1120 mg (15 mg/kg) + Bevacizumab 15 mg/kg Q3W                                                                                                                                                                                                                        | Durvalumab 1120 mg (15 mg/kg) + Bevacizumab 15 mg/kg Q3W                                                                                                                                                                                                                        |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Dose exploration                                                         | Dose exploration                                                                                                                                                                                                                                                                | Dose exploration                                                                                                                                                                                                                                                                |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Cohort 1                                                                 | Cohort 1                                                                                                                                                                                                                                                                        | Durvalumab 15 mg/kg Q4W Tremelimumab 3 mg/kg Q4W                                                                                                                                                                                                                                |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Cohort 2                                                                 | Cohort 2                                                                                                                                                                                                                                                                        | Durvalumab 10 mg/kg Q2W Tremelimumab 1 mg/kg Q4W                                                                                                                                                                                                                                |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Cohort 3                                                                 | Cohort 3                                                                                                                                                                                                                                                                        | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W                                                                                                                                                                                                                                |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Cohort 4                                                                 | Cohort 4                                                                                                                                                                                                                                                                        | Durvalumab 20 mg/kg Q2W Tremelimumab 3 mg/kg Q4W                                                                                                                                                                                                                                |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Dose exploration                                                         | Dose exploration                                                                                                                                                                                                                                                                | Dose exploration                                                                                                                                                                                                                                                                |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Cohort A PD-L1 High                                                      | Cohort A PD-L1 High                                                                                                                                                                                                                                                             | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W then Durvalumab 10 mg/kg Q2W                                                                                                                                                                                                   |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Cohort B PD-L1 Low or Negative                                           | Cohort B PD-L1 Low or Negative                                                                                                                                                                                                                                                  | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W then Durvalumab 10 mg/kg Q2W                                                                                                                                                                                                   |
| Study 11 (D4190C00011) Phase I multicentre, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomised, open-label | Cohort C prior IMTtreatme nt                                             | Cohort C prior IMTtreatme nt                                                                                                                                                                                                                                                    | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W then Durvalumab 10 mg/kg Q2W                                                                                                                                                                                                   |
| HAWK (D4193C00001) Phase II, multicentre, single-arm, global study of Durvalumab monotherapy in SCCHN                                                                                           | II | Efficacy of durvalumab monotherapy and health-related quality of life                      | Open-label, single-arm      | Durvalumab IV 10 mg/kg Q2W for 12 months or until progression of disease | Durvalumab IV 10 mg/kg Q2W for 12 months or until progression of disease                                                                                                                                                                                                        | Durvalumab IV 10 mg/kg Q2W for 12 months or until progression of disease                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in                                                                | Ib/II   | Evaluate the safety, antitumour activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy   | Randomised, multicentre, open-label, comparative study   | Phase 1b                                                                                                         | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in                                                                | Ib/II   | Evaluate the safety, antitumour activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy   | Randomised, multicentre, open-label, comparative study   | Phase 2                                                                                                          | Phase 2                                                                                                          |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in                                                                | Ib/II   | Evaluate the safety, antitumour activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy   | Randomised, multicentre, open-label, comparative study   | Arm A                                                                                                            | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                       |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in                                                                | Ib/II   | Evaluate the safety, antitumour activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy   | Randomised, multicentre, open-label, comparative study   | Arm B                                                                                                            | Durvalumab 10 mg/kg                                                                                              |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in                                                                | Ib/II   | Evaluate the safety, antitumour activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy   | Randomised, multicentre, open-label, comparative study   | Arm C                                                                                                            | Tremelimumab 10 mg/kg                                                                                            |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in                                                                | Ib/II   | Evaluate the safety, antitumour activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy   | Randomised, multicentre, open-label, comparative study   | Arm D                                                                                                            | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                       |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in                                                                | Ib/II   | Evaluate the safety, antitumour activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy   | Randomised, multicentre, open-label, comparative study   | Arm E                                                                                                            | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                       |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumours                    | I/II    | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                        | Open-label, multiple-arm, nonrandomised                  | Dose-escalation phase                                                                                            | Dose-escalation phase                                                                                            |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumours                    | I/II    | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                        | Open-label, multiple-arm, nonrandomised                  | Durvalumab 0.1, 0.3, 1, 3, 10 mg/kg Q2W + 15 mg/kg Q3W for up to 12 months or until PD                           | Durvalumab 0.1, 0.3, 1, 3, 10 mg/kg Q2W + 15 mg/kg Q3W for up to 12 months or until PD                           |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumours                    | I/II    | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                        | Open-label, multiple-arm, nonrandomised                  | Dose-exploration phase                                                                                           | Dose-exploration phase                                                                                           |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumours                    | I/II    | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                        | Open-label, multiple-arm, nonrandomised                  | Durvalumab 20 mg/kg Q4W for up to 12 months                                                                      | Durvalumab 20 mg/kg Q4W for up to 12 months                                                                      |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumours                    | I/II    | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                        | Open-label, multiple-arm, nonrandomised                  | Dose-expansion phase                                                                                             | Dose-expansion phase                                                                                             |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumours                    | I/II    | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                        | Open-label, multiple-arm, nonrandomised                  | Durvalumab 10 mg/kg Q2W up to 12 months                                                                          | Durvalumab 10 mg/kg Q2W up to 12 months                                                                          |
| Study 06 (D4190C00006) Phase Ib open-label study to evaluate the safety and tolerability of durvalumab (MEDI4736) in combination with tremelimumab in subjects with advanced NSCLC a | Ib      | Safety, tolerability, and efficacy of durvalumab in combination with tremelimumab                                                                                             | Open-label                                               | Dose-escalation phase - combination                                                                              | Dose-escalation phase - combination                                                                              |
| Study 06 (D4190C00006) Phase Ib open-label study to evaluate the safety and tolerability of durvalumab (MEDI4736) in combination with tremelimumab in subjects with advanced NSCLC a | Ib      | Safety, tolerability, and efficacy of durvalumab in combination with tremelimumab                                                                                             | Open-label                                               | Durvalumab IV 3-20 mg/kg Q4W or 10 mg/kg Q2W + Tremelimumab IV 1-10 mg/kg Q4W for 6 doses, then Q12W for 3 doses | Durvalumab IV 3-20 mg/kg Q4W or 10 mg/kg Q2W + Tremelimumab IV 1-10 mg/kg Q4W for 6 doses, then Q12W for 3 doses |
| Study 06 (D4190C00006) Phase Ib open-label study to evaluate the safety and tolerability of durvalumab (MEDI4736) in combination with tremelimumab in subjects with advanced NSCLC a | Ib      | Safety, tolerability, and efficacy of durvalumab in combination with tremelimumab                                                                                             | Open-label                                               | Dose-expansion phase - combination                                                                               | Dose-expansion phase - combination                                                                               |
| Study 06 (D4190C00006) Phase Ib open-label study to evaluate the safety and tolerability of durvalumab (MEDI4736) in combination with tremelimumab in subjects with advanced NSCLC a | Ib      | Safety, tolerability, and efficacy of durvalumab in combination with tremelimumab                                                                                             | Open-label                                               | Durvalumab 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W for 9 doses +                                           | Durvalumab 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W for 9 doses +                                           |

<div style=\"page-break-after: always\"></div>

| Japan Study 02 (D4190C00002) A Phase I, open-label, multicentre study to evaluate the safety, tolerability, and PK of MEDI4736 in patients with advanced solid tumours   | I   | Safety and tolerability of durvalumab monotherapy or in combination with tremelimumab         | Open-label, Non- randomised                                        | Durvalumab monotherapy Dose-escalation phase Durvalumab IV 1, 3, 10 mg/kg Q2W; 15 mg/kg Q3W; 20 mg/kg Q4W Dose-expansion phase Durvalumab IV 10 mg/kg Q2W Combination therapy Dose-expansion phase Durvalumab IV 20 mg/kg Q4W for 4                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 10 (D4190C00010) Phase I study of MEDI4736 (anti-PD-L1 antibody) in combination with tremelimumab (anti- CTLA-4 antibody) in subjects with advanced solid tumours  | I   | Safety, tolerability, and efficacy of the combination of durvalumab and tremelimumab          | Open-label                                                         | doses Combination therapy Dose-exploration phase Durvalumab IV at 20 mg/kg Q4W for 12 months AND Tremelimumab IV 1 mg/kg Q4W (7 doses) then Q12W (2 doses) OR Durvalumab IV 10 mg/kg Q2W for 12 months AND Tremelimumab 3 mg/kg Q4W (7 doses) then Q12W (2 doses) Dose-expansion phase - combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W + Tremelimumab IV 1 mg/kg Q4W for 4 doses |
| DANUBE (D419BC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with unresectable stage IV urothelial cancer                   | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomised, open-label, controlled (SoC), multicentre              | Durvalumab 1500 mg Q4W alone                                                                                                                                                                                                                                                                                                                                                                                       |
| DANUBE (D419BC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with unresectable stage IV urothelial cancer                   | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomised, open-label, controlled (SoC), multicentre              | Durvalumab 1500 mg Q4W + Tremelimumab 75 mg Q4W for 4 doses                                                                                                                                                                                                                                                                                                                                                        |
| DANUBE (D419BC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with unresectable stage IV urothelial cancer                   | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomised, open-label, controlled (SoC), multicentre              | SoC                                                                                                                                                                                                                                                                                                                                                                                                                |
| KESTREL (D419LC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with metastatic SCCHN                                         | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomised, open-label, multicentre, global study                  | Durvalumab 1500 mg Q4W alone Durvalumab 1500 mg Q4W + Tremelimumab 75 mg Q4W for 4 doses                                                                                                                                                                                                                                                                                                                           |
| KESTREL (D419LC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with metastatic SCCHN                                         | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomised, open-label, multicentre, global study                  | SoC                                                                                                                                                                                                                                                                                                                                                                                                                |
| POSEIDON (D419MC00004) Phase III, randomised, global study to determine the efficacy of durvalumab or                                                                    | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                             | Randomised, multicentre, open-label, comparative active comparator | Durvalumab 1500 mg Q3W for 4 doses + SoC, then Durvalumab 1500 mg Q4W until PD                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| durvalumab and tremelimumab in combination with platinum-based chemotherapy for first- line treatment in patients with metastatic NSCLC                                                                                                                                                                      |     |                                                                                                    |                                               | Durvalumab 1500 mg Q3W for 4 doses + SoC, then Durvalumab 1500 mg Q4W until PD Tremelimumab 75 mg Q3W for 4 doses + 1 dose at week 16   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| durvalumab and tremelimumab in combination with platinum-based chemotherapy for first- line treatment in patients with metastatic NSCLC                                                                                                                                                                      |     |                                                                                                    |                                               | SoC (abraxane + carboplatin, pemetrexed + cisplatin or carboplatin, or gemcitabine + cisplatin or carboplatin)                          |
| ATLANTIC (D4191C00003) Phase II non- comparative, open- label, multicentre, international study of MEDI4736 in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens including one platinum-                                     | II  | Efficacy, safety, tolerability, PK, and immunogenicity                                             | Open-label, single-arm, non-randomis ed       | Durvalumab 10 mg/kg Q2W for up to 12 months                                                                                             |
| PACIFIC (D4191C00001) Phase III, randomised, double-blind, placebo-controlled, multicentre, international study of durvalumab as sequential therapy in patients with locally advanced, unresectable NSCLC (Stage III) who have not progressed following definitive, platinum-based concurrent chemoradiation | III | Efficacy, safety, tolerability, PK, immunogenicity, and health- related quality of life versus SoC | Randomised, double-blind, placebo- controlled | Durvalumab 10 mg/kg Q2W for up to 12 months                                                                                             |
| MYSTIC (D419AC00001) Phase III, randomized, open-label, multicentre, global study of durvalumab monotherapy and durvalumab in combination with tremelimumab                                                                                                                                                  | III | Efficacy versus SoC                                                                                | Open-label, randomised, active comparator     | Durvalumab monotherapy Durvalumab IV 20 mg/kg Q4W                                                                                       |

<div style=\"page-break-after: always\"></div>

| compared to SoC in patients with advanced or metastatic NSCLC                                                                                                                                                                                                                                                                                                   |     |                                                                   |                                           | Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W until PD AND Tremelimumab IV 1 mg/kg Q4W for 4 doses                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NEPTUNE (D419AC00003) Phase III randomised, open-label, multicentre, global study of MEDI4736 in combination with tremelimumab therapy versus standard of care platinum-based chemotherapy in first line treatment of patients with advanced                                                                                                                    | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC | Open-label, randomised, active comparator | Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W AND Tremelimumab IV 1 mg/kg Q4W for 4 doses                                                                            |
| ARCTIC (D4191C00004) Phase III, open-label, randomised, multicentre, international study of durvalumab, given as monotherapy or in combination with tremelimumab, determined by PD-L1 expression, versus SoC in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens including one | III | Efficacy, safety, tolerability, PK, and immunogenicity versus SoC | Open-label, randomised, active comparator | Durvalumab monotherapy Durvalumab IV 10 mg/kg Q2W for up to 12 months                                                                                                                                  |
| ARCTIC (D4191C00004) Phase III, open-label, randomised, multicentre, international study of durvalumab, given as monotherapy or in combination with tremelimumab, determined by PD-L1 expression, versus SoC in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens including one | III | Efficacy, safety, tolerability, PK, and immunogenicity versus SoC | Open-label, randomised, active comparator | Tremelimumab monotherapy Tremelimumab IV 10 mg/kg IV Q4W for 24 weeks followed by 10 mg/kg IV Q12W for 24 weeks                                                                                        |
| ARCTIC (D4191C00004) Phase III, open-label, randomised, multicentre, international study of durvalumab, given as monotherapy or in combination with tremelimumab, determined by PD-L1 expression, versus SoC in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens including one | III | Efficacy, safety, tolerability, PK, and immunogenicity versus SoC | Open-label, randomised, active comparator | Combination therapy Durvalumab IV 20 mg/kg Q4W for 12 weeks then IV 10 mg/kg Q2W for 34 weeks + Tremelimumab IV 1 mg/kg Q4W for 12 weeks (maximum of 22 doses of durvalumab + 4 doses of tremelimumab) |

<div style=\"page-break-after: always\"></div>

| CASPIAN (D419QC00001) Phase III, randomised, multicentre, open- label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in   | III   | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                             | Open-label, randomised, active comparator   | Durvalumab IV 1500 mg Q3W for 4 doses then durvalumab IV 1500 mg Q4W until PD + EP for 4 cycles                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CASPIAN (D419QC00001) Phase III, randomised, multicentre, open- label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in   | III   | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                             | Open-label, randomised, active comparator   | Combination therapy (D + T + EP) Durvalumab IV 1500 mg Q3W for 4 doses then Durvalumab IV 1500 mg Q4W until PD + Tremelimumab IV 75 mg Q3W for 4 doses + EP for 4 cycles |
| CASPIAN (D419QC00001) Phase III, randomised, multicentre, open- label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in   | III   | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                             | Open-label, randomised, active comparator   | SoC EP for up to 6 cycles b                                                                                                                                              |
| CONDOR (D4193C00003) Phase II, randomised, open-label, multicentre, global study of durvalumab monotherapy, tremelimumab monotherapy, and durvalumab in combination with tremelimumab in patients with recurrent or metastatic SCCHN              | II    | Efficacy of durvalumab in combination with tremelimumab and health- related quality of life   | Open-label, randomised                      | Durvalumab monotherapy Durvalumab IV 10 mg/kg Q2W for up to 12 months                                                                                                    |
| CONDOR (D4193C00003) Phase II, randomised, open-label, multicentre, global study of durvalumab monotherapy, tremelimumab monotherapy, and durvalumab in combination with tremelimumab in patients with recurrent or metastatic SCCHN              | II    | Efficacy of durvalumab in combination with tremelimumab and health- related quality of life   | Open-label, randomised                      | Tremelimumab monotherapy Tremelimumab IV 10 mg/kg Q4W for 7 doses then Q12W for 2 doses for up to 12 months                                                              |
| CONDOR (D4193C00003) Phase II, randomised, open-label, multicentre, global study of durvalumab monotherapy, tremelimumab monotherapy, and durvalumab in combination with tremelimumab in patients with recurrent or metastatic SCCHN              | II    | Efficacy of durvalumab in combination with tremelimumab and health- related quality of life   | Open-label, randomised                      | Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W to complete 12 months of treatment + Tremelimumab IV 1 mg/kg Q4W for 4 doses             |
| EAGLE (D4193C00002) Phase III, randomised, open-label, multicentre, global study of durvalumab monotherapy and durvalumab in combination with tremelimumab versus SoC in patients with recurrent or metastatic SCCHN                              | III   | Efficacy of durvalumab monotherapy and durvalumab in combination with tremelimumab versus SoC | Open-label, randomised                      | Durvalumab monotherapy Durvalumab IV 10 mg/kg Q2W                                                                                                                        |
| EAGLE (D4193C00002) Phase III, randomised, open-label, multicentre, global study of durvalumab monotherapy and durvalumab in combination with tremelimumab versus SoC in patients with recurrent or metastatic SCCHN                              | III   | Efficacy of durvalumab monotherapy and durvalumab in combination with tremelimumab versus SoC | Open-label, randomised                      | Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W for 12 months or until PD + Tremelimumab IV 1 mg/kg Q4W for 4 doses                      |

<div style=\"page-break-after: always\"></div>

| D4884C00001 Phase II multicentre, open-label study of tremelimumab monotherapy in patients with advanced solid tumours                                                                                            | II   | Efficacy and safety   | Open-label                                   | Durvalumab monotherapy Durvalumab IV 1500 mg Q4W for up to 12 months                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------------------|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| D4884C00001 Phase II multicentre, open-label study of tremelimumab monotherapy in patients with advanced solid tumours                                                                                            | II   | Efficacy and safety   | Open-label                                   | Tremelimumab monotherapy Tremelimumab IV 750 mg Q4W for 7 doses then Q12W for 2 doses                                                                  |
| D4884C00001 Phase II multicentre, open-label study of tremelimumab monotherapy in patients with advanced solid tumours                                                                                            | II   | Efficacy and safety   | Open-label                                   | Combination therapy Durvalumab IV 1500 mg Q4W for 4 doses + Tremelimumab IV 75 mg/kg Q4W for 4 doses then Durvalumab IV 1500 mg Q4W for up to 8 months |
| DETERMINE (D4880C00003) Phase IIb, randomised, double-blind study comparing tremelimumab to placebo in second- or third-line treatment of subjects with unresectable pleural or peritoneal malignant mesothelioma | IIb  | Efficacy and safety   | Randomised, double-blind, placebocontroll ed | Tremelimumab monotherapy Tremelimumab IV 10 mg/kg Q4W for 7 doses (6 months) then Q12W                                                                 |

a  For Study 06, an NCA was done for an interim dataset (DCO 28 February 2017). As the final dataset (DCO 19 November 2019) only had 343 additional samples (all in the dose-expansion phase) compared to the interim, it was determined that an additional NCA for the final dataset was not required. This was supported by the sparse sampling in the dose-expansion phase patients (~2 samples per patient per treatment), which would contribute little to no value to a NCA, which typically relies on intense sampling in order to accurately estimate key PK parameters such as half-life and AUC. Therefore, only the results of the interim NCA are presented. b  Patients in the EP alone group were permitted an additional 2 cycles of EP (up to 6 cycles total) per the

Investigator's discretion.

Abbreviations; ALK, anaplastic lymphoma kinase; AUC, area under the serum concentration-time curve; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4; D, durvalumab; DCO, data cutoff; EGFR, epidermal growth factor receptor; EP, etoposide and either carboplatin or cisplatin; IV, intravenous; NCA, noncompartmental analysis; NSCLC, non-small cell lung cancer; PD, progression of disease; PD-L1, programmed cell death ligand-1; PK, pharmacokinetics; Q2W, every 2 weeks; Q3W, every 3 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; SCCHN, head and neck squamous cell carcinoma; SoC, standard of care; T, tremelimumab; TK, tyrosine kinase.

All studies included male and female patients aged 18 years and older with advanced solid tumours. No PK data has been obtained from healthy volunteers.

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

Tremelimumab and durvalumab are human monoclonal antibodies (mAb) that act as checkpoint inhibitors with distinct yet complementary mechanisms of action with respect to enhancing the antitumour immune response.

In 2018 durvalumab (Imfinzi) was approved in the EU as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on â‰¥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy

The applicant is currently seeking marketing approval for the use of a single priming dose of tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).

<div style=\"page-break-after: always\"></div>

The PK of durvalumab and tremelimumab have been investigated in patients enrolled in the studies listed below.

Data for ISS PK/anti-drug antibody (ADA) and for PopPK were taken from the following studies (most of these studies provided data for both durvalumab and tremelimumab but some for durvalumab or tremelimumab only, as indicated below):

HIMALAYA (D419CC00002) Phase III

Study 22 (D4190C00022) Phase I/II

PACIFIC (D4191C00001) Phase III (durvalumab only)

DETERMINE (D4880C00003) Phase IIb (tremelimumab only)

ATLANTIC (D4191C00003) Phase II (durvalumab only)

D4884C00001 Phase II

Study 1108 (CD-ON-MEDI4736-1108) Phase I/II (durvalumab only)

Study 06 (D4190C0000) Phase Ib

Japan Study 02 (D4190C00002) Phase I

Study 10 (D4190C00010) Phase I

Additional data for ISS PK/ADA outputs only were taken from the following studies: MYSTIC (D419AC00001) Phase III ARCTIC (D4191C00004) Phase III EAGLE (D4193C00002) Phase III NEPTUNE (D419AC00003) Phase III DANUBE (D419BC00001) Phase III KESTREL (D419LC00001) Phase III Study 21 (D4190C00021) Phase II HAWK (D4193C00001) Phase II (durvalumab only) CONDOR (D4193C00003) Phase II

Study 11 (D4190C00011) Phase I

Additional data for PopPK only were taken from the following studies: POSEIDON (D419MC00004) Phase III CASPIAN (D419QC00001) Phase III Details of the studies are described in table 1

## Key tremelimumab PK results from studies conducted in patients with unresectable hepatocellular carcinoma (uHCC)

## HIMALAYA (D419CC00002)

Himalaya was a randomised, open-label, multicentre Phase III study of durvalumab and tremelimumab as first-line treatment in patients with advanced uHCC.

<div style=\"page-break-after: always\"></div>

Patients were randomly assigned (1:1:1:1) to treatment with one of the following 4 treatment arms:

- durvalumab 1500 mg every 4 weeks (Q4W) (D)
- tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W (T300 + D)
- tremelimumab 75 mg Q4W Ã— 4 doses + durvalumab 1500 mg Q4W (T75 + D)
- sorafenib 400 mg twice daily (BID) (S)

Patients were stratified according to macrovascular invasion (yes or no), etiology of liver disease (confirmed HBV vs confirmed HCV vs others), and Eastern Cooperative Oncology Group (ECOG) PS (0 vs 1).

The study population included adult patients (aged â‰¥ 18 years) with confirmed uHCC (based on histopathology) with preserved liver function (Child-Pugh Score class A), Barcelona Clinic

Liver Cancer stage B (not eligible for locoregional therapy) or C, ECOG PS score of 0 or 1, with a lifeexpectancy of Ëƒ 12 weeks, and no prior systemic therapy for uHCC. A total of 1324 patients were randomised to one of the four treatment arms in the study.

## Tremelimumab PK Results and Conclusions

Tremelimumab PK data were available for a total of 528 patients (386 in the T300 + D arm and 142 in the T75 + D arm). Eighteen patients were excluded from the tremelimumab PK Analysis Set either because they did not receive study treatment or because they had no post-dose data.

No formal noncompartmental analysis was conducted due to the sparse PK sampling scheme in this study.

Following a single dose of tremelimumab 300 mg plus durvalumab Q4W, geometric mean concentrations (n, geometric CV%) were: Cycle 2 trough = 10.7 Î¼ g/mL (221, 84.7%) and follow up (3 months) = 0.5 Î¼ g/mL (55, 140.4%) (Table 2).

Tremelimumab PK concentrations were within the expected exposure range following a single 300 mg dose.

Following tremelimumab 75 mg Q4W in combination with durvalumab Q4W, geometric mean concentrations (n, geometric CV%) were: Cycle 2 trough = 3.2 Î¼ g/mL (132, 67.8%); Cycle 4 trough = 4.3 Î¼ g/mL (86, 85.4%); and follow-up (3 months) = 0.4 Î¼ g/mL (30, 106.1%) (Table 3:).

Tremelimumab PK concentrations were within the expected exposure range following 75 mg Q4W.

Overall, trough concentrations of tremelimumab at Cycle 2 were 3.3 times higher in the T300 + D arm than the T75 + D arm. In addition, similar tremelimumab exposures were observed in patients rechallenged with tremelimumab.

<div style=\"page-break-after: always\"></div>

Table 3: Summary of tremelimumab concentrations over time ( Î¼ g/mL) (PK Analysis Set) (HIMALAYA)

|                              | Numberofpatients   | Numberofpatients   |
|------------------------------|--------------------|--------------------|
| Analysistimepoint/parameter  | T300+D (N = 388)   | T75+D (N = 142)    |
| Cycle1pre-infusion           |                    |                    |
| N                            | 380                | 140                |
| Mean (SD)                    | NQ (NC)            | NQ (NC)            |
| Median (min, max)            | NQ (NQ, 135.7)     | NQ (NQ, 3.8)       |
| CV%                          | NC                 | NC                 |
| Geometric mean a             | NC                 | NC                 |
| Geometric CV% a              | NC                 | NC                 |
| Numberof BLQ                 | 360                | 129                |
| Cycle 1 post-infusion        |                    |                    |
| N                            | 379                | 0                  |
| Mean (SD)                    | 92.70 (34.30)      |                    |
| Median (min, max)            | 90.80 (0.2,217.1)  |                    |
| CV%                          | 37.0               |                    |
| Geometric mean a             | 78.0               |                    |
| Geometric CV% a              | 117.2              |                    |
| Number of BLQ                | 5                  | 0                  |
| Cycle2pre-infusion           |                    |                    |
| N                            | 221                | 132                |
| Mean (SD)                    | 13.00 (8.40)       | 3.70 (2.50)        |
| Median (min, max)            | 12.90 (0.2, 97.2)  | 3.40 (0.2, 19.0)   |
| CV%                          | 64.3               | 66.5               |
| Geometric mean a             | 10.7               | 3.2                |
| Geometric CV% a              | 84.7               | 67.8               |
| Number of BLQ                | 1                  | 1                  |
| Cycle4pre-infusion           |                    |                    |
| N                            | 0                  | 86                 |
| Mean (SD)                    |                    | 5.30 (3.30)        |
| Median (min, max)            |                    | 4.60 (0.3, 21.0)   |
| CV%                          |                    | 62.3               |
| Geometricmean a              |                    | 4.3                |
| Geometric CV% a              |                    | 85.4               |
| Numberof BLQ                 | 0                  | 0                  |
| Cycle4post-infusion          |                    |                    |
| N                            | 113                | 0                  |
| Mean (SD)                    | 4.2 (16.50)        |                    |
| Median (min, max)            | 1.30 (0.2, 117.2)  |                    |
| CV%                          | 396.3              |                    |
| Geometric mean a             | 1.3                |                    |
| Geometric CV% a              | 156.5              |                    |
| Number of BLQ                | 8                  | 0                  |
| 3-monthfollow-up (Follow-up) |                    |                    |
| N                            | 55                 | 30                 |
| Mean (SD)                    | 0.80 (0.90)        | 0.60 (0.50)        |
| Median (min, max)            | 0.50 (0.2,4.4)     | 0.40 (0.2,1.8)     |
| CV%                          | 106.2              | 86.8               |
| Geometric mean a             | 0.5                | 0.4                |
| Geometric CV% a              | 140.4              | 106.1              |
| Number of BLQ                | 18                 | 9                  |

a  Calculated using log transformed data.

At a time point where less than or equal to 50% of the concentration values were NQ, all NQ values were set to LLOQ, and all descriptive statistics were calculated accordingly. At a time point where more than 50% (but not all) of the values were NQ, the gmean and gCV% was set to NC. The maximum value was reported from the individual data, and the minimum, mean, and median were set to NQ. If all concentrations are NQ at a time point, no descriptive statistics were calculated for that time point. The gmean, minimum, mean, median, and maximum are reported as NQ and the gCV% as NC.

Abbreviations; BLQ, below the limit of quantitation (&lt; 0.156 Î¼ g/mL); CV, coefficient of variation; LLOQ, Lower Limit of Quantification; max, maximum; min, minimum; N/A, not available; NC, Not calculated; NQ, Not Quantifiable; PK, pharmacokinetic; Q4W, every 4 weeks; SD, standard deviation; T75 + D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300 + D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

## Study 22 (D4190C00022)

Study 22 was a Phase I/II, randomised, open-label, multicentre study examining the safety, tolerability, and clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in patients with advanced uHCC.

<div style=\"page-break-after: always\"></div>

## Tremelimumab PK Results and Conclusions

In Parts 2 and 3 of the study, the PK Analysis Set comprised 319 patients (99 in the D arm,74 in the T300 + D arm, 66 in the T arm, and 80 in the T75 + D arm). At the final data cutoff (DCO), 603 PK data points from the evaluable PK population were available for a total of 216 patients following tremelimumab administered over 60 minutes (1 mg/kg: 81 data points from 36 patients; 10 mg/kg: 94 data points from 33 patients; 75 mg: 134 data points from 43 patients; 300 mg: 187 data points from 72 patients; and 750 mg: 107 data points from 32 patients).

Table 4 summarises the tremelimumab data.

Table 4: Summary of PK parameters of tremelimumab following IV dose of tremelimumab to patients with advanced hepatocellular carcinoma (Parts 2 and 3) (PK Analysis Set) (Study 22)

| Summary   | Cmax (Î¼g/mL)   | Cmax (Î¼g/mL)   | Cmax (Î¼g/mL)   | Ctrough (Î¼g/mL)   | Ctrough (Î¼g/mL)   | Ctrough (Î¼g/mL)   |
|-----------|----------------|----------------|----------------|-------------------|-------------------|-------------------|
| Summary   | Week 1         | Week 13        | Week 25        | Week 5            | Week 13           | Week 25           |
| N         | 34             | 12             | äºŒ              | ä¸€                 | 14                |                   |
| AM        | 23.06          | 23.87          | äºŒ              | äºŒ                 | 5.478             | ä¸€                 |
| SD        | 6.175          | 4.964          | ä¸€              | ä¸€                 | 2.964             |                   |
| ACV (%)   | 26.8           | 20.8           | äºŒ              | äºŒ                 | 54.1              | äºŒ                 |
| Median    | 22.95          | 21.95          | äºŒ              | äºŒ                 | 5.720             |                   |
| Minimum   | 10.30          | 17.40          | äºŒ              | äºŒ                 | 0.7780            |                   |
| Maximum   | 36.80          | 35.40          | äºŒ              | äºŒ                 | 12.16             |                   |
| GM        | 22.22          | 23.43          | äºŒ              | äºŒ                 | 4.545             | ä¸€                 |
| GCV (%)   | 29.1           | 19.8           | äºŒ              | äºŒ                 | 82.1              | äºŒ                 |
| 95% CI    | (20.12, 24.54) | (20.69, 26.54) |                |                   | (3.003, 6.879)    |                   |
| N         | 31             | 6              | 5              | äºŒ                 | 14                | 7                 |
| AM        | 221.0          | 255.2          | 203.2          |                   | 48.61             | 39.56             |
| SD        | 62.82          | 121.6          | 20.24          |                   | 22.68             | 7.832             |
| ACV (%)   | 28.4           | 47.6           | 10.0           | äºŒ                 | 46.7              | 19.8              |
| Median    | 209.1          | 275.0          | 211.7          | ä¸€                 | 41.85             | 42.82             |
| Minimum   | 150.2          | 31.80          | 173.3          | äºŒ                 | 15.80             | 24.64             |
| Maximum   | 502.0          | 388.0          | 225.2          | äºŒ                 | 93.00             | 47.22             |
| GM        | 214.7          | 203.7          | 202.4          | äºŒ                 | 43.90             | 38.78             |
| GCV (%)   | 23.3           | 116.5          | 10.3           | äºŒ                 | 50.5              | 22.9              |
| ID %S6    | (197.3, 233.6) | (77.08, 538.3) | (178.2, 229.9) | ä¸€                 | (33.34, 57.82)    | (31.47, 47.78)    |
| N         | 40             | 11             | ä¸€              | 32                | 11                |                   |
| AM        | 30.91          | 29.54          | äºŒ              | 4.862             | 5.867             |                   |
| SD        | 21.96          | 9.870          | äºŒ              | 2.402             | 3.606             | äºŒ                 |
| ACV (%)   | 71.0           | 33.4           | äºŒ              | 49.4              | 61.5              |                   |
| Med       | 25.65          | 30.00          | äºŒ              | 4.260             | 7.100             | äºŒ                 |
| Min       | 14.10          | 14.10          | ä¸€              | 0.3820            | 0.5740            |                   |
| Max       | 129.5          | 42.70          | äºŒ              | 10.52             | 10.42             | äºŒ                 |
| GM        | 26.99          | 27.80          | äºŒ              | 4.178             | 4.113             |                   |
| GCV (%)   | 49.6           | 39.9           | ä¸€              | 71.1              | 146.0             |                   |

<div style=\"page-break-after: always\"></div>

| Dose   | Summary   | Cmax(Î¼g/mL)    | Cmax(Î¼g/mL)    | Cmax(Î¼g/mL)   | Ctrough(Î¼g/mL)   | Ctrough(Î¼g/mL)   | Ctrough(Î¼g/mL)   |
|--------|-----------|----------------|----------------|---------------|------------------|------------------|------------------|
| Dose   | Summary   | Week 1         | Week 13        | Week 25       | Week 5           | Week 13          | Week 25          |
| Dose   | 95%CI     | (23.23, 31.36) | (21.47, 35.99) |               | (3.317, 5.262)   | (2.006, 8.430)   |                  |
|        | N         | 68             |                | ä¸€             | 48               | äºŒ                |                  |
|        | AM        | 103.4          |                | ä¸€             | 13.08            |                  |                  |
|        | SD        | 34.31          | ä¸€              | äºŒ             | 5.437            | ä¸€                |                  |
|        | ACV (%)   | 33.2           | ä¸€              | ä¸€             | 41.6             | ä¸€                |                  |
|        | Median    | 95.75          | ä¸€              | äºŒ             | 13.23            | äºŒ                |                  |
|        | Minimum   | 57.70          | äºŒ              | äºŒ             | 2.740            | äºŒ                |                  |
|        | Maximum   | 239.0          | äºŒ              | äºŒ             | 26.32            |                  |                  |
|        | GM        | 99.06          | äºŒ              | äºŒ             | 11.67            | ä¸€                |                  |
|        | GCV (%)   | 28.6           | äºŒ              | äºŒ             | 57.3             | äºŒ                |                  |
|        | 95% CI    | (92.55, 106.0) |                |               | (9.997, 13.62)   |                  |                  |
|        | N         | 29             | 11             | ä¸€             | 23               | 16               | 5                |
|        | AM        | 241.8          | 260.0          |               | 32.43            | 37.79            | 35.96            |
|        | SD        | 101.9          | 130.1          | äºŒ             | 18.81            | 23.84            | 5.806            |
|        | ACV (%)   | 42.1           | 50.0           | äºŒ             | 58.0             | 63.1             | 16.1             |
|        | Median    | 219.7          | 232.0          |               | 26.12            | 34.52            | 33.14            |
|        | Minimum   | 130.3          | 52.00          | äºŒ             | 4.092            | 4.718            | 30.73            |
|        | Maximum   | 471.0          | 487.5          | ä¸€             | 83.20            | 98.90            | 44.90            |
|        | GM        | 224.8          | 225.2          | äºŒ             | 26.69            | 31.25            | 35.61            |
|        | GCV (%)   | 39.0           | 68.2           | äºŒ             | 81.6             | 78.1             | 15.6             |
|        | 95%CI     | (194.8, 259.4) | (148.7, 341.2) |               | (19.59, 36.35)   | (21.63, 45.13)   | (29.38, 43.16)   |

ACV, arithmetic coefficient of variation is calculated in the original scale with the equation: 100 Ã— (SD/AM); AM, arithmetic mean; CI, confidence interval of the geometric mean; Cmax, concentration at the end of infusion (TAD &lt; 1 day) in that visit; Ctrough, predose concentration (40 day &lt; TAD &gt; 23 day) in that visit; GCV, geometric coefficient of variation is calculated in the natural log scale; with the equation: 100 Ã— sqrt(exp( Ïƒ 2) - 1), where Ïƒ 2 is the observed variance on the natural log scale; GM, geometric mean; IV, intravenous; N, number of patients; PK, pharmacokinetic; Q4W, every 4 weeks; SD, standard deviation; TAD, time after dose.

Similar exposures were observed following the weight-based 1 mg/kg and the equivalent fixed 75 mg dose. Additionally, similar exposures were observed following the weight-based 10 mg/kg and the equivalent fixed 750 mg dose.

Maximum serum concentration (Cmax) values were 3.3-fold (arithmetic mean) or 3.7-fold (geometric mean) higher following a 300 mg dose compared to a 75 mg dose. Exposures increased generally dose-proportionally with increasing weight-based doses from 1 to 10 mg/kg and fixed doses from 75 to 750 mg, respectively.

The data in Error! Reference source not found. above show that there was no observed accumulation of tremelimumab (Cmax or trough serum concentration [Ctrough]) following repeated dosing in any of the cohorts and the geometric mean of the accumulation index ranged from 0.949 to 1.17, where adequate data were available for assessment. The Cmax (geometric mean) for tremelimumab in the T300 + D arm was approximately 3.7 times that in the T75 + D arm.

## Dose rationale for tremelimumab and durvalumab in HIMALAYA

Dose selection for tremelimumab and durvalumab in HIMALAYA was aligned with results from the dose-finding results of Study 22, in which 1500 mg durvalumab Q4W was administered in combination with tremelimumab for 4 cycles followed by durvalumab 1500 mg Q4W monotherapy.

A fixed dose of tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W for an average body weight of 75 kg) is predicted to result in similar AUC and only provide a modest difference in median peak and trough levels at steady state compared to tremelimumab 1 mg/kg Q4W, based on simulations in a Population PK model developed for tremelimumab using data from Study 10, Japan Study 02, Study 06, BASKET, DETERMINE, and POSEIDON. The Population PK model indicated that body weight is not a significant covariate on the PK of tremelimumab.

Administration of tremelimumab in combination with durvalumab has demonstrated significant elevations in proliferating CD4 + Ki67 + T cell quantities (Study 06 and Study 10). These elevations were proportional to the tremelimumab dose (Study 06). A dose of tremelimumab 1 mg/kg Q4W in combination with durvalumab 15 or 20 mg/kg Q4W was sufficient to achieve the significant elevation in

<div style=\"page-break-after: always\"></div>

proliferating T cell quantities. It was hypothesised that a single high-dose of tremelimumab may provide a stronger pharmacodynamic effect in uHCC than tremelimumab 1 mg/kg, while potentially avoiding the toxicity typically observed with repeated cycles of tremelimumab administration. This led to the proposal of evaluating a higher dose of tremelimumab in uHCC, achieved by combining the 4 doses of tremelimumab 1 mg/kg from the T75 + D regimen into a single priming dose of tremelimumab 4 mg/kg added to the first treatment cycle of durvalumab 20 mg/kg Q4W. Based on PK simulations, the predicted Cmax for a single dose of tremelimumab 4 mg/kg was approximately 3- to 4fold higher than the predicted Cmax for tremelimumab 1 mg/kg (compared to any of the 4 tremelimumab doses in the T75 + D regimen). Based on the expectation of minor impact of body weight on PK exposure, a fixed dose of tremelimumab 300 mg was considered equivalent to tremelimumab 4 mg/kg. In Study 22, pharmacodynamic results revealed that patients receiving T300 + D or T demonstrated the highest peak CD8 + Ki67 + T cell counts, and this corresponded with best overall responses of complete or partial response.

HIMALAYA results confirmed that durvalumab 1500 mg Q4W with tremelimumab 300 mg as a priming dose followed by durvalumab 1500 mg Q4W monotherapy is an appropriate dose for patients with uHCC by showing a clinically meaningful efficacy and manageable safety profile following this dosing regimen.

## Bioanalytical Methods

Bioanalysis methods for quantitation of tremelimumab drug concentration, anti-drug antibodies (ADA), and neutralizing antibodies (nAb) were developed and validated.

## Population PK analyses for tremelimumab and durvalumab

The tremelimumab population PK analysis was updated with sparse data from Study 22 and HIMALAYA in HCC patients and pooled with the previous dataset (Studies D4190C00002, D4190C00006, D4190C00010, DETERMINE, BASKET and POSEIDON). 7039 serum PK samples from 2406 patients administered tremelimumab were available in the final dataset for analysis of which 1801 samples came from HCC patients. Structurally, the final model remained the same as the previous model: a 2compartment model with linear CL and an additional time-dependent CL component for patients on combination therapy only. Residuals were described by a combined additive and proportional error model. The following covariates were identified as statistically significant and included in the final model: body weight and sex on both CL and V1; albumin, primary indication and combination therapy (chemotherapy vs. no chemotherapy) on CL.

The final model was evaluated by means of non-parametric bootstrap analysis, RSEs, GOF-plots and pcVPCs.

Parameter estimates of the final model for tremelimumab and selected diagnostic plots are shown in Table 5 and Figure 2 and Figure 3.

<div style=\"page-break-after: always\"></div>

Table 5: Tremelimumab PopPK model parameter estimates (final model)

| Parameter                   | Estimate                    | RSE (%)   | bootstrap 95%CI    | Shrinkage (%)   | Unit   |
|-----------------------------|-----------------------------|-----------|--------------------|-----------------|--------|
| Population Parameter        |                             |           |                    |                 |        |
| CL                          | 0.295                       | 1.35      | [0.283 ; 0.308]    |                 | L/day  |
| V1                          | 3.59                        | 1.11      | [3.54 ; 3.65]      |                 | L      |
| Q                           | 0.480                       | 6.94      | [0.383 ;0.624]     |                 | L/day  |
| V2                          | 2.69                        | 3.55      | [2.48 ; 2.98]      |                 | L      |
| Tmax change CL              | -0.134                      | 15.3      | [-0.283 ; -0.0219] |                 | L/day  |
| TC50 change CL              | 63.1                        | 7.22      | [4.06 ; 468]       |                 | days   |
| Covariate                   |                             |           |                    |                 |        |
| Body weight on V1           | 0.467                       | 7.99      | [0.404 ; 0.539]    |                 |        |
| Sex on V1                   | -0.116                      | 15.4      | [-0.144 ; -0.0892] |                 |        |
| Body weight on CL           | 0.384                       | 10.5      | [0.304 ; 0.469]    |                 |        |
| Albumin on CL               | -0.780                      | 5.74      | [-0.896 ; -0.669]  |                 |        |
| Sex on CL                   | -0.0985                     | 18.4      | [-0.135 ; -0.0634] |                 |        |
| Comb2 on CL                 | -0.124                      | 15.2      | [-0.166 ; -0.0772] |                 |        |
| Primary tumor 6-7 on CL     | -0.146                      | 17.2      | [-0.202 ; -0.0872] |                 |        |
| Interindividual Variability | Interindividual Variability |           |                    |                 |        |
| ETA CL                      | 0.108                       | 3.67      | [0.0873 ; 0.131]   | 21.8            |        |
| Covariance CL-V1            | 0.0621                      | 3.84      | [0.0420 ; 0.0862]  |                 |        |
| ETA V1                      | 0.0619                      | 1.71      | [0.0377 ; 0.0932]  | 24.3            |        |
| Covariance CL-V2            | 0.0898                      | 9.68      | [0.0468 ; 0.138]   |                 |        |
| Covariance V1-V2            | 0.112                       | 7.48      | [0.0694 ; 0.158]   |                 |        |
| ETA V2                      | 0.212                       | 12.3      | [0.119 ; 0.312]    | 28.3            |        |
| ETA Tmax                    | 1.42                        | 10.6      | [0.784 ; 8.14]     | 65.2            |        |
| Residual Variability        |                             |           |                    |                 |        |
| Proportionalcomponent       | 0.285                       | 0.799     | [0.271 ; 0.300]    | 18.3            |        |
| Additive component          | 0.369                       | 0.915     | [0.134 ; 0.506]    | 18.3            | Î¼g/mL  |

Source: az-tremelimumab-pk-model-himalaya-V1.0.Rmd, Reference: 04e0e5:7ef181

CI=confidence interval, CL=clearance, Comb2=durvalumab, tremelimumab and chemotherapy (standard of care), as compared to treatment arms without chemotherapy, ETA=random effect, IIV=inter-individual variability, PK=pharmacokinetics, V1=central volume of distribution, primary indication 6=biliary tract carcinoma, primary indication 7=esophagus carcinoma, Q=inter-compartmental clearance, V2=peripheral volume of distribution, RSE=relative standard error, TC50=time to 50% clearance reduction, Tmax=maximum change of CL over time.

Source: Table 16, Population PK and Exposure-Response Report, Module 5.3.3.5

<div style=\"page-break-after: always\"></div>

Figure 2: Final model GOF plots for serum tremelimumab concentration: observations vs predictions

<!-- image -->

Note:The blue line is a trend line through thedata points,and theblue area is the95%confidenceinterval around it.

GOF,goodness-of-fit.

Source: Figure 8, Population PK and Exposure-Response Report, Module 5.3.3.5

Figure 3: pcVPC of the final model vs time after dose - HIMALAYA Study

<!-- image -->

Note: The solid and dashed lines represent the median, 5th, and 95th percentiles of the observations; the shaded red and blue areas represent the 95% confidence interval of the median, 5th, and 95th percentiles predicted by the model.

Abbreviations: CI=confidence interval, pc VPC=prediction-corrected visual predictive check

Source: /projects/qcp/QCP\\_MODELING/ONC/durvalumab/poppk\\_20210729\\_himalaya/Scripts/s04\\_vpc.R

The durvalumab population PK model was updated with sparse data from HIMALAYA and Study 22 and pooled with the previous dataset (Studies CASPIAN, PACIFIC, ATLANTIC, POSEIDON and CD-ON-MEDIA-

<div style=\"page-break-after: always\"></div>

4736-1108). The final model of durvalumab PK was a 2-compartment model with time-dependent CL. The final model included the following covariate effects on CL: WT, ALB, combination therapy, sex, CrCL, LDH, ECOG and tumour type; and on V1: WT and sex. The final model was evaluated by means of nonparametric bootstrap analysis, RSEs, GOF-plots and pcVPCs. Parameter estimates of the final model for durvalumab and selected diagnostic plots are shown in Table 6 and Figure 4 and Figure 5.

Table 6: Population PK model parameter estimates durvalumab (final model)

| Parameter                  | Estimate                   | RSE (%)   | bootstrap 95%CI      | Shrinkage (%)   | Unit   |
|----------------------------|----------------------------|-----------|----------------------|-----------------|--------|
| PopulationParameter        |                            |           |                      |                 |        |
| CL                         | 0.277                      | 2.01      | [0.263 ; 0.292]      | \"               | L/day  |
| V1                         | 3.45                       | 0.807     | [3.40 ; 3.49]        | \"               | L      |
| V2                         | 2.13                       | 2.02      | [1.98 ; 2.29]        |                 | L      |
| Q                          | 0.469                      | 5.15      | [0.411 ; 0.535]      |                 | L/day  |
| Tmax                       | -0.372                     | 4.99      | [-0.419 ; -0.327]    |                 | L/day  |
| TC50                       | 88.7                       | 9.92      | [58.3 ; 150]         |                 | day    |
| LAM                        | 1.00                       |           |                      | \"               |        |
| Covariate                  |                            |           |                      |                 |        |
| Albumin on CL              | -0.659                     | 2.87      | [-0.834 ; -0.506]    |                 | \"      |
| Creatinine clearance on CL | 0.121                      | 15.6      | [0.0800 ; 0.162]     |                 |        |
| ECOG status on CL          | -0.0516                    | 20.7      | [-0.0720 ; -0.0278]  |                 |        |
| LDH on CL                  | 0.0442                     | 23.3      | [0.0208 ; 0.0642]    |                 |        |
| Sex on CL                  | -0.149                     | 7.95      | [-0.172 ; -0.126]    |                 |        |
| COMB1 on CL                | -0.0459                    | 27.0      | [-0.0688 ; -0.0195]  |                 |        |
| COMB2on CL                 | -0.0417                    | 43.2      | [-0.0886 ; 0.00746]  |                 |        |
| Body weight on CL          | 0.376                      | 8.32      | [0.317 ; 0.443]      |                 |        |
| Tumor type 1 on CL         | -0.0393                    | 46.1      | [-0.0750 ; -0.00306] |                 |        |
| Tumor type 2 on CL         | 0.0622                     | 55.8      | [-0.0131 ; 0.137]    |                 |        |
| Tumor type 3 on CL         | 0.0472                     | 46.1      | [0.00497 ; 0.0932]   |                 |        |
| Sex on V1                  | -0.140                     | 7.60      | [-0.163 ; -0.118]    |                 |        |
| Body weight on V1          | 0.499                      | 5.01      | [0.449 ; 0.549]      |                 |        |
| InterindividualVariability | InterindividualVariability |           |                      |                 |        |
| ETA CL                     | 0.0896                     | 2.85      | [0.0803 ; 0.0982]    | 17.6            |        |
| Cov CL-V1                  | 0.0389                     | 5.34      | [0.0338 ; 0.0441]    |                 |        |
| ETA V1                     | 0.0524                     | 3.32      | [0.0451 ; 0.0598]    | 29.9            |        |
| ETA Tmax                   | 0.0665                     | 9.03      | [0.0436 ; 0.109]     | 59.3            |        |
| ResidualVariability        |                            |           |                      |                 |        |
| Proportionalcomponent      | 0.250                      | 0.541     | [0.241 ; 0.258]      | 15.0            |        |
| Additive component         | 4.28                       | 6.70      | [3.39 ; 5.29]        | 15.0            | Î¼g/mL  |

<div style=\"page-break-after: always\"></div>

Figure 4: Final durvalumab PopPK model - basic GOF

<!-- image -->

Note:Thebluelineis a trendline through thedatapoints,and theblue area isthe95%CIaroundit. Source: Figure 2,Population PK and Exposure-Response Report, Module 5.3.3.5. CI,confidenceinterval;CWRES=conditional weightedresiduals.

<div style=\"page-break-after: always\"></div>

Figure 5: pcVPC of the final model vs time after dose - HIMALAYA Study

<!-- image -->

Note: The solid and dashed lines represent the median, 5th, and 95th percentiles of the observations; the shaded red and blue areas represent the 95% confidence interval of the median, 5th, and 95th percentiles predicted by the model.

Abbreviations: CI=confidence interval, pcVPC=prediction-corrected visual predictive check

Source: /projects/qcp/QCP\\_MODELING/ONC/durvalumab/poppk\\_20210729\\_himalaya/Scripts/s04\\_vpc.R

## Tremelimumab &amp; durvalumab exposure-response modelling analyses

The ER analysis for both efficacy and safety was based on patients from HIMALAYA study administered 1500 mg Q4W durvalumab and a 300 mg single dose tremelimumab IV. 388 and 397 patients were included in the ER analysis for durvalumab and tremelimumab, respectively. The final durvalumab/tremelimumab PopPK models were used to obtains EBEs of individual PK parameters.

## Exposure-efficacy:

The exposure-efficacy relationships in the HIMALAYA study were explored by Kaplan-Meier plots stratified by durvalumab and tremelimumab exposure quartiles. Several exposure metrics for tremelimumab and durvalumab were derived. For both efficacy outcomes, OS and PFS, Cox Proportional Hazard (CPH) models were developed and a stepwise covariate selection was performed (Î± = 1% and 0.1%). No significant exposure -efficacy relationships were identified for durvalumab or tremelimumab. The CPH models for OS suggested that AST and NLR were associated with shorter survival in T300+D arm as they were identified as statistically significant covariates. Maximum concentration following the first dose (Cmax, dose 1) for tremelimumab was also identified as a marginally statistically significant exposure metric (LRT: 11.92 &gt; 10.83) but was removed due to nonsignificance in the Wald test (p = 0.199), the standard error of coefficient (Î²) being large and the 95% CI of Î² containing the null. Likewise, trough concentration fo llowing the first dose (Cmin, dose 1) for tremelimumab was also identified as a marginally significant covariate within PFS based on the LRT but was removed for the same reasons. No other covariates were identified to be significant with PFS.

## Exposure-safety:

Logistic regression modelling did not identify any significant impact of durvalumab or tremelimumab exposure on the incidence of investigated adverse effects.

<div style=\"page-break-after: always\"></div>

## QTcF modelling analysis

Linear mixed-effects exposure-response modelling with an intercept was conducted to characterise the relationship of change from baseline of QTcF (Î”QTcF) with durvalumab or tremelimumab serum concentrations. The concentrationÎ”QTcF analysis population consisted of 293 observations from 67 patients administered durvalumab and 254 observations from 66 patients administered tremelimumab from Study 06. Unscheduled concentration-QTcF observations and non-central ECG records were excluded from the analysis.

For durvalumab, the slope for the relationship of Î”QTcF to d urvalumab concentration was 0.0048 ms per Î¼g/mL (p = 0.112), with a mean intercept of 0.082 ms (p = 0.950; 90% CI: -2.07, 2.24 ms; Table ).

The slope for the relationship of Î”QTcF to tremelimumab concentration was -0.012 ms per Î¼g/mL (p = 0.531), and the mean intercept was 0.581 ms (p = 0.629; 90% CI: -1.41, 2.57 ms; Table ).

The slope or the intercept for tremelimumab and durvalumab were not significantly different from zero.

Table 7: Parameter estimates of durvalumab PK âˆ†QTcF relationship

| Parameterestimates                        | Parameterestimates   | Parameterestimates   | Parameterestimates   | Parameterestimates   | Parameterestimates   | Parameterestimates   |
|-------------------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Parameter                                 | Estimate             | Standard error       | p-value              | 90%confidencelimits  | 90%confidencelimits  | Gradient             |
| Intercept (ms)                            | 0.08205              | 1.2916               | 0.9495               | -2.0726              | 2.2367               | 0.000012             |
| Slope (ms/Î¼g/mL)                          | 0.004841             | 0.003007             | 0.1123               | -0.00018             | 0.009858             | 0.003814             |
| Inter individual variability on intercept | 7.8721               | 0.8472               | <.0001               | 6.4588               | 9.2855               | 0.000021             |
| Model error                               | 9.4501               | 0.4275               | <.0001               | 8.7369               | 10.1633              | -8.91E-6             |

PK pharmacokinetic

Table 8: Parameter estimates of tremelimumab PK âˆ†QTcF relationship

| Parameter estimates                       | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   |
|-------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Parameter                                 | Estimate              | Standard error        | p- value              | 90% confidence limits | 90% confidence limits | Gradient              |
| Intercept (ms)                            | 0.5806                | 1.1952                | 0.6288                | -1.4137               | 2.5749                | -1.01E-6              |
| Slope (ms/ Î¼g/mL)                         | -0.01225              | 0.01945               | 0.5312                | -0.04470              | 0.02021               | -0.00007              |
| Inter individual variability on intercept | 7.5385                | 0.8414                | <.0001                | 6.1345                | 8.9425                | -2.99E-6              |
| Model error                               | 9.2338                | 0.4544                | <.0001                | 8.4755                | 9.9921                | 4.764E-6              |

PK pharmacokinetic

The upper bound of the 90% 2sided CI for Î”QTcF was less than 10 ms, and the highest observed concentration of durvalumab and tremelimumab had a predicted mean Î”QTcF of less than 5 ms ( Figure 6, Figure 7 and Table 8).

<div style=\"page-break-after: always\"></div>

Figure 6: QTcF (change from baseline) versus concentration of durvalumab on intercept full data

<!-- image -->

Cmax,ss maximum plasma concentration at steady state; IQR interquartile range; IV intravenous; Q2W every 2 weeks; Q4W every 4 weeks

Note: Red line is the linear regression line and the shaded area is the 90% CI based on the linear mixed-effects model prediction. Red short dashed horizontal line is 5 msec change from baseline identity line. Red long dashed horizontallineis10msecchangefrombaselineidentityline.Green dashedverticallines are observed median +/- IQR predicted Cmax,ss for a 10 mg/kg Q2W IV durvalumab dosing. Green solid line ismedian predictedCmax.ssfor a10mg/kgQ2WIVdurvalumabdosing.Blue dashedverticallines are observed median +/- IQR(interquartile range) predicted Cmax,ss for a 20 mg/kg Q4W IV durvalumab dosing. Blue solid line is median predicted Cmax,ss for a 20 mg/kg Q4W IV durvalumab dosing. Treatment cohorts are 1: 3 mg/kg durvalumab (Q4W)+1 mg/kg Tremelimumab; 2: 10 mg/kg durvalumab (Q4W)+ 1 mg/kg Tremelimumab;3: 15 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 4: 10 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 5: 20 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; o1 + (Mt) qanp sy s1 :2 q / g + (t) qap y/ 11 :9

<div style=\"page-break-after: always\"></div>

Figure 7: QTcF (change from baseline) versus concentration of tremelimumab on intercept full data

<!-- image -->

Cmax,ss maximum plasma concentration at steady state; IQR interquartile range; IV intravenous; Q2W every 2weeks;Q4Wevery4weeks

Note: Red line is the linear regression line and the shaded area is the 90% CI based on the linear mixed-effects model prediction. Red short dashed horizontal line is 5 msec change from baseline identity line. Red long dashed horizontal line is 10 msec change from baseline identity line. Treatment cohorts are 1: 3 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 2: 10 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab;3: 15 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 4: 10 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 5: 20 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 6: 15 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 7: 15 mg/kg durvalumab (Q4W) + 10 mg/kg Tremelimumab; 8: 20 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 9: 10 mg/kg durvalumab (Q2W) + 1 mg/kg Tremelimumab; 10: 10 mg/kg durvalumab (Q2W) + 3 mg/kg Tremelimumab; 11: 20 mg/kg durvalumab (Q4W) + 1 mg/kg tremelimumab (Q4W)/ 20 mg/kg durvalumab (Q4W)

Table 9: Summary of maximum observed durvalumab or tremelimumab serum concentration and predicted mean and CI of âˆ†QTcF

|              |   Observed Cmax (Î¼g/mL) |    | Cohort Dosing regimen                         | Predicted mean â–³QTcF (ms)   | 90% CI of predicted meanâ–³QTcF (ms)   |
|--------------|-------------------------|----|-----------------------------------------------|-----------------------------|--------------------------------------|
| Durvalumab   |                   866.6 | 10 | 20mg/kg durvalumab,  4.28 1mg/kg tremelimumab |                             | (0.36, 8.20)                         |
| Tremelimumab |                   233   |  4 | 10mg/kg durvalumab,-2.27 15mg/kg tremelimumab |                             | (-9.49, 4.96)                        |

## Absorption

The product is intended for intravenous administration. Clinical studies were not conducted to evaluate the bioavailability or bioequivalence compared to other formulations.

Dose-normalised tremelimumab PK Parameters (Cmax and AUC0-28) from the dose finding study (Study 06) following administration of tremelimumab in combination with durvalumab are given in Table 10:10.

<div style=\"page-break-after: always\"></div>

Table 10: Dose-normalised tremelimumab PK parameters following administration of tremelimumab and durvalumab combination (Study 06)

|                          | Tremelimumabgeometricmeanï¼ˆn,geometric%oCV)   | Tremelimumabgeometricmeanï¼ˆn,geometric%oCV)   |
|--------------------------|----------------------------------------------|----------------------------------------------|
| Dose level               | Cmax..D ï¼ˆÎ¼q/ml/mg)                           | AUC0-28D (ua:dav/mL/mg)                      |
| T1 Q4WEscalation ï¼ˆN =59) | (55,37.8)                                    | 2.82 (36,39.3)                               |
| T3 Q4WEscalation N=34ï¼‰   | 0.258 (32,60.7)                              | 2.83 (17,21.1)                               |
| T10 Q4W Escalation (N=9) | 0.261 (9,26.1)                               | 2.45 (9,32.2)                                |
| T1Q4wExpansion ï¼ˆN=251}   | 0.288                                        | 3.41                                         |
|                          | (200,41.3)                                   | (14,45.9)                                    |

Note: All data are depicted as geometric mean (n, geometric %CV), and rounded to 3 significant digits. AUC0-28\\_D, dose-normalised area under the serum concentration-time curve from Day 1 to Day 29; Cmax\\_D, dose-normalised maximum serum concentration after the first dose; CV, coefficient of variation; PK, pharmacokinetic; Q4W, every 4 weeks; T1, tremelimumab 1 mg/kg; T3, tremelimumab 3 mg/kg; T10, tremelimumab 10 mg/kg.

## Distribution

Study 22 evaluated PK parameters in patients with advanced hepatocellular carcinoma, who received a single IV dose of 300 mg on Day 1. In a subset of patients from this study (N=11) for whom intensive PK sampling was done, the estimated geometric mean volume of distribution was 7.6 L (Table ).

Based on population PK analysis that included 1605 patients who received tremelimumab monotherapy or in combination with durvalumab with or without chemotherapy in the dose range of â‰¥ 1 mg/kg, the geometric mean steady-state volume of distribution (Vss) was 6.33 L.

Table 11: Individual values and descriptive statistics of tremelimumab serum PK parameters following single IV dose of 300 mg tremelimumab on Day 1 of Week 1 to patients with advanced hepatocellular carcinoma (PK analysis set) (Study 22)

| Allocation number       | TremelinumabPK parameters   | TremelinumabPK parameters   | TremelinumabPK parameters   | TremelinumabPK parameters   | TremelinumabPK parameters   | TremelinumabPK parameters   | TremelinumabPK parameters   |
|-------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Allocation number       | AUCiast (Î¼g/mL*day)         | AUCinf (Î¼g/mL*day)          | Cmax (Î¼g/mL)                | Tmax (h)                    | Apparent terminal ti2 (day) | CL (L/day)                  | Vz (L)                      |
| D4190C00022/20015120016 | 1814                        | 1903                        | 102.7                       | 1.58                        | 28.2                        | 0.158                       | 6.42                        |
| D4190C00022/20015220014 | 1212                        | 1469                        | 100.9                       | 3.24                        | 67.9                        | 0.204                       | 20.0                        |
| D4190C00022/20015240015 | 1784                        | 1828                        | 73.60                       | 1.18                        | 23.6                        | 0.164                       | 5.59                        |
| D4190C00022/20016520005 | 1009                        | 1022                        | 95.40                       | 1.01                        | 16.0                        | 0.293                       | 6.76                        |
| D4190C00022/20018500022 | 1362                        | 1377                        | 68.50                       | 1.08                        | 25.7                        | 0.218                       | 8.09                        |
| D4190C00022/20021190008 | 1422                        | 1636                        | 117.8                       | 1.25                        | 21.7                        | 0.183                       | 5.73                        |
| D4190C00022/20021190009 | 1267                        | 1310                        | 89.30                       | 1.13                        | 24.3                        | 0.229                       | 8.02                        |
| D4190C00022/20021200007 | 1225                        | 1728                        | 122.1                       | 1.22                        | 18.3                        | 0.174                       | 4.59                        |
| D4190C00022/20021200010 | 1223                        | 1273                        | 84.60                       | 1.27                        | 19.4                        | 0.236                       | 6.58                        |
| D4190C00022/20021210007 | 1303                        | 1597                        | 92.10                       | 1.06                        | 39.4                        | 0.188                       | 10.7                        |
| D4190C00022/20021210011 | 895.5                       | 913.5                       | 80.30                       | 1.13                        | 18.6                        | 0.328                       | 8.83                        |
| Nunber of patients      | 11                          | 11                          | 11                          | 11                          | 11                          | 11                          | 11                          |
| Arithmeticmean          | 1320                        | 1460                        | 93.39                       | NR                          | 27.6                        | 0.216                       | 8.30                        |
| Standarddeviation       | 279.5                       | 317.4                       | 16.87                       | NR                          | 14.8                        | 0.0539                      | 4.24                        |
| ACV (%)                 | 21.2                        | 21.7                        | 18.1                        | NR                          | 53.8                        | 25.0                        | 51.1                        |
| Median                  | 1267                        | 1469                        | 92.10                       | 1.18                        | 23.6                        | 0.204                       | 6.76                        |
| Mininum                 | 895.5                       | 913.5                       | 68.50                       | 1.01                        | 16.0                        | 0.158                       | 4.59                        |
| Maxinum                 | 1814                        | 1903                        | 122.1                       | 3.24                        | 67.9                        | 0.328                       | 20.0                        |
| Geometric mean          | 1294                        | 1426                        | 92.02                       | NR                          | 25.1                        | 0.210                       | 7.64                        |
| GCV (%)                 | 21.1                        | 23.7                        | 18.2                        | NR                          | 43.0                        | 23.7                        | 41.3                        |
| 10 %S6                  | (1124,1489)                 | (1219,1668)                 | (81.50, 103.9)              | NR                          | (19.1, 33.2)                | (0.180, 0.246)              | (5.85, 9.97)                |

ACV, arithmetic coefficient of variation is calculated in the original scale with the equation: 100Ã—(SD/AM); AUCinf, area under the concentration versus time curve from O to infinity;AUClast,areaunder theconcentrationversustimecurvefrom Otothetimeofthelastquantifiablesample;AUCinf,areaundertheconcentrationversus timecurvefrom 0 to infinity after dosing; CI, confidence interval of the geometric mean; CL, clearance; Cmax,concentration at the end of infusion (TAD &lt;1 day) in that visit; GCV, geometric coefficient of variation is calculated in the natural log scale with the equation: 100 Ã— sqrt(exp(oÂ²) - 1), where oÂ² is the observed variance on the natural log scale; IV, intravenous; NR, not reported; PK, pharmacokinetic; ti/2, apparent first-order terminal elimination half-life; TAD, time after dose; Tmax, time to maximum serum

concentration; Vz, volume of distribution during the terminal phase.

<div style=\"page-break-after: always\"></div>

## Elimination

Tremelimumab, as a typical mAb, is not cleared renally due to its large molecular weight. The primary elimination pathways are protein catabolism via the reticuloendothelial system (RES) or targetmediated disposition.

Based on the findings from the subset of patients from Study 22, for whom intensive PK sampling was done, the geometric mean clearance was 0.21 L/day and the apparent terminal half-life was 25.1 days (Table ).

Based on population PK analysis, the geometric mean steady-state clearance (CLss) was 0.309 L/day and the geometric mean terminal half-life was approximately 14.2 days.

## Dose proportionality and time dependencies

In a dose finding study conducted in patients with NSCLC (Study 06) an approximately doseproportional increase in PK exposure (Cmax and AUC0-28) of tremelimumab was observed over the dose range of 1 to 10 mg/kg tremelimumab Q4W when administered in combination with durvalumab (Table above).

Exposure following multiple doses demonstrated accumulation consistent with PK parameters estimated from the first dose. The PK profile for tremelimumab is shown in Figure 8.

Figure 8: Mean (SD) tremelimumab PK concentration-time profiles after the first dose by tremelimumab dose following IV administration of the combination of durvalumab and tremelimumab (Study 06)

BLQ. below the limit of quantification; IV, intravenous; PK, pharmacokinetic; Q4W, every 4 weeks; Q12W, every 12 weeks; SD, standard deviation.

<!-- image -->

Based  on  the  final  Population  PK  model,  time-dependent  CL  was  identified  for  tremelimumab  in combination with durvalumab, but not for tremelimumab as monotherapy.

<div style=\"page-break-after: always\"></div>

## Intra- and inter-individual variability

For the tremelimumab population PK model, estimates of inter-individual variability (CV%) were 32.9% on CL, 24.9% on V1, 46.0% on V2 and 119.2% on Tmax.

For the durvalumab population PK model, estimates of inter-individual variability (CV%) were 29.9% on CL, 22.9% on V1 and 25.8% on Tmax.

## Special populations

The effect of intrinsic factors (i.e., renal function, hepatic function, age, race, gender, and body weight) on the PK of tremelimumab has not been studied through specific dedicated studies.

The effect of body weight, age, gender, race, renal and hepatic function and disease severity on the PK of tremelimumab has, however, been evaluated in the Population PK analysis.

In summary, the final Population PK modeling indicated that the baseline patient characteristics of age, race, renal function, and hepatic function had no effect on the PK of tremelimumab. In contrast, body weight, ALB, gender, combination therapy and primary indication had a statistically significant impact on clearance. Body weight and sex had a statistically significant impact on central volume of distribution. However, all identified covariates changed tremelimumab population parameter estimates by less than or about 20% and were therefore regarded of minor clinical relevance.

## Impaired renal function

Mild (creatinine clearance (CrCL) 60 to 89 ml/min) and moderate renal impairment (creatinine clearance (CrCL) 30 to 59 ml/min) had no clinically significant effect on the PK of tremelimumab. The effect of severe renal impairment (CrCL 15 to 29 ml/min) on the PK of tremelimumab is unknown.

## Impaired hepatic function

Mild hepatic impairment (bilirubin â‰¤ ULN and AST &gt; ULN or bilirubin &gt; 1.0 to 1.5 Ã— ULN and any AST) and moderate hepatic impairment (bilirubin &gt; 1.5 to 3 x ULN and any AST) had no clinically significant effect on the PK of tremelimumab. The effect of severe hepatic impairment (bilirubin &gt; 3.0 x ULN and any AST) on the PK of tremelimumab is unknown.

## Gender

Based on the final PopPK model of tremelimumab, gender had a statistically significant impact on CL and V1. However, since the impact was less than 20% this was not regarded as of clinical relevance.

## Age

Age (range 18 to 87 years) was not identified as a significant covariate in the final PopPK model of tremelimumab.

|                    | D alone            | D + T75            | D + T300           | SoC                | All patients in PopPK   |
|--------------------|--------------------|--------------------|--------------------|--------------------|-------------------------|
| N                  | 388                | 152                | 388                | 374                | 2406                    |
| Age sub-group (yr) | Age sub-group (yr) | Age sub-group (yr) | Age sub-group (yr) | Age sub-group (yr) | Age sub-group (yr)      |
| <65                | 201 (51.8%)        | 74 (48.7%)         | 193 (49.7%)        | 188 (50.3%)        | 1246 (51.8%)            |
| >=65-75            | 130 (33.5%)        | 55 (36.2%)         | 142 (36.6%)        | 130 (34.8%)        | 875 (36.4%)             |
| >=75               | 57 (14.7%)         | 23 (15.1%)         | 53 (13.7%)         | 56 (15.0%)         | 285 (11.8%)             |

<div style=\"page-break-after: always\"></div>

## Race

Race was not identified as a significant covariate in the final Population PK model of tremelimumab, and race did not seem to influence PK of tremelimumab. .

## Weight

Body weight (range 34 to 149 kg) had a statistically significant effect on CL and V1. However, since body weight changed tremelimumab population parameter estimates by less than 20% it was regarded of minor clinical relevance.

Table shows the simulated tremelimumab AUC, Cmax, and Cmin across body weight quartiles. At the highest weight quartile, the simulated geometric mean AUC, Cmax, and Cmin decreased by 7.67%, 11.8%, and 8.88%, respectively, compared to the geometric mean of the overall population. At the lowest quartile, the simulated AUC, Cmax, and Cmin increased by 7.73%, 14.5%, and 7.89%, respectively, compared to the mean of the overall population. These differences in exposure were not considered clinically relevant but due to the potential concern the weight limit for body weight-based dosing has been increased to 40 kg.

<div style=\"page-break-after: always\"></div>

Table 12: Tremelimumab exposure across body weight quartiles

|                      | Q1               | Q2               | Q3               | Q4               |
|----------------------|------------------|------------------|------------------|------------------|
| Individuals          |                  |                  |                  |                  |
| N                    | 97               | 100              | 95               | 95               |
| Body weight (kg)     |                  |                  |                  |                  |
| Geometric mean (%CV) | 52.5 (9.81)      | 65.4 (4.80)      | 75.0 (3.97)      | 91.9 (11.8)      |
| Median [min-max]     | 53.7 [40.5-59.4] | 66.0 [59.6-70.0] | 74.9 [70.1-80.0] | 89.0 [80.3-140]  |
| AUC, dose 1          |                  |                  |                  |                  |
| Geometric mean (%CV) | 835 (21.7)       | 785 (23.6)       | 767 (19.9)       | 715 (25.6)       |
| Median [min-max]     | 825 [391-2320]   | 784 [373-1560]   | 766 [501-1490]   | 705 [419-2190]   |
| %change              | 7.73             | 1.37             | -1.04            | -7.67            |
| Cmax, dose 1         |                  |                  |                  |                  |
| Geometric mean (%CV) | 99.7 (15.2)      | 89.1 (16.6)      | 84.0 (15.3)      | 76.8 (18.5)      |
| Median [min-max]     | 100 [64.0-174]   | 89.1 [52.8-134]  | 81.7 [61.8-141]  | 76.8 [45.8-137]  |
| %change              | 14.5             | 2.34             | -3.59            | -11.8            |
| Cmin, dose 1         |                  |                  |                  |                  |
| Geometric mean (%CV) | 13.1 (34.3)      | 12.4 (36.7)      | 12.2 (26.4)      | 11.1 (38.0)      |
| Median [min-max]     | 13.3 [3.70-74.8] | 12.4 [4.21-48.5] | 12.4 [6.50-24.3] | 11.1 [4.88-71.9] |
| %change              | 7.89             | 1.54             | -0.0657          | -8.88            |
| AUC0-inf             |                  |                  |                  |                  |
| Geometric mean (%CV) | 1140 (23.1)      | 1070 (26.3)      | 1050 (21.4)      | 955 (26.7)       |
| Median [min-max]     | 1160 [460-2130]  | 1080 [500-1810]  | 1060 [643-1960]  | 957 [527-2000]   |
| %change              | 8.28             | 1.71             | -0.299           | -9.16            |

Note: % change is computed with the geometric mean of the entire population as a reference

## Pharmacokinetic interaction studies

No formal drug-drug interaction studies have been conducted with durvalumab or tremelimumab. PK drug-drug interaction of durvalumab or tremelimumab with other therapeutics is not anticipated given that durvalumab and tremelimumab are not primarily cleared via hepatic or renal pathways; instead, the primary elimination pathways are protein catabolism via reticuloendothelial system (RES) or target-mediated disposition.

Durvalumab and tremelimumab are not expected to induce or inhibit the major drug metabolizing cytochrome P450 pathways.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics using human biomaterials

No in vitro permeability, in vitro metabolism, or in vitro metabolic drug-drug interaction studies that used human biomaterials have been performed.

## Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. Immunogenicity of tremelimumab is based on pooled data in 2075 patients who were treated with tremelimumab 75 mg or 1 mg/kg and evaluable for the presence of anti-drug antibodies (ADAs). Two-hundred fifty-two patients (12.1%) tested positive for treatment-emergent ADAs. Neutralising antibodies against tremelimumab were detected in 10.0% (208/2075) patients. The presence of ADAs did not impact tremelimumab pharmacokinetics, and there was no apparent effect on efficacy and safety.

In the HIMALAYA study, of the 182 patients who were treated with Imjudo 300 mg as a single dose in combination with durvalumab and evaluable for the presence of ADAs against tremelimumab, 20 (11.0%) patients tested positive for treatment-emergent ADAs. Neutralising antibodies against tremelimumab were detected in 4.4% (8/182) patients. The presence of ADAs did not have an apparent effect on pharmacokinetics or safety.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Tremelimumab is a human IgG2 mAb directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a critical regulatory signal for T-cell expansion and activation following an immune response, and it serves as a natural braking mechanism that maintains T-cell homeostasis. During Tcell activation, T cells upregulate CTLA-4, which binds to CD80 and CD86 ligands on antigen-presenting cells, sending an inhibitory signal and preventing CD28-mediated T-cell co-stimulation, thus limiting Tcell activation. Tremelimumab blocks these events, leading to prolongation and enhancement of T-cell activation and expansion.

Durvalumab is a human IgG1k mAb that binds to programmed cell death ligand-1 (PD-L1) and blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Expression of PD-L1 can be induced by inflammatory signals and can be expressed on both tumour cells and tumour-associated immune cells in the tumour microenvironment. PD-L1 blocks T-cell function and activation through interactions with PD-1 and CD80 (B7.1). By binding to its receptors PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

Tremelimumab and durvalumab are checkpoint inhibitors with distinct yet complementary mechanisms of action with respect to enhancing the antitumour immune response. Tremelimumab mediated blockade of CTLA-4 functions early in the immune response, lowering the threshold for T cell activation, allowing more T cells to be activated and increasing the diversity of the T cell population. This increases the probability that a T cell recognizing a tumour neoantigen can become activated. Durvalumab blockade of PD-L1 is expected to function mainly during the effector phase of T cell function, once T cells enter the tumour, where it acts to block local suppression of T-cell function by PD-L1, enhancing the ability of activated anti-tumour T cells to target and kill tumour cells.

## Primary pharmacology

Data from Study 06, Study 10 and Study 22 indicate that a pharmacodynamic effect exists on proliferating CD4+ and CD8+ T cell quantities consistent with the proposed mechanisms of action of both therapeutic agents.

<div style=\"page-break-after: always\"></div>

Data from Study 1108, Japan Study 02, Study 06 and Study 10 indicate that durvalumab treatment (with or without tremelimumab) reduces free Soluble Programmed Cell Death Ligand-1 (sPD-L1) in serum.

No PD biomarkers are proposed for monitoring of effect.

## Secondary pharmacology

## Concentration-QTc Analysis

Overall, concentration-QTc-analysis did not identify a significant linear relationship between tremelimumab or durvalumab serum concentrations and Î” QTcF. The predicted mean Î”QTcF and upper 90% CI at the maximum observed concentration for tremelimumab or durvalumab in the dataset were below the threshold of clinical concern.

## Exposure-response relationships

Assessment of an exposure-efficacy relationship was conducted using OS and PFS as efficacy parameters in patients from HIMALAYA, for whom the different exposure metrics could be calculated.

For the exposure-response analysis for efficacy (OS and PFS), only the T300 + D cohort was used, but with the SoC cohort as a comparator in some of the analyses. The exposure-response Cox proportional-hazards (CPH model) for OS and PFS was developed based on durvalumab and tremelimumab-treated patients in the HIMALAYA study. Simulated durvalumab and tremelimumab serum concentration-time PK profiles, based on individual post-hoc PK parameters, were used as a measure of exposure after T300 + D. Of the 388 patients in this cohort, 1 did not have tremelimumab exposure metrics, and therefore, 387 patients were included in the E-R analysis for tremelimumab.

## Exposure-efficacy relationship

## Overall survival (OS)

The data for OS were stratified by model-predicted exposure metrics and overlaid with data from patients in the SoC arm. There were 4 exposure metrics used for tremelimumab (AUCdose 1, Cmin, dose 1, Cmax,dose 1, and AUC0-inf).

Figure  shows the OS Kaplan-Meier (KM) plots for exposure metrics of tremelimumab. The number of patients at risk is indicated below each plot. The KM plots indicated that there was no clear relationship between efficacy and exposure to tremelimumab, with all quartiles overlapping each other.

Additional explorative analyses of the covariates, body weight, and ADA status indicated that there is no clear association between OS and body weight or ADA status. However, the results for ADA status must be considered with caution due to the small number of ADA-positive patients in the tremelimumab treatment cohort.

<div style=\"page-break-after: always\"></div>

Figure 9:  OS Kaplan-Meier plots for tremelimumab exposure metrics by quartiles at Dose 1

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

The covariates, aspartate aminotransferase (AST) and neutrophil-to-lymphocyte ratio (NLR) were identified as significant in the final model. Higher AST and NLR were associated with shorter survival in T300 + D arm, suggesting they are prognostic factors for OS. The OS Kaplan Meier plot stratified by these 2 significant covariates can be found in Figure 10. A Forest plot of the final CPH model for OS is showed in Figure.

<div style=\"page-break-after: always\"></div>

Figure 10: OS Kaplan Meier plots stratified by significant covariates

<!-- image -->

Time in days

Time in days

Figure 11: Forest plot of the final Cox proportional-hazards model for OS

<!-- image -->

Note: Numbers at the right of the graph are the predicted HR and associated 95% CI.

## Progression-free survival (PFS)

Figure shows PFS Kaplan-Meier curves for patients receiving durvalumab in combination with tremelimumab, data stratified by model-predicted exposures metrics and overlaid with data from patients in the SoC arm (Cmin, dose 1, AUC0-inf). The number of patients at risk is indicated below the plot.

These plots indicated no clear efficacy relationship to tremelimumab exposure, with all quartiles overlapping each other.

Overall, no covariate was identified to be related with PFS in this analysis.

Additional explorative analyses of the covariates, body weight, and ADA status for tremelimumab exposure did not indicate any clear trend between PFS and body weight or ADA status. However, the small number of ADA-positive patients after tremelimumab treatment mean that the Kaplan-Meier plots for ADA status should be interpreted with caution.

<div style=\"page-break-after: always\"></div>

Figure 12: PFS Kaplan-Meier plots for tremelimumab exposure metrics by quartiles at Dose 1

<!-- image -->

<!-- image -->

Strata

Numberatrisk

66669

230

90

0

120

180

270

360

450

3161081

540

630

720

810

69485

900

45444

990

01000

1260

2458150

Time indays

Note: Shaded areas are the 95% CI around the Kaplan-Meier curves. Vertical ticks represent the right censoring. AUCss, area under the serum concentration-time curve at steady state; CI, confidence interval; Cmax, maximum concentration, Cmin, minimum concentration; SoC, standard of care.

826562

422216

48162013

207126

04122

1080

OmMNO

1170

<div style=\"page-break-after: always\"></div>

## Exposure-safety relationship

For assessment of an exposure-safety relationship, the evaluated safety endpoints were Grade 3 and above treatment-related AEs from HIMALAYA, Grade 3 and above AESIs, and AEs leading to durvalumab treatment discontinuation.

## Grade 3 and above treatment-related AEs

The probability of AEs calculated in quartiles of the AUCdose 1 exposure metrics for durvalumab and tremelimumab is shown in Figure 13. This figure summarises the logistic regression results assessing the impact of exposure on the probability of AEs. The p-values associated with exposure effects were relatively large, indicating that the relationship was not statistically significant.

Figure 13: Relationship between the probability of having Grade 3 and above treatmentrelated AEs and AUCdose 1 for durvalumab and tremelimumab

<!-- image -->

Note: The black solid circles are the observed AE, and the open squares with error bars are the observed probability of response at each exposure quartile. The black lines are the logistic regression between two variables, and the gray area represents the associated confidence interval. AE, adverse event; AUC, area under the serum concentration-time curve.

## Grade 3 and Above Treatment-related AESIs

The probability of AESIs calculated in quartiles of the AUCdose 1 exposure metrics for durvalumab and tremelimumab is shown in Figure.

The p-values associated with exposure effects were relatively large, indicating that the relationship was not statistically significant.

<div style=\"page-break-after: always\"></div>

Figure 14: Relationship between the probability of having Grade 3 and above treatmentrelated AESIs and AUC, dose 1 for durvalumab and tremelimumab

<!-- image -->

Note: The black solid circles are the observed AEs, and the open squares with error bars are the observed probability of response at each exposure quartile. The black lines are the logistic regression between two variables, and the gray area represents the associated confidence interval.

Abbreviations: AE, adverse event; AUC, area under the serum concentration-time curve.

In conclusion, none of the tremelimumab or durvalumab exposure metrics in a logistic regression analysis were identified to have an influence on safety events defined as Grade 3 and above treatment-related AEs, Grade 3 and above AESIs, or AEs leading to durvalumab treatment discontinuation.

## 2.6.3. Discussion on clinical pharmacology

The pharmacokinetics (PK) of tremelimumab was assessed for Imjudo as monotherapy and in combination with durvalumab.

The PK of tremelimumab was studied in patients with doses ranging from 75 mg to 750 mg or 10 mg/kg administered intravenously once every 4 or 12 weeks as monotherapy, or at a single dose of 300 mg. PK exposure increased dose proportionally (linear PK) at doses â‰¥ 75 mg. Steady state was achieved at approximately 12 weeks. Based on population PK analysis that included patients who received tremelimumab monotherapy or in combination with other medicinal products in the dose range of â‰¥ 75 mg (or 1 mg/kg) every 3 or 4 weeks, the estimated tremelimumab clearance (CL) and volume of distribution (Vd) were 0.309 l/day and 6.33 l, respectively. The terminal half-life was approximately 14.2 days.

HIMALAYA assessed the efficacy and safety of durvalumab and tremelimumab in combination versus durvalumab alone and sorafenib as SoC. In the two arms of the study that included tremelimumab treatment, tremelimumab was administered either as a single dose of 300 mg (in combination with durvalumab 1500 mg Q4W) or as 4 doses of 75 mg tremelimumab Q4W (in combination with durvalumab 1500 mg Q4W).

Tremelimumab PK concentrations were within the expected exposure range following a single 300 mg dose as well as following four doses of 75 mg Q4W.

<div style=\"page-break-after: always\"></div>

Overall, trough concentrations of tremelimumab at Cycle 2 were 3.3 times higher in the T300 + D arm than the T75 + D arm. In addition, similar tremelimumab exposures were observed in patients rechallenged with tremelimumab.

Furthermore, PK profiles of durvalumab were overall similar between patients treated in the D arm and those in the T300 + D and T75 + D arms, suggesting that tremelimumab did not have an impact on the PK of durvalumab when administered in combination.

Study 22 evaluated the safety, tolerability, and clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC, similar exposures were observed following a weight-based dosing of 1 mg/kg and the equivalent fixed 75 mg dose. Additionally, similar exposures were observed following a weight-based dose of 10 mg/kg and the equivalent fixed 750 mg dose.

No accumulation of tremelimumab was observed following repeated dosing in any of the cohorts in Study 22. In contrast, accumulation of durvalumab was observed following repeated dosing at 1500 mg. Overall, durvalumab PK parameters were similar between patients treated with durvalumab monotherapy and those treated with durvalumab and tremelimumab combination therapy.

The PK of tremelimumab could be described by a 2-compartment model with linear CL and an additional time-dependent CL component for patients on combination therapy only. Body weight, albumin, sex, combination therapy and primary indication were identified as statistically significant covariates on CL. Body weight and sex were identified as statistically significant covariates on V1. The effect of body weight was allometrically scaled with estimated exponents of 0.384 and 0.467 for CL and V1, respectively, indicating that the effect of body weight was less than proportional. Low-to-high inter-individual variability (%CV) was identified on CL (32.9%), V1 (24.9%), V2 (46.0%) and Tmax (119.2%). The adequacy of the model was confirmed based on the GOF-plots but some deviation was observed in the DV vs. IPRED plot. The same deviation was present in the previous model which suggests this deviation is not specific to HCC patients. In general, the model seems able to describe the overall tendency of the experimental data and parameters were estimated precisely.

Age (18-87 years), body weight (34-149 kg), gender, positive anti-drug antibody (ADA) status, albumin levels, LDH levels, creatinine levels, tumour type, race or ECOG/WHO status had no clinically significant effect on the PK of tremelimumab.

The exposure-efficacy relationships in the HIMALAYA study were explored by Cox Proportional Hazard (CPH) models. The assumption of proportional hazards of OS analysis are not fully supported for AST and the utilisation of the CPH model with this covariate should be interpreted with caution.

The clinical pharmacology programme in special populations is considered adequate and typical for a monoclonal antibody product being administered intravenously. The effect of hepatic and renal impairment was not formally tested in dedicated clinical trials, and data from patients with severe renal impairment are too limited to draw conclusions on this population. Based on pop PK analyses, age, gender, race, mild/moderate renal impairment, or mild hepatic impairment had no impact on the exposure of tremelimumab. Accordingly, no dose adjustment is recommended in patients with mild or moderate renal impairment and patients with mild or moderate hepatic impairment (see section 5.2). No dose adjustment is required for elderly patients ( â‰¥ 65 years of age) (see section 5.2). Data on patients aged 75 years of age or older are limited.

The use of systemic corticosteroids or immunosuppressants before starting tremelimumab, except physiological dose of systemic corticosteroids ( â‰¤ 10 mg/day prednisone or equivalent), is not recommended because of their potential interference with the pharmacodynamic activity and efficacy of tremelimumab. However, systemic corticosteroids or other immunosuppressants can be used after starting tremelimumab to treat immune related adverse reactions (see section 4.4).

<div style=\"page-break-after: always\"></div>

No formal pharmacokinetic (PK) drug drug interaction studies have been conducted with tremelimumab. Since the primary elimination pathways of tremelimumab are protein catabolism via reticuloendothelial system or target mediated disposition, no metabolic drug-drug interactions are expected.

Assessment of an exposure-efficacy relationship was conducted using OS and PFS as efficacy parameters in patients from HIMALAYA. OS and PFS were explored by Kaplan-Meier (KM) estimates and analyzed by Cox proportional-hazards models.

For OS the KM plots indicate that there was no clear relationship between efficacy and exposure to tremelimumab, with all quartiles overlapping each other.

The covariates, aspartate aminotransferase (AST) and neutrophil-to-lymphocyte ratio (NLR) were identified as significant in the final model. Higher AST and NLR were associated with shorter survival in T300 + D arm, suggesting they are prognostic factors for OS.

For PFS the KM plots indicate no clear efficacy relationship to tremelimumab exposure, with all quartiles overlapping each other. Overall, no covariate was identified to be related with PFS in this analysis.

Additional explorative analyses of the covariates, body weight, and ADA status for tremelimumab exposure did not indicate any clear trend between OS or PFS and body weight or ADA status. However, the small number of ADA-positive patients after tremelimumab treatment mean that the Kaplan-Meier plots for ADA status should be interpreted with caution.

For assessment of an exposure-safety relationship, the evaluated safety endpoints were Grade 3 and above treatment-related AEs from HIMALAYA, Grade 3 and above AESIs, AEs leading to durvalumab treatment discontinuation.

None of the tremelimumab or durvalumab exposure metrics in a logistic regression analysis were identified to have an influence on safety events defined as Grade 3 and above treatment-related AEs, Grade 3 and above AESIs or AEs leading to durvalumab treatment discontinuation. In the HIMALAYA study, no patients received BW -based dosing of tremelimumab (4 mg/kg).

There appeared to be no clear trend between increasing body weight and the probability of AEs.

In terms of immunogenicity, the prevalence of anti-drug antibodies (ADA) and neutralizing antibodies (nAb) as well as incidence of ADA for tremelimumab in HIMALAYA were higher in the T75 + D arm than in the T300 + D arm. This could be related to the different number of tremelimumab doses in the 2 treatment arms.

The development of treatment-emergent ADA to tremelimumab did not have any apparent effect on serum concentrations of tremelimumab, efficacy or safety.

## 2.6.4. Conclusions on clinical pharmacology

Considering the nature of the product, the pharmacology package is considered adequate.

## 2.6.5. Clinical efficacy

The current marketing authorisation application for tremelimumab is based on efficacy data from HIMALAYA, a randomised, open-label, multicentre Phase III study in patients with unresectable hepatocellular carcinoma (HCC) not eligible for locoregional therapy and with no prior systemic therapy

<div style=\"page-break-after: always\"></div>

for HCC. Additional supportive evidence of clinical efficacy is provided from study 22, a randomised, phase I/II, open-label study.

Table 13: Overview of studies in the clinical development programme for durvalumab in combination with tremelimumab and durvalumab monotherapy in patients with uHCC

Table 1 OverviewofStudiesintheClinicalDevelopmentProgramforDurvalumabinCombinationWith TremelimumabandDurvalumabMonotherapyinPatientsWithuHCC

| Study number and acronym   | Study title                                                                                                                                                                                                                  | Study design                                                              | Objective                                                                                   | DCO date(s)          | Location in Module5   |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------|-----------------------|
| Pivotal Study              | Pivotal Study                                                                                                                                                                                                                | Pivotal Study                                                             | Pivotal Study                                                                               | Pivotal Study        | Pivotal Study         |
| D419CC00002 HIMALAYA       | A Randomized, Open-label, MulticenterPhaseII Study of Durvalumab and Tremelimumab asFirst-lineTreatmentinPatients With Advanced Hepatocellular Carcinoma (HIMALAYA)                                                          | Phase II, randomized, open-label, sponsor-blind, multicenter,global study | To assess the efficacy and safety of T300+D vs S and D Vs S                                 | FA: 27 August 2021   | 5.3.5.1               |
| Supportive Study           | Supportive Study                                                                                                                                                                                                             | Supportive Study                                                          | Supportive Study                                                                            | Supportive Study     | Supportive Study      |
| D4190C00022 Study22        | A Study of Safety,Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy,or DurvalumabinCombinationWith TremelimumaborBevacizumab in Subjects with Advanced Hepatocellular Carcinoma | Phase I/II, randomized, open-label, multicenter. international study      | Parts 2 and 3: To assess the safety,tolerability,and clinical activity of T300+D, D, and T. | FA: 06 November 2020 | 5.3.5.2               |

Abbreviations: D = durvalumab 1500 mg (20 mg/kg)Q4W; DCO = data cut-off;FA =Final Analysis; Q4W = every 4 weeks; Q12W = every 12 weeks; T =tremelimumab 750 mg (10 mg/kg)Q4W Ã— 7 doses followed by Q12W; T300+D = tremelimumab 300 mg(4 mg/kg)Ã—1 dose + durvalumab 1500 mg (20mg/kg)Q4W;uHCC=unresectablehepatocellularcarcinoma.

## 2.6.5.1. Dose response studies

See section 2.6.2.1.

## 2.6.5.2. Main study

A randomised, open-label, multicentre phase III study of durvalumab and tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma (HIMALAYA)

Study design for the pivotal trial is illustrated in Figure 15.

<div style=\"page-break-after: always\"></div>

Figure 9: HIMALAYA study design

T75+D: Tremelimumab 75mg x 4 doses + durvalumab 1500mg Q4W

<!-- image -->

Patient numbers shown correspond to the actual enrollment.

Enrollment into the T75+D arm was closed following protocol edition 4.0 (29 November 2018). Patients randomised to T75+D prior to protocol amendment 3 could continue on their assigned study treatment, provided the Investigator and patient agreed this was in the patient's best interest. Patients randomised to T75+D arm who had not completed or started all 4 doses of tremelimumab could either complete the full schedule or continue with durvalumab monotherapy only

## Methods

## Â· Study Participants

Patients were enrolled at 181 sites and randomised at 170 study centres in 16 countries: Brazil (13 centres), Canada (9), France (14), Germany (10), Hong Kong (5), India (10), Italy (8), Japan (27), South Korea (8), Russian Federation (10), Spain (6), Taiwan (9), Thailand (9), Ukraine (8), United States of America (21), and Vietnam (3).

## Inclusion Criteria

For inclusion in the study, patients had to fulfill all of the following criteria:

1. Age â‰¥ 18 years at the time of screening.
2. Body weight &gt; 30 kg.
3. Written informed consent and any locally required authorisation obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
4. Confirmed HCC based on histopathological findings from tumour tissues.
5. Must not have received prior systemic therapy for HCC.
6. Ineligible for locoregional therapy for unresectable HCC. For patients who progressed after locoregional therapy for HCC, locoregional therapy must have been completed â‰¥ 28 days prior to the baseline scan for the current study.
7. BCLC stage B (ie, not eligible for locoregional therapy) or stage C.
8. Child-Pugh score class A.
9. ECOG performance status of 0 or 1 at enrollment.

<div style=\"page-break-after: always\"></div>

10. Patients with HBV infection, characterised by positive HBsAg and/or anti-HBcAb with detectable HBV DNA ( â‰¥ 10 IU/mL or above the limit of detection per local or central laboratory standard), must be treated with antiviral therapy, per institutional practice, to ensure adequate viral suppression (HBV DNA â‰¤ 2000 IU/mL) prior to enrollment. Patients were to remain on antiviral therapy for the study duration and for 6 months after the last dose of study treatment. Patients who tested positive for HBc with undetectable HBV DNA (&lt; 10 IU/mL or under the limit of detection per local or central laboratory standard) did not require antiviral therapy prior to enrollment. These patients were tested at every cycle to monitor HBV DNA levels and antiviral therapy initiated if HBV DNA was detected ( â‰¥ 10 IU/mL or above the limit of detection per local or central laboratory standard). HBV DNA detectable patients were to initiate and remain on antiviral therapy for the study duration and for 6 months after the last dose of study treatment.

11. Patients with HCV infection: Confirmed diagnosis of HCV characterised by the presence of detectable HCV RNA or anti-HCV antibody upon enrollment.

12. At least 1 measurable lesion, not previously irradiated, that could be accurately measured at baseline as â‰¥ 10 mm in the longest diameter (except lymph nodes, which must have a short axis â‰¥ 15 mm) with CT or MRI, and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines. A lesion which progressed after previous ablation or transarterial chemoablation could be measurable if it met these criteria.

13. Adequate organ and marrow function, as defined below. Criteria ' a', ' b, ' ' c, ' and ' f ' could not be met with transfusions, infusions, or growth factor support administered within 14 days of starting the first dose.

- a. Hemoglobin â‰¥ 9 g/dL
- b. Absolute neutrophil count â‰¥ 1000/ Î¼ L
- c. Platelet count â‰¥ 75000/ Î¼ L
- d. TBL â‰¤ 2.0 Ã— ULN
- e. AST and ALT â‰¤ 5 Ã— ULN
- f. Albumin â‰¥ 2.8 g/dL

g. INR â‰¤ 1.6. Note: INR prolongation due to anticoagulants for prophylaxis (eg, atrial fibrillation) in patients without liver cirrhosis could be an exception h. Calculated creatinine clearance â‰¥ 50 mL/min as determined by Cockcroft-Gault (using actual body weight) or 24 h urine creatinine clearance

14. Evidence of postmenopausal status or negative urinary or serum pregnancy test for female premenopausal patients.

15. Life expectancy of at least 12 weeks.

## Exclusion Criteria

Any of the following was regarded as a criterion for exclusion from the study:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
2. Previous study treatment (s) assignment in the present study.
3. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

<div style=\"page-break-after: always\"></div>

4. Received an IP within 28 days prior to the first dose of study treatment.

5. Any unresolved toxicity NCI CTCAE Grade â‰¥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:

- a. Patients with Grade â‰¥ 2 neuropathy were evaluated on a case-by-case basis after consultation with the Study Physician
- b. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab could be included only after consultation with the Study Physician.

6. Any concurrent chemotherapy, study treatment, or biologic or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) was acceptable.

7. Known allergy or hypersensitivity to any of the study treatments or any of the study treatment excipients.

8. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of study treatment.

9. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatments. Note: Local surgery of isolated lesions for palliative intent was acceptable.

10. History of allogeneic organ transplantation (eg, liver transplant).

11. History of hepatic encephalopathy within the past 12 months or requirement for medications to prevent or control encephalopathy (eg, no lactulose, rifaximin, etc if used for purposes of hepatic encephalopathy).

12. Clinically meaningful ascites, defined as any ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose. Patients on stable doses of diuretics for ascites for â‰¥ 2 months were eligible.

13. Patients with main portal vein thrombosis (ie, thrombosis in the main trunk of the portal vein, with or without blood flow) on baseline imaging.

14. Active or prior documented GI bleeding (eg, esophageal varices or ulcer bleeding) within 12 months. Note: For patients with a history of GI bleeding for more than 12 months or assessed as high risk for esophageal varices by the Investigator, adequate endoscopic therapy according to institutional standards was required).

15. Current symptomatic or uncontrolled hypertension defined as DBP &gt; 90 mmHg or SBP &gt; 140 mmHg.

16. Any condition interfering with swallowing pills, uncontrolled diarrhoea, or other contraindication to oral therapy.

17. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). Patients without active disease in the last 5 years were excluded unless discussed with the Study Physician and considered appropriate for study participation.

The following were exceptions to this criterion:

<div style=\"page-break-after: always\"></div>

- 1 Vitiligo or alopecia
- 2 Hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
- 3 Any chronic skin condition not requiring systemic therapy
- 4 Patients with celiac disease controlled by diet alone

18. Co-infection with HBV and HCV or HBV and HDV. HBV positive (presence of HBsAg and/or antiHBcAb with detectable HBV DNA); HCV positive (presence of anti-HCV antibodies); or HDV positive (presence of anti-HDV antibodies).

19. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, ILD, serious chronic GI conditions associated with diarrhoea, inferior vena cava thrombosis, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase the risk of incurring AEs, or compromise the ability of the patient to give written informed consent.

20. History of another primary malignancy except for:

1. Malignancy treated with curative intent and with no known active disease â‰¥ 5 years before the first dose of study treatment and of low potential risk for recurrence
2. Patients with a history of prostate cancer of stage â‰¤ T2cN0M0 without biochemical recurrence or progression and who, in the opinion of the Investigator, are not deemed to require active intervention
3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
4. Adequately treated carcinoma in situ without evidence of disease
21. History of leptomeningeal carcinomatosis.

22. History of, or current, brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT, each preferably with IV contrast of the brain prior to study entry.

23. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

24. History of active primary immunodeficiency.

25. Active infection including TB (clinical evaluation that included clinical history, physical examination and radiographic findings, and TB testing in line with local practice), or HIV (positive HIV1/2 antibodies)

26. Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment, with the exception of the following:

- Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
- Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)

27. Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine while receiving study treatment and up to 30 days after the last dose of study treatment.

<div style=\"page-break-after: always\"></div>

28. Female patients who were pregnant or breastfeeding, or male or female patients of reproductive potential who were not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab plus tremelimumab combination therapy. Not engaging in sexual activity, as per the patient ' s preferred and usual lifestyle, for the total duration of the treatment and washout periods was an acceptable practice.

29. Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.

30. Patients who had received anti-PD-1, anti-PD-L1, or anti-CTLA-4 prior to the first dose of study treatment.

## Â· Treatments

## Table 7: Study treatments

| Treatmentarm   | Description                                                                                                                                                                                                                                                                           |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D              | Durvalumab monotherapy 1500 mg Q4W until confirmed PD, unacceptable toxicity, 0r any discontinuation criteria were met                                                                                                                                                                |
| T75+D          | Tremelimumab (75 mg) Ã— 4 doses + durvalumab (1500 mg) Q4W followed by durvalumab monotherapy (1500 mg) Q4W until confirmed PD, unacceptable toxicity, or any discontinuation criteria were met. a                                                                                     |
| T300+D         | Tremelimumab (300 mg) Ã— 1 dose + durvalumab (1500 mg) Q4W, followed by durvalumab 1500 mg monotherapy Q4W until confirmed PD, unacceptable toxicity, 0r any discontinuation criteriaweremet                                                                                           |
| S              | Sorafenib 400 mg (2 Ã— 200 mg tablets) orally BID, until confirmed PD at the Investigator's discretion, unacceptable toxicity, or any discontinuation criteria were met. (Suspected sorafenib-related toxicities were managed based on the approved product label for each country). b |

- Following protocol amendment 3, enrollment into the T75+D arm was closed. Patients randomized to T75+D prior to protocol amendment 3 could continue on assigned study treatment (provided the Investigator and patient agreed it was in the best interest of the patient) until confirmed PD or any other discontinuation criteria were met. If a patient assigned to T75+D had not completed or started all 4 doses of tremelimumab, the patient was able to continue to complete the full schedule or continue with durvalumab monotherapyonly.
- In countries where sorafenib was not approved, the following modification was followed: sorafenib dose may be reduced to 400 mg (2 x 200 mg tablets) orally once daily. If additional dose reduction was required, the sorafenib dose could be reduced to a single 400 mg dose (2 x 200-mg tablets) orally every other day.

BID, twice daily; CSP, Clinical Study Protocol; Q4W, every 4 weeks; PD, disease progression.

The proposed dosing regimen for the relevant arm for this procedure (T300+D, arm C) is new and encompasses one single initial dose of tremelimumab 300 mg in combination with durvalumab 1500 mg and thereafter, durvalumab monotherapy iv Q4W until PD or unacceptable toxicity.

The relevant comparator arm for the current procedure is the standard of care arm (SOC, arm D), which contains sorafenib 400 mg orally twice daily as standardly dosed, and treatment should also be given until PD or unacceptable toxicity. No cross-over was allowed.

The two other treatment arms with D (durvalumab 1500 mg Q4W, arm A) and T75+D (tremelimumab 75 mg Q4W Ã— 4 doses + durvalumab 1500 mg Q4W, followed by durvalumab 1500 mg Q4W, arm B) are not of relevance for this procedure.

It is noted that although the combination of a CTLA-4 inhibitor, such as tremelimumab, and an immunecheckpoint inhibitor such as durvalumab is not new, it is the first time that the anti-CTLA-4 is given only as an induction dose and then monotherapy with durvalumab is continued until PD.

<div style=\"page-break-after: always\"></div>

Moreover, the already approved combination therapy with ipilimumab + nivolumab differs as nivolumab is PD-1 inhibitor, while durvalumab is a PD-L1 inhibitor.

The applicant claims that pharmacodynamic results reported for tremelimumab and durvalumab in Study 006 suggest that the pharmacodynamic effects of anti-CTLA-4 are mainly associated with the first dosing cycle and subside in subsequent cycles regardless of dose. Moreover, these results led to the hypothesis that a single dose of tremelimumab might accomplish similar pharmacodynamic effects as seen in Study 006 and also seen for ipilimumab, while also limiting the toxicity associated with the second (and subsequent) anti-CTLA-4 dosing cycles.

## Â· Objectives

## Table 8. Study objectives and endpoints

| Objective                                                                                                                 | Outcomemeasure                                                                                                                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary objective:                                                                                                        | Primary endpoint/variables:                                                                                                                                                                                                                                                     |
| To assess the efficacy of T300+D vs S (for superiority)                                                                   | OS                                                                                                                                                                                                                                                                              |
| Key secondary objectives:                                                                                                 | Key secondary endpoint/variables:                                                                                                                                                                                                                                               |
| To assess the efficacy of D vs S (for non- inferiority)                                                                   | OS                                                                                                                                                                                                                                                                              |
| To assess the efficacy of D vs S (for superiority)                                                                        | OS                                                                                                                                                                                                                                                                              |
| Secondary objectives:                                                                                                     | Secondaryendpoint/variables:                                                                                                                                                                                                                                                    |
| To assess the efficacy of D vs S and T300+D vs S                                                                          | OS18,OS24, and OS36 PFS, TTP, ORR, DCR, DCR-16w, DCR-24w, and DoR, according toRECIST 1.1 usingInvestigator assessments                                                                                                                                                         |
| To assess the efficacy of D and T300+D in patients with an opportunity for 32 weeks of follow-up                          | ORR, BOR, and DoR according to RECIST1.1 and mRECIST by BICR                                                                                                                                                                                                                    |
| To assess the efficacy of Dvs S and T300+D vs S by PD-L1 expression                                                       | OS PFS,TTP,ORR,DCR,DCR-16w,DCR-24w,andDoR according toRECIST 1.1 usingInvestigator assessments                                                                                                                                                                                  |
| To assess disease-related symptoms, impacts, and HRQoL in D vs S and T300+D vs S                                          | EORTC QLQ-C30:Timetodeteriorationinglobalhealth status/QoL, functioning (physical), multi-term symptom (fatigue), single-item symptoms (appetite loss,nausea) EORTC QLQ-HCC18:Time to deterioration in single-item symptoms (shoulder pain, abdominal pain, abdominal swelling) |
| Toinvestigate theimmunogenicityof D and T300+D                                                                            | PresenceofADAfordurvalumaband tremelimumab                                                                                                                                                                                                                                      |
| To evaluate the population PK and pharmacodynamics in D and T300+D                                                        | DurvalumabandtremelimumabconcentrationsandPK parameters in individual arms                                                                                                                                                                                                      |
| Safety objectives:                                                                                                        | Safety endpoint/variables:                                                                                                                                                                                                                                                      |
| To assess the safety and tolerability profile across all treatment arms                                                   | AEs and laboratory findings a                                                                                                                                                                                                                                                   |
| Exploratory objectives:                                                                                                   | Exploratory endpoint/variables:                                                                                                                                                                                                                                                 |
| To assess PFS from rechallenge in the T300+Darm andtoassessPFSfromfirst post-discontinuation therapy in D, T300+D,and S b | PFSFR and PFSNTusingInvestigator assessments                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Objective                                                                                                                                                             | Outcomemeasure                                                                                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To assess the efficacy of D vs S and T300+D vs S using irRECIST and mRECIST for HCC b                                                                                 | PFS, TTP, ORR, DCR, DCR-16w, DCR-24w, and DoR according to irRECIST and mRECIST and by BICR, if performed                                                                                                                                |
| To investigate the relationship between the progressive changes in AFP level and efficacy parameters b                                                                | Association of AFP expression level with: OS PFS,TTP,ORR,DoR,DCR,DCR-16w,andDCR-24W according to RECIST 1.1 using Investigator assessments                                                                                               |
| To investigate the efficacy of D vs S and T300+D vs S by baseline gene expression b                                                                                   | Associationofinterferon-gamma andimmune-relatedgene expression, as measured by mRNA levels from baseline tumor biopsies and blood, with OS PFS,TTP,ORR,DoR,DCR,DCR-16w,andDCR-24w according to RECIST 1.1 using Investigator assessments |
| Toinvestigate the efficacy of Dvs Sand T300+Dvs S by candidate biomarkers that may correlate with drug activity or identify patients likely to respond to treatment b | Associationofintratumoralimmunecellnumbers (specifically CD8+ T cells), ctDNA, and/or tumor mutations with: OS PFS,TTP,ORR,DoR,DCR,DCR-16wandDCR-24w according toRECIST 1.1 usingInvestigator assessments                                |
| Toinvestigate the efficacy of Dvs S in patients who are at low risk of early mortality based on baseline characteristics b                                            | OS                                                                                                                                                                                                                                       |
| To assess the efficacy of Dvs T300+D in the overall population and in the population defined by PD-L1 expression b                                                    | OS PFS, TTP, ORR, DCR, DCR-16w, DCR-24w and DoR, by according toRECIST 1.1 using Investigator assessments                                                                                                                                |
| To assesspatient-reported treatment tolerability directly using specific items ofthePRO-CTCAE questionnairein D vsSandT300+DvsS                                       | PRO-CTCAE symptoms (11 items)                                                                                                                                                                                                            |
| Healthcareresource utilization                                                                                                                                        | EQ-5D-5L Hospital admissionform                                                                                                                                                                                                          |
| To assessphysician-reportedpatient outcomein Dvs S and T300+Dvs S                                                                                                     | ECOG performance status                                                                                                                                                                                                                  |
| To assess the efficacy of the discontinuedimmunotherapy arm (T75+D) for descriptive purposes                                                                          | OS PFS, TTP, ORR, DCR, DCR-16w, DCR-24w,and DoR according to RECIST 1.1 using Investigator assessments                                                                                                                                   |

## Â· Outcomes/endpoints

Please refer to Table 11 above regarding the objectives and endpoints for the pivotal study Himalaya.

## Â· Sample size

This study will screen approximately 1650 patients, with no prior systemic therapy for hepatocellular carcinoma (HCC) and not eligible for locoregional therapy, in order to randomise approximately 1310 patients. (This includes 1155 patients randomised to Arms A (Durvalumab monotherapy), C (T300+D), D (S) with 385 per arm; and approximately 155 patients in Arm B (T75+D), randomised prior to the closure of this arm). The study is sized to characterize the OS benefit of Arm C vs. Arm D (T300+D vs S).

<div style=\"page-break-after: always\"></div>

The sample size estimation assumes an exponentially distributed OS and a 2-month delay in separation of the OS curves for Arm C vs. Arm D. A non-uniform accrual of patients with a duration of 22 months is assumed when estimating the analysis times.

For the efficacy comparisons, the median OS for sorafenib (Arm D) is assumed to be 11.5 months, with an 18-month OS rate of 33.8%.

## Durvalumab 1500 mg plus tremelimumab 300 mg Ã— 1 dose (Arm C) versus sorafenib 400 mg BID (Arm D) (OS in FAS [ITT])

The assumed OS treatment effect is an average HR of 0.70 for Arm C versus Arm D. This translates to an increase in median OS from 11.5 months to 16.5 months, and in the 18-month OS rate from 33.8% to 46.8% in Arm C versus Arm D. Final analysis of OS will be performed when approximately 515 events in Arm C and Arm D combined (~67% maturity) have occurred. This number of OS events will provide 97% power to demonstrate a statistically significant difference in OS at a 2-sided 4.25% significance level. The smallest treatment difference that could be observed as statistically significant at the final analysis is an average HR of 0.84 (an increase in median OS from 11.5 months to 13.7 months in Arm C versus Arm D).

No formal sample size calculations were associated with the analyses planned for IA1. However, global enrollment was required to be completed prior to the DCO for IA1.

There were 2 IAs and a FA planned for HIMALAYA. Any major changes to the planned analyses were addressed in protocol amendments finalised prior to the date of the first DCO for Interim analysis 1 for ORR (02 September 2019). These changes were informed by the open-label Study 22 and study readouts from external studies in the same disease area, including KEYNOTE-240 and CheckMate-459. No HIMALAYA data were available for use to modify the protocol design or statistical analysis plan.

The sample size calculations were updated several times while the study was ongoing. Major changes were implemented in the Protocol version 4 (29 Nov 2018) and in Protocol version 6 (20 Aug 2019). In protocol version 4, the arm durvalumab + tremelimumab 75 mg was closed due to unfavourable results obtained in the supportive Study 22. At this point, the sample size for the remaining arms was increased to 385 and the number of required events at the second interim analysis and at the final analysis was changed. In protocol version 6, the median OS and 18-month OS rate for sorafenib was increased from 10 months and 28.7 % to 11.5 months and 33.8 %, respectively. The required number of events at the second interim analysis and at the final analysis were also changed.

The applicant claimed that the changes made in the protocol and SAP were solely informed by external data including Study 22 and KEYNOTE-240 and CheckMate-459. Nevertheless, changes in the sample size while the study is ongoing can jeopardise the interpretation of the results since they may alter the behaviour of study participants and personnel. The changes were implemented between 1 and 2 years from study start, and one month before the first interim analysis (2 Sep 2019). Therefore, the sample size calculations are not considered relevant and the study results will be assessed based on the size of the confidence intervals.

## Â· Randomisation and Blinding (masking)

Subjects will be randomised in a 1:1:1:1 ratio to one of the following 4 arms:

- 1) Arm A: Durvalumab 1500 mg monotherapy
- 2) Arm B: Tremelimumab 75 mg Ã— 4 doses plus Durvalumab 1500 mg combination therapy
- 3) Arm C: Tremelimumab 300 mg Ã— 1 dose plus Durvalumab 1500 mg combination therapy
- 4) Arm D: Sorafenib 400 mg BID.

<div style=\"page-break-after: always\"></div>

Protocol amendment 4 closed enrolment to Arm B. As a result of protocol amendment 4, subjects will be randomised in a 1:1:1 ratio to Arm A, Arm C and Arm D. Subjects randomised to Arm B prior to amendment 4 can remain on study as planned until discontinuation criteria are met at the discretion of the investigator.

Randomisation will be stratified according to macrovascular invasion (yes versus no), aetiology of liver disease (hepatitis B virus [confirmed HBV] versus hepatitis C virus [confirmed HCV] versus others), and ECOG PS (0 versus 1).

A randomisation list was produced for each of the randomisation stratum. A blocked randomisation was generated, and all centres used the same list in order to minimise any imbalance in the number of patients assigned to each treatment arm.

The study was open-label. Measures were in place to ensure that the Study team was blinded to treatment assignment and results from the interim analyses. An IDMC assessed safety data ongoing and performed the interim analyses.

## Â· Statistical methods

## Full analysis set

The full analysis set (FAS) was to include all randomised patients, including patients who were randomised in error. The FAS will be used for all efficacy analyses (including PROs). Treatment arms were to be compared on the basis of randomised study drug(s), regardless of the study drug(s) actually received. Patients who were randomised but did not subsequently go on to receive study drug(s) were included in the analysis in the treatment arm to which they were randomised.

For IA1 an additional analysis set will be defined: FAS subjects with an opportunity for 32 weeks of follow up at the time of IA1 (FAS-32w, i.e., randomise d â‰¥ 32 weeks prior to IA1 DCO).

The primary analysis was performed using the FAS, which includes all randomised patients. For the first IA, only subjects who had the opportunity to attend at least 32 weeks of follow-up were included. The results of the first IA are not related to the primary objectives of the study.

<div style=\"page-break-after: always\"></div>

## Statistical analyses

Table 14: Formal statistical analyses to be conducteed and pre-planned sensitivity

Table 13 Formal Statistical Analyses to be Conducted and Pre-planned Sensitivity Analyses

| Endpoint                        | Analysis                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Overall survival (OS)           | Primary analysis: Stratified log-rank test (for p-value), HR from Cox model (with 95% CI) Sensitivity analyses: Attrition bias. Kaplan-Meier plot of time-to-censoring where the censoring indicator of the primary analysis is reversed. Exploratory analysis using max-combo test. Impact of COVID19. OS analysis will be repeated but subjects who died from COVID-19 Infection will be censored at their COVID |
| Progression Free Survival (PFS) | Primary analysis: Stratified log-rank test using Investigator assessments per RECIST 1.1 (for p-value), HR from Cox mode1 (with 95% CI)                                                                                                                                                                                                                                                                            |
| Time to progression (TTP)       | Primary analysis: Stratified 1log-rank test using Investigator assessments per RECIST 1.1 (for p-value), HR from Cox mode1 (with 95% CI)                                                                                                                                                                                                                                                                           |

| Endpoint                                                                  | Analysis                                                                                                                                            |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective response rate (ORR)                                             | IA1: Exact confidence intervals; IA2 and FA: Logistic regression using Investigator assessments per RECIST 1.1 (odds ratio with 95% CI and p-value) |
| Best Objective Response (BoR)                                             | Descriptive statistics                                                                                                                              |
| Duration of response (DoR)                                                | Descriptive statistics including KM plot                                                                                                            |
| Disease control rate (DCR, DCR-16w, DCR-24w)                              | Descriptive statistics                                                                                                                              |
| Proportion of subjects alive at 18m (Os18)                                | KM estimates ofOS at18months                                                                                                                        |
| Proportion of subjects alive at 24m (Os24)                                | KMestimatesofOS at 24months                                                                                                                         |
| Proportion of subjects alive at 36m (OS36)                                | KMestimatesofOSat36months Stratified chi-square test of difference in KM estimators at a fixed time point (36 months) (for p-value)                 |
| PFS from rechallenge                                                      | Summarized by treatment arm using Investigator assessments per RECIST 1.1.                                                                          |
| PFS on next treatment                                                     | Summarized by treatment arm                                                                                                                         |
| Time to deterioration (EORTC QLQ-C30 and EORTC QLQ-HCC18)                 | Stratified log-rank test (for p-value), HR from Cox mode1 (with 95% CI), KM plot                                                                    |
| EORTC QLQ-C30, EORTC QLQ-HCC18                                            | Average change from baseline using an MMRM analysis, Summary statistics                                                                             |
| Improvement based best overall response (EORTC QLQ-C30, EORTC QLQ- HCC18) | Logistic regression with odds ratio, 95% CI and p-value                                                                                             |
| EQ-5D-5L, PGIC, PRO-CTCAE                                                 | Summary statistics                                                                                                                                  |

EORTCEuropean Organisation for Research and Treatment of Cancer;EQ-5D-5LEuroQoL 5-Dimension, 5-Level health state utility index;MMRM Mixed effect model repeat measurement; OS overall survival; QLQ-C30 30-item core quality of life questionnaire; QLQ-HCC18 18-item hepatocellular cancer healthrelated quality of life questionnaire.

<div style=\"page-break-after: always\"></div>

## Overall survival

The primary OS endpoint was to be analysed using a stratified log-rank tests adjusting for aetiology of liver disease (confirmed HBV versus confirmed HCV versus others), ECOG (0 versus 1), and macrovascular invasion (yes versus no) for generation of the p-value and using rank tests for association as the testing approach, which corresponds to Cox regression with the Breslow approach for handling ties (Breslow, 1974).

The effect of Arm C vs. Arm D treatment was to be estimated by the HR from stratified Cox proportional hazards model (with ties=Efron and stratification variables as listed above) together with its corresponding 95% confidence interval (CI) calculated using a profile likelihood approach. The stratification variable used the values recorded in the randomisation system (IWRS).

If there is &gt;10% discordance in stratification factors as recorded in IWRS versus the Case Report Form (CRF), then a sensitivity analysis of the primary endpoint OS were to be performed using CRF based stratification factors.

Secondary OS analyses were to be performed using the same methodology as for primary analysis described above.

## Censoring rules for OS

Any subject not known to have died at the time of analysis will be censored based on the last recorded date on which the subject was known to be alive

## Assumptions of Proportionality

The assumption of proportionality of hazard was to be assessed first by examining plots of complementary log-log (event times) versus log (time) and, if these raise concerns, by fitting a timedependent covariate to assess the extent to which this represents random variation. If a lack of proportionality of hazard is evident, the variation in treatment effect will be described by presenting piecewise HR calculated over distinct time periods. The Grambsch-Therneau test and Schoenfeld residuals may also be used to check violation of the proportional hazards assumption. As a lack of proportionality is expected (due to delayed effect in IO agents), a three-component stratified MaxCombo test will be used as a sensitivity analysis with the same stratification factors as the primary analysis. The Restricted Mean Survival Time (RMST) will also be analysed up to the minimum of the largest observed event time in each of the two arms and /or suitable clinically relevant timepoint. In addition, an area-under-the-curve approach (Kaplan-Meier method) and Royston-Parmar model (Royston and Parmar 2011, 2013) may also be used.

Sensitivity analysis

- Censoring patterns: A sensitivity analysis for OS will examine the censoring patterns to rule out attrition bias, achieved by a Kaplan-Meier plot of time-to-censoring where the censoring indicator of OS is reversed.
- Impact of switching (crossover outside of this study) to other immunotherapies (or other potentially active investigational agents) on OS analyses: Exploratory analyses of OS adjusting for the impact of subsequent switching of immunotherapy or the investigational treatment may be performed, if a sufficient proportion of subjects switch.
- Effect of COVID-19: A sensitivity analysis will be conducted to assess for the potential impact of COVID deaths on OS. This was to be assessed by repeating the OS analysis except that any subject who had a death with primary/secondary cause as COVID-19 Infection will be censored at their COVID infection death date.

<div style=\"page-break-after: always\"></div>

- Effect of covariates on the HR estimate: Cox proportional hazards modelling was to be employed to assess the effect of pre-specified covariates on the HR estimate for the primary OS treatment comparisons. As an exploratory analysis, the covariates from the model in the primary analysis and the model containing additional covariates may be presented.

## OS12, OS18, OS24, and OS36

OS12, OS18, OS24, and OS36 were to be defined as the Kaplan-Meier estimate of OS at 12 months, 18 months, 24 months, and 36 months. OS12, OS18, OS24, and OS36, along with their 95% CI, will be summarised (using the Kaplan- Meier curve) and presented by treatment arm. An analysis of OS36 will be performed to compare Arm C vs. Arm D using a stratified chisquare test for the difference in KM estimators (cloglog transformed) for Arms C and D at a fixed time point (36 months). The test will be conducted using the methods described in (Klein et al., 2007), including cloglog transformation on KM estimators, with randomisation stratification factors (macrovascular invasion, etiology of liver disease, and ECOG). Note that the adjustment for the stratification factors will be applied only if there are sufficient number of events and subjects at risk available in each strata at 36 months. Otherwise, an unstratified chisquare test will be used to compare the difference in KM estimators at 36 months.

OS was analysed using a stratified log-rank tests adjusting for the factors used at randomisation: etiology of liver disease (confirmed HBV versus confirmed HCV versus others), ECOG (0 versus 1), and macrovascular invasion (yes versus no). The HR will be estimated using a stratified Cox model. The fulfilment of the proportional hazard assumption was investigated using a graphical approach and a maxcombo test. Sensitivity analyses were planned to explore the impact of treatment switch, covid 19 and effect of covariates. Censoring pattern were examined using the reverse Kaplan-Meier method. Patients not known to have died were censored at the last observation date.

The statistical method implemented to analysis OS is overall endorsed. The applicant has clarified that he concordance rate between stratification factors entered in the IWRS vs eCRF at screening and baseline is high and due to &lt;10% discordance rate, the threshold for triggering the sensitivity analysis was not met. Hence, no sensitivity analysis for primary efficacy analysis of OS adjusted for eCRF stratification factors at baseline has been conducted, which is acceptable.

## Objective response rate based on Investigator assessment (ORR)

Data obtained up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR. Subjects who go off treatment without progression, receive a subsequent therapy, and then respond will not be included as responders in the ORR. ORR based on at least one confirmed response will also be derived and reported in CSR.

Logistic regression models adjusting for the same factors as the primary endpoint (etiology of liver disease, ECOG, and macrovascular invasion) will be fitted. The results of the analysis will be presented in terms of an odds ratio together with its associated profile likelihood 95% CI (e.g. using the option 'LRCI' in SAS procedure GENMOD) and p-value (based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model).

Additionally, at IA2 and FA a stratified Cochran Mantel-Haenszel (CMH) test will be performed using randomisation stratification factors (macrovascular invasion, etiology of liver disease, and ECOG). CMH test results will include odds ratios and p-values.

## Progression Free Survival by Investigator (PFS)

Analysis of PFS (time to first progression) will be performed to compare Arm C vs. Arm D and Arm A vs. Arm D using the same methodology as for OS. Exploratory analyses will compare Arm A vs. Arm C.

<div style=\"page-break-after: always\"></div>

Table 15: Censoring rules for PFS

| Assessment                                                                                             | Outcome    | Date of Progression or Censoring                             |
|--------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------|
| No baseline assessments or no evaluable response visits (excluding deaths within 2 visits of baseline) | Censored   | Randomizationdate                                            |
| No baseline or evaluable tumor assessments and death ProgressedDate of death within2visitsofbaseline   |            |                                                              |
| Progression documented between scheduled visits                                                        |            | Progressed  Date of assessment of progression                |
| No progression (or death) at time of analysis                                                          | Censored   | Dateoflastevaluabletumor assessment                          |
| Death between assessment visits                                                                        | Progressed | 1Date ofdeath                                                |
| Death or progression after 2 or more missed visits                                                     | Censored   | Dateoflast evaluabletumor assessmentpriortothe2missed visits |

PFS Progression-free survival.

## Interim analyses

Two interim analyses and a final analysis are planned as described below:

Interim Analysis 1 (IA1): The first interim analysis will be performed after approximately 100 subjects per treatment arm have had the opportunity for 32 weeks of follow-up and not prior to the last subject enrolled. The objective is to evaluate the efficacy of Arm A and Arm C in terms of ORR and DoR. The analysis set for ORR and DoR will be the FAS-32wA BICR of radiological scans will be performed on all subjects included in IA1 who have been randomised and have had the opportunity for at least 32 weeks follow-up. Both Investigator (using RECIST 1.1) and BICR (using RECIST 1.1 and mRECIST) assessments are planned for IA1. Therefore, ORR and DoR (for both confirmed and unconfirmed responses) according to both Investigator using RECIST 1.1 and BICR using RECIST 1.1 and mRECIST will be reported for IA1.

Interim Analysis 2 (IA2): The second interim analysis will be performed when approximately 404 OS events in Arm C and Arm D combined (~52% maturity), approximately 30 months after the first subject is randomised. The goal is to evaluate the efficacy of Arm C vs. Arm D (for superiority) and then Arm A vs. Arm D (for non-inferiority, then superiority) in terms of OS. It is anticipated that approximately 453 OS events will have occurred across Arms A and D combined (~59% maturity) at the time of the DCO for IA2.

Final Analysis (FA): The final analysis is expected to be performed when approximately 515 OS events in Arm C and Arm D combined (~67% maturity), approximately 37.5 months after the first subject is randomised. The primary objective is to assess the efficacy of Arm C vs. Arm D in terms of OS for superiority. The key secondary objectives are to assess the efficacy of Arm A vs. Arm D in terms of OS (for non-inferiority, then superiority). It is anticipated that approximately 560 OS events will have occurred across Arms A and D combined (~73% maturity) at the time of the DCO for the final analysis. Efficacy data for Arm B (which was closed for enrollment with Amendment 4) will be summarised descriptively, however will not be formally analysed.

## Multiplicity

To strongly control the familywise error rate (FWER) at the 5% level (2-sided), an alpha level of 0.1% will be spent on the interim ORR analysis (IA1) while the remaining 4.9% alpha level will be spent on

<div style=\"page-break-after: always\"></div>

all OS analyses. The primary objective of OS will be tested (H1: Arm C vs. Arm D) with 4.9% for this comparison.

Since two analyses of OS are planned (Interim Analysis, Final Analysis), the Lan DeMets approach (Lan and DeMets 1983) that approximates the O'Brien and Fleming spending function will be used to maintain an overall 2-sided 4.9% type I error across the two planned analyses of OS (Interim and Final) for the primary comparison (H1: Arm C vs. Arm D).

If all the OS analyses (H1, H2, and H3) are considered successful (superiority tests are statistically significant and non-inferiority is achieved), the 4.9% alpha level will be passed to test the difference in the three-year survival rates (OS36) between Arm C and Arm D; Otherwise the test will not be conducted. The study will be considered positive (a success) if the primary OS analysis result is statistically significant at either IA2 or FA. If significance is achieved at IA2, it does not need to be tested again at FA.

Figure 16: Multiple testing strategy

<!-- image -->

The MAH planned to perform 2 interim and 1 final analyses. The first interim analysis was planned to be performed after 100 subjects per treatment arm have had the opportunity for 32 weeks of followup. The objective is to evaluate the efficacy of Arm A and Arm C in terms of ORR and DoR. This analysis was not related to the primary objective of the study. The second interim analysis was related to OS and planned to be performed after 404 OS events were observed (~52% maturity). The final OS analysis was planned to be performed after 515 OS events (~67% maturity) had been observed. The MAH implemented a hierarchical approach to protect the type I error due to multiple hypotheses being tested (OS superiority for T300+D vs S, OS non-inferiority for D vs S, OS superiority D vs S). An inflation of the type I error due to multiple looks was avoided using an alpha spending function.

The implemented strategy to control the type I error is endorsed. Of note, the results presented in the CSR corresponds to the final analysis for OS.

## Changes to Planned Analyses

Changes to the statistical analyses planned are shown in Table . The AstraZeneca study team was responsible for all changes to the planned statistical analyses. All major changes were made prior to the DBL for the final analysis (DCO: 27 August 2021) (data not shown). Minor changes to the algorithms for counting the number of dose delays for S and for determination of analysis windows for T and D were made after the SAP was finalised.

<div style=\"page-break-after: always\"></div>

Table 16: Changes to planned analyses

| Key Details of Change (Section of Report Affected)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Reason for Change                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Two additional efficacy endpoints that were not detailed in the CSP were calculated: time to response and time from randomization to first subsequent therapy or death. Neither endpoint is reported in the CSR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | To support the payer analysis                                                      |
| Section 6.5 of the CSP (see Appendix 16.1.1) does not define or provide instructions for determining AEPIs. The latest list of PTs was used to determine both AESIs and AEPIs (Section 9.8.6.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | For completeness                                                                   |
| The following details of the non-inferiority approach were added to the SAP (see Sections 1.3 and 4.2.2.1 of Appendix 16.1.9) to supplement the information provided on the non-inferiority margin in Sections 8.2 and 8.5 of the CSP (see Appendix 16.1.1): results of the 3 studies used to determine the non-inferiority margin clarificationthattheassumedHRforthecomparisonof Dvs Sisbasedon theresultsinCheckmate459fornivolumabvs sorafenib in the same population (Yau et al 2019) results from 4 other studies that were designed with non-inferiority to a sorafenib control in first-line HCC Section 4.2.2.1 also specifies that for the interim and final analyses of the primary OS and key secondary analyses (including non-inferiority), adjusted alphalevels are derived based on the exact number of OS events using the Lan and DeMets approach that approximates the O'Brien Fleming spending function. Section 4.2.2.1 clarifies that the primary analysis method (log-rank test) will be used to assess non-inferiority and superiority for the OS comparisons of D vs S | Provisionofadditionaldetailsandsources for the chosen statistical analysis methods |
| TheCSPindicated thatdetailsoftheChinacohort and the corresponding analysis plan would be outlined in a China-specific amendment and SAP. As no patients were enrolled in the China cohort, a China-specific SAP was not prepared                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | No longer required                                                                 |
| A test of the 3-year overall survival rate (OS36) between T300+D and Swas added to theMTPinSAPSection 4.2.1.Thetestis described in SAP Section 4.2.3.7. Section 4.2.1 clarifies that only in the case that all OS analyses were statistically significant and non- inferiority was achievedfor Dvs S,would the 4.9% alphalevel be passed to test the difference in the 3-year survival rates (OS36) betweenT300+D and S.Section4.2.3.7providesthe details ofthe test for OS36; the test would be performed using the stratified method described in (Klein et al 2007), using stratification factors collected at randomization (macrovascular invasion, etiology of liverdisease,andECOG).The adjustmentforstratificationfactors would be applied only if there are sufficient number of events and numberofsubjectsatriskavailableineachstratum at36months, otherwise unstratified methods from (Klein et al 2007) would be used.                                                                                                                                                             | To further assess efficacy between T300+D and S                                    |

AEPI, adverse event of possible interest; AESI, adverse event of special interest; CSP, clinical study protocol; CSR, clinical study report; D, durvalumab monotherapy 1500 mg Q4W; ECOG, Eastem Cooperative Oncology Group; HCC, hepatocellular carcinoma; HR, hazard ratio; OS, overall suvival; OS36, OS at 36 months; PT, preferred term; S, sorafenib 400 mg twice daily; SAP, statistical analysis plan; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

There are 4 versions of the SAP: SAP edition 1 (25 Oct 2017), SAP edition 2 (23 Aug 2019), SAP edition 3 (15 May 2020), and SAP edition 4 (30 July 2021). Several amendments were done to the study protocol throughout the study and the SAP was therefore updated. Major changes to the study design were made in Protocol version 5 (20 Aug 2019) where the objectives of the study, primary endpoints and the testing hierarchy were modified.

<div style=\"page-break-after: always\"></div>

## Results

## Â· Participant flow

## Figure 17: Patient disposition

<!-- image -->

- Informed consent received. The reported value of 2011 includes 61 rescreened subjects who each received a new subject ID code during the rescreening phaseperprotocol.The actual number ofsubjects enrolledwas1950.
- Patients confirmed alive in follow-up or on active study treatiment at the time of final analysis reported 'study completion' on the disposition eCRF.
- C Patients ongoing in study are the same as patients who completed the final analysis.
- d Percentages are calculated from the number of patients who received treatment in the Global Study. For combination therapy patients durvalumab reason is reported.

Compl., completed;D, durvalumab monotherapy 1500 mg Q4W;DCO, data cutoff; Discont., discontinued or discontinuation; PD,disease progression; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300mgÃ—1dose+durvalumab1500mgQ4W Source:Table 14.1.1

<div style=\"page-break-after: always\"></div>

## Table 17: Subject Disposition (All subjects, DCO 27 Aug 2021)

## AstraZeneca

Durvalumab (MED14736) and TremelimumabProtocol D419CC00002

DataCut-Off:27AUG2021

Table14.1.1 Subject disposition (All subjects)

|                                                        | Number (%) of subjects   | Number (%) of subjects               | Number (%) of subjects               | Number (%) of subjects   | Number (%) of subjects   |
|--------------------------------------------------------|--------------------------|--------------------------------------|--------------------------------------|--------------------------|--------------------------|
|                                                        | Durva 1500 mg            | Treme 300 mg x1 dose + Durva 1500 mg | Treme 75 mg x4 doses + Durva 1500 mg | Sora 400 mg BID          | Total                    |
| Subjects enrolleda                                     |                          |                                      |                                      |                          | 2011                     |
| Subjectsrandomized                                     | 389                      | 393                                  | 153                                  | 389                      | 1324                     |
| Subjects who were not randomizedb                      |                          |                                      |                                      |                          | 687                      |
| Eligibility criteria not fulfilled                     |                          |                                      |                                      |                          | 654 (95.2)               |
| Other                                                  |                          |                                      |                                      |                          | 33 (4.8)                 |
| Subjectswhoreceivedtreatment                           | 386 (99.2)               | 389 (99.0)                           | 153 (100)                            | 374 (96.1)               | 1302 (98.3)              |
| Subjectswho did notreceive treatment                   | 3 (0.8)                  | 4 (1.0)                              | 0                                    | 15 (3.9)                 | 22 (1.7)                 |
| Subjects ongoing study treatment at data cut-off       | 44 (11.4)                | 44 (11.3)                            | 5 (3.3)                              | 21 (5.6)                 | 114 (8.8)                |
| Subjects who discontinued initial study treatmented    | 342 (88.6)               | 345 (88.7)                           | 148 (96.7)                           | 353 (94.4)               | 1188 (91.2)              |
| Subject decision                                       | 23 (6.0)                 | 19 (4.9)                             | 6 (3.9)                              | 34 (9.1)                 | 82 (6.3)                 |
| Adverse event                                          | 30 (7.8)                 | 52 (13.4)                            | 24 (15.7)                            | 63 (16.8)                | 169 (13.0)               |
| Severenon-compliance toprotocol                        | 1 (0.3)                  | 0                                    | 0                                    | 1 (0.3)                  | 2 (0.2)                  |
| Objective disease progression                          | 222 (57.5)               | 183 (47.0)                           | 88 (57.5)                            | 170 (45.5)               | 663 (50.9)               |
| Development of study specific discontinuation criteria | 3 (0.8)                  | 5 (1.3)                              | 0                                    | 2 (0.5)                  | 10 (0.8)                 |
| Subject lost to follow-up                              | 0                        | 1 (0.3)                              | 0                                    | 0                        | 1 (0.1)                  |
| Subjective disease progression                         | 44 (11.4)                | 61 (15.7)                            | 21 (13.7)                            | 66 (17.6)                | 192 (14.7)               |
| Other                                                  | 19 (4.9)                 | 24 (6.2)                             | 9 (5.9)                              | 17 (4.5)                 | 69 (5.3)                 |
| Subjects ongoing studyef                               | 0                        | 0                                    | 0                                    | 0                        | 0                        |
| Subjectswho terminated studye                          | 389 (100)                | 393 (100)                            | 153 (100)                            | 389 (100)                | 1324 (100)               |
| Death                                                  | 275 (70.7)               | 260 (66.2)                           | 122 (79.7)                           | 280 (72.0)               | 937 (70.8)               |
| Lost to follow-up                                      | 1 (0.3)                  | 1 (0.3)                              | 0                                    | 7 (1.8)                  | 9 (0.7)                  |
| Screen failure                                         | 0                        | 0                                    | 0                                    | 0                        | 0                        |
| Withdrawal by subject                                  | 9 (2.3)                  | 7 (1.8)                              | 1 (0.7)                              | 20 (5.1)                 | 37 (2.8)                 |
| Other                                                  | 104 (26.7)               | 125 (31.8)                           | 30 (19.6)                            | 82 (21.1)                | 341 (25.8)               |
| Completed final analysisf                              | 104 (26.7)               | 125 (31.8)                           | 30 (19.6)                            | 80 (20.6)                | 339 (25.6)               |

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/dm001.sasdm001afa.rtf01DEC2021:11:26kwxd463

<div style=\"page-break-after: always\"></div>

## Table 18: Important protocol deviations (FAS)

Table 13 Important Protocol Deviations (FAS)

|                                                                                                                                                                                        | N (%) of patients   | N (%) of patients   | N (%) of patients   | N (%) of patients   | N (%) of patients   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Important protocol deviations *                                                                                                                                                        | D (N= 389)          | T300+D (N=393)      | T75+D (N=153)       | S (N= 389)          | Total (N=1324)      |
| Number of subjects with at least 1 inportant deviation                                                                                                                                 | Î² (0.8)             | 9 (2.3)             | 3 (2.0)             | 21 (5.4)            | 36 (2.7)            |
| Active or prior documented autoinmme or inflammatory disorders b                                                                                                                       | 0                   | 0                   | 0                   | 1 (0.3)             | 1 (0.1)             |
| Additional investigational systemic anticancer therapy concuurent with those umder investigation in this study (as specified in CSP Section 7.7)                                       | 0                   | 1 (0.3)             | 0                   | 0                   | 1(0.1)              |
| Baseline tumor assessments (RECIST1.1) performed more than 28 days before the first dose of study treatment                                                                            | 0                   | 0                   | 0                   | 2 (0.5)             | 2 (0.2)             |
| Child-Pugh score was not class A                                                                                                                                                       | 0                   | 1 (0.3)             | 1 (0.7)             | 3 (0.8)             | 5 (0.4)             |
| Concurent chemotherapy. radiotherapy, immmotherapy. biologic or hormonal therapy for cancer treatment other than those umder investigation in this study while the patient is on study | 0                   | 1 (0.3)             | 1 (0.7)             | 0                   | 2 (0.2)             |
| Patient randomized but did not receive study treatment                                                                                                                                 | 3 (0.8)             | 4 (1.0)             | 0                   | 15 (3.9)            | 22 (1.7)            |
| Patientreceived/usedincorrect medication (ie, expired medication, incorect kit ID, incomect dose, altermative study treatment to what which they were randomized)                      | 0                   | 2 (0.5)             | 0                   | 0                   | 2 (0.2)             |
| Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D vinus (HDV). *                                                                                          | 0                   | 1 (0.3)             | 0                   | 0                   | 1 (0.1)             |
| Patients with main portal vein tumor tlhrombosis (Vp4)                                                                                                                                 | 0                   | 1 (0.3)             | 1 (0.7)             | 0                   | 2 (0.2)             |

The same patient may have had more than 1 important protocol deviation

Includes inflammatory bowel disease (eg, colitis or Crohn's disease), diverticulitis (with the exception of diverticulosis), systemic hupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome disease (outside of the allowed exceptions) in the last 5 years that has not been discussed with the Study

HBV positive (presence of HbsAg and/or anti-HbcAb with detectable HBV DNA); HCV positive (presence of anti-HCV antibodies); HDV positive (presence of anti-HDV antibodies)

ï¼ˆgramlomatosis with polyangitis, GravesÂ² disease, heumatoid arthritis, hypophysitis, uveitis, etc.). Active Physician and considered appropriate for study participation

<div style=\"page-break-after: always\"></div>

Table 19: Not randomised patients with 'other' reason for screening failure

| Reason for screening failure                                                                                |   Number of patients |
|-------------------------------------------------------------------------------------------------------------|----------------------|
| Because it was possible that selection criterion 12 would not be satisfied.                                 |                    1 |
| Eligibility was not able to be verified within 28 days so patient was reconsented with a new screening id:. |                    1 |
| Exceeded screening time (new screening number)                                                              |                    1 |
| Incorrect activation of the patient                                                                         |                    1 |
| Issue due to sorafenib shipment                                                                             |                    1 |
| Not recorded                                                                                                |                    7 |
| Patient died due to progression disease, before randomisation.                                              |                    1 |
| Patient doesn't meet inclusion criteria 3, as patient withdrew informed consent                             |                    1 |
| Patient was withdrawal                                                                                      |                    1 |
| Screen fail due to insurance reasons                                                                        |                    1 |
| Screen failure                                                                                              |                    2 |
| Screening assessment could not be completed during screening date                                           |                    1 |
| Screening assessments were not completed during screening.                                                  |                    2 |
| Screening period was greater than 28 days because some examinations was missing                             |                    1 |
| Sf due to death                                                                                             |                    1 |
| Subject does not come to site                                                                               |                    1 |
| Subject fell out of screening window.                                                                       |                    1 |
| Subject was unable to provide tumour sample                                                                 |                    1 |
| Subject withdrawn in the middle of screening                                                                |                    1 |
| Time for screening was exceeded.                                                                            |                    1 |
| Screening assessments were not completed during screening.                                                  |                    1 |
| Unable to be randomised within 28 days of icf                                                               |                    1 |
| Unable to submit tumour sample                                                                              |                    1 |
| Withdrawal during screening                                                                                 |                    2 |

Of 1950 patients enrolled in the pivotal study, 61 were rescreened and 1324 were randomised to 1 of the 4 original treatment arms. The applicant has clarified that of the 687 non-randomised patients, 654 did not fulfil eligibility criteria and 33 were not randomised due to other reasons. The screen failure reasons of these 33 patients as collected as free text field in CRF are summarised in Table : 10/33 patients were not randomised due to inability to complete screening procedures within the 28-day window, 6/33 withdrew informed consent or failed to return to clinic, 2/33 were unable to provide the required tumour tissue sample, and 2/33 died prior to randomisation. In addition, 9/33 did not report more specific screen failure reasons. Other reasons were reported in 1 patient each and included insurance coverage issues, incorrect screening, inability to verify eligibility, or local issues with sorafenib supply. The clarification is accepted and the screen failure reasons are in line with what could be expected for a clinical trial with the targeted patient population.

## Â· Recruitment

The first patient was enrolled on 11 October 2017 and the last patient on 19 June 2019. The median follow-up for OS at DCO (27 August 2021) was ~33 months in the T300+D arm and ~32 months in the S arm.

<div style=\"page-break-after: always\"></div>

## Â· Conduct of the study

## Table 20: Protocol amendments and other significant changes to study conduct

Table 11 Protocol Amendments and Other Significant Changes to Study Conduct

| Key details of amendment (section of this report affected)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Reasonforamendment                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocolamendment1,Protocol version 2.0(20December 2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Protocolamendment1,Protocol version 2.0(20December 2017)                                                                                                                                                                      |
| Updated descriptions of risksfordurvalumab,tremelimumab,and the combination of durvalumabwith tremelimumab(Section12.2.4).Toxicity Management Guidelines replaced with new version from 01 November 2017.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | To align with updates across the clinical program and Investigator's Brochure                                                                                                                                                 |
| Inclusion of the exploratory objective:to assessPFSfrom rechallengein the durvalumab plus tremelimumab combination arms only, and to assess PFS from first post-IP discontinuation therapy in all arms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Additional exploratory objectiveof interest                                                                                                                                                                                   |
| Section 9.3 IC10 amended toclarify treatment ofpatients withHBVinfection with antiviral therapytoensure adequateviralsuppressionpriorto enrollment,andtofurther clarifythatpatientswhotestpositiveforHBcwithundetectableHBVDNA (< 10 IU/ml) do not require antiviral therapy prior to enrollment. These patients were if HBV DNA was detected (>10 IU/ml).HBV DNA detectable patients were to initiate and remain on antiviral therapy for the study duration and for 6 months after thelastdoseofIP New IC15 requiring patients tohave a life expectancy of at least 12weeks EC12 amended to specify â€œclinically meaningful ascites (defined as ascites requiring non-pharmacologic intervention eg, paracentesis or escalation in pharmacologic intervention tomaintain symptomatic control),within 6 months prior tothefirst scheduled dose\", rather than â€œascites that require ongoing paracentesis, within 6 weeks prior to the first scheduled dose to control symptoms.\" The amended EC12 also indicates patients on stable doses of diuretics for ascites for â‰¥2 months are eligible EC22 qualified to indicate that a history of, or current,brain metastaseswas an exclusion | IC10: to ensure patients receive antiviral medication as clinically indicated IC15: for compliance with new CSP template EC12: to clarify protocol definition of clinically meaningful ascites EC22: to ensure patient safety |
| Updated AESI terminology (Section 12.2.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | To alignwithupdates across the clinicalprogram                                                                                                                                                                                |
| Protocol amendment 2,Protocolversion3.0(23January 2018)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Protocol amendment 2,Protocolversion3.0(23January 2018)                                                                                                                                                                       |
| No major updates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ReleasedtocorrecterrorsnotedinCSPversion 2.0                                                                                                                                                                                  |
| Protocolamendment3,Protocolversion 4.0(29Noveimber 2018)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Protocolamendment3,Protocolversion 4.0(29Noveimber 2018)                                                                                                                                                                      |

| Key details of amendment (section of this report affected)                                                                                                                                                                                                                                                                                                                                                                                                                                 | Reasonforamendment                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Enrollment into the T75+D arm was closed, based on results from a pre-planned IA evaluating tolerability and clinical activityinStudyD419CC00022.Allother arms were unchanged (Section 9.1)                                                                                                                                                                                                                                                                                                | In the ongoingStudy 22,safety data showed that the T75+Dregimen was tolerable with no new safety signals.However,efficacy data for theT75+Dregimendidnotdifferentiateitfromthedurvalumab monotherapy arm.Thus,therewas insufficient clinical activity observed to warrant continuing enrollment in the T75+D arm in the current study |
| Following closure of enrollment in the T75+D arm, the primary and secondary objectives were re-aligned: The original primary objective of OS for T75+D vs S was replaced with D vs S and T300+D vs S for OS. Other supportive endpoints were clarified for consistency across the CSP, and a new endpoint (DCR-16w)was added (Section 8)                                                                                                                                                   | To align with study design changes                                                                                                                                                                                                                                                                                                    |
| Themultiple testing strategy was updated toreflect the procedure for controlling the type 1 error as a result of the changes to the primary and secondary objectives.PRO endpoints were added to the MTP (Section 9.8.3)                                                                                                                                                                                                                                                                   | To alignwithstudy designchanges                                                                                                                                                                                                                                                                                                       |
| Update such that IA1 was performed after approximately 100 patients per treatment arm had the opportunity for 32 rather than 24 weeks of follow-up (Section 9.8.9)                                                                                                                                                                                                                                                                                                                         | To ensure 24 weeks of imaging follow-up, the baseline scan needs to be 8 weeks prior to the first follow-up scan, ie, a total of 32 weeks                                                                                                                                                                                             |
| The sample sizewas updated to align with closure ofenrollment in the T75+D arm.The number of events, maturity, power and 2-sided significance levels for these analyses were updated accordingly and theMTPwas updated toreflect therevised procedure for controlling the type 1 error. No changes were made to the assumed HRs, timelines, or medianOS.Thestatisticalmethodswererevised toindicatetheT75+Darmwould be summarized descriptively, but not formally analyzed (Section 9.8.1) | To alignwith study design changes                                                                                                                                                                                                                                                                                                     |
| Patientsin theT75+D arm could continue toreceivetheir assignedtreatment according to the CSP (Section 9.4)                                                                                                                                                                                                                                                                                                                                                                                 | To align with study design changes                                                                                                                                                                                                                                                                                                    |
| Patients in the T75+D arm whowere eligibleforrechallenge couldbe rechallengedwith either75mg tremelimumabÃ—4dosesor300mgtremelimumabx1doseincombination with durvalumab 1500 mg (with prior approval from the AstraZeneca clinical team) (Section 9.4.1.5)                                                                                                                                                                                                                                  | To alignwithstudy designchanges                                                                                                                                                                                                                                                                                                       |
| EC19 amended to include â€œinferior vena cava thrombosis\" (Section9.3.2)                                                                                                                                                                                                                                                                                                                                                                                                                     | Patientswithinferiorvenacavathrombosiswereexcludedduetothe riskofpulmonaryembolismandsuddendeath                                                                                                                                                                                                                                      |
| Protocolamendment4,Protocolversion5.0(17December2018)                                                                                                                                                                                                                                                                                                                                                                                                                                      | Protocolamendment4,Protocolversion5.0(17December2018)                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| No major updates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Released to correct administrative errors noted in CSPversion 4.0                                                                                                                                                                                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocol amendment 5,Protocol version 6.0 (20 August 2019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Protocol amendment 5,Protocol version 6.0 (20 August 2019)                                                                                                                                                                                                                                                                                                                 |
| Statistical analysis methods revised to change dual primary objectives to hierarchical approach with a single primary objective (T300+D vs S for superiority) and 2 key secondary objectives (D vs S for non-inferiority, then D vs S for superiority) of OS (Section 9.8): Themultipletestingstrategywas updated toreflect the procedurefor controlling the type 1 error given the update from dual primary objectives to a hierarchical approach with a singleprimary objective and 2key secondary objectives of OS ORR and PRO endpoints wereremoved from theMTP The number of events, maturity, power and 2-sided significance levels for these analyses were updated | AnIA of theongoingStudy 22suggested that thebest clinicalbenefit (in terms of ORR and Os) was observed in patients who received the T300+D combination when compared to durvalumab monotherapy, tremelimumabmonotherapy,orT75+D.As a result,the primary analysis for the current study was revised                                                                         |
| Efficacy assessments inIA1,ie,RECIST 1.1 and mRECIST analyses(ORR,BOR,DoR) by BICR for the IA1 set of patients with an opportunity for 32 weeks of follow-up were added as a secondary objective. It was also clarified that enrollment had to be completed before IA1 could be performed (Section 8)                                                                                                                                                                                                                                                                                                                                                                     | To clarify analyses in IA1                                                                                                                                                                                                                                                                                                                                                 |
| The order of hypotheses for superiority was changed: H1: T300+D vs S and H3: D vs S. A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | To align with revised objectives                                                                                                                                                                                                                                                                                                                                           |
| The assessment ofefficacyfor the comparison of Dvs T300+Din the overall population and in the population definedbyPD-L1 expressionwas changed from a secondaryto an exploratoryobjective(Section8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Archival tissue up to3years of agewas allowed for the HIMALAYA study. Data suggest that sample age may affect PD-L1 expression status (eg,PD-L1 expression measured in an older sample might be lower than PD-L1 expression at the current time for a patient). Therefore,it was decided to change the assessment ofefficacy by PD-L1expression to anexploratory objective |
| An exploratory objective relating to patients with early mortality risk was added (Section 8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | This was anexploratory objective of interest                                                                                                                                                                                                                                                                                                                               |
| Protocolamendment 6,Protocolversion7.0 (22September 2021)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Protocolamendment 6,Protocolversion7.0 (22September 2021)                                                                                                                                                                                                                                                                                                                  |

| Key details of amendment (section of thisreportaffected)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Reasonfor amendment        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| The OS at 36months (OS36)was added to the secondary objectives (proportion of patients alive at 36 months after randomization [OS36]). The OS36 was defined as the KM estimate of OS at 36 months after randomization (Section 9.8.4.1). Clarifiedthatpatientsin all treatment arms,notjustdurvalumab,maycontinuetoreceive treatmentfollowing thefinal primary analysisDCO. Added that long-term follow-up data may be collected in eCRFs post final primary analysis for approximately 3years and defined end of study,if long-termfollow-up is collected post final primary analysis, as the last visit of the last patient in the study. | To further assess efficacy |

AESI,adverse event of special interest;BICR,blinded independent central review;BOR,best overall response;CSP,Clinical StudyProtocol;D,durvalumab monotherapy 1500 mg Q4W; DCO, data cut-off; DCR-16w, disease control rate at 16 weeks; DNA, deoxyribonucleic acid; DoR, duration of response; EC,exclusion criterion;HBc,hepatitis B core;HBV,hepatitis Bvirus;HR,hazard ratio;IA1,interim analysis 1;IC,inclusion criterion;IP,investigational product;KM,Kaplan-Meier; mRECIST, modified Response Evaluation Criteria inSolid Tumors;MTP,multiple testing procedure; ORR, objective response rate; OS, overall survival;PD-L1, programmed cell death ligand-1; PFS, progression-free survival; PRO, patient-reported outcome;Q4W, every 4 weeks; RECIST 1.1,Response Evaluation Criteria in Solid Tumors version 1.1; S, sorafenib 400 mg twice daily;T75+D, tremelimumab75 mg Ã— 4 doses + durvalumab 1500mgQ4W;T300+D,tremelimumab300mgÃ—1dose+durvalumab1500mgQ4W.

Table 21: Summary of overall survival: T300+D versus sorafenib and D versus sorafenib (PD-L1 analysis set)

| Subgroup                   | Treatment   |   Number of Patients | Events (%)   | Median (months) (95% CI)   | Hazard Ratio (95% CI)   |
|----------------------------|-------------|----------------------|--------------|----------------------------|-------------------------|
| PD-L1 Evaluable patients a | T300+D      |                  337 | 229 (68.0)   | 16.00 (13.11, 19.58)       | 0.84 (0.70, 1.00)       |
|                            | D           |                  344 | 248 (72.1)   | 16.46 (13.83, 19.12)       | 0.90 (0.76, 1.08)       |
|                            | Sorafenib   |                  329 | 248 (75.4)   | 14.55 (12.75, 16.85)       |                         |
| TIP <1% b                  | T300+D      |                  189 | 128 (67.7)   | 14.26 (11.43, 21.29)       | 0.83 (0.65, 1.05)       |
|                            | D           |                  190 | 141 (74.2)   | 15.06 (12.68, 18.53)       | 0.93 (0.73, 1.17)       |
|                            | Sorafenib   |                  181 | 138 (76.2)   | 13.93 (12.39, 16.69)       |                         |
| TIP â‰¥1% b                  | T300+D      |                  148 | 101 (68.2)   | 17.35 (13.50, 23.03)       | 0.85 (0.65, 1.11)       |
|                            | D           |                  154 | 107 (69.5)   | 17.22 (12.29, 24.38)       | 0.87 (0.66, 1.13)       |
|                            | Sorafenib   |                  148 | 110 (74.3)   | 15.93 (10.68, 21.72)       | -                       |

Â· The analysis was performed using stratified log-rank test adjusting for treatment, aetiology of liver disease (HBV versus HCV versus others), ECOG PS (0 versus 1), and macro-vascular invasion (yes versus no). The values of the stratification factors were obtained from the interactive web response system. Unstratified analyses.

<div style=\"page-break-after: always\"></div>

CI = confidence interval; D = durvalumab 1500 mg Q4W; ECOG = Eastern Cooperative Oncology Group; HBV = hepatitis B virus; HCV = hepatitis C virus; PDL1 = programmed cell death ligand 1; PS = performance status; QxW = every X weeks; T300+D = tremelimumab 300 mg for a single dose and durvalumab 1500 mg Q4W; TIP = Tumour and Immune Cell Positivity. Source:CSR table 14.2.1.3

## Â· Baseline data

## Table 22: Demographic and baseline patient characteristics in HIMALAYA (pivotal study) and Study 22 (supportive study)

| Study Analysis set (DCO)                  | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|-------------------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                           | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| Age (years)                               |                                 |                                 |                                 |                                                 |                                                 |
| Mean                                      | 62.6                            | 63.0                            | 63.5                            | 64.0                                            | 64.4                                            |
| SD                                        | 11.47                           | 11.65                           | 11.12                           | 10.81                                           | 11.24                                           |
| Median                                    | 64.0                            | 65.0                            | 64.0                            | 64.5                                            | 66.0                                            |
| Min                                       | 20                              | 22                              | 18                              | 32                                              | 26                                              |
| Max                                       | 86                              | 86                              | 88                              | 89                                              | 86                                              |
| Age group (years), n (%)                  |                                 |                                 |                                 |                                                 |                                                 |
| < 65                                      | 203 (52.2)                      | 195 (49.6)                      | 195 (50.1)                      | 52 (50.0)                                       | 34 (45.3)                                       |
| â‰¥ 65 - < 75                               | 130 (33.4)                      | 145 (36.9)                      | 137 (35.2)                      | 33 (31.7)                                       | 31 (41.3)                                       |
| â‰¥ 75                                      | 56 (14.4)                       | 53 (13.5)                       | 57 (14.7)                       | 19 (18.3)                                       | 10 (13.3)                                       |
| Sex, n (%)                                |                                 |                                 |                                 |                                                 |                                                 |
| Male                                      | 323 (83.0)                      | 327 (83.2)                      | 337 (86.6)                      | 92 (88.5)                                       | 65 (86.7)                                       |
| Female                                    | 66 (17.0)                       | 66 (16.8)                       | 52 (13.4)                       | 12 (11.5)                                       | 10 (13.3)                                       |
| Region group, n (%)                       |                                 |                                 |                                 |                                                 |                                                 |
| Asia (excl. Japan)                        | 167 (42.9)                      | 156 (39.7)                      | 156 (40.1)                      | 47 (45.2)                                       | 31 (41.3)                                       |
| Rest of World (incl. Japan)               | 222 (57.1)                      | 237 (60.3)                      | 233 (59.9)                      | 57 (54.8)                                       | 44 (58.7)                                       |
| Race, n (%)                               |                                 |                                 |                                 |                                                 |                                                 |
| White                                     | 160 (41.1)                      | 182 (46.3)                      | 179 (46.0)                      | 35 (33.7)                                       | 27 (36.0)                                       |
| Black or African American                 | 2 (0.5)                         | 7 (1.8)                         | 10 (2.6)                        | 10 (9.6)                                        | 4 (5.3)                                         |
| Asian                                     | 212 (54.5)                      | 195 (49.6)                      | 189 (48.6)                      | 55 (52.9)                                       | 44 (58.7)                                       |
| Native Hawaiian or other Pacific Islander | 0                               | 1 (0.3)                         | 0                               | 2 (1.9)                                         | 0                                               |
| American Indian or Alaska Native          | 0                               | 0                               | 0                               | 1 (1.0)                                         | 0                                               |
| Other                                     | 15 (3.9)                        | 7 (1.8)                         | 5 (1.3)                         | 1 (1.0)                                         | 0                                               |
| Ethnic group, n (%)                       |                                 |                                 |                                 |                                                 |                                                 |
| Hispanic or Latino                        | 13 (3.3)                        | 21 (5.3)                        | 21 (5.4)                        | 5 (4.8)                                         | 4 (5.3)                                         |
| Not Hispanic or Latino                    | 376 (96.7)                      | 372 (94.7)                      | 362 (93.1)                      | 99 (95.2)                                       | 71 (94.7)                                       |
| Weight group (kg), n (%)                  |                                 |                                 |                                 |                                                 |                                                 |
| < 70                                      | 218 (56.0)                      | 190 (48.3)                      | 202 (51.9)                      | 47 (45.2)                                       | 49 (65.3)                                       |
| â‰¥ 70 - < 90                               | 130 (33.4)                      | 158 (40.2)                      | 137 (35.2)                      | 41 (39.4)                                       | 20 (26.7)                                       |

<div style=\"page-break-after: always\"></div>

Table 22: Demographic and baseline patient characteristics in HIMALAYA (pivotal study) and Study 22 (supportive study)

| Study Analysis set (DCO)     | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                              | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| â‰¥ 90                         | 41 (10.5)                       | 45 (11.5)                       | 50 (12.9)                       | 15 (14.4)                                       | 5 (6.7)                                         |
| BMI group (kg/m 2 ), n (%)   | BMI group (kg/m 2 ), n (%)      | BMI group (kg/m 2 ), n (%)      | BMI group (kg/m 2 ), n (%)      | BMI group (kg/m 2 ), n (%)                      | BMI group (kg/m 2 ), n (%)                      |
| Underweight (< 18.5)         | 15 (3.9)                        | 19 (4.8)                        | 17 (4.4)                        | 7 (6.7)                                         | 4 (5.3)                                         |
| Normal (â‰¥ 18.5 - < 25.0)     | 210 (54.0)                      | 188 (47.8)                      | 195 (50.1)                      | 47 (45.2)                                       | 47 (62.7)                                       |
| Overweight (â‰¥ 25.0 - < 30.0) | 114 (29.3)                      | 128 (32.6)                      | 125 (32.1)                      | 32 (30.8)                                       | 17 (22.7)                                       |
| Obese (â‰¥ 30.0)               | 47 (12.1)                       | 56 (14.2)                       | 48 (12.3)                       | 17 (16.3)                                       | 6 (8.0)                                         |
| Alcohol use, n (%) a         | Alcohol use, n (%) a            | Alcohol use, n (%) a            | Alcohol use, n (%) a            | Alcohol use, n (%) a                            | Alcohol use, n (%) a                            |
| Never                        | 150 (38.6)                      | 162 (41.2)                      | 147 (37.8)                      | NA                                              | NA                                              |
| Current                      | 62 (15.9)                       | 54 (13.7)                       | 60 (15.4)                       | NA                                              | NA                                              |
| Former                       | 176 (45.2)                      | 176 (44.8)                      | 182 (46.8)                      | NA                                              | NA                                              |
| Missing                      | 1 (0.3)                         | 1 (0.3)                         | 0                               | NA                                              | NA                                              |

a Alcohol use was not captured in the Study 22 eCRF.

Baseline is the last assessment prior to the intake of the first dose of any study drug; for patients not treated, the last assessment on or prior to treatment allocation (Study 22 Part 2B) or randomisation (HIMALAYA and Study 22 Parts 2A and 3) was used.

Abbreviations: BMI = body mass index; DCO = data cut-off; eCRF = electronic case report form; Excl. = excluding; FAS = full analysis set; Max = maximum; Min = minimum; N = total number of patients; n = number of patients in a treatment arm; NA = not applicable; SD = standard deviation.

Table 23: Disease characteristics at screening in HIMALAYA (pivotal study) and Study 22 (supportive study)

| Study Analysis set (DCO)         | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|----------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                  | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| ECOG performance status, n (%)   |                                 |                                 |                                 |                                                 |                                                 |
| 0                                | 244 (62.7)                      | 246 (62.6)                      | 239 (61.4)                      | 52 (50.0)                                       | 46 (61.3)                                       |
| 1                                | 145 (37.3)                      | 147 (37.4)                      | 148 (38.0)                      | 52 (50.0)                                       | 29 (38.7)                                       |
| BCLC stage, n (%) a              |                                 |                                 |                                 |                                                 |                                                 |
| Early (A)                        | NA                              | NA                              | NA                              | 1 (1.0)                                         | 1 (1.3)                                         |
| Intermediate (B)                 | 80 (20.6)                       | 77 (19.6)                       | 66 (17.0)                       | 9 (8.7)                                         | 13 (17.3)                                       |
| Advanced (C)                     | 309 (79.4)                      | 316 (80.4)                      | 323 (83.0)                      | 80 (76.9)                                       | 58 (77.3)                                       |
| Etiology of liver disease, n (%) |                                 |                                 |                                 |                                                 |                                                 |
| HBV-positive                     | 119 (30.6)                      | 122 (31.0)                      | 119 (30.6)                      | 40 (38.5)                                       | 27 (36.0)                                       |
| HCV-positive                     | 107 (27.5)                      | 110 (28.0)                      | 104 (26.7)                      | 29 (27.9)                                       | 21 (28.0)                                       |
| Others                           | 163 (41.9)                      | 161 (41.0)                      | 166 (42.7)                      | 35 (33.7)                                       | 27 (36.0)                                       |
| MVI and/or EHS, n (%)            | MVI and/or EHS, n (%)           | MVI and/or EHS, n (%)           | MVI and/or EHS, n (%)           | MVI and/or EHS, n (%)                           | MVI and/or EHS, n (%)                           |

<div style=\"page-break-after: always\"></div>

Table 23: Disease characteristics at screening in HIMALAYA (pivotal study) and Study 22 (supportive study)

| Study Analysis set (DCO)                          | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|---------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                   | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| MVI = Yes and/or EHS = Yes b                      | 255 (65.6)                      | 263 (66.9)                      | 251 (64.5)                      | 72 (69.2)                                       | 58 (77.3)                                       |
| MVI = No and EHS=No                               | 133 (34.2)                      | 128 (32.6)                      | 137 (35.2)                      | 12 (11.5)                                       | 13 (17.3)                                       |
| Child-Pugh score, n (%)                           |                                 |                                 |                                 |                                                 |                                                 |
| A/5                                               | 284 (73.0)                      | 295 (75.1)                      | 277 (71.2)                      | 79 (76.0)                                       | 51 (68.0)                                       |
| A/6                                               | 96 (24.7)                       | 92 (23.4)                       | 102 (26.2)                      | 23 (22.1)                                       | 23 (30.7)                                       |
| B/7                                               | 1 (0.3)                         | 2 (0.5)                         | 10 (2.6)                        | 2 (1.9)                                         | 1 (1.3)                                         |
| Alpha-fetoprotein, n (%)                          |                                 |                                 |                                 |                                                 |                                                 |
| < 400 ng/ml                                       | 247 (63.5)                      | 243 (61.8)                      | 256 (65.8)                      | 62 (59.6)                                       | 39 (52.0)                                       |
| â‰¥ 400 ng/ml                                       | 137 (35.2)                      | 145 (36.9)                      | 124 (31.9)                      | 39 (37.5)                                       | 35 (46.7)                                       |
| Missing                                           | 5 (1.3)                         | 5 (1.3)                         | 9 (2.3)                         | 3 (2.9)                                         | 1 (1.3)                                         |
| ALBI score                                        |                                 |                                 |                                 |                                                 |                                                 |
| 1                                                 | 198 (50.9)                      | 217 (55.2)                      | 203 (52.2)                      | NA                                              | NA                                              |
| 2                                                 | 189 (48.6)                      | 174 (44.3)                      | 185 (47.6)                      | NA                                              | NA                                              |
| 3                                                 | 2 (0.5)                         | 1 (0.3)                         | 1 (0.3)                         | NA                                              | NA                                              |
| Missing                                           | 0                               | 1 (0.3)                         | 0                               | NA                                              | NA                                              |
| PD-L1 expression level, n (%) c                   |                                 |                                 |                                 |                                                 |                                                 |
| Positive (TIP â‰¥ 1%)                               | 154 (39.6)                      | 148 (37.7)                      | 148 (38.0)                      | 55 (52.9)                                       | 27 (36.0)                                       |
| Negative (TIP < 1%)                               | 190 (48.8)                      | 189 (48.1)                      | 181 (46.5)                      | 35 (33.7)                                       | 38 (50.7)                                       |
| Missing                                           | 42 (10.8)                       | 52 (13.2)                       | 45 (11.6)                       | 14 (13.5)                                       | 10 (13.3)                                       |
| Prior treatment with sorafenib/VEGFR TKI, n (%) d |                                 |                                 |                                 |                                                 |                                                 |
| Yes                                               | NA                              | NA                              | NA                              | 66 (63.5)                                       | 55 (73.3)                                       |
| No                                                | NA                              | NA                              | NA                              | 38 (36.5)                                       | 20 (26.7)                                       |

a In HIMALAYA, patients were enrolled only if they had BCLC Stage B (not eligible for locoregional therapy) or Stage C. In Study 22, BCLC Stage was not specified in the inclusion criteria and collection of BCLC scores was not mandated at screening until protocol amendment 3 (20 July 2017); as a result, baseline BCLC scores were missing for some patients in Part 2A (see Section 9.2.2, Study 22 CSR, Module 5.3.5.2).

b Includes all patients with 'MVI = Yes and EHS = No/Missing,' 'MVI = No/Missing and EHS = Yes,' and 'MVI = Yes and EHS = Yes.'

- c PD-L1 expression level was defined as 'Positive' if PD-L1 staining of any intensity in tumour cell membranes and/or tumourassociated immune cells covered â‰¥ 1% of tumour area (TIP â‰¥ 1%), and 'Negative' if PD -L1 staining of any intensity in tumour cell membranes and/or tumourassociated immune cells covered &lt; 1% of tumour area (TIP &lt; 1%).
- d Per inclusion criteria, no patients in HIMALAYA received prior systemic therapy for HCC (first-line setting only). In Study 22, patients were required to be immunotherapy-naÃ¯ve and had either progressed on, were intolerant to, or have refused treatment with sorafenib or another approved VEGFR TKI (first-line and second-line settings).

Abbreviations: BCLC = Barcelona Clinic Liver Cancer; eCRF = electronic case report form; DCO = data cut-off; ECOG = Eastern Cooperative Oncology Group; EHS = extrahepatic spread; FAS = full analysis set; HBV = hepatitis B virus; HCV = hepatitis C virus; MVI = macrovascular invasion; N = total number of patients; n = number of patients in a treatment arm; NA, not applicable; PD-L1 = programmed cell death ligand-1; TIP = tumour immune percentage; TKI = tyrosine kinase inhibitor; VEGFR = vascular endothelial growth factor receptor.

<div style=\"page-break-after: always\"></div>

## Prior cancer therapy

Per inclusion criteria, no patients in HIMALAYA received prior systemic therapy for HCC (first-line setting only). Overall, the most common disease-related medical procedures prior to study entry, including ablative therapy, therapeutic embolisation, regional chemotherapy, and HCC-related surgery, were similar across treatment arms and consistent with that typically seen in the target patient population.

In study 22, the prior anticancer treatment modalities reported were prior treatment with sorafenib/VEGFR TKI (55/75 patients, 73.3%). Most patients had undergone prior TACE or RFA Per protocol, all patients were immunotherapy-naÃ¯ve.

Post-IP Discontinuation Anticancer Systemic Therapy

Table 24: Post- discontinuation anticancer systemic therapy

<!-- image -->

|                               | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|-------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Anticancer therapy            | D (N =389)               | T300+D (N=393)           | T75+D (N =153)           | S (N = 389)              | Total (N =1324)          |
| Total number of subjects      | 168 (43.2)               | 160 (40.7)               | 67 (43.8)                | 175 (45.0)               | 570 (43.1)               |
| Immunotherapy                 | 20 (5.1)                 | 15 (3.8)                 | 5 (3.3)                  | 89 (22.9)                | 129 (9.7)                |
| Atezolizumab                  | 11 (2.8)                 | 6 (1.5)                  | 1 (0.7)                  | 14 (3.6)                 | 32 (2.4)                 |
| Avelumab                      | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Cancer Vaccines               | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Durvalumab                    | 0                        | 0                        | 0                        | 2 (0.5)                  | 2 (0.2)                  |
| Immunotherapy                 | 0                        | 0                        | 0                        | 4 (1.0)                  | 4 (0.3)                  |
| Investigational Immunotherapy | 1 (0.3)                  | 0                        | 0                        | 0                        | 1 (0.1)                  |
| Ipilimumab                    | 2 (0.5)                  | 0                        | 0                        | 2 (0.5)                  | 4 (0.3)                  |
| Mgd 013                       | 0                        | 2 (0.5)                  | 0                        | 2 (0.5)                  | 4 (0.3)                  |
| Monoclonal Antibodies         | 3 (0.8)                  | 2 (0.5)                  | 1 (0.7)                  | 7 (1.8)                  | 13 (1.0)                 |
| Nivolumab                     | 5 (1.3)                  | 5 (1.3)                  | 3 (2.0)                  | 47 (12.1)                | 60 (4.5)                 |
| Pembrolizumab                 | 1 (0.3)                  | 0                        | 0                        | 17 (4.4)                 | 18 (1.4)                 |
| Spartalizumab                 | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Tremelimumab                  | 0                        | 0                        | 0                        | 2 (0.5)                  | 2 (0.2)                  |
| Cytotoxic chemotherapy        | 18 (4.6)                 | 20 (5.1)                 | 7 (4.6)                  | 25 (6.4)                 | 70 (5.3)                 |
| Capecitabine                  | 5 (1.3)                  | 3 (0.8)                  | 1 (0.7)                  | 4 (1.0)                  | 13 (1.0)                 |
| Capecitabine;oxaliplatin      | 1(03)                    | 0                        | 0                        | 0                        | 1 (0.1)                  |
| Carboplatin                   | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Carboplatin;etoposide         | 0                        | 1 (0.3)                  | 0                        | 0                        | 1 (0.1)                  |
| Cisplatinb                    | 9 (2.3)                  | 6 (1.5)                  | 5 (3.3)                  | 5 (1.3)                  | 25 (1.9)                 |
| Cisplatin;doxorubicin         | 0                        | 2 (0.5)                  | 0                        | 0                        | 2 (0.2)                  |
| Cisplatin;fluorouracil        | 0                        | 1 (0.3)                  | 0                        | 2 (0.5)                  | 3 (0.2)                  |
| Cyclophosphamide              | 1 (0.3)                  | 0                        | 0                        | 1 (0.3)                  | 2 (0.2)                  |
| Doxorubicin                   | 0                        | 4 (1.0)                  | 1 (0.7)                  | 7 (1.8)                  | 12 (0.9)                 |
| Fluorouracil                  | 5 (1.3)                  | 5 (1.3)                  | 3 (2.0)                  | 7 (1.8)                  | 20 (1.5)                 |
| Folfox                        | 0                        | 4 (1.0)                  | 0                        | 2 (0.5)                  | 6 (0.5)                  |
| Gemcitabine                   | 3 (0.8)                  | 1 (0.3)                  | 0                        | 2 (0.5)                  | 6 (0.5)                  |
| Gemcitabine;oxaliplatin       | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                      | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Anticancer therapy                   | D (N=389)                | T300+D (N=393)           | T75+D (N =153)           | S (N = 389)              | Total (N =1324)          |
| Irinotecan                           | 1 (0.3)                  | 0                        | 0                        | 1 (0.3)                  | 2 (0.2)                  |
| Oxaliplatinb                         | 7 (1.8)                  | 2 (0.5)                  | 1 (0.7)                  | 8 (2.1)                  | 18 (1.4)                 |
| Tegafur                              | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Uracil                               | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Vinorelbine                          | 0                        | 1 (0.3)                  | 0                        | 0                        | 1 (0.1)                  |
| Targeted therapy                     | 155 (39.8)               | 147 (37.4)               | 64 (41.8)                | 108 (27.8)               | 474 (35.8)               |
| Cabozantinib                         | 20 (5.1)                 | 24 (6.1)                 | 6 (3.9)                  | 26 (6.7)                 | 76 (5.7)                 |
| Capmatinib                           | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| H3b 6527                             | 0                        | 1 (0.3)                  | 0                        | 0                        | 1 (0.1)                  |
| Lenvatinib                           | 68 (17.5)                | 55 (14.0)                | 23 (15.0)                | 32 (8.2)                 | 178 (13.4)               |
| Olaparib                             | 1 (0.3)                  | 0                        | 0                        | 0                        | 1 (0.1)                  |
| Pegargiminase                        | 1 (0.3)                  | 1 (0.3)                  | 0                        | 1 (0.3)                  | 3 (0.2)                  |
| Regorafenib                          | 26 (6.7)                 | 29 (7.4)                 | 17 (11.1)                | 62 (15.9)                | 134 (10.1)               |
| Sorafenib                            | 98 (25.2)                | 105 (26.7)               | 51 (33.3)                | 12 (3.1)                 | 266 (20.1)               |
| Tyrosine Kinase Inhibitors           | 0                        | 2 (0.5)                  | 0                        | 0                        | 2 (0.2)                  |
| Antiangiogenic therapy               | 20 (5.1)                 | 11 (2.8)                 | 9 (5.9)                  | 19 (4.9)                 | 59 (4.5)                 |
| Bevacizumab                          | 12 (3.1)                 | 6 (1.5)                  | 1 (0.7)                  | 16 (4.1)                 | 35 (2.6)                 |
| Ramucirumab                          | 8 (2.1)                  | 7 (1.8)                  | 7 (4.6)                  | 3 (0.8)                  | 25 (1.9)                 |
| Thalidomide                          | 2 (0.5)                  | 0                        | 1 (0.7)                  | 0                        | 3 (0.2)                  |
| Homeopathic therapy                  | 1 (0.3)                  | 0                        | 0                        | 2 (0.5)                  | 3 (0.2)                  |
| Herbal anticancer remedies           | 1 (0.3)                  | 0                        | 0                        | 2 (0.5)                  | 3 (0.2)                  |
| Other                                | 1 (0.3)                  | 3 (0.8)                  | 0                        | 9 (2.3)                  | 13 (1.0)                 |
| Fenbendazole                         | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Folinic Acid                         | 1 (0.3)                  | 1 (0.3)                  | 0                        | 3 (0.8)                  | 5 (0.4)                  |
| Investigational Antineoplastic Drugs | 0                        | 2 (0.5)                  | 0                        | 3 (0.8)                  | 5 (0.4)                  |
| Investigational Drug                 | 0                        | 0                        | 0                        | 2 (0.5)                  | 2 (0.2)                  |

Patients may have received more than 1 post-IP discontinuation therapy.

D, durvalumab monotherapy 1500 mg Q4W; FAS, Full Analysis Set; N, number of patients in treatment group;

Q4W,every4weeks;S,sorafenib400mg twicedaily;T75+D,tremelimumab75mgÃ—4doses+durvalumab

1500mgQ4W;T300+D,tremelimumab300mgÃ—1dose+durvalumab1500mgQ4W.

Source:Iable 14.1.17

<div style=\"page-break-after: always\"></div>

## Â· Numbers analysed

## Table 25: Analysis sets

|                                                    | Durva 1500 mg   |   Treme 300 mg x1 dose + Durva1500 mg |   Treme 75 mg x4 doses + Durva1500mg | Sora 400 mg BID   |   Total |
|----------------------------------------------------|-----------------|---------------------------------------|--------------------------------------|-------------------|---------|
| Subjectsrandomized                                 | 389             |                                   393 |                                  153 | 389               |    1324 |
| Subjects includedinfull analysis set               | 389             |                                   393 |                                  153 | 389               |    1324 |
| Subjects included in safety analysisset            | 388             |                                   388 |                                  152 | 374               |    1302 |
| Subjects excluded from safety analysis set         | 3               |                                     4 |                                    0 | 15                |      22 |
| Didnotreceive treatment                            | 3               |                                     4 |                                    0 | 15                |      22 |
| SubjectsincludedinDurvalumabPKanalysisset          | 357             |                                   348 |                                  142 |                   |     847 |
| Subjects excluded from Durvalumab PK analysis seta | 34              |                                    44 |                                   10 |                   |      88 |
| Did notreceive treatment                           | 3               |                                     4 |                                    0 |                   |       7 |
| No post-dose data available                        | 31              |                                    40 |                                   10 |                   |      81 |
| SubjectsincludedinTremelimumabPKanalysisset        |                 |                                   386 |                                  142 |                   |     528 |
| SubjectsexcludedfromTremelimumabPKanalysissetb     |                 |                                     6 |                                   12 |                   |      18 |
| Did not receive treatment                          |                 |                                     4 |                                    2 |                   |       6 |
| No post-dose data available                        |                 |                                     2 |                                   10 |                   |      12 |

Safety analysis set -all subjects who received at least one dose of study treatment.

Full analysis set - all randomized subjects analysed on an ITT basis.

PKanalysissets-all subjectswhoreceived at least 1dose of studydrugs andforwhom anypostdose data are available.

Results in categories'Subjects included in safety analysis set','Subjects included in PK analysis set' and'Subjects included in ADA evaluable set' are calculated on basis of actual arm, in other categories on basis of planned arm.

ADA evaluable sets - all subjects who have non-missing baseline ADA and at least one non-missing post-baseline ADA result

Subjects excluded from theDurvalumab PK analysis are either not part of the safety analysis set or belong to the safety analysis set but are missing a Durvalumab postdose PK assessment.

Subjects excluded from the Tremelimumab PK analysis are either not part of the safety analysis set or belong to the safety analysis set but are missing a Tremelimumab postdose PK assessment.

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/dm003.sasdm003fa.rtf08NOV2021:16:23kwxd463

<div style=\"page-break-after: always\"></div>

## Â· Outcomes and estimation

## Primary endpoint: Overall survival

## Table 26. Overall Survival in HIMALAYA (Pivotal Study)

| Study Analysis set (DCO)                                             | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   |
|----------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                      | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     |
| HR (compared to sorafenib) a                                         | 0.86                            | 0.78                            | -                               |
| 95% CI a                                                             | 0.73 - 1.02                     | 0.66 - 0.92                     | -                               |
| 96.02% CI for HR (T300+D vs S) a, b                                  | -                               | 0.65 - 0.93                     | -                               |
| 2-sided p - value (T300+D vs S)                                      | -                               | 0.0035                          | -                               |
| 95.67% CI for HR (D vs S) a, c                                       | 0.73 - 1.03                     | -                               | -                               |
| 2-sided p-value (D vs S) d                                           | 0.0674                          | -                               | -                               |
| Median OS (months) e                                                 | 16.56                           | 16.43                           | 13.77                           |
| 95% CI for median OS e                                               | 14.06 - 19.12                   | 14.16 - 19.58                   | 12.25 - 16.13                   |
| OS rate at 12 months,% e                                             | 59.3                            | 60.2                            | 56.2                            |
| OS rate at 18 months,% e                                             | 47.4                            | 48.7                            | 41.5                            |
| OS rate at 24 months,% e                                             | 39.6                            | 40.5                            | 32.6                            |
| OS rate at 36 months,% e                                             | 24.7                            | 30.7                            | 20.2                            |
| Deaths, n (%)                                                        | 280 (72.0)                      | 262 (66.7)                      | 293 (75.3)                      |
| Censored patients, n (%)                                             | 109 (28.0)                      | 131 (33.3)                      | 96 (24.7)                       |
| Still in survival follow-up at DCO f                                 | 104 (26.7)                      | 125 (31.8)                      | 79 (20.3)                       |
| Terminated prior to death g                                          | 109 (28.0)                      | 131 (33.3)                      | 96 (24.7)                       |
| Lost to follow-up                                                    | 1 (0.3)                         | 1 (0.3)                         | 7 (1.8)                         |
| Withdrawn consent                                                    | 4 (1.0)                         | 5 (1.3)                         | 10 (2.6)                        |
| Median (range) duration of follow-up in censored patients (months) h | 31.61 (1.91 - 45.70)            | 32.36 (6.18 - 42.84)            | 30.36 (0.03 - 43.60)            |
| Median (95% CI) duration of follow-up in all patients (months) i     | 32.56 (31.57 - 33.71)           | 33.18 (31.74 - 34.53)           | 32.23 (30.42 - 33.71)           |

a The HR was calculated using a Cox proportional hazards model adjusting for treatment arm, etiology of liver disease (HBV vs HCV vs all others), ECOG (0 vs 1), and MVI (yes vs no). An HR &lt; 1 favors either the T300+D arm or the D arm compared with the S arm in terms of being associated with a longer OS.

b T300+D vs S (primary objective in HIMALAYA). Statistical significance for T300+D vs S was based on a 2-sided interim p &lt; 0.0419 (overall alpha 4.9%), as defined in the MTP.

c D vs S (key secondary objective in HIMALAYA). The non-inferiority margin for D vs S was 1.08, as defined in the MTP.

d The analysis was performed using a stratified log-rank test adjusting for treatment arm, etiology of liver disease (HBV vs HCV vs all others), ECOG (0 vs 1), and MVI (yes vs no).

e Calculated using the Kaplan-Meier method.

- f Patients confirmed alive in follow-up or on active study treatment at the time of final analysis reported 'study completion' on the disposition CRF.

g Includes patients with unknown survival status or patients who were lost to follow-up.

h Median for duration of follow-up is the arithmetic median.

i Calculated using the reverse Kaplan-Meier technique (with censor indicator reversed).

Abbreviations: CI = confidence interval; CRF = case report form; DCO = data cut-off; FAS = full analysis set; HR = hazard ratio; IA = interim analysis; OS = overall survival.

<div style=\"page-break-after: always\"></div>

Figure 18 Kaplan-Meier Plot of Overall Survival in the T300+D and S Arms in HIMALAYA, FAS (Final Analysis)

<!-- image -->

Abbreviations: FAS = Full Analysis Set; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

Figure 19 Kaplan-Meier Plot of Overall Survival in the D and S Arms in HIMALAYA, FAS (Final Analysis)

<!-- image -->

Abbreviations: D = durvalumab monotherapy 1500 mg Q4W; FAS = Full Analysis Set; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily

<div style=\"page-break-after: always\"></div>

## Secondary endpoints:

## Progression-free survival (PFS)

## Table 27: Progression-free Survival by Investigator Assessment According to RECIST 1.1 (FAS)

|                                                                    | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                                    | D (N = 389)              | T300+D (N = 393)         | S (N = 389)              |
| Hazard ratio (D vs S and T300+D vs S)                              | 1.02                     | 0.90                     | -                        |
| 95% CI for hazard ratio                                            | 0.88 - 1.19              | 0.77 - 1.05              | -                        |
| 2-sided p-value                                                    | 0.7736                   | 0.1625                   | -                        |
| Median PFS (months) a                                              | 3.65                     | 3.78                     | 4.07                     |
| 95% CI for median PFS a                                            | 3.19 - 3.75              | 3.68 - 5.32              | 3.75 - 5.49              |
| Total PFS events, n (%) b                                          | 345 (88.7)               | 335 (85.2)               | 327 (84.1)               |
| Median (range) duration of follow-up in all patients (months)      | 3.61 (0.03 - 44.02)      | 3.75 (0.03 - 41.46)      | 3.75 (0.03 - 33.41)      |
| Median (range) duration of follow-up in censored patients (months) | 27.63 (0.03 - 44.02)     | 27.55 (0.03 - 41.46)     | 1.95 (0.03 - 33.18)      |

Â· Calculated using the Kaplan-Meier technique.

Â· Patients who had not progressed or died, or who progressed or died after 2 or more missed visits, were censored at the latest evaluable RECIST 1.1 assessment, or Day 1 if there were no evaluable visits. Patients who have no evaluable visits or baseline data were censored at Day 1 unless they died within 2 visits of baseline. Patients who die without tumour progression will be censored at the time of death.

Progression determined by Investigator assessment. Lost to follow-up is defined as patients who have no RECIST 1.1 progression or death at the time of the DCO and have a termination status of 'Lost to follow-up' from the Disposition module. Withdrawn consent is defined as patients who have no RECIST 1.1 progression or death at the time of DCO and whose termination status is 'Withdrawn consent' on the Disposition module. The analysis methods used to obtain the hazard ratio, confidence interval, and 2-sided p-value are the same as for the primary OS analysis.

A hazard ratio of &lt; 1 favours IO treatment arms to be associated with a longer progression-free survival than sorafenib.

Abbreviations: CI = confidence interval; D = durvalumab monotherapy 1500 mg; Q4W; DCO = data cut-off; ECOG PS, Eastern Cooperative Oncology Group performance status; FAS = Full Analysis Set; IO = immuno-oncology; HBV, hepatitis B virus; HCV, hepatitis C virus; N = total number of patients; n = number of PFS events;  PFS = progression-free survival; Q4W = every 4 weeks; RECIST 1.1 = Response Evaluation Criteria in Solid Tumours Version 1.1; S = sorafenib 400 mg twice daily; T75+D = tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D = tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

<div style=\"page-break-after: always\"></div>

Figure 20: Kaplan-Meier plot for progression-free survival by investigator assessment according to RECIST 1.1 (FAS)

<!-- image -->

Abbreviations: D = durvalumab monotherapy 1500 mg; Q4W; FAS = Full Analysis Set; Q4W = every 4 weeks; N = total number of patients; PFS = progression-free survival; RECIST 1.1 = Response Evaluation Criteria in Solid Tumours Version 1.1; S = sorafenib 400 mg twice daily; T75+D = tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D = tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

<div style=\"page-break-after: always\"></div>

Table 28: Progression-free survival (FAS 32w FUP) based on BICR assessments per RECIST 1.1 (DCO 27-AUG-2021)

|                                                               | Number(%)of subjects   | Number(%)of subjects                         | Number(%)of subjects                         | Number(%)of subjects    |
|---------------------------------------------------------------|------------------------|----------------------------------------------|----------------------------------------------|-------------------------|
|                                                               | Durva1500mg (N=236)    | Treme 300 mg x1 dose + Durva 1500 mg (N=234) | Treme 75 mg x4 doses + Durva 1500 mg (N=153) | Sora 400 mg BID (N=236) |
| Total eventsa, n (%)                                          | 194 (82.2)             | 172 (73.5)                                   |                                              | 163 (69.1)              |
| RECIST progression                                            | 175 (74.2)             | 148 (63.2)                                   |                                              | 137 (58.1)              |
| Target Lesionsb                                               | 106 (44.9)             | 81 (34.6)                                    |                                              | 76 (32.2)               |
| Non Target Lesionsb                                           | 101 (42.8)             | 74 (31.6)                                    |                                              | 68 (28.8)               |
| New Lesionsb                                                  | 50 (21.2)              | 53 (22.6)                                    |                                              | 45 (19.1)               |
| Death in the absence of progression                           | 19 (8.1)               | 24 (10.3)                                    |                                              | 26 (11.0)               |
| Censored subjects, n (%)                                      | 42 (17.8)              | 62 (26.5)                                    |                                              | 73 (30.9)               |
| Censored RECIST progressionc                                  | 0                      | 0                                            |                                              | 1 (0.4)                 |
| Censored deathd                                               | 11 (4.7)               | 17 (7.3)                                     |                                              | 44 (18.6)               |
| Progression-free at time of analysis                          | 0                      | 0                                            |                                              | 0                       |
| Lost to follow-up                                             | 0                      | 0                                            |                                              | 2 (0.8)                 |
| Withdrawn consent                                             | 0                      | 0                                            |                                              | 2 (0.8)                 |
| Study completione                                             | 31 (13.1)              | 45 (19.2)                                    |                                              | 24 (10.2)               |
| Median progression-free survival (months)f                    | 3.48                   | 3.65                                         |                                              | 3.78                    |
| 95% CI for median progression-free survivalf                  | 2.17-3.68              | 3.52- 3.94                                   |                                              | 3.68-5.32               |
| Hazard ratio                                                  | 1.19                   | 0.96                                         |                                              |                         |
| 95%CIforhazardratio                                           | 0.97 -1.47             | 0.77 - 1.19                                  |                                              |                         |
| 2-sided p-value                                               | 0.0971                 | 0.6668                                       |                                              |                         |
| Median (range) duration of follow-up in all subjects (months) | 3.07 (0.03 -19.42)     | 3.61 (0.03 -16.59)                           |                                              | 3.61 (0.03 -16.43)      |
| Median(range)durationoffollow-upincensoredsubjects(months)    | 8.99 (0.03 -19.42)     | 9.33 (0.03 - 16.59)                          |                                              | 5.49 (0.03 - 13.96)     |

Progression is determined by BICR, RECIST 1.1. CI=Confidence interval. NR = Not reached. FAS 32w FUP = Fullanalysis set with opportunity for 32 weeks of follow-up at IA1 DCO.

Lost tofollow upis defined as subjectswhom havenoRECIST 1.1progression ordeath at the timeof the data cutoff and have a termination status ofLost tofollow-up'from theDisposition module.

Withdrawn consent is defined as all subjects whom have no RECIST 1.1 progression or death at the time of data cut off and whose termination Status is 'Withdrawn consent' on the Disposition module.

evaluablevisits.Subjectswhohave noevaluablevisits or donot have baseline data will be censored at study day1 unless they diewithin 2visits of baseline.

aSubjects whohavenotprogressed or died,orwho progress or die after two ormore missedvisits,are censored at thelatest evaluableRECISTassessment,or day1if there areno

b Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. RECIST progression event occurred after 2 or more missed visits after last evaluable RECIST assessment (or randomization).

Other recorded on disposition eCRF with specified status of'Study terminated by sponsor.fCalculated using theKaplan-Meier technique.

dDeath occurred after 2or more missedvisits after lastevaluableRECISTassessment(orrandomization).

The analysis methods used to obtain the hazard ratio, confidence interval and 2-sided p-value are the same as for the primary OS analysis. A hazard ratio &lt; 1 favours IO treatment arms to be associated with a longer progression-free survival than sorafenib.

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/eff004.saseff004hfa.rtf08NOV2021:16:24kwxd463

PFS by BICR by mRECIST was also performed in the FAS 32w FUP (not shown), and this did not show a statistically significant difference of PFS between the three arms (D vs T300+D vs S) either.

<div style=\"page-break-after: always\"></div>

## Overall response rate (ORR) and best objective response

Table 29: Objective response rate based on investigator assessment (confirmed responses) according to RECIST 1.1 (FAS)

|               |     | Number of                |                   | Comparison between arms   | Comparison between arms   | Comparison between arms   |
|---------------|-----|--------------------------|-------------------|---------------------------|---------------------------|---------------------------|
| Treatment arm | N   | patients with response a | Response rate (%) | Odds ratio b              | 95% CI                    | 2-sided p-value           |
| D             | 389 | 66                       | 17.0              | 3.80                      | 2.29, 6.57                | <0.0001                   |
| T300+D        | 393 | 79                       | 20.1              | 4.69                      | 2.85, 8.04                | <0.0001                   |
| S             | 389 | 20                       | 5.1               | -                         | -                         | -                         |

The analysis was performed using a logistic regression model adjusted for treatment with factors for etiology of liver disease, ECOG PS, and MVI. An odds ratio of &gt; 1 favors IO treatment arms.

Abbreviations: CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; FAS = Full Analysis Set; IO = immuno-oncology; MVI = macrovascular invasion; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

Table 30: Best objective response based on investigator assessment (confirmed response) according to RECIST 1.1 (FAS)

|                 |                    | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-----------------|--------------------|--------------------------|--------------------------|--------------------------|
| Response status | BOR                | D (N = 389)              | T300+D (N = 393)         | S (N = 389)              |
| Response        | Total              | 66 (17.0)                | 79 (20.1)                | 20 (5.1)                 |
| Response        | Complete response  | 6 (1.5)                  | 12 (3.1)                 | 0                        |
| Response        | Partial response   | 60 (15.4)                | 67 (17.0)                | 20 (5.1)                 |
| Non-response    | Total              | 323 (83.0)               | 314 (79.9)               | 369 (94.9)               |
| Non-response    | Stable disease     | 147 (37.8)               | 157 (39.9)               | 216 (55.5)               |
| Non-response    | Progression        | 160 (41.1)               | 141 (35.9)               | 118 (30.3)               |
| Non-response    | RECIST progression | 143 (36.8)               | 117 (29.8)               | 91 (23.4)                |
| Non-response    | Death              | 17 (4.4)                 | 24 (6.1)                 | 27 (6.9)                 |
| Non-response    | Not evaluable      | 16 (4.1)                 | 16 (4.1)                 | 35 (9.0)                 |

Abbreviations: BOR = best objective response; D = durvalumab monotherapy 1500 mg; Q4W; FAS = Full Analysis Set; N = total number of patients; Q4W = every 4 weeks; RECIST 1.1 = Response Evaluation Criteria In Solid Tumours Version 1.1; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

Table 31: Objective response rate based on BICR assessment (confirmed response) according to RECIST 1.1 (FAS 32w FUP) - DCO 27 AUG 2021

|                                    | Durva1500 mg (N=236)   | Treme300mgx1dose+ Durva1500mg (N=234)   | Treme75mgx4doses+ Durva1500mg (N=153)   | Sora400mg BID (N=236)   |
|------------------------------------|------------------------|-----------------------------------------|-----------------------------------------|-------------------------|
| SubjectswithObjectiveresponse,n(%) | 36 (15.3)              | 44 (18.8)                               |                                         | 12 (5.1)                |
| Objectiveresponserate(%)           | 15.3                   | 18.8                                    |                                         | 5.1                     |
| 95%exact CI                        | 10.92,20.49            | 14.01, 24.41                            |                                         | 2.65, 8.71              |

CI=Confidenceinterval

RECISTversion 1.1.

Lost tofollowup andwithdrawnconsent are defined assubjectswhohave noRECIST1.1progression or death at the timeof theDCOand have atermination status ofLost tofollow-up or'Withdrawn consent'respectivelyin theDispositionmodule.FAS32wFUP=Full analysisset with opportunityfor32weeksof follow-up at IA1DCO

<div style=\"page-break-after: always\"></div>

Table 32: Disagreements between investigator and BICR of RECIST progression per RECIST 1.1 (FAS 32w FUP) - DCO 27 AUG 2021

|                                                                | Number (%) of subjects   | Number (%) of subjects                       | Number (%) of subjects                       | Number (%) of subjects   | Difference                      | Difference                                            |
|----------------------------------------------------------------|--------------------------|----------------------------------------------|----------------------------------------------|--------------------------|---------------------------------|-------------------------------------------------------|
|                                                                | Durva 1500 mg (N=236)    | Treme 300 mg x1 dose + Durva 1500 mg (N=234) | Treme 75 mg x4 doses + Durva 1500 mg (N=153) | Sora 400 mg BID (N=236)  | Durva 1500 mg - Sora 400 mg BID | Treme 300 mg x1 dose +Durva 1500 mg - Sora 400 mg BID |
| RECISTprogressiona declared by:                                |                          |                                              |                                              |                          |                                 |                                                       |
| Investigator and centralreview                                 | 160 (67.8)               | 138 (59.0)                                   |                                              | 123 (52.1)               |                                 |                                                       |
| Progression date agreement (within 2 weeks)                    | 90 (38.1)                | 61 (26.1)                                    |                                              | 63 (26.7)                |                                 |                                                       |
| Progression date>=2weeks earlier by central reviewthan by      | 47 (19.9)                | 61 (26.1)                                    |                                              | 46 (19.5)                |                                 |                                                       |
| Investigator                                                   |                          |                                              |                                              |                          |                                 |                                                       |
| Progression date>=2weeks earlierbyInvestigator than by central | 23 (9.7)                 | 16 (6.8)                                     |                                              | 14 (5.9)                 |                                 |                                                       |
| review                                                         |                          |                                              |                                              |                          |                                 |                                                       |
| Investigatorbutnotcentralreview                                | 26 (11.0)                | 36 (15.4)                                    |                                              | 45 (19.1)                |                                 |                                                       |
| CentralreviewbutnotInvestigator                                | 15 (6.4)                 | 10 (4.3)                                     |                                              | 14 (5.9)                 |                                 |                                                       |
| No Progression by both                                         | 35 (14.8)                | 50 (21.4)                                    |                                              | 54 (22.9)                |                                 |                                                       |
| Early Discrepancy Rate (EDR)b                                  | 0.26                     | 0.30                                         |                                              | 0.35                     | -0.09                           | -0.05                                                 |
| Late Discrepancy Rate (LDR)c                                   | 0.56                     | 0.58                                         |                                              | 0.50                     | 0.05                            | 0.07                                                  |

## Duration of response and time to response

Table 33: Duration of response and time to onset of objective response in HIMALAYA (final analysis) according to investigator assessment per RECIST 1.1 (FAS)

| Study Analysis set (DCO)                 | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   |
|------------------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Response assessment                      | Investigator per RECIST 1.1 a   | Investigator per RECIST 1.1 a   | Investigator per RECIST 1.1 a   |
|                                          | D (N = 66)                      | T300+D (N = 79)                 | S (N = 20)                      |
| Patients with objective response, n (%)  | 38                              | 44                              | 13                              |
| DoR from onset of response (months) b, c |                                 |                                 |                                 |
| 25th percentile                          | 7.43                            | 8.54                            | 6.51                            |
| Median                                   | 16.82                           | 22.34                           | 18.43                           |
| 75th percentile                          | NR                              | NR                              | 25.99                           |
| Percentage remaining in response c       |                                 |                                 |                                 |
| At 6 months                              | 81.8                            | 82.3                            | 78.9                            |
| At 12 months                             | 57.8                            | 65.8                            | 63.2                            |
| TTR from randomisation (months)          |                                 |                                 |                                 |
| 25th percentile                          | 1.87                            | 1.84                            | 1.89                            |
| Median                                   | 2.09                            | 2.17                            | 3.78                            |
| 75th percentile                          | 3.98                            | 3.98                            | 8.44                            |

<div style=\"page-break-after: always\"></div>

## Patient-reported outcomes (PROs)

Patient-reported symptoms, function, and health-related quality of life (HRQoL) were collected in the HIMALAYA study using the EORTC QLQ C30 and its HCC module (EORTC QLQ HCC18). At baseline, patient-reported symptoms, functioning, and HRQoL scores were comparable between the HIMALAYA study arms.

<div style=\"page-break-after: always\"></div>

Table 34: Summary of change from baseline using MMRM in EORTC QLQ-30 (FAS)

<!-- image -->

| Synptom Scale Item   |                       | Number (%o) ofpatients   | Number (%o) ofpatients   | Number (%o) ofpatients   | Number (%o) ofpatients   |
|----------------------|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Synptom Scale Item   |                       | (N=389)                  | C+0001 (N=393)           | T75+D (N= 153)           | S (N=389)                |
| GHS/QoL              | Statistic             |                          |                          |                          |                          |
| GHS/QoL              | n                     | 282                      | 249                      | 116                      | 254                      |
| GHS/QoL              | Adjusted mean (SE)    | -1.8 (1.26)              | -5.8 (1.29)              | -6.2 (2.04)              | NE                       |
| GHS/QoL              | 95% CI                | -4.30, 0.65              | -8.37, -3.32             | -10.22,-2.21             | NE                       |
| GHS/QoL              | Estimated difference  | NE                       | NE                       |                          |                          |
| GHS/QoL              | 95% CI for difference | NE                       | NE                       |                          |                          |
| GHS/QoL              | p-value               | NE                       | NE                       |                          |                          |
| Fumction             |                       |                          |                          |                          |                          |
| Physical fumctioning | n                     | 282                      | 249                      | 116                      | 254                      |
| Physical fumctioning | Adjusted mean (SE)    | -0.9 (1.16)              | -2.7 (1.19)              | -4.4 (1.87)              | NE                       |
| Physical fumctioning | 95% CI                | -3.18, 1.37              | -5.05, -0.39             | -8.05, -0.71             | NE                       |
| Physical fumctioning | Estimated difference  | NE                       | NE                       |                          |                          |
| Physical fumctioning | 95% CI for difference | NE                       | NE                       |                          |                          |
| Physical fumctioning | p-value               | NE                       | NE                       |                          |                          |
| Symptoms             |                       |                          |                          |                          |                          |
| Fatigue              | n1                    | 282                      | 249                      | 116                      | 254                      |
| Fatigue              | Adjusted mean (SE)    | 1.7 (1.40)               | 1.9 (1.43)               | 4.3 (2.27)               | NE                       |
| Fatigue              | 95% CI                | -1.09,4.43               | -0.91, 4.72              | -0.14, 8.75              | NE                       |
| Fatigue              | Estimated difference  | NE                       | NE                       |                          |                          |
| Fatigue              | 95% CI for difference | NE                       | NE                       |                          |                          |
| Fatigue              | p-value               | NE                       | NE                       |                          |                          |
| Appetite loss        | n                     | 282                      | 249                      | 116                      | 254                      |
| Appetite loss        | Adjusted mean (SE)    | 3.8 (1.62)               | 1.7 (1.65)               | 2.8 (2.63)               | NE                       |
| Appetite loss        | 95%CI                 | 0.64, 7.00               | -1.58, 4.91              | -2.36, 7.97              | NE                       |
| Appetite loss        | Estimated difference  | NE                       | NE                       |                          |                          |
| Appetite loss        | 95% CI for difference | NE                       | NE                       |                          |                          |
| Appetite loss        | p-value               | NE                       | NE                       |                          |                          |
| Nausea               | n                     | 282                      | 249                      | 116                      | 254                      |
| Nausea               | Adjusted mean (SE)    | 1.2 (1.18)               | 0.7 (1.20)               | 3.1 (1.91)               | NE                       |
| Nausea               | 95% CI                | -1.16, 3.47              | -1.64, 3.08              | -0.61,6.87               | NE                       |
| Nausea               | Estimated difference  | NE                       | NE                       |                          |                          |
|                      | 95%CIfordifference    | NE                       | NE                       |                          |                          |
|                      | p-value               | NE                       | NE                       |                          |                          |
| Diarhea              | n                     | 282                      | 249                      | 116                      | 254                      |
|                      | Adjusted mean (SE)    | 1.2 (1.43)               | -1.0 (1.45)              | 5.7 (2.31)               | NE                       |
|                      | 95%CI                 | -1.62, 3.97              | -3.83,1.86               | 1.20,10.28               | NE                       |
|                      | Estimateddifference   | NE                       | NE                       |                          |                          |
|                      | 95% CI for difference | NE                       | NE                       |                          |                          |
|                      | p-value               | NE                       | NE                       |                          |                          |

All scales and single-item measuuresrangein scorefrom0 to100.A high scale score represents ahigher response level. A high score for fiuctional scales (physical, role, emotional, cogmitive, social) and global health status/QoL represents a high fimctioning/QoL,but a high score for a symptom scale/itemrepresents a high level of symptomatology/problems.

The analysis set includes a subset of the FAS with an evaluable baseline assessment and at least 1 evaluable post-baseline assessment. Change from baseline is derived using a MMRM analysis of all the post-baseline scores for each visit. The modelincludes treatment, visit, and treatment by visit interaction as explanatory vaniables and the baseline score as a covariate.

Adjusted mean:adjusted mean changefrombaseline.

Estimated difference:overall estimate of the treahment differencebetween D(monotherapy or combination therapy) and S.

95%CI:95%CIfor adjustedmeanchange.

CIconfidence interval;D,dhuvalumabmonotherapy 1500mg:EORTC QLQ-C30,Euopean Organization for Research and Treatment of Cancer 30-item core quality oflife questionnaire; FAS, Full Analysis Set; MvRM mixed-effect model for repeated measurement; N, mumber ofpatients in treatment arm NE, not evaluable;QoL,QualityofLife;Q4W,every4weeks;S,sorafenib400mgtwice daily;SE,standarderor; T75+D, tremelimumab 75 mg Ã— 4 doses + duuvahmab 1500mg Q4W; T300+D, tremelimumab 300 mg

x1dose+dhuvalumab1500mgQ4W.

<div style=\"page-break-after: always\"></div>

Table 35: Summary of change from baseline in EORTC QLQ-HCC19 symptoms (FAS)

<!-- image -->

|                    |                       | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Symptom Scale Item | Statistic             | D (N=389)                | T300+D (N=393)           | T75+D (N=153)            | S (N=389)                |
| Abdominal swelling | n                     | 280                      | 238                      | 112                      | 253                      |
| Abdominal swelling | Adjusted mean (SE)    | 1.0 (1.32)               | -0.1 (1.37)              | -0.7 (2.15)              | NE                       |
| Abdominal swelling | D %56                 | -1.64, 3.56              | -2.84, 2.55              | -4.93, 3.52              | NE                       |
| Abdominal swelling | Estimated difference  | NE                       | NE                       |                          |                          |
|                    | 95% CI for difference | NE                       | NE                       |                          |                          |
|                    | p-value               | NE                       | NE                       |                          |                          |
| Abdominal pain     |                       | 280                      | 238                      | 112                      | 253                      |
| Abdominal pain     | Adjusted mean (SE)    | 0.6 (1.49)               | -1.4(1.54)               | -0.5 (2.42)              | NE                       |
| Abdominal pain     | 1D %56                | -2.30, 3.53              | -4.41, 1.62              | -5.29, 4.20              | NE                       |
| Abdominal pain     | Estimated difference  | NE                       | NE                       |                          |                          |
| Abdominal pain     | 95%CI for difference  | NE                       | NE                       |                          |                          |
| Abdominal pain     | p-value               | NE                       | NE                       |                          |                          |
| Shoulder pain      | n                     | 280                      | 238                      | 112                      | 253                      |
| Shoulder pain      | Adjusted mean (SE)    | -2.4 (1.51)              | -1.7 (1.56)              | 4.8 (2.46)               | NE                       |
| Shoulder pain      | I0 %56                | -5.35, 0.59              | -4.75, 1.35              | -9.66, 0.01              | NE                       |
| Shoulder pain      | Estimated difference  | NE                       | NE                       |                          |                          |
| Shoulder pain      | 95% CI for difference | NE                       | NE                       |                          |                          |
| Shoulder pain      | p-value               | NE                       | NE                       |                          |                          |

EORTC Score Interpretation: All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for fuctional scales (physical, role, emotional, coguitive, social) and global health status/QoL represents a high fiuctioning/QoL, but a high score for a symptom

CI, confidence interval; D, duvalumab monotherapy i500 mg: EORIC QLQ-HCC18,Euopean Organization for Research and Treatment of Cancer 18-item hepatocellular cancer health-related quality of life questiommaire; FAS, Full Analysis Set; N, mumber of patients in treatment anm; NE, not evaluable; QoL, Quality of Life; Q4W, every 4 weeks; S, sorafenmib 400 mg twice daily; SE, standard eiror; T75+D, tremelimumab 75 mg

xÃ— 4 doses + duvalumab 1500mg Q4W; T300+D, tremelimumab 300mg x 1 dose + dhuvalumab 1500 mg Q4W. Source: [able 14.2.9.

<div style=\"page-break-after: always\"></div>

## Â· Ancillary analyses

## Subgroup analyses

Figure 21: Forest plots of overall survival, subgroup analysis, FAS, DCO 27 AUG 2021

TreatmentArms:T300+DVs.S

<!-- image -->

## Hazard ratio and 95% CI.

A hazard ratio &lt;1 implies a lower risk of death for the Treme 300 mg x 1 dose + Durva 1500 mg treatment arm.

For analysismethods,refertoTable14.2.1.3.

Subgroup analyses for stratification factors, etiology of liver disease (HBV versus HCV versus others) and macro-vascular invasion (yes versus no) are performed using values collected from the pathology at screening eCRF. Others (for etiology of liver disease) is defined as no active viral hepatitis identified.

ValuesofECOGareobtainedfromperformancestatuseCRF.

Size of circle is proportional to the number of events.

Grey band represents the 95% confidence interval for the overall (all subjects) hazard ratio.

D = Durva 1500 mg,T300+D = Treme 300 mg x1 dose + Durva 1500 mg, S = Sora 400 mg BID

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/ef003.saseff003fa.rtf 08NOV2021:16:24kwxd463

Abbreviations: AFP = alpha-fetoprotein; BCLC = Barcelona Clinic Liver Cancer; ECOG = Eastern Cooperative Oncology Group; EHS = extrahepatic spread; FAS = full analysis set; HBV = hepatitis B virus; HCV = hepatitis C virus; HR = hazard ratio; MVI = macrovascular invasion; OS = overall survival; PD-L1 = programmed cell death ligand-1; TIP = tumour immune percentage.

<div style=\"page-break-after: always\"></div>

Table 36: Subgroup analysis of overall survival by PD-L1 expression level, HIMALAYA (FAS)

| PD-L1 expression      | Treatment   |     | Number (%) of events   | Comparison to S   | Comparison to S   |
|-----------------------|-------------|-----|------------------------|-------------------|-------------------|
| subgroup              | arm         | N   |                        | HR a              | 95% CI            |
| Positive: TIPâ‰¥1% b    | D           | 154 | 107 (69.5)             | 0.87              | 0.66, 1.13        |
| Positive: TIPâ‰¥1% b    | T300+D      | 148 | 101 (68.2)             | 0.85              | 0.65, 1.11        |
| Positive: TIPâ‰¥1% b    | S           | 148 | 110 (74.3)             | -                 | -                 |
| Negative: TIP<1% b    | D           | 190 | 141 (74.2)             | 0.93              | 0.73, 1.17        |
| Negative: TIP<1% b    | T300+D      | 189 | 128 (67.7)             | 0.83              | 0.65, 1.05        |
| Negative: TIP<1% b    | S           | 181 | 138 (76.2)             | -                 | -                 |
| Positive: TIPâ‰¥5% c    | D           | 70  | 47 (67.1)              | 0.90              | 0.59, 1.38        |
| Positive: TIPâ‰¥5% c    | T300+D      | 67  | 44 (65.7)              | 0.94              | 0.60, 1.47        |
| Positive: TIPâ‰¥5% c    | S           | 66  | 46 (69.7)              | -                 | -                 |
| Negative: TIP<5% c    | D           | 274 | 201 (73.4)             | 0.92              | 0.75, 1.12        |
| Negative: TIP<5% c    | T300+D      | 270 | 185 (68.5)             | 0.84              | 0.69, 1.03        |
| Negative: TIP<5% c    | S           | 263 | 202 (76.8)             | -                 | -                 |
| Positive: TIP â‰¥ 10% c | D           | 37  | 26 (70.3)              | 0.88              | 0.47, 1.66        |
| Positive: TIP â‰¥ 10% c | T300+D      | 34  | 21 (61.8)              | 0.88              | 0.44, 1.79        |
| Positive: TIP â‰¥ 10% c | S           | 33  | 21 (63.6)              | -                 | -                 |
| Negative: TIP < 10% c | D           | 307 | 222 (72.3)             | 0.89              | 0.74, 1.08        |
| Negative: TIP < 10% c | T300+D      | 303 | 208 (68.6)             | 0.83              | 0.69, 1.01        |
| Negative: TIP < 10% c | S           | 296 | 227 (76.7)             | -                 | -                 |

a HR &lt; 1 favors the IO treatment arm.

b HR and 95% CI were estimated from an unstratified Cox proportional hazards model with treatment as the only covariate and using the Efron method to control for ties.

c HR and 95% CI were estimated from a Cox proportional hazards model adjusting for treatment, etiology of liver disease (HBV vs HCV vs others), ECOG performance status (0 vs 1), and MVI (yes vs no).

PD-L1 expression level is based on the TIP score method as: PDL1 Positive (TIP â‰¥ 1%) or PD -L1 Negative (TIP &lt; 1%). The TIP 1% cut-off is the only validated cut-off at which HIMALAYA patient samples were read. Additional PD-L1 TIP cut-offs of 5% and 10% should be interpreted in an exploratory manner.

Abbreviations: CI = confidence interval; D = durvalumab monotherapy 1500 mg Q4W; ECOG = Eastern Cooperative Oncology Group; FAS = Full Analysis Set; HR = hazard ratio; IO, immuno-oncology; MVI = macrovascular invasion; PD-L1 = programmed cell death ligand 1; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W; TIP = tumour and immune cell positivity.

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses

Figure 22: Complementary log-log(event) vs log(time) to assess assumptions of proportionality of hazards for OS (FAS)

<!-- image -->

D, durvalumab monotherapy 1500 mg Q4W; FAS, Full Analysis Set; Q4W, every 4 weeks; OS, Overall Survival; S, sorafenib 400 mg twice daily; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

Source:Figure14.2.1.9

## Inversed Censoring

The reverse KM survival curve shown in Figure  is constructed by reversing the 'censor' and 'event' of the standard KM curve (data not shown). Figure 8 shows that the curves for arms D, T300+D and S remain close to 1 for the first 26 months post randomisation, indicating nearly complete follow-up for this period of time. No meaningful difference in the length of follow-up among arms D, T300+D and S can be seen in the figure, which is also evidenced by similar median follow-up times in censored patients (D: 31.61 months, T300+D: 32.36 months, and S: 30.36 months).

<div style=\"page-break-after: always\"></div>

Figure 23: Overall survival, sensitivity analysis, KM plot with inversed censoring indicators (FAS)

<!-- image -->

D, durvalumab monotherapy 1500 mg Q4W; FAS, Full Analysis Set; KM, Kaplan Meier; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W. Source:Figure 14.2.1.1.3

## Contribution of components

Table 37:  Data From HIMALAYA (pivotal study) and Study 22 (supportive study) relevant to the recommended T300+D regimen in patients with uHCC

| Study Analysis set            | HIMALAYA FAS (Final Analysis)          | HIMALAYA FAS (Final Analysis)          | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|-------------------------------|----------------------------------------|----------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                               | D (N = 389)                            | T300+D (N = 393)                       | D (N = 104)                                     | T300+D (N = 75)                                 | T (N = 69)                                      |
| Median OS (months) a          | 16.56                                  | 16.43                                  | 12.91                                           | 17.05                                           | 17.05                                           |
| 95% CI for median OS          | 14.06, 19.12                           | 14.16, 19.58                           | 8.74, 16.79                                     | 10.55, 22.83                                    | 11.33, 20.24                                    |
| HR (95% CI) for T300+D vs D   | 0.90 (0.76, 1.07)                      | 0.90 (0.76, 1.07)                      | -                                               | -                                               | -                                               |
| OS rate at 12 months,% a      | 59.3                                   | 60.2                                   | 50.4                                            | 57.6                                            | 59.8                                            |
| OS rate at 18 months,% a      | 47.4                                   | 48.7                                   | 34.0                                            | 47.8                                            | 43.3                                            |
| OS rate at 24 months,% a      | 39.6                                   | 40.5                                   | 26.2                                            | 38.3                                            | 30.9                                            |
| OS rate at 36 months,% a      | 24.7                                   | 30.7                                   | -                                               | -                                               | -                                               |
| Tumour response assessment    | Investigator assessment per RECIST 1.1 | Investigator assessment per RECIST 1.1 | BICR per RECIST 1.1                             | BICR per RECIST 1.1                             | BICR per RECIST 1.1                             |
|                               | D (N = 389)                            | T300+D (N = 393)                       | D (N = 104)                                     | T300+D (N = 75)                                 | T (N = 69)                                      |
| Median PFS a                  | 3.65                                   | 3.78                                   | 2.07                                            | 2.17                                            | 2.69                                            |
| 95% CI for median PFS         | 3.19, 3.75                             | 3.68, 5.32                             | 1.84, 2.86                                      | 1.91, 5.42                                      | 1.87, 5.29                                      |
| Progression-free at DCO n (%) | 32 (8.2)                               | 49 (12.5)                              | 8 (7.7)                                         | 11 (14.7)                                       | 4 (5.8)                                         |
| ORR (%) b                     | 17.0                                   | 20.1                                   | 11.5                                            | 24.0                                            | 7.2                                             |
| Complete Response b           | 6 (1.5)                                | 12 (3.1)                               | 0                                               | 1 (1.3)                                         | 0                                               |
| Partial Response b            | 60 (15.4)                              | 67 (17.0)                              | 12 (11.5)                                       | 17 (22.7)                                       | 5 (7.2)                                         |

<div style=\"page-break-after: always\"></div>

Table 37:  Data From HIMALAYA (pivotal study) and Study 22 (supportive study) relevant to the recommended T300+D regimen in patients with uHCC

| Study Analysis set       | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|--------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| DCR (%) c                | 54.8 d                          | 60.1 d                          | 37.5 b                                          | 45.3 b                                          | 49.3 b                                          |
| Median DoR (months) d, e | 16.82                           | 22.34                           | 14.95                                           | 18.43                                           | 23.95                                           |
| Median TTR (months) d, f | 2.09                            | 2.17                            | 3.65                                            | 2.28                                            | 1.81                                            |

a Calculated using the Kaplan-Meier method.

b Confirmed responses only.

Â· Disease control = complete response + partial response + stable disease.

d Response did not require confirmation.

- e DoR is the time from the first documentation of CR/PR until the date of progression, death, or the last evaluable RECIST assessment for subjects that do not progress.
- f TTR is the time to onset of confirmed response from from randomisation (HIMALAYA; Study 22 Parts 2A and 3) or from treatment allocation (Study 22 Part 2B).

Abbreviations: BICR = blinded independent central review; CI = confidence interval; CR = complete response; DCO = data cutoff; DCR = disease control rate; DoR = duration of response; FAS = Full Analysis Set; HR = hazard ratio; ORR = objective response rate; OS = overall survival; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumours; TTR = time to onset of objective response; uHCC = unresectable hepatocellular carcinoma.

## Additional sensitivity analyses following inaccurate survival information at site 6208

GCP findings from the PMDA concerning the HIMALAYA trial, indicated that survival information was inaccurate for 4 subjects at site 6208. Following question regarding this issue, the supplementary analysis of OS with the corrected data was provided.

In total the site 6208 enrolled 14 patients in HIMALAYA study. Overall survival data for 4/14 enrolled patients was affected, and no discrepancies in survival information were identified for the remaining 10/14 patients after onsite review.

Table 38 : Overall survival data for affected 4/14 enrolled patients at site 6208

|                |                                   |                | Survival Status/Date of Death (mm/dd/yyyy)   | Survival Status/Date of Death (mm/dd/yyyy)   | Survival Status/Date of Death (mm/dd/yyyy)   | Survival Status/Date of Death (mm/dd/yyyy)   | Varianc e (days): CRF vs death certifica te   |
|----------------|-----------------------------------|----------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------|
| Subject Number | Randomisati on Date (mm/dd/yyy y) | Treatme nt Arm | CRF                                          | Source docume nt/medi cal record             | Local oncolog y registry                     | Death certifica te                           |                                               |
|                | 01/26/2018                        | S              | 03/05/2 018                                  | N/A                                          | 03/04/2 018                                  | 03/04/2 018                                  | 1                                             |
|                | 04/05/2018                        | S              | Alive on 09/03/2 021                         | Alive on 09/03/2 021                         | 08/12/2 021                                  | 08/12/2 021                                  | 22                                            |
|                | 07/15/2019                        | T300+D         | 08/05/2 019                                  | 08/05/2 019                                  | 07/25/2 019                                  | 07/25/2 019                                  | 11                                            |
|                | 07/16/2019                        | D              | 04/23/2 020                                  | 04/23/2 020                                  | 07/23/2 019                                  | 07/23/2 019                                  | 275                                           |

D = durvalumab 1500mg Q4W; N/A = not applicable; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg for a single dose and durvalumab 400 mg Q4W; T75+D = tremelimumab 75 mg Q4W x 4 doses and durvalumab 1500 mg Q4W.

<div style=\"page-break-after: always\"></div>

Table 39: Sensitivity analysis of OS by removing site 6208 (full analysis set)

|                                   | Number (%)of subjects   | Number (%)of subjects   | Number (%)of subjects   | Number (%)of subjects   |
|-----------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                   | D (N=385)               | T300+D (N=391)          | T75 +D (N=151)          | S (N=383)               |
| Deaths, n (%)                     | 277 (71.9)              | 260 (66.5)              | 121 (80.1)              | 288 (75.2)              |
| Censoredsubjects,n(%)             | 108 (28.1)              | 131 (33.5)              | 30 (19.9)               | 95 (24.8)               |
| Median overall survival (months)a | 16.56                   | 16.66                   | 16.56                   | 13.77                   |
| 95%CIformedianoverall survivala   | 14.06 - 19.12           | 14.19 -20.37            | 12.71-19.78             | 12.25 - 16.13           |
| Hazardratiob                      | 0.87                    | 0.77                    |                         |                         |
| 95% CIforhazard ratiob            | 0.73 - 1.02             | 0.65-0.91               |                         |                         |

The analysis was performed using a Cox proportional hazards model adjusting for treatment, etiology of liver disease (hepatitis B virus vs. hepatitis C virus vs. others), Eastern Cooperative Oncology Group performance status (0 vs. 1), and macro-vascular invasion (yes vs. no). Values of the variables used for adjustment were obtained from the Interactive Voice Response System. Note: Table does not include subjects from Russian site 6208. A hazard ratio &lt; 1 favors IO treatment arms to be associated with a longer overall survival than sorafenib. A hazard ratio &lt; 1 favors IO treatment arms to be associated with a longer overall survival than sorafenib.

Calculated using the Kaplan-Meier technique.

(sxaem  AaAa = M+ peqpeeu 1ou = dN A5ojoouo-ounww! = OI =mt bw 00sT qewn|eunp = @ fjeAuaqui aouepyuos = I S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg for a single dose and durvalumab 400 mg Q4W; T75+D = tremelimumab 75 mg Q4W Ã— 4 doses and durvalumab 1500 mg Q4W.

Figure 24: KM plot of OS by removing site 6208 (full analysis set)

<!-- image -->

Figure does sot include subjects firom Russian site 6208.

D  Duma 1500 mg, T300+D = Treme 300 mg x1 dese + Durva 1500 mg. T75=D = Tseme 75 mgx4 doses + Durva 1500 mg. S = Sora 400 mg BD

The applicant has provided the requested sensitivity analysis, using the most conservative approach by removing all 14 patients enrolled at this site and this showed that the OS HR was of 0.77 (95%CI: 0.65, 0.91) for T300+D vs. S comparison, which is the main scope of the current procedure. There is overall consistency between the sensitivity analysis and the primary analysis, which is considered reassuring.

## Â· Summary of main efficacy results

The following table summarises the efficacy results from the main studies supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Â· Table 40: Summary of efficacy for trial HIMALAYA

| First-line Treatment Study identifier Design   | EudraCT number: 2016-005126-11, NCT number: NCT03298451                        | EudraCT number: 2016-005126-11, NCT number: NCT03298451                        | EudraCT number: 2016-005126-11, NCT number: NCT03298451                                                                                                |
|------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| First-line Treatment Study identifier Design   | Randomised, open-label, multicentre Phase III study                            | Randomised, open-label, multicentre Phase III study                            | Randomised, open-label, multicentre Phase III study                                                                                                    |
| First-line Treatment Study identifier Design   | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Not applicable Not applicable Not applicable                                                                                                           |
| Hypothesis                                     | Superiority for T300+D vs S                                                    | Superiority for T300+D vs S                                                    | Superiority for T300+D vs S                                                                                                                            |
| Hypothesis                                     | D                                                                              | D                                                                              | Durvalumab 1500 mg Q4W until PD or unacceptable toxicity, N=389                                                                                        |
| Hypothesis                                     | T300+D                                                                         | T300+D                                                                         | Tremelimumab 300 mg as single dose plus durvalumab 1500 mg Q4W followed by durvalumab monotherapy 1500 mg Q4W until PD or unacceptable toxicity, N=393 |
| Hypothesis                                     | S                                                                              | S                                                                              | Sorafenib monotherapy 400 mg twice daily until PD or unacceptable toxicity, N=389                                                                      |
| Hypothesis                                     | T75+D                                                                          | T75+D                                                                          | Tremelimumab 75 mg Q4W Ã— 4 doses + durvalumab 1500 mg Q4W, followed by durvalumab monotherapy 1500 mg Q4W. Arm closed prematurely, results not shown.  |
| Endpoints and definitions                      | Primary endpoint                                                               | OS                                                                             | OS of T300+D vs S                                                                                                                                      |
| Endpoints and definitions                      | Key Secondary endpoints                                                        | OS                                                                             | Non-Inferiority of D vs S and superiority of D vs S.                                                                                                   |
| Endpoints and definitions                      | Other secondary endpoints                                                      | PFS, ORR, DoR                                                                  | Progression-free survival, overall response rate and duration of response                                                                              |
| Database lock                                  | 27 August 2021                                                                 | 27 August 2021                                                                 | 27 August 2021                                                                                                                                         |

## Results and Analysis

| Analysis description                            | Primary Analysis                | Primary Analysis                | Primary Analysis                | Primary Analysis                | Primary Analysis                |
|-------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Analysis population and time point description  | Intent to treat, final analysis | Intent to treat, final analysis | Intent to treat, final analysis | Intent to treat, final analysis | Intent to treat, final analysis |
| Descriptive statistics and estimate variability | Treatment group                 | D                               | T300+D                          | T300+D                          | S                               |
| Descriptive statistics and estimate variability | Number of subjects              | 389                             | 393                             | 393                             | 389                             |
| Descriptive statistics and estimate variability | OS (Months)                     | 16.56                           | 16.43                           | 16.43                           | 13.77                           |
| Descriptive statistics and estimate variability | 95%CI                           | 14.06; 19.12                    | 14.16; 19.58                    | 14.16; 19.58                    | 12.25; 16.13                    |
| Descriptive statistics and estimate variability | PFS by INV (months)             | 3.65                            | 3.78                            | 3.78                            | 4.07                            |
| Descriptive statistics and estimate variability | 95%CI                           | 3.19; 3.75                      | 3.68; 5.32                      | 3.68; 5.32                      | 3.75; 5.49                      |
| Descriptive statistics and estimate variability | ORR (%)                         | 17                              | 20.1                            | 20.1                            | 5.1                             |
| Descriptive statistics and estimate variability | DoR (%)                         | 16.82                           | 22.34                           | 22.34                           | 18.43                           |
| Effect estimate per comparison                  | Primary endpoint OS             | Comparison groups               | Comparison groups               | T300+D vs S                     | T300+D vs S                     |
| Effect estimate per comparison                  | Primary endpoint OS             | Stratified HR                   | Stratified HR                   | 0.78                            | 0.78                            |
| Effect estimate per comparison                  | Primary endpoint OS             | 95% CI                          | 95% CI                          | 0.66, 0.92                      | 0.66, 0.92                      |
| Effect estimate per comparison                  | Primary endpoint OS             | P-value                         | P-value                         | 0.0035                          | 0.0035                          |
| Effect estimate per comparison                  | Secondary                       | Comparison groups               | Comparison groups               | D vs S (non-inferior)           | D vs S (non-inferior)           |

<div style=\"page-break-after: always\"></div>

| Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)   | Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)   | Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)   | Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                     | EudraCT number: 2016-005126-11, NCT number: NCT03298451                                                                                                                              | EudraCT number: 2016-005126-11, NCT number: NCT03298451                                                                                                                              | EudraCT number: 2016-005126-11, NCT number: NCT03298451                                                                                                                              |
|                                                                                                                                                                                      | endpoint OS                                                                                                                                                                          | Stratified HR                                                                                                                                                                        | 0.86                                                                                                                                                                                 |
|                                                                                                                                                                                      | endpoint OS                                                                                                                                                                          | 95.67% CI                                                                                                                                                                            | 0.73; 1.03*                                                                                                                                                                          |
|                                                                                                                                                                                      | endpoint OS                                                                                                                                                                          | P-value                                                                                                                                                                              | NA                                                                                                                                                                                   |
|                                                                                                                                                                                      | Secondary endpoint OS                                                                                                                                                                | Comparison groups                                                                                                                                                                    | D vs S (superior)                                                                                                                                                                    |
|                                                                                                                                                                                      | Secondary endpoint OS                                                                                                                                                                | Stratified HR                                                                                                                                                                        | 0.86                                                                                                                                                                                 |
|                                                                                                                                                                                      | Secondary endpoint OS                                                                                                                                                                | 95.67% CI                                                                                                                                                                            | 0.73; 1.03                                                                                                                                                                           |
|                                                                                                                                                                                      | Secondary endpoint OS                                                                                                                                                                | P-value                                                                                                                                                                              | 0.0674 (NS)                                                                                                                                                                          |
| Notes                                                                                                                                                                                | *below prespecified clinical NI (non-inferiority) margin of 1.08                                                                                                                     | *below prespecified clinical NI (non-inferiority) margin of 1.08                                                                                                                     | *below prespecified clinical NI (non-inferiority) margin of 1.08                                                                                                                     |

## 2.6.5.3. Clinical studies in special populations

## Table 41: Patient counts by age category-controlled trial versus non-controlled trial (full analysis set)

| Age   | Controlled trials (N=1324)   | Non-controlled trials (N=332)   |
|-------|------------------------------|---------------------------------|
| < 65  | 667 (50.4)                   | 175 (52.7)                      |
| 65-74 | 467 (35.3)                   | 108 (32.5)                      |
| 75-84 | 181 (13.7)                   | 46 (13.9)                       |
| 85+   | 9 (0.7)                      | 3 (0.9)                         |

Note: Controlled trial includes only HIMALAYA and non-controlled trail includes only Study 22.

## 2.6.5.4. In vitro biomarker test for patient selection for efficacy

## PD-L1 testing

The relationship between PD-L1 expression level and clinical outcomes (eg, OS, PFS, and ORR) was investigated, and the results are presented by treatment arm.

PD-L1 expression was determined by the analytically validated VENTANA PD-L1 (SP263) assay using the TIP score method. The TIP score was defined as the total percentage of the tumour area covered by tumour cells with PD-L1 membrane staining at any intensity and/or tumour-associated immune cells with any pattern of PD-L1 staining at any intensity. Two PD-L1 expression subgroups were defined:

- PD-L1 TIP â‰¥ 1% (Positive): PD-L1 staining of any intensity in tumour cell membranes and/or tumour-associated immune cells covering â‰¥ 1% of the tumour area
- PD-L1 TIP &lt; 1% (Negative): PD-L1 staining of any intensity in tumour cell membranes and/or tumour-associated immune cells covering &lt; 1% of the tumour area.

## Collection of patient samples for analysis of PD-L1 expression

Patients were strongly encouraged to provide a fresh tissue biopsy for the purpose of PD-L1 expression analyses at screening. The tumour specimen submitted to the central laboratory for PD-L1 expression analysis should be of sufficient quantity and quality (with pathology quality control) to allow for PD-L1 immunohistochemical (IHC) analyses. Newly acquired or archived specimens with limited tumour content and fine needle aspirates were not acceptable for defining tumour PD-L1 expression.

- MANDATORY: Provision of a tumour biopsy, formalin fixed and embedded in paraffin, for the purpose of PD-L1 expression analyses (and for enabling exploratory analyses as described in the proceeding section). A newly acquired tumour biopsy (&lt;3 months) was strongly preferred; however, if not feasible with an acceptable clinical risk, an archival sample taken â‰¤ 3 years prior

<div style=\"page-break-after: always\"></div>

to screening could have been submitted. Note: the tumour biopsy was optional for the China cohort.

- Samples should have been collected via an image-guided core needle (at least 18 gauge) or an excisional archival tumour biopsy sample. Where institutional practice, in this setting, uses a smaller gauge needle, samples should have been submitted with tissue adequate to ensure that a valid result can be achieved (ie, total tissue quantity submitted should have been similar to core needle or excisional biopsy requirements).
- When fresh tissue was obtained, 2 cores should have been placed in formalin and processed to a single paraffin-embedded block. It was anticipated that 4 passes of an 18 gauge core needle would provide sufficient tissue for both PD-L1 analyses and exploratory analyses as described below. Tumour lesions used for fresh biopsies should not have been the same lesions used as RECIST 1.1 TLs, unless there were no other lesions suitable for biopsy, and in this instance, only core needle (not excisional/incisional) biopsy was allowed. For patients with a single TL, if screening biopsy was collected prior to screening imaging for baseline tumour assessment, allowed approximately 2 weeks before imaging scans were acquired.
- OPTIONAL: Additional archived tumour tissue block (formalin fixed and paraffin embedded), where such samples exist in a quantity sufficient to allow for analysis. Tumour tissue block was preferred. If a tissue block was unavailable, unstained sections from the tissue block may be submitted.
- OPTIONAL: Tumour biopsy at the time of progression was requested
- OPTIONAL: Additional tumour biopsies collected as part of clinical care (eg, for mixed responses or upon PD) could have been submitted for further analysis.
- Additional archived tissue not intended for PD-L1 testing, and optional biopsies obtained at the time of progression or part of clinical care were not to be collected in China. Additionally, China study sites were not to submit tumour tissue blocks and only unstained sections from the tissue block were to be submitted for analysis.
- The Ventana SP263 IHC assay was to be used to determine PD-L1 expression in all available specimens. To meet the requirement of the United States Food and Drug Administration for approval of a companion diagnostic, sections of the tumour were to be retained at Ventana and/or at the Investigation Use only testing laboratory for potential additional studies to support potential test approval.

The Ventana SP163 PD-L1 assay was validated as an appropriate method for the selection of patients who would obtain benefit from durvalumab monotherapy in the PACIFIC trial, whose outcome led to the PD-L1 restricted indication of this anti-PD-L1 product in the locally advanced unresectable NSCLC setting after chemoradiotherapy. Thus, the choice of PD-L1 assay is acceptable.

## 2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable

<div style=\"page-break-after: always\"></div>

## 2.6.5.6. Supportive study - Study 22

## Figure 25: Study 22 study design

<!-- image -->

Following protocol amendment 5, enrollment into the T75+D arm in Part 3 was closed. Patients already randomised to T75+D could continue on assigned study treatment (provided the Investigator and patient thought it in the best interests of the patient) until confirmed progressive disease or any other discontinuation criteria were met. Weight-based dosing regimen was used in Parts 2A; fixed-dosing regimens were used in Part 2B and Part 3 (durvalumab only).

Abbreviations: D = durvalumab 1500 mg (20 mg/kg) Q4W; DoR, duration of response; HCC = hepatocellular carcinoma; n = number of subjects in a treatment arm; PD-L1 = programmed cell death ligand-1; OS, overall survival; ORR, objective response rate; Q8W, every 8 weeks; Q4W = every 4 weeks; Q8 = every 8 weeks; Q12W = every 12 weeks; T = tremelimumab 750 mg (10 mg/kg) Q4W Ã— 7 doses followed by Q12W; T300+D = tremelimumab 300 mg (4 mg/kg) Ã— 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W; T75+D = tremelimumab 75 mg (1 mg/kg) Q4W Ã— 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W, followed by durvalumab 1500 mg (20 mg/kg) Q4W.

Study 22 was a randomised, multicentre, international, open-label, multipart study designed to evaluate the safety, tolerability, and clinical activity of durvalumab and tremelimumab administered as monotherapy, and durvalumab in combination with tremelimumab or bevacizumab, in patients with advanced HCC. The study was comprised of multiple parts but only Parts 2 and 3 of Study 22 are relevant for this procedure.

The primary objectives of Parts 2 and 3 were to:

- Assess the safety and tolerability of durvalumab and tremelimumab administered as monotherapy and durvalumab administered in combination with tremelimumab to subjects with advanced HCC.

## The secondary objectives were to:

- Evaluate the efficacy of durvalumab and tremelimumab administered as monotherapy and durvalumab in combination with tremelimumab in subjects with advanced HCC.
- Evaluate the relationship between baseline and pharmacodynamic biomarkers and measures of clinical outcomes of durvalumab and tremelimumab administered as monotherapy, and durvalumab in combination with tremelimumab in subjects with advanced HCC.

The final analysis of data in all study parts was performed 12 months after the first dose of investigational product was given to the last patient enrolled in the study (DCO: 06â€¯Novemberâ€¯2020).

## Patient population

In Study 22, eligible patients were aged â‰¥ 18 years (â‰¥ 20 years for Japanese patients) with advanced HCC confirmed pathologically or with non-invasive methods. This study enrolled immunotherapy-naÃ¯ve patients who progressed on, were intolerant to, or refused treatment with sorafenib or another approved VEGFR TKI. Patients with co-infection of viral hepatitis B and hepatitis C, active or prior documented GI bleeding within 12 months, ascites requiring non-pharmacologic intervention within 6 months, hepatic encephalopathy within 12 months before the start of treatment, and active or prior documented autoimmune or inflammatory disorders were excluded.

<div style=\"page-break-after: always\"></div>

In Part 2A of Study 22, eligible patients were randomised in a 1:1:1 ratio to each of the following 3 treatment arms: D: Durvalumab 20 mg/kg Q4W; T: Tremelimumab 10 mg/kg Q4W Ã— 7 doses followed by Q12W; T75+D: Tremelimumab 1 mg/kg Q4W Ã— 4 doses + durvalumab 20 mg/kg Q4W, followed by durvalumab 20 mg/kg Q4W

Part 2B was a safety run-in for the combination regimen consisting of a single, priming dose of tremelimumab (300 mg) added to durvalumab Q4W. Part 3 was a dose expansion cohort of patients enrolled in Parts 2A and B. Eligible patients were randomised in a 2:2:1:2 ratio to each of the following 4 treatment arms: D: Durvalumab 1500 mg (20 mg/kg) Q4W; T300+D: Tremelimumab 300 mg (4 mg/kg) Ã— 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W; T: Tremelimumab 750 mg (10 mg/kg) Q4W Ã— 7 doses followed by Q12W; T75+D: Tremelimumab 75 mg (1 mg/kg) Q4WÃ— 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W, followed by durvalumab 1500 mg (20 mg/kg) Q4W.

In Part 2A, patients were stratified based on viral status (uninfected, HCV infected, or HBV infected) and PD-L1 expression (positive, negative, or non-evaluable). In Part 3, patients were stratified based on viral status (uninfected, HCV infected, or HBV infected) and sorafenib-based therapy (refusers or all others).

Table 42: Previous disease-related treatment modalities in Parts 2 and 3 (FAS)

|                        | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                        | D (N = 104)              | T300+D (N = 75)          | T (N = 69)               | T75+D (N =84)            | Total (N = 332)          |
| Systemic therapy a     | 66 (63.5)                | 55 (73.3)                | 44 (63.8)                | 55 (65.5)                | 220 (66.3)               |
| Carotuximab            | 1 (1.0)                  | 0                        | 0                        | 0                        | 1 (0.3)                  |
| Regorafenib            | 1 (1.0)                  | 0                        | 0                        | 0                        | 1 (0.3)                  |
| Sorafenib              | 66 (63.5)                | 55 (73.3)                | 44 (63.8)                | 55 (65.5)                | 220 (66.3)               |
| Radiotherapy           | 16 (15.4)                | 22 (29.3)                | 15 (21.7)                | 22 (26.2)                | 75 (22.6)                |
| Cancer-related surgery | 37 (35.6)                | 34 (45.3)                | 23 (33.3)                | 37 (44.0)                | 131 (39.5)               |
| Other                  | 49 (47.1)                | 25 (33.3)                | 31 (44.9)                | 39 (46.4)                | 144 (43.4)               |

D, durvalumab monotherapy 1500 mg (20 mg/kg) Q4W; FAS, Full Analysis Set; Q4W, every 4 weeks; T, tremelimumab monotherapy 750 mg (10 mg/kg) Q4W x 7 doses followed by every 12 weeks; T75+D, tremelimumab 75 mg (1 mg/kg) Ã— 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W; T300+D, tremelimumab 300 mg (4 mg/kg) Ã— 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W.

## Results

A total of 326 (98.2%) patients in the FAS of Parts 2 and 3 received study treatment. At the final DCO, 93.3% of patients across all treatment arms discontinued study treatment. The most frequently reported reason for discontinuing study treatment was HCC disease progression in 66.6% of patients; 11% of patients discontinued due to AEs. The rate of study treatment discontinuation due to PD or AEs was similar across the T300+D and D treatment arms.

The number of patients in Parts 2 and 3 with important protocol deviations with the potential to affect the analyses was low (13 patients overall [3.9%]).

For patient demographics and disease characteristics, please refer to Table  and Error! Reference source not found. in the Results section above (2.6.5.2. ).

<div style=\"page-break-after: always\"></div>

Table 43: Overall survival in Parts 2 and 3 (FAS)

<!-- image -->

|                                                                        | D (N =104)         | T300+D (N = 75)    | T (N = 69)         | T75+D (N =84)      |
|------------------------------------------------------------------------|--------------------|--------------------|--------------------|--------------------|
| Median OS (months) a                                                   | 12.91              | 17.05              | 17.05              | 11.30              |
| 95% CI for median OS                                                   | 8.74-16.79         | 10.55-22.83        | 11.33-20.24        | 8.38-14.95         |
| Deaths, n (%)                                                          | 78 (75.0)          | 49 (65.3)          | 55 (79.7)          | 64 (76.2)          |
| Censored patients, n (%)                                               | 26 (25.0)          | 26 (34.7)          | 14 (20.3)          | 20 (23.8)          |
| Still in survival follow-up b                                          | 20 (19.2)          | 23 (30.7)          | 12 (17.4)          | 15 (17.9)          |
| Terminated prior to death c                                            | 6 (5.8)            | 3 (4.0)            | 2 (2.9)            | 5 (6.0)            |
| Lost to follow-up                                                      | 0                  | 1 (1.3)            | 0                  | 2 (2.4)            |
| Withdrawn consent                                                      | 3 (2.9)            | 2 (2.7)            | 2 (2.9)            | 2 (2.4)            |
| Other                                                                  | 3 (2.9) d          | 0                  | 0                  | 1 (1.2) e          |
| OS rate at 12 months, % a                                              | 50.4               | 57.6               | 59.8               | 49.4               |
| 95% CI for OS rate at 12 months a                                      | 40.3-59.7          | 45.5-68.0          | 47.1-70.4          | 38.1-59.7          |
| OS rate at 18 months, % a                                              | 34.0               | 47.8               | 43.3               | 35.5               |
| 95% CIfor OS rate at 18 months a                                       | 24.9-43.3          | 35.9-58.7          | 31.3-54.7          | 25.2-45.9          |
| OS rate at 24 months, % a                                              | 26.2               | 38.3               | 30.9               | 30.3               |
| 95% CI for OS rate at 24 months a                                      | 17.9-35.3          | 26.9-49.6          | 20.3-42.2          | 20.7-40.6          |
| Duration of follow-up in censored  patients (months), median (range) f | 23.18 (1.84-44.29) | 24.61 (0.95-35.58) | 31.03 (1.81-44.02) | 29.82 (0.03-43.14) |

- a Calculated using the Kaplan-Meier technique.
- b Includes patients known to be alive at the data cut-off.
- C Includespatientswith unknownsurvivalstatus whoterminated studyparticipation and patientswhowere lost to follow-up.
- d *Other' reasons (1 patient each): psychiatric issues and study compliance, adverse event, and patient did not receivetreatment.
- â€˜Other*reason: patient did not receive treatment.
- f Medianfordurationof follow-upisthe arithmeticmedian.Durationof follow-upwascalculatedfrom date ofrandomization(Part 2A,Part 3) or date of first study treatment dose (Part 2B).

CI, confidence interval; D, durvalumab monotherapy 1500 mg (20 mg/kg) Q4W; FAS, Full Analysis Set; OS, overall survival; Q4W,every 4weeks;T, tremelimumab monotherapy 750mg(10 mg/kg)Q4W x 7 doses followed by every 12 weeks; T75+D, tremelimumab 75 mg (1 mg/kg) Ã— 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W; T300+D, tremelimumab 300 mg (4 mg/kg) x 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W.

<div style=\"page-break-after: always\"></div>

| D      |   104 |   82 |   68 |   58 |   50 |   42 |   33 |   24 |   17 |   14 |   12 |   7 |   7 |    |   6 |   3 0 |
|--------|-------|------|------|------|------|------|------|------|------|------|------|-----|-----|----|-----|-------|
| T300+D |    75 |   68 |   56 |   49 |   42 |   38 |   34 |   27 |   19 |   17 |   11 |   5 |   0 |  0 |   0 |     0 |
| T      |    69 |   62 |   52 |   47 |   40 |   35 |   29 |   21 |   18 |   16 |   13 |   9 |   8 |  6 |   2 |     0 |
| T75+D  |    84 |   69 |   56 |   48 |   39 |   31 |   28 |   24 |   23 |   61 |   11 |   6 |   5 |  4 |   2 |     0 |

Figure 26: Kaplan-Meier plot of overall survival in Parts 2 and 3 (FAS)

<!-- image -->

CI, confidence interval; D, durvalumab monotherapy 1500 mg (20 mg/kg) Q4W; FAS, full analysis set; OS, overall survival; Q4W, every 4 weeks; T, tremelimumab monotherapy 750 mg (10 mg/kg) Q4W x 7 doses followed by every 12 weeks; T75+D, tremelimumab 75 mg (1 mg/kg) Ã— 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W; T300+D, tremelimumab 300 mg (4 mg/kg) Ã— 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W. Source: Figure 14.2.1.

Table 44: Confirmed objective response rate in parts 2 and 3 based on BICR according to RECIST 1.1 (FAS)

|                                           | D (N =104)   | T300+D (N = 75)   | T (N = 69)   | T75+D (N =84)   |
|-------------------------------------------|--------------|-------------------|--------------|-----------------|
| Patients with objective response, n (%) a | 12 (11.5)    | 18 (24.0)         | 5 (7.2)      | 8 (9.5)         |
| ORR (%)                                   | 11.5         | 24.0              | 7.2          | 9.5             |
| 95%exact CI                               | 6.1, 19.3    | 14.9.35.3         | 2.4, 16.1    | 4.2,17.9        |

<div style=\"page-break-after: always\"></div>

Table 45: Duration and onset of objective response in patients with confirmed objective response in parts 2 and 3 based on BICR according to RECIST 1.1 (FAS)

|                                                                                                      | D (N =104)                                                                                           | T300+D (N = 75)                                                                                      | T (N =69)                                                                                            | T75+D (N =84)                                                                                        |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Number ofpatientswith objective response, n (%)                                                      | 12 (11.5)                                                                                            | 18 (24.0)                                                                                            | 5 (7.2)                                                                                              | 8 (9.5)                                                                                              |
| Number ofresponderswho subsequently progressed or died, n                                            | 6                                                                                                    | 9                                                                                                    | 3                                                                                                    | 4                                                                                                    |
| Duration of response from onset of response (months) a, b                                            | Duration of response from onset of response (months) a, b                                            | Duration of response from onset of response (months) a, b                                            | Duration of response from onset of response (months) a, b                                            | Duration of response from onset of response (months) a, b                                            |
| Median                                                                                               | 14.95                                                                                                | 18.43                                                                                                | 23.95                                                                                                | 13.21                                                                                                |
| 25th, 75th percentile                                                                                | 8.54, NR                                                                                             | 5.59, 23.95                                                                                          | 4.07, NR                                                                                             | 10.15, NR                                                                                            |
| Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   |
| 6 months                                                                                             | 83.3                                                                                                 | 71.8                                                                                                 | 60.0                                                                                                 | 87.5                                                                                                 |
| 12 months                                                                                            | 56.3                                                                                                 | 64.6                                                                                                 | 60.0                                                                                                 | 58.3                                                                                                 |
| Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) |
| Median                                                                                               | 3.65                                                                                                 | 2.28                                                                                                 | 1.81                                                                                                 | 2.86                                                                                                 |
| 25th, 75th percentile                                                                                | 2.71, 5.59                                                                                           | 1.81, 3.68                                                                                           | 1.81, 1.84                                                                                           | 1.84, 3.83                                                                                           |

BICR, blinded independent central review; D, durvalumab monotherapy 1500 mg (20 mg/kg) Q4W; FAS, Full Analysis Set; NR, not reached; Q4W, every 4 weeks; RECIST 1.1, Response Evaluation Criteria In Solid Tumours Version 1.1; T, tremelimumab monotherapy 750 mg (10 mg/kg) Q4W x 7 doses followed by every tremelimumab 300 mg (4 mg/kg) Ã— 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W.

## Overall Survival (Part 2 Only)

A total of 125 patients were randomised/allocated to treatment in Part 2: 40 in the D arm, 10 in the T300+D arm, 36 in the T arm, and 39 in the T75+D arm. At the final DCO, 81.6% of patients in part 2 had died (FAS): 80.0% in the D arm, 70.0% in the T300+D arm, 80.6% in the T arm, and 87.2% in the T75+D arm. The percentage of patients alive at the final DCO and in survival follow-up (including those still receiving study treatment) was highest in the T300+D arm (30.0%) compared to the other 3 arms (10.3% to 17.5%).

The Kaplan-Meier estimate of median OS was highest for patients receiving T300+D (28.06 months) compared to patients receiving D (11.78 months), T (17.05 months), or T75+D (13.34 months).

## Overall Survival (Part 3 Only)

Part 3 included the following number of patients per treatment arm: 64 in D arm; 65 in T300+D arm; 33 in T arm; 45 in T75+D arm. Median OS was higher for patients in the T300+D (16.16 months) and T arms (17.54 arms) compared to D (13.57 months) and T75+D (11.30 months).

## ADA Response to tremelimumab (in Parts 2 and 3)

At the final DCO, immunogenicity data for tremelimumab were available for 56.9% of patients evaluable for ADA.

ADA prevalence for tremelimumab was 12.7% in the T300+D arm, 15.6% in the T arm, and 7.3% in the T75+D  arm  and  the  majority  of  ADA-positive  patients  were  classified  as  treatment-emergent  ADA positive. ADA incidence for tremelimumab appeared to be numerically higher in the T treatment arm (15.6%) relative to the T300+D (7.3%) and T75+D (7.3%) arms (

<div style=\"page-break-after: always\"></div>

Table ). However, due to the small number of ADApositive patients in all treatment arms (â‰¤ 5 in all arms), it is not possible to draw a definitive conclusion.

All 12 of the tremelimumab treatment-emergent ADA positive patients in the study were classified as persistently ADA positive. However, 11 of these were classified as such due to the last ADA assessment being positive, rather than based on the duration of the ADA response being â‰¥ 16 weeks.

Table 46: Summary of anti-drug antibody responses to tremelimumab in parts 2 and 3 (safety analysis set)

| Category, n (%)                                     | T300+D (N =74)   | T (N = 69)   | T75+D (N =82)   |
|-----------------------------------------------------|------------------|--------------|-----------------|
| Tremelimumab ADA evaluable patients                 | 55 (74.3)        | 32 (46.4)    | 41 (50.0)       |
| ADA positive at any visit (ADA prevalence) a        | 7 (12.7)         | 5 (15.6)     | 3 (7.3)         |
| Treatment-emergent ADA positive (ADA incidence) b   | 4 (7.3)          | 5 (15.6)     | 3 (7.3)         |
| Treatment-boosted ADA c                             | 0                | 1 (3.1)      | 0               |
| Treatment-induced ADA (Positive post-baseline only) | 4 (7.3)          | 4 (12.5)     | 3 (7.3)         |
| ADA positive at baseline only                       | 2 (3.6)          | 0            | 0               |
| ADA positive post-baseline and positive at baseline | 1 (1.8)          | 1 (3.1)      | 0               |
| Persistently positive d                             | 5 (9.1)          | 5 (15.6)     | 3 (7.3)         |
| Transiently positive e                              | 0                | 0            | 0               |
| nAb positive at any time                            | 5 (9.1)          | 5 (15.6)     | 0               |

RefertoTable48forfootnotedefinitions.

ADA, anti-drug antibody; nAb, neutralizing antibody; Q4W, every 4 weeks; T, tremelimumab monotherapy

X 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W; T300+D, tremelimumab 300 mg (4 mg/kg)

750 mg (10 mg/kg) Q4W Ã— 7 doses followed by every 12 weeks; T75+D, tremelimumab 75 mg (1 mg/kg)

x 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W.

Source:Table 14.3.9.2

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

The efficacy of the new active substance, tremelimumab (T), in combination with the already approved PD-L1 inhibitor durvalumab (D) for the treatment of unresectable hepatocellular carcinoma (uHCC) is primarily based on the pivotal Himalaya study. This was a randomised, open-label, multicentre Phase III study in patients with uHCC not eligible for locoregional therapy. Patients were recruited from 181 sites across 16 countries, mostly from countries with an EU-like population. No prior systemic therapy was allowed and only patients with mild or no symptoms pertaining to the HCC and/or liver cirrhosis were eligible, which is not considered reflective of the general patient population with uHCC. However, the inclusion and exclusion criteria are reflected in the SmPC section 5.1, so this is acceptable. 1324 patients were randomised to 4 arms, durvalumab monotherapy (D, n=389); tremelimumab single dose 300 mg + durvalumab (T300+D, n=393); Tremelimumab 75 mg x 4 + durvalumab (T75+D, n=153); and sorafenib (S, n=389). Randomisation was stratified according to macrovascular invasion (yes versus no), etiology of liver disease (hepatitis B virus [confirmed HBV] versus hepatitis C virus [confirmed HCV] versus others), and ECOG PS (0 versus 1). The stratification factors are considered clinically relevant as they are important prognostic factors for the outcome of uHCC. Other important prognostic factors could have been added, such as AFP levels; however, considering the size of the pivotal trial, it is considered appropriate to limit the number of stratification

<div style=\"page-break-after: always\"></div>

factors to three. Additional supportive evidence of clinical efficacy was provided from study 22, a randomised, phase I/II, open-label study.

The overall design of the pivotal Himalaya study is endorsed as it allows to assess the efficacy of the proposed dosing of tremelimumab single dose 300 mg + durvalumab 1500 mg iv followed by durvalumab monotherapy 1500 mg iv Q4W (T300+D) versus standard of care (Sorafenib - S) in the proposed first-line setting. Moreover, the applicant included a durvalumab monotherapy arm and an arm with another combination regimen of T75+D, which was abolished after some time.

Baseline characteristics for patients included in the Himalaya study showed that the median age in the relevant arms (T300+D vs the S arm vs the T300+D arm of study 22) were 65 vs 64 vs 66 years of age; however, approximately half of the patients were &lt;65 years of age and the vast majority of the patients were male (83.2% vs 86.6% vs 86.7%) and of white (46.3% vs 46% vs 36%) or Asian (49.6% vs 48.6% vs 58.7%) race.  Alcohol use was only registered in the pivotal Himalaya study and it is noted that a large proportion was never users (~40%) or former users (~45%). The baseline characteristics are well balanced between the arms, but only approximately 46% of the study population are considered EU like according to region and race characteristics. Moreover, the alcohol use in the study population is considered lower than for the EU population.

Disease characteristics showed that most patients were ECOG PS 0 (~60%) and of advanced Barcelona Clinic Liver Cancer (BCLC) stage C (~80%). Additionally, macrovascular invasion and/or extrahepatic spread was observed for many (~65%). However, the poor prognostic factor of AFP &gt;400 ng/ml was observed in approximately a third of the patients, which is also reflected by the distribution of the Child-Pugh score categories, showing that many of the included patients have a favourable prognosis.

It is noted that only a third of the included patients had tumours that were PD-L1 positive (TIP â‰¥ 1%) and that there were ~13% of the patients in the D+T containing arms, who had missing data on PD-L1 status. Overall, the important disease characteristics are well distributed between the treatment arms. Regarding the level of poor prognostic factors, it is considered that these are lower than expected for the targeted patient population, which should be kept in mind when interpreting the results of the studies.

The primary objective of the pivotal Himalaya study was to assess superiority of efficacy of T300+D vs standard of care (sorafenib) regarding OS for the ITT population. The two key secondary objectives of the trial were to assess non-inferiority of the efficacy of durvalumab monotherapy versus SoC (sorafenib) regarding OS and superiority of the efficacy of durvalumab monotherapy versus SoC (sorafenib) regarding OS. Other important secondary endpoints are PFS and overall response rate plus duration of response. The current MAA for tremelimumab is based on efficacy results from the primary objective of the pivotal study. The primary objective and key secondary objectives pertain to overall survival, and this is endorsed, considering the targeted patient population and the robustness of OS as an endpoint.

Although it does not preclude a benefit/risk assessment, the overall conduct of the study is considered suboptimal due to the changes in primary endpoints and sample size especially considering the open label design.  Additionally, interpretation of radiological assessments of tumour response is hindered because of the lack of blinded central review of the assessments in the final analysis.

## Efficacy data and additional analyses

## The pivotal Himalaya study:

The primary objective was met as treatment with T300+D showed a statistically significant and clinically relevant improvement in OS compared to standard of care, sorafenib. Median OS was improved from 13.77 months to 16.43 months, HR 0.78 (96.02% CI: 0.65, 0.92). The analysis was

<div style=\"page-break-after: always\"></div>

performed after ~33 months of follow up and 66.7% of events in the T300+D arm and 75.3% events in the S arm, respectively, so the OS data are considered mature. The KM curves begin to separate after 4 months of therapy and stay separated.

It is acknowledged that Himalaya was primarily designed to demonstrate superiority of T300+D vs S in terms of OS and was amended to demonstrate non-inferiority of D vs S for OS as the next analysis in the hierarchical testing. Moreover, the study design allowed for assessment of the contribution of tremelimumab to the combination regimen, through prespecified exploratory analyses of T300+D vs D, which showed an HR of 0.90 (95%CI: 0.76, 1.07) for OS, which was 16.43 months vs 16.56 months, respectively. The applicant has further argued that due to the complementary mechanisms of action of tremelimumab and durvalumab, the reduction in risk of death, more patients achieving a BOR of CR plus more durable responses in the T300+D arm that the addition of tremelimumab is justified. Additionally, a post-hoc analysis calculating piecewise constant treatment effects favoured T300+D independent of selected time interval when compared to either S or D, further illustrating the OS benefit offered by T300+D compared with D. . However, there are remaining uncertainties regarding the optimal dosing regimen e.g. would more than one single dose of tremelimumab have had a significant contribution to added efficacy compared to T300+D and is 300 mg the optimal dose or could the same efficacy and maybe a better safety profile have been obtained with several but lower doses of tremelimumab.

The secondary endpoint of ORR by investigator was 20.1% for the T300+D arm compared to 5.1% in the sorafenib arm, while 3.1% of the patients in the T300+D arm had a complete response (CR) vs no patients in the S arm. Confirmed ORR by BIRC was slightly lower in the T300+D arm (18.8%), but this is not directly comparable with ORR by Investigator, since the evaluation was only done in a subset of patients. The improvement of the response rate both by INV and by BIRC is considered borderline clinically meaningful in its magnitude; however, the responders in the T300+D arm (n=79) had durable responses with a median DoR of 22.34 months.

The PFS analyses were not in the testing hierarchy, so they are not controlled for multiplicity. PFS by investigator was not clinically significantly improved, since the median PFS was 3.78 months in the T300+D arm versus 4.07 months in the S arm; HR 0.90 (95%CI: 0.77, 1.05). The PFS analyses are mature with 85.2% and 84.1% events in the T300+D and S arms, respectively and the KM curves do not clearly separate at any time. This finding is considered consistent with the pattern of efficacy generally observed for immunotherapy, where PFS benefit is often lacking or of a small magnitude, while OS is often clinically significantly improved. Hence, this could be considered an acceptable result as the primary endpoint was OS, and that an OS benefit has been shown for the proposed treatment regimenT300+D vs S.

However, there are uncertainties when interpreting PFS and ORR considering that the final analysis in an open label setting was done by investigators. Additionally, assessments were performed using RECIST 1.1. although in the immunotherapy setting, irRECIST may have been more appropriate/more informative. Nevertheless, rate of possible pseudoprogression of HCC with CTLA-4/PD-L1 inhibition is currently unknown, which creates uncertainty around PFS and ORR data, since patients with confirmed PD (according to RECIST 1.1) were discontinued from IP. Confirmation of PD required a follow-up scan evaluated by Confirmation of Radiological Progression criteria preferably at the next scheduled visit and no earlier than 4 weeks after the initial assessment of PD. In the HIMALAYA study, confirmation of PD was not mandatory as RECIST 1.1 used for final analysis does not require confirmation of progression and therefore was not done in the study. The lack of data on potential pseudoprogression is of concern as patients could be denied potentially beneficial treatment. This issue remains to be answered in clinical practice.

<div style=\"page-break-after: always\"></div>

Additionally, assessments by BICR were performed only on a subset of patients evaluable for 32 weeks of follow up (for interim analysis 1), and included RECIST 1.1, irRECIST, and mRECIST. Following interim analysis 1, no further BICR assessments were performed. In view of the robustness of the primary endpoint (OS) the applicant's approach regarding PFS can be accepted.

The study design of Himalaya allowed for assessment of the contribution of tremelimumab to the combination regimen, through prespecified exploratory analyses of T300+D vs D, which showed an HR of 0.90 (95%CI: 0.76, 1.07) for OS, which was 16.43 months vs 16.56 months, respectively. The applicant has also provided a rationale for the addition of tremelimumab to durvalumab for the HCC indication, which is primarily based on the following: The combined blockade of CTLA-4 and PD-(L)1 to increase effector T-cell response through two distinct yet complementary mechanisms of action and an approximately 10% reduction in the average risk of death was observed with T300+D versus D. Moreover, while the objective response rates with T300+D and D were similar in HIMALAYA (20.1% vs. 17.0%), twice as many BORs of CR were observed in HIMALAYA with T300+D (12 [3.1%]) compared to D (6 [1.5%]).

The provided arguments are acknowledged and it is accepted that the applicant seeks an approval for the T300+D regimen. However, there remains to be unanswered questions to what would have been the optimal dosing regimen e.g. would more than one single dose of tremelimumab have had a significant contribution to added efficacy compared to T300+D and is 300 mg the optimal dose or could the same efficacy and maybe a better safety profile have been obtained with several but lower doses of tremelimumab. This remains to be unknown.

PRO data was collected as a secondary endpoint. Since the pivotal study was open-label and PRO endpoints were not multiplicity-protected, clinical meaningfulness of PRO data is not considered relevant and the applicant has agreed to delete them from the SmPC.

No additional information on changes in AFP were provided as these data were not collected in the HIMALAYA study.

Relevant subgroup analyses of the primary endpoint of OS show that the benefit of T300+D vs S is maintained across important subgroups of age of less than or â‰¥ 65 years, HBV or other reasons for liver disease, ECOG performance status, macrovascular invasion (MVI), AFP at baseline and BCLB score C.

## The supportive Study 22:

The supportive study 22 was a randomised, multicentre, open-label, multipart study designed to evaluate the safety and efficacy of durvalumab and/or tremelimumab in patients with advanced HCC in the 2L+ setting. The study was comprised of multiple parts, but the results from the T300+D arm is considered of most relevance for the proposed indication (n=75), although the study randomised patients to 4 treatment arms. Patients were immunotherapy-naÃ¯ve patients with advanced HCC, who had progressed on, were intolerant to, or refused treatment with sorafenib or another approved Vascular endothelial growth factor receptor (VEGFR) TKI. Due to different stratification factors in Parts 2A and 3 and lack of randomisation altogether in Part 2B, pooling of efficacy data is inappropriate. Fortunately, OS data from Part 2 and 3 is available separately as well. Although there were no interim analyses planned in the Original Protocol (09 April 2015), in the end 6 interim analyses were performed (and added through Protocol Amendments).

Baseline data for the T300+D arm showed that the median age was 66 years and the vast majority of the patients were male (86.7%) and of white (36%) or Asian (58.7%) race. Disease characteristics show that the vast majority of patients were ECOC PS 0 (61.3%) and disease of advanced BCLC stage C (77.3%) plus macrovascular invasion and/or extrahepatic spread (77.3%).

<div style=\"page-break-after: always\"></div>

In conclusion, Study 22 is an early phase, exploratory study that was amended several times. The primary objective of the study was to assess the safety and tolerability, whereas efficacy was a secondary objective and there was no hierarchical testing procedure or correction for multiplicity. The efficacy data quality should be viewed in this light. Moreover, out of the 75 patients in Study 22, who were treated with T300+D, only 55 patients had received prior treatment with sorafenib and were thus truly 'second line'. Due to the lack of a SoC comparator arm in Study 22, there is no benchmark for the results of the T300+D study arm, as there is insufficient understanding of the relevance of the efficacy as observed in the other study arms. In addition, the exploratory design of Study 22 and in particular the lack of a SAP that would provide for formal comparisons between the study arms, hampers both the contextualisation and interpretation of the efficacy results obtained in these 55 patients. As a consequence, the time-to-event endpoints cannot be interpreted adequately. It is noted that the ORR in these 55 patients was only 20%, which cannot be considered dramatic (EMA/CHMP/205/95 Rev.5).

The final analysis showed a median OS of 17 months (65.3% events) for patients who received the proposed dosing regimen of T300+D, while the ORR was 24% and the duration of response (DoR) was 18 months. The applicant compares this result to durvalumab monotherapy; however, this is not approved for or is standard of care (SOC) in the 2L+ setting, so this comparison is not considered relevant for the current application. Since none of the arms of Study 22 contained any SOC, the results for the T300+D arm are considered supportive of efficacy for the proposed dosing regimen in the firstline setting.

## 2.6.7. Conclusions on the clinical efficacy

The results from the pivotal Himalaya study show a statistically significant and clinically relevant OS benefit over standard of care in the first-line setting of unresectable HCC.

## 2.6.8. Clinical safety

Table 47: Summary of clinical studies included in the submission package

| Study Name (Study Number) Status DCO        | Phase Study Design                                         | Patient Population                                  | No. of patients Assigned and Treated (Treatment group)        |
|---------------------------------------------|------------------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------------|
| Studies in HCC                              | Studies in HCC                                             | Studies in HCC                                      | Studies in HCC                                                |
| HIMALAYA (D419CC00002) Ongoing 27 Aug 2021  | Phase III Randomised, open-label, comparative, multicentre | Advanced HCC with no prior systemic therapy for HCC | 1324 (total) 393 (T300+D) 389 (D) 389 (Sorafenib) 153 (T75+D) |
| Study 22 (D4190C00022) Complete 06 Nov 2020 | Phase II Randomised, open-label, comparative, multicentre  | Advanced unresectable HCC                           | 326 (total) 74 (T300+D) 101 (D) 82 (T75+D) 69 (T)             |

## HCC-tumour Pools

The pivotal safety dataset used to characterise the safety profile of durvalumab in combination with tremelimumab in the proposed indication was derived from pooled data from HIMALAYA and Study 22. The populations in the HCC-tumour pools are described below:

- HCC T300+D pool: This population consists of all patients who have received at least 1 dose of durvalumab  given  at  a  dose  of  1500mg  IV  Q4W  (or  equivalent)  in  combination  with tremelimumab 300 mg IV x 1 dose (or equivalent) for HCC.

<div style=\"page-break-after: always\"></div>

- HCC  D  pool: This  population  consists  of  all patients  who  have  received  at  least  1  dose  of durvalumab monotherapy given at a dose of 20 mg/kg Q4W IV (or equivalent) for HCC.

## 2.6.8.1. Patient exposure

Table 48: Summary of study treatment exposure (safety analysis set)

|                                         | HCC-tumour pool                         | HCC-tumour pool                         | Pan-tumour pool                         | Pan-tumour pool                         | Pan-tumour pool                         |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                         | T300+D                                  | D                                       | D                                       | T75+D                                   | T750                                    |
|                                         | (N = 462)                               | (N = 492)                               | (N = 4045)                              | (N = 3319)                              | (N = 643)                               |
| Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      |
| n                                       | 462                                     | 492                                     | 4045                                    | 3319                                    | 643                                     |
| Mean (SD)                               | 41.9 (44.34)                            | 38.0 (41.49)                            | 28.9 (32.18)                            | 30.1 (37.06)                            | 17.1 (18.46)                            |
| Median (min, max)                       | 20.0 (2, 185)                           | 19.9 (1, 193)                           | 16.1 (0, 220)                           | 16.0 (1, 222)                           | 12.0 (1, 176)                           |
| Total treatment years                   | 370.6                                   | 358.6                                   | 2240.4                                  | 1912.2                                  | 210.5                                   |
| Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) |
| â‰¥ 24                                    | 222 (48.1)                              | 225 (45.7)                              | 1671 (41.3)                             | 1219 (36.7)                             | 129 (20.1)                              |
| â‰¥ 52                                    | 131 (28.4)                              | 120 (24.4)                              | 793 (19.6)                              | 590 (17.8)                              | 36 (5.6)                                |
| â‰¥ 76                                    | 92 (19.9)                               | 82 (16.7)                               | 246 (6.1)                               | 292 (8.8)                               | 14 (2.2)                                |
| â‰¥ 104                                   | 66 (14.3)                               | 53 (10.8)                               | 179 (4.4)                               | 219 (6.6)                               | 6 (0.9)                                 |

Table 49: Duration of exposure (Safety analysis set)

|                                              |                       | D               | T300+D (N =388)      | T300+D (N =388)   | T300+D (N =388)   | T75+D (N =152)      | T75+D (N =152)   | T75+D (N =152)   | S               |
|----------------------------------------------|-----------------------|-----------------|----------------------|-------------------|-------------------|---------------------|------------------|------------------|-----------------|
|                                              |                       | (N =388)        | Tremelimumab         | Tremelimumab      | Durvalumab        | Tremelimumab        | Tremelimumab     | Durvalumab       | (N =374)        |
|                                              |                       | Total study a   | Initial treatinent b | Rechallenge       | Total study a     | Initial treatment b | Rechallenge      | Total study a    |                 |
| Total treatment duration c (months)          | N                     | 388             | 388                  | 30                | 388               | 152                 | 12               | 152              | 374             |
| Total treatment duration c (months)          | Mean (SD)             | 9.7 (10.16)     | 0.9 (0.04)           | 0.9 (0.00)        | 10.6 (10.82)      | 3.0 (1.14)          | 2.2 (1.27)       | 9.3 (10.38)      | 7.5 (8.48)      |
| Total treatment duration c (months)          | Median (min, max)     | 5.5 (0.2, 44.4) | 0.9 (0.4, 0.9)       | 0.9 (0.9, 0.9)    | 5.5 (0.4, 42.7)   | 3.6 (0.7, 5.6)      | 1.9 (0.9, 3.7)   | 4.6 (0.7, 44.2)  | 4.1 (0.1, 38.6) |
| Total treatment duration c (months)          | Total treatment years | 312.7           | 29.6                 | 2.3               | 341.7             | 38.6                | 2.2              | 118.0            | 234.9           |
| Actual treatment duration d (months)         | N                     | 388             | 388                  | 30                | 388               | 152                 | 12               | 152              | 374             |
| Actual treatment duration d (months)         | Mean (SD)             | 9.3 (9.84)      | 0.9 (0.04)           | 0.9 (0.00)        | 10.1 (10.47)      | 2.9 (1.02)          | 2.1 (1.26)       | 8.9 (9.98)       | 7.2 (8.35)      |
| Actual treatment duration d (months)         | Median (min, max)     | 4.6 (0.2, 44.4) | 0.9 (0.4, 0.9)       | 0.9 (0.9, 0.9)    | 5.5 (0.4, 42.6)   | 3.6 (0.7, 3.7)      | 1.8 (0.9, 3.7)   | 4.6 (0.7, 41.9)  | 3.7 (0.1, 38.6) |
| Actual treatment duration d (months)         | Totaltreatmentyears   | 301.4           | 29.6                 | 2.3               | 326.2             | 36.6                | 2.1              | 112.7            | 224.5           |
| Total duration of cycle delays - total study | N                     | 180             | 0                    | 0                 | 194               | 60                  | 60               | 88               | 182             |
| (months)                                     | Mean (SD)             | 0.7 (1.22)      | NA                   | NA                | 1.0 (1.28)        | 0.4 (0.54)          | 0.4 (0.54)       | 0.7 (0.95)       | 0.7 (0.69)      |
| (months)                                     | Median (min, max)     | 0.3 (0.0, 10.3) | NA                   | NA                | 0.5 (0.0, 94)     | 0.1 (0.0, 1.9)      | 0.1 (0.0, 1.9)   | 0.3 (0.0, 5.4)   | 0.5 (0.0, 3.7)  |

Source:Table 14.3.1.1l.

<div style=\"page-break-after: always\"></div>

## 2.6.8.2. Adverse events

## Table 50: Overview of AEs in the HIMALAYA T300+D and S arms and the HCC T300+D pool (safety analysis set)

|                                                                                                                   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|-------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|
|                                                                                                                   | HCC T300+D pool            | HIMALAYA T300+D arm        | HIMALAYA S arm             |
| AE category                                                                                                       | (N = 462)                  | (N = 388)                  | (N = 374)                  |
| Any AE                                                                                                            | 451 (97.6)                 | 378 (97.4)                 | 357 (95.5)                 |
| Any AE possibly related to any study treatment b                                                                  | 355 (76.8)                 | 294 (75.8)                 | 317 (84.8)                 |
| Any AE possibly related to durvalumab b                                                                           | 349 (75.5)                 | 288 (74.2)                 | NA                         |
| Any AE possibly related to tremelimumab b                                                                         | 224 (48.5)                 | 175 (45.1)                 | NA                         |
| Any AE possibly related to sorafenib b                                                                            | NA                         | NA                         | 317 (84.8)                 |
| Any AE of CTCAE Grade 3 or 4 c                                                                                    | 240 (51.9)                 | 196 (50.5)                 | 196 (52.4)                 |
| Any AE of CTCAE Grade 3 or 4 c possibly related to any study treatment b                                          | 127 (27.5)                 | 100 (25.8)                 | 138 (36.9)                 |
| Any AE with outcome of death                                                                                      | 34 (7.4)                   | 30 (7.7)                   | 27 (7.2)                   |
| Any SAE (including events with outcome of death) d                                                                | 189 (40.9)                 | 157 (40.5)                 | 111 (29.7)                 |
| Any AE leading to discontinuation of any study treatment                                                          | 63 (13.6)                  | 53 (13.7)                  | 63 (16.8)                  |
| Any AE leading to discontinuation of any study treatment, possibly related to any study treatment b               | 41 (8.9)                   | 32 (8.2)                   | 41 (11.0)                  |
| Any AE leading to dose delay or interruption of any study treatment e                                             | 149 (32.3)                 | 134 (34.5)                 | 178 (47.6)                 |
| Any AE leading to dose delay or interruption of any study treatment e , possibly related to any study treatment b | NE                         | 83 (21.4)                  | 144 (38.5)                 |

a Patients with multiple events in the same category are counted only once in that category; patients with events in more than 1 category are counted once in each of those categories.

b As assessed by the investigator. Missing responses are counted as related.

c All CTCAE grades per patient, not just the maximum, are considered when identifying whether there is a Grade 3 or 4.

d Seriousness, as assessed by the investigator. An AE with missing seriousness is considered serious.

e Includes AEs on the AE CRF form with action taken indicating dose delay or dose interruption, and AEs meeting study level dose delay definitions, where applicable.

Note: Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study treatment or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

AE, adverse event; CRF, case report form; CSR, Clinical Study Report; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); HCC, hepatocellular carcinoma; HCC T300+D pool, all patients from HIMALAYA and Study 22 who have received at least 1 dose of durvalumab given at a dose of 1500 mg IV Q4W (or equivalent) in combination with tremelimumab 300 mg IV Ã— 1 dose (or equivalent) for HCC for any line of therapy; IV, intravenous; NA, not applicable; NE, not evaluated; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; SAE, serious adverse event; T300+D, tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W.

<div style=\"page-break-after: always\"></div>

Table 51: Adverse events by preferred term occurring in â‰¥ 10% of patients in any treatment arm (safety analysis set)

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| System organ class MedDRA preferred term             | D (N=388)                  | T300+D (N=388)             | T75+D (N=152)              | S (N= 374)                 |
| Patients with any AE                                 | 345 (88.9)                 | 378 (97.4)                 | 145 (95.4)                 | 357 (95.5)                 |
| Gastrointestinal disorders                           | 195 (50.3)                 | 236 (60.8)                 | 79 (52.0)                  | 265 (70.9)                 |
| Dianhoea                                             | 58 (14.9)                  | 103 (26.5)                 | 32 (21.1)                  | 167 (44.7)                 |
| Constipation                                         | 42 (10.8)                  | 36 (9.3)                   | 12 (7.9)                   | 35 (9.4)                   |
| Abdominal pain                                       | 37 (9.5)                   | 46 (11.9)                  | 26 (17.1)                  | 63 (16.8)                  |
| Nausea                                               | 37 (9.5)                   | 47 (12.1)                  | 14 (9.2)                   | 53 (14.2)                  |
| Skin and subcutaneous tissue disorders               | 135 (34.8)                 | 198 (51.0)                 | 70 (46.1)                  | 243 (65.0)                 |
| Pnuitus                                              | 56 (14.4)                  | 89 (22.9)                  | 27 (17.8)                  | 24 (6.4)                   |
| Rash                                                 | 40 (10.3)                  | 87 (22.4)                  | 27 (17.8)                  | 51 (13.6)                  |
| Alopecia                                             | 5 (1.3)                    | 2 (0.5)                    | 1 (0.7)                    | 53 (14.2)                  |
| Palmar-plantar erythrodysaesthesia syndrome          | 1 (0.3)                    | 3 (0.8)                    | 3 (2.0)                    | 174 (46.5)                 |
| Investigations                                       | 123 (31.7)                 | 155 (39.9)                 | 50 (32.9)                  | 122 (32.6)                 |
| Aspartate aminotransferase increased                 | 56 (14.4)                  | 48 (12.4)                  | 16 (10.5)                  | 24 (6.4)                   |
| Alanine aminotransferase increased                   | 44 (11.3)                  | 36 (9.3)                   | 10 (6.6)                   | 20 (5.3)                   |
| Metabolism and nutrition disorders                   | 101 (26.0)                 | 145 (37.4)                 | 42 (27.6)                  | 123 (32.9)                 |
| Decreased appetite                                   | 53 (13.7)                  | 66 (17.0)                  | 25 (16.4)                  | 67 (17.9)                  |
| General disorders and adminishration site conditions | 149 (38.4)                 | 180 (46.4)                 | 73 (48.0)                  | 174 (46.5)                 |
| Asthenia                                             | 49 (12.6)                  | 39 (10.1)                  | 20 (13.2)                  | 44 (11.8)                  |
| Fatigue                                              | 38 (9.8)                   | 66 (17.0)                  | 25 (16.4)                  | 71 (19.0)                  |
| Pyrexia                                              | 36 (9.3)                   | 50 (12.9)                  | 16 (10.5)                  | 33 (8.8)                   |
| Oedema peripheral                                    | 24 (6.2)                   | 33 (8.5)                   | 16 (10.5)                  | 19 (5.1)                   |
| Respiratory, thoracic and mediastinal disorders      | 73 (18.8)                  | 90 (23.2)                  | 34 (22.4)                  | 95 (25.4)                  |
| Cough                                                | 31 (8.0)                   | 30 (7.7)                   | 17 (11.2)                  | 22 (5.9)                   |
| Psychiatric disorders                                | 41 (10.6)                  | 57 (14.7)                  | 14 (9.2)                   | 26 (7.0)                   |
| Insommia                                             | 21 (5.4)                   | 40 (10.3)                  | 10 (6.6)                   | 16 (4.3)                   |
| Endocrine disorders                                  | 41 (10.6)                  | 92 (23.7)                  | 32 (21.1)                  | 20 (5.3)                   |
| Hypothyroidism                                       | 19 (4.9)                   | 47 (12.1)                  | 20 (13.2)                  | 16 (4.3)                   |
| Vascular disorders                                   | 31 (8.0)                   | 48 (12.4)                  | 12 (7.9)                   | 73 (19.5)                  |
| Hypertension                                         | 17 (4.4)                   | 23 (5.9)                   | 6 (3.9)                    | 68 (18.2)                  |

- Each patient has only beenrepresented withthe maximumreported CTCAEgradeforeach system organ class/preferred term

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90daysfollowing the date of last dose of studymedication or up to and including the date of initiation of the first subsequent therapy (whichever occured first).

Preferred terms are ordered by decreasing frequency in the D am.

PatientswithanAEofmaximumCTCAE Grade5aftertheDCOhavebeenresetto'uknownattheDCO.This affected0patients inthe D am, 0patients in theT300+D amOpatients in theT75+D am, and 0patients in the S amm.

MedDRA version 23.1. CTCAE version 4.03.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; D, duvalumab monotherapy 1500 mg Q4W; DCO, data cut-off IP, investigational product; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg Ã—4 doses + duvalumab1500mgQ4W;T300+D,tremelimumab300mgÃ—1dose+duuvalumab1500mgQ4W.

<div style=\"page-break-after: always\"></div>

Table 52: Adverse events and event rate occurring in â‰¥ 10% of patients in any treatment group by preferred term (safety analysis set)

|                                       | HCC-tumour pool            | HCC-tumour pool                 | HCC-tumour pool            | HCC-tumour pool              | Pan-tumour pool            | Pan-tumour pool                 | Pan-tumour pool           | Pan-tumour pool                 | Pan-tumour pool            | Pan-tumour pool                 |
|---------------------------------------|----------------------------|---------------------------------|----------------------------|------------------------------|----------------------------|---------------------------------|---------------------------|---------------------------------|----------------------------|---------------------------------|
|                                       | T300+D (N = 462)           | T300+D (N = 462)                | D                          | D                            | D = 4045)                  | D = 4045)                       | T75+D (N = 3319)          | T75+D (N = 3319)                | T750 (N = 643)             | T750 (N = 643)                  |
| MedDRA preferred                      | Numbe r (%) of patient s a | Event rate (per 100 pt years) b | Numbe r (%) of patient s a | Event rate (per 100 pt years | Numbe r (%) of patient s a | Event rate (per 100 pt years) b | Number (%) of patient s a | Event rate (per 100 pt years) b | Numbe r (%) of patient s a | Event rate (per 100 pt years) b |
| term Patients with any AE             | 451 (97.6)                 | 121.7                           | 443 (90.0)                 | ) 123.5                      | 3825 (94.6)                | 170.7                           | 3151 (94.9)               | 164.8                           | 609 (94.7)                 | 289.3                           |
| Pruritus                              | 118 (25.5)                 | 31.8                            | 76 (15.4)                  | 21.2                         | 463 (11.4)                 | 20.7                            | 623 (18.8)                | 32.6                            | 173 (26.9)                 | 82.2                            |
| Diarrhoea                             | 117 (25.3)                 | 31.6                            | 78 (15.9)                  | 21.7                         | 650 (16.1)                 | 29.0                            | 780 (23.5)                | 40.8                            | 257 (40.0)                 | 122.1                           |
| Rash                                  | 115 (24.9)                 | 31.0                            | 53 (10.8)                  | 14.8                         | 395 (9.8)                  | 17.6                            | 442 (13.3)                | 23.1                            | 128 (19.9)                 | 60.8                            |
| Fatigue                               | 83 (18.0)                  | 22.4                            | 62 (12.6)                  | 17.3                         | 997 (24.6)                 | 44.5                            | 775 (23.4)                | 40.5                            | 150 (23.3)                 | 71.3                            |
| Decreased appetite                    | 76 (16.5)                  | 20.5                            | 68 (13.8)                  | 19.0                         | 769 (19.0)                 | 34.3                            | 687 (20.7)                | 35.9                            | 166 (25.8)                 | 78.9                            |
| Aspartate aminotransfer ase increased | 71 (15.4)                  | 19.2                            | 85 (17.3)                  | 23.7                         | 277 (6.8)                  | 12.4                            | 268 (8.1)                 | 14.0                            | 35 (5.4)                   | 16.6                            |
| Pyrexia                               | 64 (13.9)                  | 17.3                            | 44 (8.9)                   | 12.3                         | 525 (13.0)                 | 23.4                            | 494 (14.9)                | 25.8                            | 100 (15.6)                 | 47.5                            |
| Abdominal pain                        | 58 (12.6)                  | 15.7                            | 54 (11.0)                  | 15.1                         | 318 (7.9)                  | 14.2                            | 307 (9.2)                 | 16.1                            | 84 (13.1)                  | 39.9                            |
| Nausea                                | 57 (12.3)                  | 15.4                            | 49 (10.0)                  | 13.7                         | 678                        | 30.3                            | 625 (18.8)                | 32.7                            | 166 (25.8)                 | 78.9                            |
| Hypothyroidis m                       | 55 (11.9)                  | 14.8                            | 33 (6.7)                   | 9.2                          | (16.8) 380 (9.4)           | 17.0                            | 378 (11.4)                | 19.8                            | 29 (4.5)                   | 13.8                            |
| Alanine aminotransfer ase increased   | 53 (11.5)                  | 14.3                            | 70 (14.2)                  | 19.5                         | 256 (6.3)                  | 11.4                            | 242 (7.3)                 | 12.7                            | 31 (4.8)                   | 14.7                            |
| Lipase increased                      | 46 (10.0)                  | 12.4                            | 28 (5.7)                   | 7.8                          | 87 (2.2)                   | 3.9                             | 212 (6.4)                 | 11.1                            | 37 (5.8)                   | 17.6                            |
| Constipation                          | 45 (9.7)                   | 12.1                            | 54 (11.0)                  | 15.1                         | 652 (16.1)                 | 29.1                            | 571 (17.2)                | 29.9                            | 103 (16.0)                 | 48.9                            |
| Cough                                 | 45 (9.7)                   | 12.1                            | 43 (8.7)                   | 12.0                         | 643 (15.9)                 | 28.7                            | 435 (13.1)                | 22.7                            | 102 (15.9)                 | 48.5                            |
| Anaemia                               | 43 (9.3)                   | 11.6                            | 36 (7.3)                   | 10.0                         | 509 (12.6)                 | 22.7                            | 532 (16.0)                | 27.8                            | 96 (14.9)                  | 45.6                            |
| Arthralgia                            | 43 (9.3)                   | 11.6                            | 45 (9.1)                   | 12.5                         | 559 (13.8)                 | 25.0                            | 376 (11.3)                | 19.7                            | 54 (8.4)                   | 25.7                            |
| Asthenia                              | 42 (9.1)                   | 11.3                            | 52 (10.6)                  | 14.5                         | 463 (11.4)                 | 20.7                            | 437 (13.2)                | 22.9                            | 77 (12.0)                  | 36.6                            |
| Vomiting                              | 34 (7.4)                   | 9.2                             | 23 (4.7)                   | 6.4                          | 423 (10.5)                 | 18.9                            | 405 (12.2)                | 21.2                            | 107 (16.6)                 | 50.8                            |
| Weight decreased                      | 32 (6.9)                   | 8.6                             | 15 (3.0)                   | 4.2                          | 285 (7.0)                  | 12.7                            | 349 (10.5)                | 18.3                            | 71 (11.0)                  | 33.7                            |
| Back pain                             | 30 (6.5)                   | 8.1                             | 50 (10.2)                  | 13.9                         | 448 (11.1)                 | 20.0                            | 329 (9.9)                 | 17.2                            | 41 (6.4)                   | 19.5                            |
| Dyspnoea                              | 28 (6.1)                   | 7.6                             | 26 (5.3)                   | 7.2                          | 598 (14.8)                 | 26.7                            | 456 (13.7)                | 23.8                            | 151 (23.5)                 | 71.7                            |

a Number (%) of patients with AEs, sorted in decreasing frequency of preferred term (HCC-tumour pool T300+D column).

b Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.

Patients with multiple AEs are counted once for each preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.MedDRA version 23.1.

<div style=\"page-break-after: always\"></div>

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; pt, patient; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types). Source: Table 2.7.4.2.5, Pooled Safety Outputs, Module 5.3.5.3.

Table 53: Adverse events of maximum CTCAE grade 3 or 4 by system organ class and preferred term (frequency â‰¥ 5% in any treatment arm) (safety analysis set)

|                                             | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|---------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| System organclass MedDRApreferred term      | D (N =388)                 | T300+D (N = 388)           | T75+D (N = 152)            | S (N =374)                 |
| PatientswithAEof maximumCTCAEGrade3or4      | 144 (37.1)                 | 196 (50.5)                 | 60 (39.5)                  | 196 (52.4)                 |
| Investigations                              | 56 (14.4)                  | 69 (17.8)                  | 27 (17.8)                  | 53 (14.2)                  |
| Aspartate aminotransferase increased        | 26 (6.7)                   | 20 (5.2)                   | 10 (6.6)                   | 12 (3.2)                   |
| Lipase increased                            | 16 (4.1)                   | 24 (6.2)                   | 5 (3.3)                    | 11 (2.9)                   |
| Vascular disorders                          | 5 (1.3)                    | 11 (2.8)                   | 5 (3.3)                    | 23 (6.1)                   |
| Hypertension                                | 4 (1.0)                    | 7 (1.8)                    | 3 (2.0)                    | 23 (6.1)                   |
| Skin andsubcutaneoustissuedisorders         | 1 (0.3)                    | 15 (3.9)                   | 4 (2.6)                    | 49 (13.1)                  |
| Palmar-plantar erthyrodysaesthesia syndrome | 0                          | 0                          | 1 (0.7)                    | 34 (9.1)                   |

Preferred terms are ordered by decreasingfrequency in the D arm.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurred first).

MedDRAversion23.1.CTCAEversion4.03.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; DCO, data cut-off; IP, investigational product; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

Table 54: Adverse events of maximum CTCAE grade 3 or 4 by preferred term ( â‰¥ 5% of patients in any treatment group) (safety analysis set)

|                                                    | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|----------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                    | HCC-tumour pool            | HCC-tumour pool            | Pan-tumour pool            | Pan-tumour pool            | Pan-tumour pool            |
|                                                    | T300+D                     | D                          | D                          | T75+D                      | T750                       |
| MedDRA preferred term                              | (N = 462)                  | (N = 492)                  | (N = 4045 )                | (N = 3319 )                | (N = 643)                  |
| Patients with any AE of maximum CTCAE Grade 3 or 4 | 222 (48.1)                 | 188 (38.2)                 | 1600 (39.6)                | 1642 (49.5)                | 344 (53.5)                 |
| Aspartate aminotransferase increased               | 34 (7.4)                   | 36 (7.3)                   | 83 (2.1)                   | 73 (2.2)                   | 15 (2.3)                   |
| Lipase increased                                   | 33 (7.1)                   | 17 (3.5)                   | 51 (1.3)                   | 143 (4.3)                  | 20 (3.1)                   |
| Diarrhoea                                          | 18 (3.9)                   | 8 (1.6)                    | 34 (0.8)                   | 92 (2.8)                   | 81 (12.6)                  |
| Anaemia                                            | 13 (2.8)                   | 11 (2.2)                   | 177 (4.4)                  | 169 (5.1)                  | 20 (3.1)                   |
| Colitis                                            | 10 (2.2)                   | 0                          | 10 (0.2)                   | 44 (1.3)                   | 32 (5.0)                   |
| Dyspnoea                                           | 3 (0.6)                    | 4 (0.8)                    | 126 (3.1)                  | 93 (2.8)                   | 40 (6.2)                   |

Patients with multiple AEs are counted once for each preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication, or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

<div style=\"page-break-after: always\"></div>

MedDRA version 23.1.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types).

Table 55: Adverse events with CTCAE grade 3 or 4, possibly related to investigational product (frequency of â‰¥ 2%) by system organ class, preferred term and maximum reported CTCAE grade (HCC pool; safety analysis set)

|                                            |                              | Number (%) of patients a HCC-tumour pool   | Number (%) of patients a HCC-tumour pool   |
|--------------------------------------------|------------------------------|--------------------------------------------|--------------------------------------------|
| System organ class / MedDRA Preferred term | Maximum reported CTCAE grade | T300 + D (N = 462)                         | D (N = 492)                                |
| Patients with any treatment-related AE     | Total                        | 57 (12.3)                                  | 27 (5.5)                                   |
| Patients with any treatment-related AE     | Grade 3                      | 50 (10.8)                                  | 24 (4.9)                                   |
| Patients with any treatment-related AE     | Grade 4                      | 7 (1.5)                                    | 3 (0.6)                                    |
| Gastrointestinal disorders                 | Total                        | 14 (3.0)                                   | 6 (1.2)                                    |
| Gastrointestinal disorders                 | Grade 3                      | 14 (3.0)                                   | 6 (1.2)                                    |
| Diarrhoea                                  | Total                        | 14 (3.0)                                   | 6 (1.2)                                    |
| Diarrhoea                                  | Grade 3                      | 14 (3.0)                                   | 6 (1.2)                                    |
| Investigations                             | Total                        | 44 (9.5)                                   | 22 (4.5)                                   |
| Investigations                             | Grade 3                      | 37 (8.0)                                   | 19 (3.9)                                   |
| Investigations                             | Grade 4                      | 7 (1.5)                                    | 3 (0.6)                                    |
| Amylase increased                          | Total                        | 15 (3.2)                                   | 3 (0.6)                                    |
| Amylase increased                          | Grade 3                      | 14 (3.0)                                   | 2 (0.4)                                    |
| Amylase increased                          | Grade 4                      | 1 (0.2)                                    | 1 (0.2)                                    |
| Aspartate aminotransferase increased       | Total                        | 18 (3.9)                                   | 12 (2.4)                                   |
| Aspartate aminotransferase increased       | Grade 3                      | 18 (3.9)                                   | 11 (2.2)                                   |
| Aspartate aminotransferase increased       | Grade 4                      | 0                                          | 1 (0.2)                                    |
| Lipase increased                           | Total                        | 22 (4.8)                                   | 8 (1.6)                                    |
| Lipase increased                           | Grade 3                      | 16 (3.5)                                   | 7 (1.4)                                    |
| Lipase increased                           | Grade 4                      | 6 (1.3)                                    | 1 (0.2)                                    |

Each patient has only been represented with the maximum reported CTCAE grade for each system organ class / preferred term.

Number (%) of patients with AEs, sorted by international SOC order and alphabetical PT and then maximum grade.

Table includes events occurring in greater than or equal to 2% of patients in either group.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Possibly related to treatment, as assessed by the investigator. Missing responses are counted as related.

MedDRA version 23.1.

CTCAE (version 4.03).

AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; D = durvalumab 1500 mg Q4W; HCC = hepatocellular carcinoma; PT = preferred term; MedDRA = Medical Dictionary for Regulatory Activities; QxW = every X weeks; SOC = System Organ Class; T300+D = tremelimumab 300 mg for single dose and durvalumab 1500 mg Q4W.

## Adverse drug reactions (ADRs)

Table 56: Adverse reactions in patients with HCC treated with tremelimumab 300 mg in combination with durvalumab

|                                          | Tremelimumab 300 mg in combination with durvalumab (n=462)   | Tremelimumab 300 mg in combination with durvalumab (n=462)   | Tremelimumab 300 mg in combination with durvalumab (n=462)   | Tremelimumab 300 mg in combination with durvalumab (n=462)   |
|------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Adverse Reaction                         | Frequency of any Grade                                       | Frequency of any Grade                                       | Frequency of Grade 3-4                                       | Frequency of Grade 3-4                                       |
| Infections and infestations              |                                                              |                                                              |                                                              |                                                              |
| Upper respiratory tract infections a     | Common                                                       | 39 (8.4%)                                                    |                                                              |                                                              |
| Pneumonia b                              | Common                                                       | 20 (4.3%)                                                    | Common                                                       | 6 (1.3%)                                                     |
| Influenza                                | Common                                                       | 10 (2.2%)                                                    |                                                              |                                                              |
| Dental and oral soft tissue infections c | Common                                                       | 6 (1.3%)                                                     |                                                              |                                                              |
| Oral candidiasis                         | Uncommon                                                     | 3 (0.6%)                                                     |                                                              |                                                              |
| Blood and lymphatic system disorders     | Blood and lymphatic system disorders                         | Blood and lymphatic system disorders                         | Blood and lymphatic system disorders                         | Blood and lymphatic system disorders                         |
| Immune thrombocytopenia d                | Not known                                                    |                                                              |                                                              |                                                              |
| Endocrine disorders                      | Endocrine disorders                                          | Endocrine disorders                                          | Endocrine disorders                                          | Endocrine disorders                                          |
| Hypothyroidism e                         | Very common                                                  | 60 (13.0%)                                                   |                                                              |                                                              |

<div style=\"page-break-after: always\"></div>

|                                                      | Tremelimumab 300 mg in combination with durvalumab (n=462)   | Tremelimumab 300 mg in combination with durvalumab (n=462)   | Tremelimumab 300 mg in combination with durvalumab (n=462)   | Tremelimumab 300 mg in combination with durvalumab (n=462)   |
|------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Adverse Reaction                                     | Frequency of any Grade                                       | Frequency of any Grade                                       | Frequency of Grade 3-4                                       | Frequency of Grade 3-4                                       |
| Hyperthyroidism f                                    | Common                                                       | 44 (9.5%)                                                    | Uncommon                                                     | 1 (0.2%)                                                     |
| Thyroiditis g                                        | Common                                                       | 8 (1.7%)                                                     |                                                              |                                                              |
| Adrenal insufficiency                                | Common                                                       | 6 (1.3%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Hypopituitarism/Hypophysitis                         | Uncommon                                                     | 4 (0.9%)                                                     |                                                              |                                                              |
| Diabetes insipidus d                                 | Not known                                                    |                                                              |                                                              |                                                              |
| Type 1 diabetes mellitus d                           | Not known                                                    |                                                              |                                                              |                                                              |
| Nervous system disorders                             |                                                              |                                                              |                                                              |                                                              |
| Myasthenia gravis                                    | Uncommon                                                     | 2 (0.4%)                                                     |                                                              |                                                              |
| Meningitis                                           | Uncommon                                                     | 1 (0.2%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Guillain-BarrÃ© syndrome d                            | Not known                                                    |                                                              |                                                              |                                                              |
| Encephalitis d                                       | Not known                                                    |                                                              |                                                              |                                                              |
| Cardiac disorders                                    |                                                              |                                                              |                                                              |                                                              |
| Myocarditis Uncommon                                 | Myocarditis Uncommon                                         | 2 (0.4%)                                                     |                                                              |                                                              |
| Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders              |                                                              |                                                              |                                                              |
| Cough/Productive cough                               | Very common                                                  | 50 (10.8%)                                                   | Uncommon                                                     | 1 (0.2%)                                                     |
| Pneumonitis h                                        | Common                                                       | 11 (2.4%)                                                    | Uncommon                                                     | 1 (0.2%)                                                     |
| Dysphonia                                            | Uncommon                                                     | 4 (0.9%)                                                     |                                                              |                                                              |
| Interstitial lung disease                            | Uncommon                                                     | 1 (0.2%)                                                     |                                                              |                                                              |
| Gastrointestinal disorders Diarrhoea                 | Very common                                                  | 117 (25.3%)                                                  | Common                                                       | 18 (3.9%)                                                    |
| Abdominal pain i                                     | Very common                                                  | 91 (19.7%)                                                   | Common                                                       | 10 (2.2%)                                                    |
| Lipase increased                                     | Common                                                       | 46 (10.0%)                                                   | Common                                                       | 33 (7.1%)                                                    |
| Amylase increased                                    | Common                                                       | 41 (8.9%)                                                    | Common                                                       | 20 (4.3%)                                                    |
| Colitis j                                            | Common                                                       | 16 (3.5%)                                                    | Common                                                       | 12 (2.6%)                                                    |
| Pancreatitis k                                       | Common                                                       | 6 (1.3%)                                                     | Uncommon                                                     | 3 (0.6%)                                                     |
| Intestinal perforation d                             | Not known                                                    |                                                              |                                                              |                                                              |
| Large intestine perforation d                        | Not known                                                    |                                                              |                                                              |                                                              |
| Hepatobiliary disorders                              |                                                              |                                                              |                                                              |                                                              |
| Aspartate aminotransferase increased/Alanine         | Very common                                                  | 83 (18.0%)                                                   | Common                                                       | 41 (8.9%)                                                    |
| aminotransferase increased l Hepatitis m             | Common                                                       | 23 (5.0%)                                                    | Common                                                       | 8 (1.7%)                                                     |
| Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       |
| Rash n                                               | Very common                                                  | 150 (32.5%)                                                  | Common                                                       | 14 (3.0%)                                                    |
| Pruritus                                             | Very common                                                  | 118 (25.5%)                                                  |                                                              |                                                              |
| Dermatitis o                                         | Common                                                       | 6 (1.3%)                                                     |                                                              |                                                              |
| Night sweats                                         | Common                                                       | 6 (1.3%)                                                     |                                                              |                                                              |
| Pemphigoid                                           |                                                              |                                                              |                                                              |                                                              |
|                                                      | Uncommon                                                     | 1 (0.2%)                                                     |                                                              |                                                              |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              |
| Myalgia                                              | Common                                                       | 16 (3.5%)                                                    | Uncommon                                                     | 1 (0.2%)                                                     |
| Myositis                                             | Uncommon                                                     | 3 (0.6%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Polymyositis                                         | Uncommon                                                     | 1 (0.2%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Renal and urinary disorders                          | Renal and urinary disorders                                  | Renal and urinary disorders                                  | Renal and urinary disorders                                  | Renal and urinary disorders                                  |
| Blood creatinine increased                           | Common                                                       | 21 (4.5%)                                                    | Uncommon                                                     | 2 (0.4%)                                                     |
| Dysuria                                              | Common                                                       | 7 (1.5%)                                                     |                                                              |                                                              |
| Nephritis p                                          | Uncommon                                                     | 3 (0.6%)                                                     | Uncommon                                                     | 2 (0.4%)                                                     |
| Cystitis noninfective d                              | Not known                                                    |                                                              |                                                              |                                                              |
| General disorders and administration site conditions | General disorders and administration site conditions         | General disorders and administration site conditions         | General disorders and administration site conditions         | General disorders and administration site conditions         |
| Pyrexia                                              | Very common                                                  | 64 (13.9%)                                                   | Uncommon                                                     | 1 (0.2%)                                                     |
| Oedema peripheral q                                  | Very common                                                  | 48 (10.4%)                                                   | Uncommon                                                     | 2 (0.4%)                                                     |
| Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications               | Injury, poisoning and procedural complications               | Injury, poisoning and procedural complications               | Injury, poisoning and procedural complications               |
| Infusion-related reaction r                          | Common                                                       | 6 (1.3%)                                                     |                                                              |                                                              |

<div style=\"page-break-after: always\"></div>

a  Includes nasopharyngitis, pharyngitis, rhinitis, tracheobronchitis and upper respiratory tract infection.

b  Includes pneumocystis jirovecii pneumonia and pneumonia.

c  Includes periodontitis, pulpitis dental, tooth abscess and tooth infection.

d  Adverse reaction was not observed in the HCC pool, but was reported in patients treated with durvalumab or durvalumab + tremelimumab in AstraZeneca-sponsored clinical studies.

e  Includes blood thyroid stimulating hormone increased, hypothyroidism and immune-mediated hypothyroidism.

f  Includes blood thyroid stimulating hormone decreased and hyperthyroidism.

g  Includes autoimmune thyroiditis, immune-mediated thyroiditis, thyroiditis and thyroiditis subacute.

h  Includes immune-mediated pneumonitis and pneumonitis.

i  Includes abdominal pain, abdominal pain lower, abdominal pain upper and flank pain.

j  Includes colitis, enteritis and enterocolitis.

k  Includes pancreatitis and pancreatitis acute.

l  Includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased and transaminases increased.

m  Includes autoimmune hepatitis, hepatitis, hepatocellular injury, hepatotoxicity and immune-mediated hepatitis.

n  Includes eczema, erythema, rash, rash macular, rash maculo-papular, rash papular and rash pruritic.

o  Includes dermatitis and immune-mediated dermatitis.

p  Includes autoimmune nephritis and immune-mediated nephritis.

q  Includes oedema peripheral and peripheral swelling.

r  Includes infusion-related reaction and urticaria.

## Adverse events of special interest

## Table 57: Overview of imAEs in the HIMALAYA T300+D and S arms and the HCC T300+D pool (safety analysis set)

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------|
| AE category                                          | HCC T300+D pool            | HIMALAYA T300+D arm        | HIMALAYA S arm             |
| AE category                                          | (N = 462)                  | (N = 388)                  | (N = 374)                  |
| Any AE                                               | 167 (36.1)                 | 142 (36.6)                 | 28 (7.5)                   |
| Any AE of CTCAE Grade 3 or 4                         | 62 (13.4)                  | 51 (13.1)                  | 9 (2.4)                    |
| Any SAE (including AEs with outcome of death) b      | 47 (10.2)                  | 40 (10.3)                  | 4 (1.1)                    |
| Any AE with outcome of death                         | 6 (1.3)                    | 6 (1.5)                    | 0                          |
| Received systemic corticosteroids                    | 119 (25.8)                 | 97 (25.0)                  | 15 (4.0)                   |
| Received high dose corticosteroids                   | 94 (20.3)                  | 78 (20.1)                  | 7 (1.9)                    |
| Received endocrine therapy                           | 69 (14.9)                  | 65 (16.8)                  | 13 (3.5)                   |
| Received other immunosuppressants                    | 15 (3.2)                   | 15 (3.9)                   | 0                          |
| Any AE leading to discontinuation of study treatment | 26 (5.6)                   | 22 (5.7)                   | 6 (1.6)                    |

f Patients with multiple events in the same category are counted only once in that category; patients with events in more than 1 category are counted once in each of those categories.

g Seriousness, as assessed by the investigator. An AE with missing seriousness is considered serious.

Note: Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study treatment or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

AE, adverse event; CSR, Clinical Study Report; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); HCC, hepatocellular carcinoma; HCC T300+D pool, all patients from HIMALAYA and Study 22 who have received at least 1 dose of durvalumab given at a dose of 1500 mg IV Q4W (or equivalent) in combination with tremelimumab 300 mg IV Ã— 1 dose (or equivalent) for HCC for any line of therapy; IV, intravenous; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; SAE, serious adverse event; T300+D, tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W.

<div style=\"page-break-after: always\"></div>

Table 58: Immune-mediated adverse events categories reported for &gt; 2% of patients in the HCC pool (safety analysis set)

|                           | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|---------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                           | HCC T300+D Pool (N = 462)  | HCC T300+D Pool (N = 462)  | HCC D Pool (N = 492)       | HCC D Pool (N = 492)       |
| imAE category             | Any Grade                  | CTCAE Grade 3 or 4         | Any Grade                  | CTCAE Grade 3 or 4         |
| Any imAE                  | 167 (36.1)                 | 62 (13.4)                  | 81 (16.5)                  | 31 (6.3)                   |
| Hypothyroid events        | 45 (9.7)                   | 0                          | 25 (5.1)                   | 0                          |
| Hepatic events            | 34 (7.4)                   | 23 (5.0)                   | 31 (6.3)                   | 21 (4.3)                   |
| Diarrhoea/colitis         | 30 (6.5)                   | 17 (3.7)                   | 7 (1.4)                    | 3 (0.6)                    |
| Dermatitis/rash           | 26 (5.6)                   | 9 (1.9)                    | 4 (0.8)                    | 1 (0.2)                    |
| Hyperthyroid              | 21 (4.5)                   | 1 (0.2)                    | 6 (1.2)                    | 0                          |
| Other rare/ miscellaneous | 10 (2.2)                   | 2 (0.4)                    | 2 (0.4)                    | 0                          |

Includes AEs with an onset date on or after the date of first date or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study treatment or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (20 mg/kg) Q4W; HCC, hepatocellular carcinoma; imAE, immune-mediated adverse event; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W.

In the HCC pool (n=462), the following immune mediated adverse drug reactions have been reported:

- immune-mediated pneumonitis occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient and Grade 5 (fatal) in 1 (0.2%) patient. The median time to onset was 29 days (range: 5-774 days). Six patients received systemic corticosteroids, and 5 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient also received other immunosuppressants. Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.

- immune-mediated hepatitis occurred in 34 (7.4%) patients, including Grade 3 in 20 (4.3%) patients, Grade 4 in 1 (0.2%) patient and Grade 5 (fatal) in 3 (0.6%) patients. The median time to onset was 29 days (range: 13-313 days). All patients received systemic corticosteroids, and 32 of the 34 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Nine patients also received other immunosuppressants. Treatment was discontinued in 10 patients. Resolution occurred in 13 patients.

- immune-mediated colitis or diarrhoea occurred in 31 (6.7%) patients, including Grade 3 in 17 (3.7%) patients. The median time to onset was 23 days (range: 2-479 days). All patients received systemic corticosteroids, and 28 of the 31 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Four patients also received other immunosuppressants. Treatment was discontinued in 5 patients. Resolution occurred in 29 patients.

Intestinal perforation was observed in patients receiving Imjudo in combination with durvalumab (rare) in studies outside of the HCC pool.

- immune-mediated hypothyroidism occurred in 46 (10.0%) patients. The median time to onset was 85 days (range: 26-763 days). One patient received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone replacement

<div style=\"page-break-after: always\"></div>

therapy . Resolution occurred in 6 patients. Immune-mediated hypothyroidism was preceded by immune-mediated hyperthyroidism in 4 patients.

-  immune-mediated hyperthyroidism occurred in 21 (4.5%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 30 days (range: 13-60 days). Four patients received systemic corticosteriods, and all of the four patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Twenty patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker). One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 17 patients.

- immune-mediated thyroiditis occurred in 6 (1.3%) patients. The median time to onset was 56 days (range: 7-84 days). Two patients received systemic corticosteroids, and 1 of the 2 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone replacement therapy, Resolution occurred in 2 patients.

-  immune-mediated adrenal insufficiency occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 64 days (range: 43-504 days). All patients received systemic corticosteroids, and 1 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Resolution occurred in 2 patients.

- immune-mediated hypophysitis/hypopituitarism occurred in 5 (1.1%) patients. The median time to onset for the events was 149 days (range: 27-242 days). Four patients received systemic corticosteroids, and 1 of the 4 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Three patients also required endocrine therapy. Resolution occurred in 2 patients.

- immune-mediated nephritis occurred in 4 (0.9%) patients, including Grade 3 in 2 (0.4%) patients. The median time to onset was 53 days (range: 26-242 days). All patients received systemic corticosteroids, and 3 of the 4 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.

- immune-mediated rash or dermatitis (including pemphigoid) occurred in 26 (5.6%) patients, including Grade 3 in 9 (1.9%) patients and Grade 4 in 1 (0.2%) patient. The median time to onset was 25 days (range: 2-933 days). All patients received systemic corticosteroids and 14 of the 26 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient received other immunosuppressants. Treatment was discontinued in 3 patients. Resolution occurred in 19 patients.

Immune-mediated type 1 diabetes mellitus was observed in patients receiving Imjudo in combination with durvalumab (uncommon) in studies outside of the HCC pool.

<div style=\"page-break-after: always\"></div>

## 2.6.8.3. Serious adverse event/deaths/other significant events

Table 59: Serious adverse events by system organ class and preferred term ( â‰¥ 2% patients in any treatment arm; safety analysis set)

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| System Organ Class MedDRAPreferredTerm               | D (N = 388)                | T300+D (N =388)            | T75+D (N = 152)            | S (N =374)                 |
| Patients with any SAE                                | 115 (29.6)                 | 157 (40.5)                 | 52 (34.2)                  | 111 (29.7)                 |
| Gastrointestinal disorders                           | 22 (5.7)                   | 48 (12.4)                  | 14 (9.2)                   | 35 (9.4)                   |
| Oesophageal varices haemorrhage                      | 4 (1.0)                    | 1 (0.3)                    | 3 (2.0)                    | 2 (0.5)                    |
| Diarrhoea                                            | 2 (0.5)                    | 9 (2.3)                    | 4 (2.6)                    | 6 (1.6)                    |
| Infections and infestations                          | 21 (5.4)                   | 43 (11.1)                  | 10 (6.6)                   | 23 (6.1)                   |
| Sepsis                                               | 4 (1.0)                    | 8 (2.1)                    | 2 (1.3)                    | 0                          |
| Pneumonia                                            | 3 (0.8)                    | 7 (1.8)                    | 6 (3.9)                    | 8 (2.1)                    |
| General disorders and administration site conditions | 18 (4.6)                   | 11 (2.8)                   | 7 (4.6)                    | 9 (2.4)                    |
| Death                                                | 8 (2.1)                    | 4 (1.0)                    | 5 (3.3)                    | 5 (1.3)                    |
| Hepatobiliary disorders                              | 16 (4.1)                   | 14 (3.6)                   | 8 (5.3)                    | 15 (4.0)                   |
| Hepatitis                                            | 1 (0.3)                    | 3 (0.8)                    | 4 (2.6)                    | 0                          |
| Respiratory, thoracic, and mediastinal disorders     | 11 (2.8)                   | 9 (2.3)                    | 6 (3.9)                    | 9 (2.4)                    |
| Pneumonitis                                          | 2 (0.5)                    | 4 (1.0)                    | 3 (2.0)                    | 1 (0.3)                    |
| Blood and lymphaticsystem disorders                  | 2 (0.5)                    | 6 (1.5)                    | 4 (2.6)                    | 3 (0.8)                    |
| Anaemia                                              | 1 (0.3)                    | 5 (1.3)                    | 3 (2.0)                    | 2 (0.5)                    |

Preferred terms are ordered by decreasingfrequency in the Darm.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of firstdoseup to and including9odaysfollowing the date oflast dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurred first).

Patients with anAE of maximum CTCAE Grade 5 after the DCOhave been reset to'unknown' at the DCO. This affected 0 patients in the D arm, 0 patients in the T300+D arm, 0 patients in the T75+D arm, and 0 patients in the S arm.

MedDRA version 23.1. CTCAE version 4.03.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; DCO, data cut-off; IP, investigational product; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mgÃ— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

- 17.5% of the SAEs (40.5%) in the T300+D arm were treatment-related. The below table describes treatment-related SAEs for the T300+D and S arms of the Himalaya study and the HCC pool (frequency more than 1%).

Table 60: Time to onset, discontinuation, resolution and duration of treatment related serious adverse events (frequency of â‰¥ 1%) by preferred term

|                |                   |                        | HIMALAYA           | HIMALAYA    | HIMALAYA    | HCC-tumour pool    | HCC-tumour pool   |
|----------------|-------------------|------------------------|--------------------|-------------|-------------|--------------------|-------------------|
| Preferred term | Parameters (days) | Descriptive statistics | T300 + D (N = 388) | D (N = 388) | S (N = 374) | T300 + D (N = 462) | D (N = 492)       |
| Colitis        | Time to onset     | n                      | 6                  | 2           | 0           | 9                  | 2                 |
| Colitis        |                   | Mean                   | 219.5              | 104.0       |             | 228.2              | 104.0             |
| Colitis        |                   | Minimum                | 8                  | 11          |             | 8                  | 11                |
| Colitis        |                   | Median                 | 21.5               | 104.0       |             | 25.0               | 104.0             |
| Colitis        |                   | Maximum                | 815                | 197         |             | 815                | 197               |
| Colitis        | Duration of       | n                      | 6                  | 2           | 0           | 9                  | 2                 |
| Colitis        | events            | Mean                   | 54.2               | 39.5        |             | 50.3               | 39.5              |
| Colitis        |                   | Minimum                | 7                  | 36          |             | 7                  | 36                |

<div style=\"page-break-after: always\"></div>

|                           |                    |                | HIMALAYA   | HIMALAYA   | HCC-tumour   | HCC-tumour   | HCC-tumour   |
|---------------------------|--------------------|----------------|------------|------------|--------------|--------------|--------------|
|                           |                    |                | T300 + D   | D          | S            | T300 + D     | D            |
|                           |                    | Median         | 51.0       | 39.5       | S            | 43.0         | 39.5         |
|                           |                    | Maximum        | 99         | 43         |              | 99           | 43           |
|                           | Time to            | n              | 2          | 1          | 0            | 2            | 1            |
|                           | discontinuation    | Mean           | 1.0        | 1.0        |              | 1.0          | 1.0          |
|                           |                    | Minimum        | 1          | 1          |              | 1            | 1            |
|                           |                    | Median         | 1.0        | 1.0        |              | 1.0          | 1.0          |
|                           |                    | Maximum        | 1          | 1          |              | 1            | 1            |
|                           | Time to resolution | n              | 6          | 1          | 0            | 9            | 1            |
|                           |                    | Mean           | 54.2       | 43.0       |              | 50.3         | 43.0         |
|                           |                    | Minimum        | 7          | 43         |              | 7            | 43           |
|                           |                    | Median         | 51.0       | 43.0       |              | 43.0         | 43.0         |
|                           |                    | Maximum        | 99         | 43         |              | 99           | 43           |
| Diarrhoea                 | Time to onset      | n              | 7          | 1          | 6            | 9            | 2            |
| Diarrhoea                 |                    | Mean           | 24.1       | 63.0       | 78.7         | 37.8         | 39.5         |
| Diarrhoea                 |                    | Minimum        | 2          | 63         | 25           | 2            | 16           |
| Diarrhoea                 |                    | Median         | 14.0       | 63.0       | 67.5         | 24.0         | 39.5         |
| Diarrhoea                 |                    | Maximum        | 66         | 63         | 162          | 115          | 63           |
| Diarrhoea                 | Duration of        | n              | 7          | 1          | 6            | 9            | 2            |
| Diarrhoea                 | events             | Mean           | 37.3       | 82.0       | 22.3         | 34.6         | 43.5         |
| Diarrhoea                 |                    | Minimum        | 7          | 82         | 1            | 7            | 5            |
| Diarrhoea                 |                    | Median         | 52.0       | 82.0       | 4.5          | 25.0         | 43.5         |
| Diarrhoea                 |                    | Maximum        | 72         | 82         | 112          | 72           | 82           |
| Diarrhoea                 | Time to            | n              | 0          | 0          | 1            | 0            | 1            |
| Diarrhoea                 | discontinuation    | Mean           |            |            | 102.0        |              | 1.0          |
| Diarrhoea                 |                    | Minimum        |            |            | 102          |              | 1            |
| Diarrhoea                 |                    | Median         |            |            | 102.0        |              | 1.0          |
| Diarrhoea                 |                    | Maximum        |            |            | 102          |              | 1            |
| Diarrhoea                 | Time to resolution | n              | 7          | 0          | 5            | 9            | 1            |
| Diarrhoea                 |                    | Mean           | 37.3       |            | 4.4          | 34.6         | 5.0          |
| Diarrhoea                 |                    | Minimum        | 7          |            | 1            | 7            | 5            |
| Diarrhoea                 |                    | Median         | 52.0       |            | 4.0          | 25.0         | 5.0          |
| Diarrhoea                 |                    | Maximum        | 72         |            | 8            | 72           | 5            |
| Hepatic function abnormal | Time to onset      | n              | 1          | 5          | 1            | 2            | 9            |
|                           |                    | Mean           | 36.0       | 119.2      | 7.0          | 257.0        | 115.1        |
|                           |                    | Minimum        | 36         | 15         | 7            | 36           | 15           |
|                           |                    | Median         | 36.0       | 29.0       | 7.0          | 257.0        | 43.0         |
|                           |                    | Maximum        | 36         | 467        | 7            | 478          | 467          |
|                           | Duration of        | n              | 1          | 5          | 1            | 2            | 9            |
|                           | events             | Mean           | 141.0      | 133.8      | 37.0         | 169.5        | 124.2        |
|                           |                    | Minimum        | 141        | 13         | 37           | 141          | 9            |
|                           |                    | Median         | 141.0      | 92.0       | 37.0         | 169.5        | 57.0         |
|                           |                    | Maximum        | 141        |            |              | 198          |              |
|                           | Time to            |                |            | 413        | 37           |              | 413          |
|                           |                    | n              | 1          | 0          | 0            | 2            | 3            |
|                           | discontinuation    | Mean           | 29.0       |            |              | 200.5        | 112.0        |
|                           |                    | Minimum        | 29         |            |              | 29           | 1            |
|                           |                    | Median         | 29.0       |            |              | 200.5        | 57.0         |
|                           |                    | Maximum        | 29         |            |              | 372          | 278          |
|                           | Time to resolution | n              | 1          | 3          | 1            | 1            | 4            |
|                           |                    | Mean           | 141.0      | 66.3       | 37.0         | 141.0        | 52.0         |
|                           |                    | Minimum        | 141        | 13         | 37           | 141          | 9            |
|                           |                    | Median Maximum | 141.0 141  | 92.0       | 37.0         | 141.0        | 52.5         |
|                           |                    |                |            | 94         | 37           | 141          | 94           |

Note: Table includes events occurring in â‰¥ 1% of patients in either group.

D = durvalumab 1500 mg Q4W; HCC = hepatocellular carcinoma; QxW = every X weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg for single dose and durvalumab 1500 mg Q4W.

<div style=\"page-break-after: always\"></div>

## Deaths

Table 61: All deaths (full analysis set) - DCO: 27 AUG 2021

|                                                                               | Number(%)ofsubjects   | Number(%)ofsubjects                   | Number(%)ofsubjects                   | Number(%)ofsubjects   |
|-------------------------------------------------------------------------------|-----------------------|---------------------------------------|---------------------------------------|-----------------------|
| Category                                                                      | Durva1500mg (N=389)   | Treme300mgxldose+ Durva1500mg (N=393) | Treme75mgI4doses+ Durva1500mg (N=153) | Sora400mg BID (N=389) |
| Totalnumberofdeaths                                                           | 280 (72.0)            | 262 (66.7)                            | 123 (80.4)                            | 293 (75.3)            |
| Deathrelatedtodiseaseunderinvestigationonly                                   | 245 (63.0)            | 221 (56.2)                            | 103 (67.3)                            | 256 (65.8)            |
| AEwithoutcomeofdeathonly                                                      | 19 (4.9)              | 24 (6.1)                              | 9 (5.9)                               | 20 (5.1)              |
| AEwithoutcomeof deathonly(AEstartdatefallingafter90daysfollowupperiod)        | 2 (0.5)               | 3 (0.8)                               | 1 (0.7)                               | 0                     |
| NumberofsubjectswithdeathrelatedtodiseaseprogressionandanAEwithoutcomeofdeath | 6 (1.5)               | 8 (2.0)                               | 4 (2.0)                               | 7 (1.8)               |
| Otherdeathsa                                                                  | 8 (2.1)               | 6 (1.5)                               | 6 (3.9)                               | 10 (2.0)              |

Deathrelated todisease underinvestigationis determined by theinvestigator.

Rows are mutually exclusive,subjects are only reportedin one category.

Table 62: Adverse events with outcome of death by preferred term (safety analysis set)

|                                     | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|-------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| MedDRAPreferredTerm                 | D (N =388)                 | T300+D (N = 388)           | T75+D (N = 152)            | S (N =374)                 |
| Immune-mediated hepatitis           | 0                          | 2 (0.5)                    | 0                          | 0                          |
| Intemal haemorrhage                 | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Myocarditis                         | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Liver abscess                       | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Peritonitis                         | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Pneumonia                           | 0                          | 0                          | 2 (1.3)                    | 2 (0.5)                    |
| Sepsis                              | 0                          | 1 (0.3)                    | 1 (0.7)                    | 0                          |
| Cerebral haematoma                  | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Cerebral haemorrhage                | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Haemorhage intracranial             | 0                          | 2 (0.5)                    | 0                          | 0                          |
| Hepatic encephalopathy              | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Myasthenia gravis                   | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Nervous system disorder             | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Thrombocytopenia                    | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Haematuria                          | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Acute respiratory distress syndrome | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Dyspnoea                            | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Epistaxis                           | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Pneumonitis                         | 0                          | 2 (0.5)                    | 0                          | 0                          |
| Pulmonary embolism                  | 0                          | 1 (0.3)                    | 0                          | 1 (0.3)                    |
| Respiratory failure                 | 0                          | 0                          | 0                          | 1 (0.3)                    |

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurred first).

PatientswithanAEofmaximumCTCAEGrade5aftertheDCOhavebeenresetto'unknownattheDCO.This affected 0patients in the D arm, 0 patients in the T300+D arm,0patients in the T75+D arm,and 0 patients in the S arm.

MedDRAversion23.1.CTCAE version 4.03.

<div style=\"page-break-after: always\"></div>

Below is the table of the treatment-related (as assessed by the investigator) AEs leading to death.

Table 63: Adverse events with outcome of death, possibility related to investigational product by system organ class, preferred term and maximum reported CTCAE grade (safety analysis set)

|                                                  |                              | Number (%) of subjectsa   | Number (%) of subjectsa   | Number (%) of subjectsa                                      | Number (%) of subjectsa   |
|--------------------------------------------------|------------------------------|---------------------------|---------------------------|--------------------------------------------------------------|---------------------------|
| System organ class / MedDRAPreferred term        | Maximum reported CICAE grade | Durva 1500 mg (N=388)     | Duva 1500 mg (N=388)      | Treme300mg xl dose +Ireme75mgx4 doses + Duva 1500 mg (N=152) | Sora 400mg BD (N=374)     |
| Subjects with any AE                             | Grade 5                      | 0                         | 9 (2.3)                   | 2 (1.3)                                                      | 3 (0.8)                   |
| Infections and infestations                      | Grade 5                      | 0                         | 0                         | 1 (0.7)                                                      | 0                         |
| Septic shock                                     | Grade 5                      | 0                         | 0                         | 1 (0.7)                                                      | 0                         |
| Nervous system disorders                         | Grade 5                      | 0                         | 2 (0.5)                   | 0                                                            | 1 (0.3)                   |
| Cerebral haematoma                               | Grade 5                      | 0                         |                           | 0                                                            | 1 (0.3)                   |
| Myasthenia gravis                                | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                            |                           |
| Nervous system disorder                          | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                            | 0                         |
| Cardiac disorders                                | Grade 5                      | 0                         | 1 (0.3)                   |                                                              |                           |
| Myocarditis                                      | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                            |                           |
| Respiratory,thoracicandmediastinaldisorders      | Grade 5                      |                           | 2 (0.5)                   |                                                              |                           |
| Acuterespiratorydistresssyndrome                 | Grade 5                      |                           | 1 (0.3)                   | 0                                                            |                           |
| Pneumonitis                                      | Grade 5                      |                           | 1 (0.3)                   | 0                                                            |                           |
| Hepatobiliary disorders                          | Grade 5                      | 0                         | 4 (1.0)                   | 1 (0.7)                                                      | 1 (0.3)                   |
| Hepatic failure                                  | Grade 5                      | 0                         | 1 (0.3)                   | 1 (0.7)                                                      | 1 (0.3)                   |
| Hepatitis                                        | Grade 5                      |                           | 1 (0.3)                   | 0                                                            | 0                         |
| Immune-mediated hepatitis                        | Grade 5                      | 0                         | 2 (0.5)                   |                                                              | 0                         |
| Renal and urinary disorders                      | Grade 5                      | 0                         |                           | 0                                                            | 1 (0.3)                   |
| Haematuria                                       | Grade 5                      |                           | 0                         | 0                                                            | 1 (0.3)                   |
| Generaldisordersand administrationsiteconditions | Grade 5                      |                           | 0                         | 1 (0.7)                                                      | 0                         |
| Multiple organ dysfunction syndrome              | Grade 5                      |                           | 0                         | 1 (0.7)                                                      |                           |

Number (%) of subjects with AEs, sorted by intemational SOC order and alphabetical PT and then maximum grade.

Includes adverse events with an onset date onoraferthe date offirst doseor pre-treatment AEsthatincrease in severity on orafterthe dateoffist dose upto

Subjects who have a maximum CTCAEgrade 5 post the DCO,have been reset to uknown at the DCO.This affects 0 subjects in group Durva 1500 mgÂ² and 0 subjects in group Treme 300 mgx1 dose+Duva 1500 mg

Possibly related to treatment, as assessed by the investigator. Missing responses are counted as related.

CTCAE=CommonTerminology Criteria forAdverse Events(version 4.03).

MedDRA version 23.1.

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/ae003c.sas ae003cefa.rtf 08NOV2021:16:41 kwxd463

<div style=\"page-break-after: always\"></div>

## 2.6.8.4. Laboratory findings

## Haematology

## Table 64: Clinically important changes in haematology and clinical chemistry parameters (safety analysis set) - DCO: 27 AUG 2021

|               | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects           | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects           |
|---------------|-------------------------|-------------------------|------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-------------------------|-------------------------|------------------------------|
|               | Durva1500mg (N=388)     | Durva1500mg (N=388)     | Durva1500mg (N=388)          | Treme300mgx1dose+Durva 1500mg (N=388) | Treme300mgx1dose+Durva 1500mg (N=388) | Treme300mgx1dose+Durva 1500mg (N=388) | Treme75mgx4doses+Durva 1500mg (N=152) | Treme75mgx4doses+Durva 1500mg (N=152) | Treme75mgx4doses+Durva 1500mg (N=152) | Sora400mgBID (N=374)    | Sora400mgBID (N=374)    | Sora400mgBID (N=374)         |
| Parameter     | >=1 CTCAE grade changes | >=2 CTCAE grade changes | CTCAE grade changes to 3or 4 | >=1 CTCAE grade changes               | >=2 CTCAE grade changes               | CTCAE grade changes to 3or 4          | >=1 CTCAE grade changes               | >=2 CTCAE grade changes               | CTCAE grade changes to 3or 4          | >=1 CTCAE grade changes | >=2 CTCAE grade changes | CTCAE grade changes to 30r 4 |
| B-Hemoglobin  | 158/373 (42.4)          | 24/ 373 (6.4)           | 18/373 (4.8)                 | 195/378 (51.6)                        | 26/378 (6.9)                          | 18/378 (4.8)                          | 61/148 (41.2)                         | 14/ 148 (9.5)                         | 8/148 (5.4)                           | 142/352 (40.3)          | 25/352 (7.1)            | 21/352 (6.0)                 |
| B-Leukocytes  | 112/370 (30.3)          | 11/ 370 (3.0)           | 5/370 (1.4)                  | 76/376 (20.2)                         | 8/376 (2.1)                           | 3/376 (0.8)                           | 35/147 (23.8)                         | 2/147 (1.4)                           | 2/147 (1.4)                           | 106/352 (30.1)          | 11/352 (3.1)            | 4/352 (1.1)                  |
| B-Lymphocytes | 160/371 (43.1)          | 64/ 371 (17.3)          | 32/371 (8.6)                 | 156/ 377 (41.4)                       | 78/377 (20.7)                         | 42/ 377 (11.1)                        | 62/147 (42.2)                         | 25/147 (17.0)                         | 19/ 147 (12.9)                        | 138/351 (39.3)          | 68/351 (19.4)           | 35/351 (10.0)                |
| B-Neutrophils | 58/372 (15.6)           | 20/372 (5.4)            | 5/372 (1.3)                  | 48/378 (12.7)                         | 15/378 (4.0)                          | 3/378 (0.8)                           | 22/148 (14.9)                         | 7/148 (4.7)                           | 2/148 (1.4)                           | 48/ 351 (13.7)          | 21/ 351 (6.0)           | 7/351 (2.0)                  |
| B-Platelets   | 108/372 (29.0)          | 12/372 (3.2)            | 8/372 (2.2)                  | 109/378 (28.8)                        | 14/ 378 (3.7)                         | 6/378 (1.6)                           | 41/148 (27.7)                         | 7/148 (4.7)                           | 5/148 (3.4)                           | 122/352 (34.7)          | 16/352 (4.5)            | 11/352 (3.1)                 |

Table 65: Clinically important changes in haematology parameters (safety analysis set)

|                  | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients             |
|------------------|------------------------|-----------------------------|------------------------|-----------------------------|------------------------|-----------------------------|------------------------|-----------------------------|------------------------|------------------------------|
|                  | HCC-tumorpool          | HCC-tumorpool               | HCC-tumorpool          | HCC-tumorpool               | Pan-tumorpool          | Pan-tumorpool               | Pan-tumorpool          | Pan-tumorpool               | Pan-tumorpool          | Pan-tumorpool                |
|                  | T300+D (N = 462)       | T300+D (N = 462)            | D (N = 492)            | D (N = 492)                 | D (N = 4045)           | D (N = 4045)                | T75+D (N =3319)        | T75+D (N =3319)             | T750 (N =643)          | T750 (N =643)                |
| Parameter        | â‰¥2 CTCAE grade changes | CTCAE grade changes to 3or4 | â‰¥2 CTCAE grade changes | CTCAE grade changes to 3or4 | â‰¥2 CTCAE grade changes | CTCAE grade changes to 3or4 | â‰¥2 CTCAE grade changes | CTCAE grade changes to 3or4 | â‰¥2 CTCAE grade changes | CTCAE grade changes to 3or 4 |
| Hemoglobin       | 31/452 (6.9)           | 22/452 (4.9)                | 31/476 (6.5)           | 23/476 (4.8)                | 209/3868 (5.4)         | 193/3868 (5.0)              | 195/3162 (6.2)         | 178/3162 (5.6)              | 28/538 (5.2)           | 25/538 (4.6)                 |
| Leukocytes       | 14/450 (3.1)           | 5/450 (1.1)                 | 15/473 (3.2)           | 6/473 (1.3)                 | 75/3868 (1.9)          | 22/3868 (0.6)               | 59/3158 (1.9)          | 16/3158 (0.5)               | 11/585 (1.9)           | 4/585 (0.7)                  |
| Lymphocytes- Low | 86/431 (20.0)          | 51/431 (11.8)               | 81/450 (18.0)          | 38/450 (8.7)                | 738/3828 (19.3)        | 506/3828 (13.2)             | 617/3126 (19.7)        | 418/3126 (13.4)             | 48/513 (9.4)           | 37/513 (7.2)                 |
| Neutrophils      | 19/431 (4.4)           | 4/431 (0.9)                 | 24/451 (5.3)           | 6/451 (1.3)                 | 119/3833 (3.1)         | 37/3833 (1.0)               | 87/3104 (2.8)          | 18/3104 (0.6)               | 15/544 (2.8)           | 5/544 (0.9)                  |
| Platelets        | 14/452 (3.1)           | 6/452 (1.3)                 | 16/475 (3.4)           | 14/475 (2.9)                | 64/3865 (1.7)          | 44/3865 (1.1)               | 59/3154 (1.9)          | 36/3154 (1.1)               | 14/585 (2.4)           | 9/585 (1.5)                  |

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study medication or until the initiation of the first subsequent therapy (whichever occurred first).

Patient's worst(highest CTCAEgrade)changes from baseline are used.

Percentageshadbeencalculatedusing thenumberofpatientswithabaselinevalue and a postbaselinevalue.

CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types).

Source:Table 2.7.4.10.2, Pooled Safety Outputs,Module 5.3.5.3.

<div style=\"page-break-after: always\"></div>

## Clinical chemistry

Table 66: Clinically important changes in clinical chemistry parameters (safety analysis set)

|                              | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients         | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients      | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients      | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients         |
|------------------------------|-------------------------|-------------------------|-------------------------------|-------------------------|-------------------------|----------------------------|-------------------------|-------------------------|----------------------------|-------------------------|-------------------------|-------------------------------|
|                              | D (N =388)              | D (N =388)              | D (N =388)                    | T300+D (N =388)         | T300+D (N =388)         | T300+D (N =388)            | T75+D (N =152)          | T75+D (N =152)          | T75+D (N =152)             | S (N =374)              | S (N =374)              | S (N =374)                    |
| Clinical chemistry parameter | â‰¥1 CTCAE grade changes  | â‰¥2 CTCAE grade changes  | CTCAE grade changes to 3 or 4 | â‰¥1 CTCAE grade changes  | â‰¥2 CTCAE grade changes  | CTCAE grade changes to3or4 | â‰¥1 CTCAE grade changes  | â‰¥2 CTCAE grade changes  | CTCAE grade changes to3or4 | â‰¥1 CTCAE grade changes  | â‰¥2 CTCAE grade changes  | CTCAE grade changes to 3 or 4 |
| ALT                          | 194/374 (51.9)          | 52/374 (13.9)           | 49/374 (13.1)                 | 212/377 (56.2)          | 71/377 (18.8)           | 67/377 (17.8)              | 76/148 (51.4)           | 24/148 (16.2)           | 22/148 (14.9)              | 185/352 (52.6)          | 41/352 (11.6)           | 43/352 (12.2)                 |
| Albumin                      | 89/370 (24.1)           | 62/370 (16.8)           | 2/370 (0.5)                   | 116/371 (31.3)          | 66/371 (17.8)           | 2/371 (0.5)                | 42/147 (28.6)           | 26/147 (17.7)           | 1/147 (0.7)                | 130/350 (37.1)          | 81/350 (23.1)           | 6/350 (1.7)                   |
| ALP                          | 145/371 (39.1)          | 22/371 (5.9)            | 30/371 (8.1)                  | 154/374 (41.2)          | 34/374 (9.1)            | 31/374 (8.3)               | 70/148 (47.3)           | 11/148 (7.4)            | 18/148 (12.2)              | 156/351 (44.4)          | 17/351 (4.8)            | 19/351 (5.4)                  |
| AST                          | 205/373 (55.0)          | 65/373 (17.4)           | 86/373 (23.1)                 | 238/377 (63.1)          | 87/377 (23.1)           | 101/377 (26.8)             | 80/148 (54.1)           | 28/148 (18.9)           | 40/148 (27.0)              | 191/350 (54.6)          | 48/350 (13.7)           | 74/350 (21.1)                 |
| Bilirubin                    | 153/374 (40.9)          | 62/374 (16.6)           | 28/374 (7.5)                  | 156/377 (41.4)          | 76/377 (20.2)           | 31/377 (8.2)               | 64/147 (43.5)           | 22/147 (15.0)           | 14/147 (9.5)               | 167/352 (47.4)          | 71/352 (20.2)           | 37/352 (10.5)                 |
| Calcium increased            | 16/367 (4.4)            | 9/367 (2.5)             | 6/367 (1.6)                   | 11/367 (3.0)            | 2/367 (0.5)             | 2/367 (0.5)                | 4/146 (2.7)             | 1/146 (0.7)             | 0/146                      | 8/344 (2.3)             | 3/344 (0.9)             | 2/344 (0.6)                   |
| Calcium decreased            | 130/367 (35.4)          | 1/367 (0.3)             | 1/367 (0.3)                   | 123/367 (33.5)          | 5/367 (1.4)             | 0/367                      | 50/146 (34.2)           | 2/146 (1.4)             | 0/146                      | 148/344 (43.0)          | 3/344 (0.9)             | 1/344 (0.3)                   |
| Creatinine                   | 70/372 (18.8)           | 6/372 (1.6)             | 1/372 (0.3)                   | 78/374 (20.9)           | 10/374 (2.7)            | 5/374 (1.3)                | 25/148 (16.9)           | 7/148 (4.7)             | 0/148                      | 52/352 (14.8)           | 11/352 (3.1)            | 3/352 (0.9)                   |
| Glucose increased            | 142/368 (38.6)          | 63/368 (17.1)           | 31/368 (8.4)                  | 144/370 (38.9)          | 70/370 (18.9)           | 50/370 (13.5)              | 55/145 (37.9)           | 22/145 (15.2)           | 21/145 (14.5)              | 101/347 (29.1)          | 43/347 (12.4)           | 13/347 (3.7)                  |
| Glucose decreased            | 16/368 (4.3)            | 6/368 (1.6)             | 3/368 (0.8)                   | 22/370 (5.9)            | 12/370 (3.2)            | 4/370 (1.1)                | 5/145 (3.4)             | 3/145 (2.1)             | 2/145 (1.4)                | 19/347 (5.5)            | 8/347 (2.3)             | 3/347 (0.9)                   |
| Magnesium increased          | 0/12                    | 0/12                    | 0/12                          | 0/18                    | 0/18                    | 0/18                       | 0/9                     | 0/9                     | 6/0                        | 0/5                     | 0/5                     | 0/5                           |
| Magnesium decreased          | 0/12                    | 0/12                    | 0/12                          | 2/18 (11.1)             | 1/18 (5.6)              | 0/18                       | 0/9                     | 0/9                     | 6/0                        | 1/5 (20.0)              | 0/5                     | 0/5                           |
| Potassium increased          | 94/369 (25.5)           | 27/369 (7.3)            | 17/369 (4.6)                  | 105/370 (28.4)          | 31/370 (8.4)            | 14/370 (3.8)               | 35/147 (23.8)           | 9/147 (6.1)             | 4/147 (2.7)                | 75/352 (21.3)           | 24/352 (6.8)            | 9/352 (2.6)                   |
| Potassium decreased          | 35/369 (9.5)            | 5/369 (1.4)             | 5/369 (1.4)                   | 57/370 (15.4)           | 11/370 (3.0)            | 11/370 (3.0)               | 25/147 (17.0)           | 4/147 (2.7)             | 4/147 (2.7)                | 46/352 (13.1)           | 10/352 (2.8)            | 10/352 (2.8)                  |
| Sodium increased             | 17/371 (4.6)            | 0/371                   | 0/371                         | 19/372 (5.1)            | 2/372 (0.5)             | 1/372 (0.3)                | 13/147 (8.8)            | 0/147                   | 0/147                      | 23/352 (6.5)            | 3/352 (0.9)             | 1/352 (0.3)                   |
| Sodium decreased             | 139/371 (37.5)          | 23/371 (6.2)            | 25/371 (6.7)                  | 171/372 (46.0)          | 57/372 (15.3)           | 57/372 (15.3)              | 70/147 (47.6)           | 15/147 (10.2)           | 15/147 (10.2)              | 140/352 (39.8)          | 39/352 (11.1)           | 39/352 (11.1)                 |

N corresponds to the number of patientswith baselinevaluerecorded.

Only worsening of CTCAE grades are presented.

Derived from laboratory assessiments between the start of treatiment and up to and including 90 days following the date oflast dose of study treatment or until the initiation of the first subsequent therapy (whichever occurred first).

CTCAE version 4.03.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W.

Source: Table 14.3.7.1.2.2.

<div style=\"page-break-after: always\"></div>

Table 67: Clinically important changes in clinical chemistry parameters (safety analysis set)

|                         | T300+D (N = 462)       | T300+D (N = 462)              | D (N = 492)            | D (N = 492)                   |
|-------------------------|------------------------|-------------------------------|------------------------|-------------------------------|
| Parameter               | M2 CTCAE grade changes | CTCAE grade changes to 3 or 4 | â‰¥2 CTCAE grade changes | CTCAE grade changes to 3 or 4 |
| AST                     | 101/451 (22.4)         | 121/451 (26.8)                | 87/476 (18.3)          | 112/476 (23.5)                |
| Alkaline  phosphatase   | 38/448 (16.0)          | 35/448 (7.8)                  | 30/474 (6.3)           | 44/474 (9.3)                  |
| ALT                     | 85/451 (18.8)          | 80/451 (17.7)                 | 62/477 (13.0)          | 56/477 (11.7)                 |
| Albumin                 | 71/445 (16.0%)         | 2/445 (0.4)                   | 74/473 (15.6)          | 7/473 (1.5)                   |
| Total bilirubin         | 91/451 (20.2%)         | 35/451 (7.8)                  | 81/477 (17.0)          | 40/477 (8.4)                  |
| Creatinine              | 22/448 (4.9)           | 8/448 (1.8)                   | 19/475 (4.0)           | 3/475 (0.6)                   |
| GGT                     | 9/93 (9.7)             | 20/93 (21.5)                  | 8/116 (6.9)            | 20/116 (17.2)                 |
| Lipase                  | 117/423 (27.7)         | 101/423 (23.9)                | 75/460 (16.3)          | 54/460 (11.7)                 |
| Amylase                 | 81/426 (19.0)          | 63/426 (14.8)                 | 37/459 (8.1)           | 32/459 (7.0)                  |
| Glucose (high)          | 86/444 (19.4)          | 65/444 (14.6)                 | 75/471 (15.9)          | 39/471 (8.3)                  |
| Potassium (high)        | 36/444 (8.1)           | 17/444 (3.8)                  | 38/471 (8.1)           | 21/471 (4.5)                  |
| Sodium (low)            | 64/446 (14.3)          | 64/446 (14.3)                 | 35/474 (7.4)           | 37/474 (7.8)                  |
| Corrected Calcium (low) | 5/367 (1.4)            | 0/367 (0)                     | 1/367 (0.3)            | 1/367 (0.3)                   |

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study medication or until the initiation of the first subsequent therapy (whichever occurred first).Patient's worst (highest CTCAE grade) changes from baseline are used. Percentages had been calculated using the number of patients with a baseline value and a post baseline value. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (or equivalent); GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; IV, intravenous; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types).

<div style=\"page-break-after: always\"></div>

Table 9: Hyperglycaemia/new onset diabetes mellitus SMQ AEs in the HCC T300+D tumour pool

|                                           |          |          |                 |                | Receivedintervention       | Receivedintervention   | Receivedintervention        | Receivedintervention       |                                              |                     |                |            |
|-------------------------------------------|----------|----------|-----------------|----------------|----------------------------|------------------------|-----------------------------|----------------------------|----------------------------------------------|---------------------|----------------|------------|
| SMQCategory/ MedDRA Preferred Term        | Any AE   | Any SAEa | CTCAE Grade 3-4 | CTCAE Grade â‰¥3 | Systemic Cortico- Steroids | High Dose Steroid      | Other Immuno Suppre- ssants | Requires Endocrine Therapy | Leading to Dis- contin- uation of Study Drug | Resul- ted in Death | Not Resol- ved | Resol- ved |
| Hyperglycaemia/newonset diabetes mellitus | 39 (8.4) | 8 (1.7)  | 16 (3.5)        | 16 (3.5)       | 0                          | 0                      | 0                           | 0                          | 2 (0.4)                                      | 0                   | 18 (3.9)       | 21 (4.5)   |
| Diabetes mellitus                         | 11 (2.4) | 4 (0.9)  | 4 (0.9)         | 4 (0.9)        | 0                          | 0                      | 0                           | 0                          | 0                                            | 0                   | 7 (1.5)        | 4 (0.9)    |
| Diabetes mellitus inadequate control      | 2 (0.4)  | 0        | 0               | 0              | 0                          | 0                      | 0                           | 0                          | 0                                            | 0                   | 0              | 2 (0.4)    |
| Diabetic ketoacidosis                     | 1 (0.2)  | 1 (0.2)  | 1 (0.2)         | 1 (0.2)        | 0                          | 0                      | 0                           | 0                          | 0                                            | 0                   | 0              | 1 (0.2)    |
| Hyperglycaemia                            | 22 (4.8) | 2 (0.4)  | 10 (2.2)        | 10 (2.2)       | 0                          | 0                      | 0                           | 0                          | 1 (0.2)                                      | 0                   | 7 (1.5)        | 15 (3.2)   |
| Type 2 diabetes mellitus                  | 6 (1.3)  | 2 (0.4)  | 2 (0.4)         | 2 (0.4)        | 0                          | 0                      | 0                           | 0                          | 1 (0.2)                                      | 0                   | 4 (0.9)        | 2 (0.4)    |

IncludesAEswith an onset date on or after the date offirst dose orpre-treatmentAEs that increase inseverity on or afterdate offirst doseuptoandincluding90daysfollowing thedate of last dose of study medication, orup to and including the date of initiation of thefirst subsequent therapy (whichever occurs first). MedDRAVersion 23.1

AE = adverse event;CTCAE =CommonTerminology Criteria for Adverse Events;HCC =hepatocellular carcinoma; Q4W = every 4 weeks;SAE= serious adverse event;T300+D = tremelimumab 300 mg for a single dose and durvalumab 1500 mg Q4W; SMQ = Standardised MedDRA Query.

Source:IEMT 0316.2b0.

## Liver chemistry

Table 69: Proportin of patients with elevated ALT or AST ( â‰¥ 3 x ULN), and elevated total bilirubin ( â‰¥ 2 x ULN; safety analysis set)

|                                                            | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Category                                                   | D (N =388)               | T300+D (N =388)          | T75+D (N = 152)          | S (N=374)                |
| ALT or AST â‰¥3 x ULN and BILI>2 x ULNa                      | 46 (11.9)                | 51 (13.1)                | 17 (11.2)                | 47 (12.6)                |
| ALT or AST â‰¥ 3 x ULN and BILI> 2 x ULN and no ALPâ‰¥2 x ULNa | 19 (4.9)                 | 15 (3.9)                 | 3 (2.0)                  | 23 (6.1)                 |

Percentages were calculated based on the number of patients with measurements.

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of IP or until initiation of the first subsequent therapy (whichever occurred first). ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BILI, total bilirubin; D, durvalumab monotherapy 1500 mg Q4W; Q4W, every 4 weeks; IP, investigational product; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W; ULN upper limit of normal.

Source:Table 14.3.7.1.4

Table 70: Liver function abnormalities (safety analysis set)

|                    | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                    | HCC-tumour pool          | HCC-tumour pool          | Pan-tumour pool          | Pan-tumour pool          | Pan-tumour pool          |
| Category           | T300+D (N = 462)         | D (N = 492)              | D (N = 4045)             | T75+D (N = 3319)         | T750 (N = 643)           |
| ALT or AST         |                          |                          |                          |                          |                          |
| â‰¥ 3 Ã— to â‰¤ 5 Ã— ULN | 93 (20.1)                | 84 (17.1)                | 242 (6.0)                | 217 (6.5)                | 27 (4.2)                 |
| > 5 Ã— to â‰¤ 8 Ã— ULN | 65 (14.1)                | 56 (11.4)                | 127 (3.1)                | 111 (3.3)                | 16 (2.5)                 |

<div style=\"page-break-after: always\"></div>

|                      | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                      | HCC-tumour pool          | HCC-tumour pool          | Pan-tumour pool          | Pan-tumour pool          | Pan-tumour pool          |
| Category             | T300+D (N = 462)         | D (N = 492)              | D (N = 4045)             | T75+D (N = 3319)         | T750 (N = 643)           |
| > 8 Ã— to â‰¤ 10 Ã— ULN  | 26 (5.6)                 | 31 (6.3)                 | 57 (1.4)                 | 28 (0.8)                 | 7 (1.1)                  |
| > 10 Ã— to â‰¤ 20 Ã— ULN | 39 (8.4)                 | 33 (6.7)                 | 67 (1.7)                 | 66 (2.0)                 | 4 (0.6)                  |
| > 20 Ã— ULN           | 14 (3.0)                 | 11 (2.2)                 | 29 (0.7)                 | 36 (1.1)                 | 5 (0.8)                  |
| TBL                  |                          |                          |                          |                          |                          |
| â‰¥ 2 Ã— to â‰¤ 3 Ã— ULN   | 29 (6.3)                 | 41 (8.3)                 | 67 (1.7)                 | 39 (1.2)                 | 6 (0.9)                  |
| > 3 Ã— to â‰¤ 5 Ã— ULN   | 16 (3.5)                 | 18 (3.7)                 | 48 (1.2)                 | 33 (1.0)                 | 1 (0.2)                  |
| > 5 Ã— ULN            | 19 (4.1)                 | 22 (4.5)                 | 56 (1.4)                 | 32 (1.0)                 | 7 (1.1)                  |
| Potential Hy's law a | 57 (12.3)                | 65 (13.2)                | 131 (3.2)                | 85 (2.6)                 | 7 (1.1)                  |

a The onset date of ALT or AST elevation should be prior to or on the date of TBL elevation.

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study medication or until the initiation of the first subsequent therapy (whichever occurred first).

Patients were counted only once in the worst reported subcategory.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types); TBL, total bilirubin; ULN, upper limit of normal.

## Thyroid function

Table 71: Abnormal thyroid function (safety analysis set)

|                                                | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Category                                       | D (N =388)               | T300+D (N = 388)         | T75+D (N =152)           | S (N =374)               |
| Elevated TSH> ULN                              | 150 (38.7)               | 157 (40.5)               | 67 (44.1)                | 178 (47.6)               |
| Elevated TSH>ULNwith TSHâ‰¤ULN at baseline       | 94 (24.2)                | 107 (27.6)               | 47 (30.9)                | 114 (30.5)               |
| Elevated TSH>3xULN                             | 40 (10.3)                | 66 (17.0)                | 28 (18.4)                | 30 (8.0)                 |
| Elevated TSH>3 x ULN with TSHâ‰¤ ULN at baseline | 21 (5.4)                 | 42 (10.8)                | 18 (11.8)                | 4 (1.1)                  |
| Elevated TSH>10 x ULN                          | 15 (3.9)                 | 37 (9.5)                 | 13 (8.6)                 | 6 (1.6)                  |
| Elevated TSH>10x ULN with TSHâ‰¤ULN at baseline  | 8 (2.1)                  | 25 (6.4)                 | 11 (7.2)                 | 1 (0.3)                  |
| Low TSH<LLN                                    | 66 (17.0)                | 129 (33.2)               | 43 (28.3)                | 35 (9.4)                 |
| Low TSH < LLN with TSHâ‰¥ LLN at baseline        | 60 (15.5)                | 114 (29.4)               | 39 (25.7)                | 31 (8.3)                 |

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of investigational product or until initiation of the first subsequent therapy (whichever occurred first).

D, durvalumab monotherapy 1500 mg Q4W; Q4W, every 4 weeks; LLN, lower limit of normal; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W; TSH, thyroid-stimulating hormone; ULN, upper limit of normal.

Source: Table 14.3.7.1.6.

<div style=\"page-break-after: always\"></div>

Table 72: Abnormal on-treatment thyroid tests (safety analysis set)

|                                                                              | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                                              | HCC-tumour pool          | HCC-tumour pool          | Pan-tumour pool          | Pan-tumour pool          | Pan-tumour pool          |
| Category                                                                     | T300+D (N = 462)         | D (N = 492)              | D (N = 4045)             | T75+D (N = 3319)         | T750 (N = 64 3)          |
| On-treatment elevated TSH > ULN                                              | 180 (39.0)               | 180 (36.6)               | 1269 (31.4)              | 1152 (34.7)              | 127 (19.8)               |
| On-treatment elevated TSH > ULN with TSH â‰¤ ULN at baseline *                 | 124                      | 116                      | 780                      | 697                      | 76                       |
| with at least one T3 free/T4 free < LLN a                                    | 73 (58.9)                | 68 (58.6)                | 456 (58.5)               | 420 (60.3)               | 21 (27.6)                |
| with all other T3 free/T4 free â‰¥ LLN a                                       | 41 (33.1)                | 38 (32.8)                | 270 (34.6)               | 216 (31.0)               | 19 (25.0)                |
| with T3 free/T4 free missing a                                               | 10 (8.1)                 | 10 (8.6)                 | 54 (6.9)                 | 61 (8.8)                 | 36 (47.4)                |
| On-treatment low TSH < LLN                                                   | 154 (33.3)               | 82 (16.7)                | 880 (21.8)               | 896 (27.0)               | 86 (13.4)                |
| On-treatment low TSH < LLN with TSH â‰¥ LLN at baseline *                      | 136                      | 74                       | 709                      | 778                      | 66                       |
| with at least one T3 free/T4 free > ULN a                                    | 72 (52.9)                | 28 (37.8)                | 310 (43.7)               | 364 (46.8)               | 11 (16.7)                |
| with all other T3 free/T4 free â‰¤ ULN a                                       | 57 (41.9)                | 36 (48.6)                | 348 (49.1)               | 353 (45.4)               | 19 (28.8)                |
| with T3 free/T4 free missing a                                               | 7 (5.1)                  | 10 (13.5)                | 51 (7.2)                 | 61 (7.8)                 | 36 (54.5)                |
| Number of patients with at least one baseline and post-baseline TSH result * | 437                      | 464                      | 3679                     | 3028                     | 543                      |
| On-treatment elevated TSH > ULN and above baseline a                         | 165 (37.8)               | 162 (34.9)               | 1108 (30.1)              | 1011 (33.4)              | 106 (19.5)               |
| On-treatment decreased TSH < LLN and below baseline a                        | 148 (33.9)               | 80 (17.2)                | 816 (22.2)               | 848 (28.0)               | 76 (14.0)                |

a Percentage is based on number of patients in the main category above denoted with a *.

Baseline is defined as the last result obtained prior to the start of study treatment.

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study medication or until the initiation of the first subsequent therapy (whichever occurred first).

D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; LLN, lower limit of normal; Q4W, every 4 weeks; T3, free triiodothyronine; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T4, free thyroxine; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab

1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types); TSH, thyroid stimulating hormone; ULN, upper limit of normal.

## 2.6.8.5. In vitro biomarker test for patient selection for safety

Not applicable

<div style=\"page-break-after: always\"></div>

## 2.6.8.6. Safety in special populations

Age

## Table 73: Adverse events in any category - patient level by age group

|                                                          | Number (%) of patients a                                 | Number (%) of patients a                                 | Number (%) of patients a                                 | Number (%) of patients a                                 | Number (%) of patients a                                 |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                          | HCC-tumour pool                                          | HCC-tumour pool                                          | Pan-tumour pool                                          | Pan-tumour pool                                          | Pan-tumour pool                                          |
| AE category                                              | T300+D (N1 = 226) (N2 = 173) (N3 = 63)                   | D (N1 = 25 4) (N2 = 16 3) (N3 = 75)                      | D (N1 = 22 50) (N2 = 13 56) (N3 = 43 9)                  | T75+D (N1 = 18 52) (N2 = 11 26) (N3 = 34 1)              | T750 (N1 = 315 ) (N2 = 253 ) (N3 = 75)                   |
| Any AE possibly related to any study treatment b         | Any AE possibly related to any study treatment b         | Any AE possibly related to any study treatment b         | Any AE possibly related to any study treatment b         | Any AE possibly related to any study treatment b         | Any AE possibly related to any study treatment b         |
| < 65 years                                               | 163 (72.1)                                               | 132 (52.0)                                               | 1287 (57.2)                                              | 1223 (66.0)                                              | 214 (67.9)                                               |
| â‰¥ 65 to < 75 years                                       | 138 (79.8)                                               | 93 (57.1)                                                | 804 (59.3)                                               | 781 (69.4)                                               | 182 (71.9)                                               |
| â‰¥ 75 years                                               | 54 (85.7)                                                | 42 (56.0)                                                | 248 (56.5)                                               | 249 (73.0)                                               | 64 (85.3)                                                |
| Any AE possibly related to durvalumab b                  | Any AE possibly related to durvalumab b                  | Any AE possibly related to durvalumab b                  | Any AE possibly related to durvalumab b                  | Any AE possibly related to durvalumab b                  | Any AE possibly related to durvalumab b                  |
| < 65 years                                               | 162 (71.7)                                               | 132 (52.0)                                               | 1283 (57.0)                                              | 1201 (64.8)                                              | 0                                                        |
| â‰¥ 65 to < 75 years                                       | 136 (78.6)                                               | 93 (57.1)                                                | 801 (59.1)                                               | 770 (68.4)                                               | 0                                                        |
| â‰¥ 75 years                                               | 51 (81.0)                                                | 42 (56.0)                                                | 248 (56.5)                                               | 244 (71.6)                                               | 1 (1.3)                                                  |
| Any AE possibly related to tremelimumab b                | Any AE possibly related to tremelimumab b                | Any AE possibly related to tremelimumab b                | Any AE possibly related to tremelimumab b                | Any AE possibly related to tremelimumab b                | Any AE possibly related to tremelimumab b                |
| < 65 years                                               | 102 (45.1)                                               | 0                                                        | 0                                                        | 1137 (61.4)                                              | 208 (66.0)                                               |
| â‰¥ 65 to < 75 years                                       | 87 (50.3)                                                | 0                                                        | 0                                                        | 720 (63.9)                                               | 180 (71.1)                                               |
| â‰¥ 75 years                                               | 35 (55.6)                                                | 0                                                        | 0                                                        | 231 (67.7)                                               | 64 (85.3)                                                |
| Any AE with outcome of death                             | Any AE with outcome of death                             | Any AE with outcome of death                             | Any AE with outcome of death                             | Any AE with outcome of death                             | Any AE with outcome of death                             |
| < 65 years                                               | 9 (4.0)                                                  | 11 (4.3)                                                 | 112 (5.0)                                                | 110 (5.9)                                                | 19 (6.0)                                                 |
| â‰¥ 65 to < 75 years                                       | 19 (11.0)                                                | 13 (8.0)                                                 | 90 (6.6)                                                 | 80 (7.1)                                                 | 20 (7.9)                                                 |
| â‰¥ 75 years                                               | 6 (9.5)                                                  | 6 (8.0)                                                  | 29 (6.6)                                                 | 39 (11.4)                                                | 5 (6.7)                                                  |
| Any AE leading to discontinuation of any study treatment | Any AE leading to discontinuation of any study treatment | Any AE leading to discontinuation of any study treatment | Any AE leading to discontinuation of any study treatment | Any AE leading to discontinuation of any study treatment | Any AE leading to discontinuation of any study treatment |
| < 65 years                                               | 19 (8.4)                                                 | 19 (7.5)                                                 | 188 (8.4)                                                | 261 (14.1)                                               | 62 (19.7)                                                |
| â‰¥ 65 to < 75 years                                       | 29 (16.8)                                                | 19 (11.7)                                                | 156 (11.5)                                               | 200 (17.8)                                               | 69 (27.3)                                                |
| â‰¥ 75 years                                               | 15 (23.8)                                                | 9 (12.0)                                                 | 53 (12.1)                                                | 89 (26.1)                                                | 24 (32.0)                                                |
| Any AE leading to discontinuation of durvalumab          | Any AE leading to discontinuation of durvalumab          | Any AE leading to discontinuation of durvalumab          | Any AE leading to discontinuation of durvalumab          | Any AE leading to discontinuation of durvalumab          | Any AE leading to discontinuation of durvalumab          |
| < 65 years                                               | 19 (8.4)                                                 | 19 (7.5)                                                 | 183 (8.1)                                                | 235 (12.7)                                               | 0                                                        |
| â‰¥ 65 to < 75 years                                       | 29 (16.8)                                                | 19 (11.7)                                                | 151 (11.1)                                               | 189 (16.8)                                               | 0                                                        |
| â‰¥ 75 years                                               | 15 (23.8)                                                | 9 (12.0)                                                 | 53 (12.1)                                                | 77 (22.6)                                                | 0                                                        |
| Any AE leading to discontinuation of tremelimumab        | Any AE leading to discontinuation of tremelimumab        | Any AE leading to discontinuation of tremelimumab        | Any AE leading to discontinuation of tremelimumab        | Any AE leading to discontinuation of tremelimumab        | Any AE leading to discontinuation of tremelimumab        |
| < 65 years                                               | 2 (0.9)                                                  | 0                                                        | 0                                                        | 166 (9.0)                                                | 62 (19.7)                                                |
| â‰¥ 65 to < 75 years                                       | 3 (1.7)                                                  | 0                                                        | 0                                                        | 128 (11.4)                                               | 68 (26.9)                                                |
| â‰¥ 75 years                                               | 2 (3.2)                                                  | 0                                                        | 0                                                        | 58 (17.0)                                                | 24 (32.0)                                                |

i Patients with multiple events in the same category are counted only once in that category. patients with events in more than 1 category are counted once in each of those categories.

j As assessed by the investigator. Missing responses are counted as related.

<div style=\"page-break-after: always\"></div>

Percentages are calculated from N1, N2, and N3 for &lt; 65 years, â‰¥ 65 to &lt; 75 year s, and â‰¥ 75 years, respectively.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; N1, total number of &lt; 65 years patients, N2, total number of â‰¥ 65 to &lt; 75 years patients, N3, total number of â‰¥ 75 years patients; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types).

Table 74: adverse events by age category in the HCC T300+D tumour pool

|                                                                                                                  | Number (%) of patients   | Number (%) of patients      | Number (%) of patients   |
|------------------------------------------------------------------------------------------------------------------|--------------------------|-----------------------------|--------------------------|
| AE Category or System Organ Class                                                                                | < 65 years (N = 226)     | â‰¥ 65 - < 75 years (N = 173) | â‰¥ 75 years (N = 63)      |
| Any AE                                                                                                           | 218 (96.5)               | 170 (98.3)                  | 63 (100.0)               |
| Any SAE                                                                                                          | 91 (40.3)                | 72 (41.6)                   | 26 (41.3)                |
| Hospitalisation/prolong existing hospitalisation                                                                 | 88 (38.9)                | 66 (38.2)                   | 25 (39.7)                |
| Life-threatening                                                                                                 | 14 (6.2)                 | 18 (10.4)                   | 9 (14.3)                 |
| Disability/incapacity                                                                                            | 3 (1.3)                  | 11 (6.4)                    | 1 (1.6)                  |
| Other (medically significant)                                                                                    | 23 (10.2)                | 29 (16.8)                   | 8 (12.7)                 |
| Any AE with outcome of death                                                                                     | 9 (4.0)                  | 19 (11.0)                   | 6 (19.5)                 |
| Any AE leading to discontinuation of study treatment                                                             | 19 (8.4)                 | 29 (16.8)                   | 15 (23.8)                |
| Psychiatric disorders                                                                                            | 24 (10.6)                | 28 (16.2)                   | 10 (15.9)                |
| Nervous system disorders                                                                                         | 30 (13.3)                | 39 (22.5)                   | 12 (19.0)                |
| Injuries, poisoning, and procedural complications                                                                | 9 (4.0)                  | 15 (8.7)                    | 11 (17.5)                |
| Cardiac disorders                                                                                                | 7 (3.1)                  | 11 (6.4)                    | 5 (7.9)                  |
| Vascular disorders                                                                                               | 18 (8.0)                 | 28 (16.2)                   | 8 (12.7)                 |
| Cerebrovascular disorders                                                                                        | 0                        | 0                           | 0                        |
| Infections and infestations                                                                                      | 824 (36.6)               | 550 (40.6)                  | 167 (38.0)               |
| Cholinergic syndrome                                                                                             | 0                        | 0                           | 0                        |
| Sum of selected AEs (e.g. postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures, etc) b | 5 (2.2)                  | 13 (7.5)                    | 5 (7.9)                  |
| Anticholinergic syndrome                                                                                         | 0                        | 0                           | 0                        |
| Ataxia                                                                                                           | 0                        | 0                           | 0                        |
| Dizziness                                                                                                        | 4 (1.8)                  | 9 (5.2)                     | 2 (3.2)                  |
| Fall                                                                                                             | 1 (0.4)                  | 2 (1.2)                     | 2 (3.2)                  |
| Hand fracture                                                                                                    | 0                        | 0                           | 0                        |
| Multiple fractures                                                                                               | 0                        | 0                           | 0                        |
| Orthostatic hypotension                                                                                          | 0                        | 0                           | 0                        |
| Spinal fracture                                                                                                  | 0                        | 0                           | 0                        |
| Syncope                                                                                                          | 1 (0.4)                  | 2 (1.2)                     | 1 (1.6)                  |
| Other AEs appearing more frequently in older patients c                                                          |                          |                             |                          |
| Anaemia                                                                                                          | 14 (6.2)                 | 17 (9.8)                    | 12 (19.0)                |

<div style=\"page-break-after: always\"></div>

| Category or System Organ Class   | Number (%) of patients   | Number (%) of patients      | Number (%) of patients   |
|----------------------------------|--------------------------|-----------------------------|--------------------------|
| Category or System Organ Class   | < 65 years (N = 226)     | â‰¥ 65 - < 75 years (N = 173) | â‰¥ 75 years (N = 63)      |
| Hypothyroidism                   | 21 (9.3)                 | 23 (13.3)                   | 11 (17.5)                |
| Hyperkalaemia                    | 7 (3.1)                  | 9 (5.2)                     | 6 (9.5)                  |
| Pneumonitis                      | 1 (0.4)                  | 4 (2.3)                     | 5 (7.9)                  |
| Abdominal pain                   | 35 (15.5)                | 17 (9.8)                    | 6 (9.5)                  |
| Constipation                     | 24 (10.6)                | 18 (10.4)                   | 3 (4.8)                  |
| Diarrhoea                        | 55 (24.3)                | 48 (27.7)                   | 14 (22.2)                |
| Nausea                           | 24 (10.6)                | 19 (11.0)                   | 14 (22.2)                |
| Pruritus                         | 51 (22.6)                | 54 (31.2)                   | 13 (20.6)                |
| Rash                             | 58 (25.7)                | 44 (25.4)                   | 13 (20.6)                |
| Fatigue                          | 33 (14.6)                | 33 (19.1)                   | 17 (27.0)                |
| Oedema peripheral                | 14 (6.2)                 | 24 (13.9)                   | 7 (11.1)                 |

AE = adverse event; HCC = hepatocellular carcinoma; Q4W = every 4 weeks; SAE = serious adverse event; T300+D = tremelimumab 300 mg for a single dose and durvalumab 1500 mg Q4W.

a The details of each SAE and the criteria met individually are found in the patient narratives b Patients with multiple AEs are counted once for each category and sub-category.

c &gt;5% difference between the &lt;65, 65 to 74, and â‰¥75 age categories.

## Body weight

In the HCC D pool, a slight increasing trend for Grade 3 to 4 AEs was observed for patients with body weight â‰¥ 90 kg (N=55), compared to patients &lt; 70 kg (54.5% vs 36.2%), and similarly for SAEs (49.1% vs 29.4%). A similar trend was observed in the Pan-tumour D pool.

## ECOG performance status

In both of the HCC-tumour pools, patients with a baseline ECOG status of 1 experienced a higher incidence of Grade 3 to 4 AEs (T300+D pool: 56.6% vs 49.1%) and AEs leading to death (T300+D pool: 10.3% vs 5.6%). In the HCC-tumour pools, no other clinically meaningful differences were observed in the safety profile of T300+D versus D alone with respect to performance status.

## Geographical region

In the HCC tumour pools, the applicant claimed that there were no clinically meaningful differences in the safety profile of the T300+D pool compared with the D pool with respect to geographical region .

<div style=\"page-break-after: always\"></div>

## 2.6.8.7. Immunological events

## Table 75: Adverse events in any category, by ADA category to durvalumab (safety analysis set)

|                                                                                        | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|----------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| AE category a                                                                          | D (N =388)               | D (N =388)               | D (N =388)               | D (N =388)               | T300+D (N =388)          | T300+D (N =388)          | T300+D (N =388)          | T300+D (N =388)          | T75+D (N =152)           | T75+D (N =152)           | T75+D (N =152)           | T75+D (N =152)           |
| AE category a                                                                          | TE- ADA+ b               | nAb+                     | ADA+c                    | ADA-d                    | TE- ADA+b                | nAb+                     | ADA+c                    | ADA-d                    | TE- ADA+ b               | nAb+                     | ADA+c                    | ADA-d                    |
| NumberofdurvalumabADA evaluable patients in the category                               | 8                        | 2                        | 20                       | 262                      | 9                        | 5                        | 24                       | 270                      | 5                        | 0                        | 8                        | 100                      |
| Any AE                                                                                 | 6 (75.0)                 | (100) 2                  | (90.0) 18                | (89.7) 235               | 9 (100)                  | (100) 5                  | (95.8) 23                | (97.8) 264               | 5 (100)                  | 0                        | 8 (100)                  | (97.0) 97                |
| Any AE possibly related to treatmente                                                  | 4 (50.0)                 | 0                        | 9 (45.0)                 | (56.5) 148               | 5 (55.6)                 | (60.0) 3                 | (70.8) 17                | (78.9) 213               | 4 (80.0)                 | 0                        | 5 (62.5)                 | (76.0) 76                |
| AnyAEofCTCAEGrade3or 4                                                                 | 2 (25.0)                 | 0                        | 9 (45.0)                 | (34.0) 89                | 5 (55.6)                 | (60.0) 3                 | (41.7) 10                | (50.0) 135               | 2 (40.0)                 | 0                        | 2 (25.0)                 | (40.0) 40                |
| Any AE of CTCAE grade 3 or 4, possibly related to treatmente                           | 0                        | 0                        | 2 (10.0)                 | (12.2) 32                | 2 (22.2)                 | (20.0) 1                 | 5 (20.8)                 | (24.4) 66                | 0                        | 0                        | 0                        | (19.0) 19                |
| Any AE with outcome of death                                                           | 0                        | 0                        | 1 (5.0)                  | 9 (3.4)                  | 0                        | 0                        | 2 (8.3)                  | 8 (3.0)                  | 1 (20.0)                 | 0                        | 1 (12.5)                 | 5 (5.0)                  |
| Any AE with outcome of death, possibly related to treatmente                           | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 2 (0.7)                  | 0                        | 0                        | 0                        | 1 (1.0)                  |
| with outcome of death) Any SAE (including events                                       | 0                        | 0                        | 5 (25.0)                 | (24.8) 65                | 3 (33.3)                 | (40.0) 2                 | 8 (33.3)                 | (38.1) 103               | 3 (60.0)                 | 0                        | 3 (37.5)                 | (30.0) 30                |
| Any SAE (including events with outcome of death), possibly related to treatment e      | 0                        | 0                        | 0                        | 17 (6.5)                 | 0                        | 0                        | 1 (4.2)                  | 43 (15.9)                | 1 (20.0)                 | 0                        | 1 (12.5)                 | 16 (16.0)                |
| Any AE leading to discontinuation of study treatment f                                 | 0                        | 0                        | 1 (5.0)                  | 13 (5.0)                 | 1 (11.1)                 | (20.0) 1                 | 2 (8.3)                  | 26 (9.6)                 | 0                        | 0                        | 0                        | (15.0) 15                |
| Any AE leading to treatment, possibly related to discontinuation of study treatment ef | 0                        | 0                        | 0                        | 6 (2.3)                  | 1(11.1)                  | (20.0) 1                 | 1 (4.2)                  | 16 (5.9)                 | 0                        | 0                        | 0                        | 8 (8.0)                  |
| delay/interruption g Any AE leading to dose                                            | 0                        | 0                        | 4 (20.0)                 | (27.9) 73                | 4 (44.4)                 | 0                        | (45.8) 11                | (36.7) 99                | 1 (20.0)                 | 0                        | 2 (25.0)                 | (39.0) 39                |
| Any AESI                                                                               | 1 (12.5)                 | 0                        | 4 (20.0)                 | (43.1) 113               | 4 (44.4)                 | (40.0) 2                 | (50.0) 12                | (71.5) 193               | 5 (100)                  | 0                        | 6 (75.0)                 | (62.0) 62                |
| Any AESI, possibly related to treatmente                                               | 1 (12.5)                 | 0                        | 1 (5.0)                  | 81 (30.9)                | 4 (44.4)                 | 1 (20.0)                 | 10 (41.7)                | 162 (60.0)               | 4 (80.0)                 | 0                        | 5 (62.5)                 | 53 (53.0)                |
| Any infusion reaction AEs h                                                            | 0                        | 0                        | 0                        | 5 (1.9)                  | 0                        | 0                        | 0                        | 16 (5.9)                 | 0                        | 0                        | 0                        | 3 (3.0)                  |

- Positive and negative results are with respect to durvalumab. Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories.
- b Treatment-emergent ADA positive is defined as either treatment-induced or treatment-boosted.
- ADA positive, ie, positive ADA result at any time, baseline or post-baseline.
- P ADA negative,ie,without anyADA positive results (at baseline or post-baseline).
- e Possibly related to any of the study treatments, as assessed by the Investigator. Missing responses are counted as related.
- f AEs on the AE eCRF with action taken of \"drug permanently discontinued' for at least one treatment.
- g AEs on the AE eCRF with action taken of \"drug interrupted' for either molecule.
- As assessedby theInvestigator.

MedDRAversion23.1.CTCAEversion4.03

Denominator is the number of ADA evaluable patients (patients in the Safety Analysis Set who have a non-missing baseline ADA and at least one non-missing post-baseline result) in the ADA category.

Includes TEAEs.

ADA, anti-drug antibody; AE, adverse event; AESI, adverse event of special interest; eCRF, electronic case report form; CTCAE, Common Terminology Criteria for AdverseEvents;D,durvalumab monotherapy 1500 mgQ4W;MedDRA,MedicalDictionary forRegulatory Activities;N,total number ofpatients; nAb, neutralizing antibody; Q4W, every 4 weeks; SAE, serious adverse event; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W; TE, treatment-emergent.

Source: Table 14.3.9.3.

<div style=\"page-break-after: always\"></div>

Table 76: Adverse events in any category, by ADA category to tremelimumab (safety analysis set)

|                                                                                        | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                                                        | T300+D (N=388)           | T300+D (N=388)           | T300+D (N=388)           | T300+D (N=388)           | T75+D (N = 152)          | T75+D (N = 152)          | T75+D (N = 152)          | T75+D (N = 152)          |
| AE category a                                                                          | TE- ADA+b                | nAb+                     | ADA+c                    | ADA-d                    | TE- ADA+ b               | nAb+                     | ADA+c                    | ADA-d                    |
| Number of tremelimumabADA-evaluablepatientsin the category                             | 20                       | 8                        | 29                       | 153                      | 23                       | 16                       | 30                       | 72                       |
| Any AE                                                                                 | 19 (95.0)                | 8 (100)                  | 28 (96.6)                | 150 (98.0)               | 23 (100)                 | 16 (100)                 | 30 (100)                 | 70 (97.2)                |
| Any AE possibly related to treatment e                                                 | 15 (75.0)                | 8 (100)                  | 23 (79.3)                | 120 (78.4)               | 18 (78.3)                | 13 (81.3)                | 23 (76.7)                | 54 (75.0)                |
| Any AE of CTCAE Grade 3 or 4                                                           | 9 (45.0)                 | 6 (75.0)                 | 13 (44.8)                | 77 (50.3)                | 10 (43.5)                | 8 (50.0)                 | 12 (40.0)                | 27 (37.5)                |
| Any AE of CTCAE Grade 3 or 4, possibly related to treatmente                           | 4 (20.0)                 | 3 (37.5)                 | 7 (24.1)                 | 37 (24.2)                | 1 (4.3)                  | 1 (6.3)                  | 1 (3.3)                  | 15 (20.8)                |
| Any AE with outcome of death                                                           | 0                        | 0                        | 0                        | 5 (3.3)                  | 2 (8.7)                  | 1 (6.3)                  | 4 (13.3)                 | 2 (2.8)                  |
| AnyAEwithoutcome of death,possiblyrelated to treatment e                               | 0                        | 0                        | 0                        | 2 (1.3)                  | 0                        | 0                        | 1 (3.3)                  | 0                        |
| Any SAE (including events with outcome of death)                                       | 9 (45.0)                 | 5 (62.5)                 | 12 (41.4)                | 58 (37.9)                | 5 (21.7)                 | 3 (18.8)                 | 8 (26.7)                 | 24 (33.3)                |
| Any SAE (including events with outcome of death), possibly related to treatment e      | 6 (30.0)                 | 3 (37.5)                 | 7 (24.1)                 | 25 (16.3)                | 1 (4.3)                  | 1 (6.3)                  | 3 (10.0)                 | 13 (18.1)                |
| Any AE leading to discontinuation of study treatment f                                 | 3 (15.0)                 | 2 (25.0)                 | 4 (13.8)                 | 14 (9.2)                 | 3 (13.0)                 | 3 (18.8)                 | 4 (13.3)                 | 10 (13.9)                |
| Any AE leading to discontinuation of study treatment, possibly related to treatment ef | 2 (10.0)                 | 2 (25.0)                 | 3 (10.3)                 | 11 (7.2)                 | 0                        | 0                        | 1 (3.3)                  | 7 (9.7)                  |
| Any AE leading to dose delay/interruption g                                            | 8 (40.0)                 | 2 (25.0)                 | 10 (34.5)                | 57 (37.3)                | 9 (39.1)                 | 8 (50.0)                 | 10 (33.3)                | 28 (38.9)                |
| Any AESI                                                                               | 16 (80.0)                | 6 (75.0)                 | 20 (69.0)                | 104 (68.0)               | 15 (65.2)                | 9 (56.3)                 | 19 (63.3)                | 46 (63.9)                |
| Any AESI, possibly related to treatment e                                              | 14 (70.0)                | 6 (75.0)                 | 17 (58.6)                | 89 (58.2)                | 12 (52.2)                | 9 (56.3)                 | 16 (53.3)                | 40 (55.6)                |
| Any infusion reaction AEs h                                                            | 2 (10.0)                 | 1 (12.5)                 | 2 (6.9)                  | 10 (6.5)                 | 0                        | 0                        | 0                        | 3 (4.2)                  |

- Positive and negative results are with respect to tremelimumab. Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
- b Treatment-emergent ADA positive is defined as either treatment-induced or treatment-boosted.
- c ADA positive, ie, positive ADA result at any time, baseline or post-baseline.
- P ADA negative,ie,without anyADA positive results(at baseline or post-baseline).
- e Possibly related to any of the study treatments, as assessed by the Investigator. Missing responses are counted as related.

f

AEs on the AE eCRF with action taken ofâ€˜drug permanently discontinuedâ€™ for at least one treatment.

- g AEs on the AE eCRF with action taken of Â°drug interrupted' for either molecule.
- h As assessed by Investigator.

MedDRA version 23.1. CTCAE version 4.03.

Denominator is the number of ADA evaluable patients (patients in the Safety Analysis Set who have a non-missing baseline ADA and at least one non-missing post-baseline result) in the ADA category.

Includes TEAEs.

ADA, antidrug antibody; AE, adverse event; AESI, adverse event of special interest; eCRF, electronic case report form; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; MedDRA, Medical Dictionary for Regulatory Activities; N, total number of patients; nAb, neutralizing antibody; Q4W, every 4 weeks; SAE, serious adverse event; T75+D, tremelimumab 75 mg Ã— 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg Ã— 1 dose + durvalumab 1500 mg Q4W; TE, treatment-emergent.

## 2.6.8.8. Safety related to drug-drug interactions and other interactions

Durvalumab and tremelimumab are immunoglobulins, therefore, no formal pharmacokinetic drug-drug interaction studies have been conducted.

<div style=\"page-break-after: always\"></div>

## 2.6.8.9. Discontinuation due to adverse events

## Table 77: Adverse events leading to discontinuation of study medication by system organ class, preferred term and maximum reported CCAE grade (safety analysis aet) - DCO: 27 AUG 2021

|                                        |                            | Number(%o)of subjectsa   | Number(%o)of subjectsa   | Number(%o)of subjectsa                                 | Number(%o)of subjectsa   |
|----------------------------------------|----------------------------|--------------------------|--------------------------|--------------------------------------------------------|--------------------------|
| Systemorganclass/ MIedDRAPreferredterm | Maximumreported CTCAEgrade | Durva 1500 mg (N=388)    | Durva 1500 mg (N=388)    | Treme300mgx1dose+Treme75mgx4doses+ Durva1500mg (N=152) | Sora400mg BID (N=374)    |
| Subjects with any AE                   | Total                      | 32 (8.2)                 | 53 (13.7)                | 23 (15.1)                                              | 63 (16.8)                |
|                                        | Grade1                     | 0                        | 2 (0.5)                  | 0                                                      | 2 (0.5)                  |
|                                        | Grade 2                    | 6 (1.5)                  | 7 (1.8)                  | 5 (3.3)                                                | 16 (4.3)                 |
|                                        | Grade3                     | 13 (3.4)                 | 21 (5.4)                 | 6 (3.9)                                                | 27 (7.2)                 |
|                                        | Grade 4                    | 2 (0.5)                  | 4 (1.0)                  | 5 (3.3)                                                | 1 (0.3)                  |
|                                        | Grade5                     | 11 (2.8)                 | 19 (4.9)                 | 7 (4.6)                                                | 17 (4.5)                 |
|                                        | Grade>=3                   | 26 (6.7)                 | 44 (11.3)                | 18 (11.8)                                              | 45 (12.0)                |
|                                        | Grade 3-4                  | 15 (3.9)                 | 25 (6.4)                 | 11 (7.2)                                               | 28 (7.5)                 |

## Table 78: Adverse events leading to discontinuation by system organ class and preferred term ( â‰¥ 1% patients in any treatment group) (safety analysis set)

|                                                                        | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                        | HCC-tumour pool            | HCC-tumour pool            | Pan-tumour pool            | Pan-tumour pool            | Pan-tumour pool            |
|                                                                        | T300+D                     | D                          | D                          | T75+D                      | T750                       |
| MedDRA preferred term                                                  | (N = 462)                  | (N = 492)                  | (N = 4045)                 | (N = 3319)                 | (N = 643)                  |
| Patients with any AE leading to discontinuation of any study treatment | 63 (13.6)                  | 47 (9.6)                   | 397 (9.8)                  | 550 (16.6)                 | 155 (24.1)                 |
| Respiratory, thoracic and mediastinal disorders                        | 4 (0.9)                    | 2 (0.4)                    | 84 (2.1)                   | 113 (3.4)                  | 9 (1.4)                    |
| Pneumonitis                                                            | 2 (0.4)                    | 1 (0.2)                    | 36 (0.9)                   | 49 (1.5)                   | 2 (0.3)                    |
| Gastrointestinal disorders                                             | 14 (3.0)                   | 9 (1.8)                    | 41 (1.0)                   | 125 (3.8)                  | 98 (15.2)                  |
| Colitis                                                                | 2 (0.4)                    | 1 (0.2)                    | 6 (0.1)                    | 32 (1.0)                   | 26 (4.0)                   |
| Diarrhoea                                                              | 3 (0.6)                    | 2 (0.4)                    | 8 (0.2)                    | 37 (1.1)                   | 63 (9.8)                   |
| Investigations                                                         | 8 (1.7)                    | 6 (1.2)                    | 25 (0.6)                   | 42 (1.3)                   | 11 (1.7)                   |
| Aspartate aminotransferase increased                                   | 5 (1.1)                    | 3 (0.6)                    | 6 (0.1)                    | 8 (0.2)                    | 1 (0.2)                    |

k Number (%) of patients with AEs leading to discontinuation, sorted by international order for system organ class and alphabetically for preferred term.

Patients with multiple AEs are counted once for each system organ class/preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication, or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

Percentages are based on the total numbers of patients in the treatment group (N).

MedDRA version 23.1.

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types).

<div style=\"page-break-after: always\"></div>

Table 79: Adverse events leading to dose delay/interruption by system organ class and preferred term ( â‰¥ 1% patients in any treatment group) (safety analysis set)

|                                                                                | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|--------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                                | HCC-tumour pool            | HCC-tumour pool            | Pan-tumour pool            | Pan-tumour pool            | Pan-tumour pool            |
|                                                                                | T300+D                     | D                          | D                          | T75+D                      | T750                       |
| MedDRA preferred term                                                          | (N = 462)                  | (N = 492)                  | (N = 4045)                 | (N = 3319)                 | (N = 643)                  |
| Patients with any AE leading to dose delay/interruption of any study treatment | 149 (32.3)                 | 112 (22.8)                 | 1120 (27.7)                | 945 (28.5)                 | 144 (22.4)                 |
| Infections and infestations                                                    | 22 (4.8)                   | 12 (2.4)                   | 255 (6.3)                  | 183 (5.5)                  | 18 (2.8)                   |
| Pneumonia                                                                      | 6 (1.3)                    | 1 (0.2)                    | 88 (2.2)                   | 63 (1.9)                   | 7 (1.1)                    |
| Blood and lymphatic system disorders                                           | 12 (2.6)                   | 11 (2.2)                   | 64 (1.6)                   | 53 (1.6)                   | 9 (1.4)                    |
| Anaemia                                                                        | 6 (1.3)                    | 4 (0.8)                    | 39 (1.0)                   | 28 (0.8)                   | 7 (1.1)                    |
| Endocrine disorders                                                            | 9 (1.9)                    | 6 (1.2)                    | 75 (1.9)                   | 88 (2.7)                   | 7 (1.1)                    |
| Hyperthyroidism                                                                | 5 (1.1)                    | 0                          | 28 (0.7)                   | 34 (1.0)                   | 0                          |
| Respiratory, thoracic and mediastinal disorders                                | 7 (1.5)                    | 5 (1.0)                    | 171 (4.2)                  | 116 (3.5)                  | 12 (1.9)                   |
| Pneumonitis                                                                    | 3 (0.6)                    | 1 (0.2)                    | 48 (1.2)                   | 39 (1.2)                   | 3 (0.5)                    |
| Gastrointestinal disorders                                                     | 23 (5.0)                   | 12 (2.4)                   | 140 (3.5)                  | 186 (5.6)                  | 54 (8.4)                   |
| Colitis                                                                        | 5 (1.1)                    | 0                          | 4 (< 0.1)                  | 25 (0.8)                   | 1 (0.2)                    |
| Diarrhoea                                                                      | 16 (3.5)                   | 4 (0.8)                    | 48 (1.2)                   | 82 (2.5)                   | 43 (6.7)                   |
| Hepatobiliary disorders                                                        | 18 (3.9)                   | 15 (3.0)                   | 44 (1.1)                   | 38 (1.1)                   | 1 (0.2)                    |
| Hepatic function abnormal                                                      | 3 (0.6)                    | 5 (1.0)                    | 8 (0.2)                    | 7 (0.2)                    | 1 (0.2)                    |
| Hepatitis                                                                      | 6 (1.3)                    | 1 (0.2)                    | 6 (0.1)                    | 9 (0.3)                    | 0                          |
| Skin and subcutaneous tissue disorders                                         | 21 (4.5)                   | 12 (2.4)                   | 64 (1.6)                   | 91 (2.7)                   | 19 (3.0)                   |
| Rash                                                                           | 10 (2.2)                   | 3 (0.6)                    | 14 (0.3)                   | 34 (1.0)                   | 7 (1.1)                    |
| General disorders and administration site conditions                           | 13 (2.8)                   | 3 (0.6)                    | 147 (3.6)                  | 112 (3.4)                  | 19 (3.0)                   |
| Pyrexia                                                                        | 9 (1.9)                    | 1 (0.2)                    | 43 (1.1)                   | 25 (0.8)                   | 5 (0.8)                    |
| Investigations                                                                 | 47 (10.2)                  | 45 (9.1)                   | 214 (5.3)                  | 203 (6.1)                  | 19 (3.0)                   |
| Alanine aminotransferase increased                                             | 13 (2.8)                   | 15 (3.0)                   | 47 (1.2)                   | 52 (1.6)                   | 2 (0.3)                    |
| Amylase increased                                                              | 14 (3.0)                   | 1 (0.2)                    | 22 (0.5)                   | 34 (1.0)                   | 2 (0.3)                    |
| Aspartate aminotransferase increased                                           | 12 (2.6)                   | 23 (4.7)                   | 64 (1.6)                   | 53 (1.6)                   | 4 (0.6)                    |
| Lipase increased                                                               | 11 (2.4)                   | 7 (1.4)                    | 27 (0.7)                   | 58 (1.7)                   | 6 (0.9)                    |
| Injury, poisoning and procedural complications                                 | 5 (1.1)                    | 0                          | 73 (1.8)                   | 40 (1.2)                   | 4 (0.6)                    |
| Radiation pneumonitis                                                          | 0                          | 0                          | 41 (1.0)                   | 1 (< 0.1)                  | 0                          |

Number (%) of patients with AE leading to dose delay or interruption, sorted by international order for system organ class and alphabetically for preferred term.

Patients with multiple AEs are counted once for each system organ class/preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

MedDRA version 23.1.

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumour types).

<div style=\"page-break-after: always\"></div>

## 2.6.8.10. Post marketing experience

Tremelimumab is not yet approved for use in any country.

## 2.6.9. Discussion on clinical safety

The safety population of interest are patients with unresectable HCC (uHCC), who have received the proposed dosing regimen of a single dose of Tremelimumab 300 mg + durvalumab in combination followed by durvalumab monotherapy (T300+D), which consists of 388 patients from the pivotal Himalaya study and 74 patients from the supportive study 22, in total 462 patients.

The median treatment duration in the Himalaya study were 5.5 months, while the median treatment duration was 4.1 months in the Sorafenib arm (n=374). In the HCC pool, the median duration of exposure was 20 weeks and approximately 50% of patients received at least 24 weeks of treatment at DCO, while ~28% had 52 weeks of treatment. Hence, the exposure to the proposed regimen and the size of the safety database are considered sufficient for a safety assessment.

Almost all patients in the HCC pool, who received T300+D, experienced at least one adverse event (AE) (97.6%), and 51.9% experienced a grade 3 or 4 AEs. For the Himalaya study, a similar pattern was observed in T300+D arm: 97.4% experienced at least one AE, 50.5% experienced a grade 3 or 4 AE, and SAEs were observed in 40.5% of the patients, noting 7.7% had an SAE leading to death. The discontinuation rate due to AEs was 13.7%. In comparison, 95.5% of the patients in the Sorafenib arm also experienced at least one AE, and 52.4% experienced a grade 3 or 4 AE. SAEs were observed in 29.7% of the patients, of which 7.2% had an SAE leading to death, while the discontinuation rate due to AEs was 16.8%.

Treatment-related AEs or adverse drug reactions (ADRs) in the T300+D arm of the pivotal Himalaya study were rash (19.6%), pruritus (17%), diarrhoea (16.5%), and hypothyroidism (10.8%). In comparison, common ADRs in the Sorafenib arm were diarrhoea (38.8%), palmar-plantar erythrodysaesthesia (PPE) (43.9%), hypertension (15%), and fatigue (14.7%). The most common grade 3 or 4 ADRs in the T300+D arm were increased lipase (4.4%), diarrhoea (3.4%), amylase increased (2.6%) and ASAT increased (2.3%). Common grade 3 or 4 ADRs in the S arm were PPE (8.8%), hypertension (5.3%), and diarrhoea (4%), so in comparison there are more high-grade toxicity with sorafenib in favour of T300+D.

Adverse events of special interest for T300+D include immune-mediated AEs (imAEs) and as expected, the occurrence of imAEs are much more common in the HCC pool vs the Sorafenib arm (36.1% vs 7.5%), and these were of grade 3 or 4 in 13.4% vs 2.4% of the patients, respectively. Serious imAEs are considered common (10.2% vs 1.1%) and 6 patients (1.3%) died from these, while a quarter of the patients need systemic corticosteroids in the HCC pool versus only 4% in the Sorafenib arm. Moreover, many patients needed endocrine therapy, when treated with T300+D vs Sorafenib (14.9% vs 3.5%). It is noted that very few patients had to discontinue treatment due to imAEs (5.6% vs 1.6%), which is reassuring. Other common imAEs with T300+D were hepatic events (7.4%) and diarrhoea/colitis (6.5%). Grade 3 or 4 hepatic events (5%) and diarrhoea/colitis (3.7%) were the most frequent high-grade events, and these are difficult to manage in the clinic, so it is important that this is clear from the SmPC section 4.4, which is the case. Overall, imAEs were frequently reported and the number of AESIs and imAEs significantly differ for dermatitis/rash, pancreatic events, hepatic events, diarrhoea/colitis, hypothyroid and hyperthyroid events, pneumonitis. Some imAEs such as endocrinopathies, hepatotoxicity, dermatitis/rash are expected to be more manageable than others, such as diarrhoea/colitis, pancreatic events and pneumonitis. The latter are more difficult to manage, often require hospitalisation, and might not be assumed as immune-mediated events by clinicians.

<div style=\"page-break-after: always\"></div>

Events of Stevens-Johnson Syndrome or toxic epidermal necrolysis have been reported in patients treated with PD-1 inhibitors and CTLA-4 inhibitors. Patients should be monitored for signs and symptoms of rash or dermatitis and managed through dose interruption, treatment discontinuation and/or corticosteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Patients should be monitored for alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase levels prior to initiation of treatment and prior to each subsequent infusion. Additional monitoring is to be considered based on clinical evaluation. Patients should be monitored for abnormal renal function tests prior to and periodically during treatment. Patients should also be monitored for signs and symptoms of immune-mediated pancreatitis and myocarditis. Immune mediated hepatitis, nephritis, pancreatitis and myocarditis should be managed through dose interruption, treatment discontinuation and/or corticosteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed through dose interruption, treatment discontinuation and corticosteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Patients should be monitored for signs and symptoms of colitis/diarrhoea and intestinal perforation and managed through dose interruption, treatment discontinuation and/or corticosteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and as indicated based on clinical evaluation. Immune-mediated hypothyroidism, hyperthyroidism, and thyroiditis should be managed through dose interruption, symptomatic treatment or thyroid hormone replacement as clinically indicated (see sections 4.2 and 4.4 of the SmPC).

Immune mediated adrenal insufficiency occurred in patients receiving Tremelimumab AstraZeneca in combination with durvalumab. Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed through dose interruption, corticosteroid treatment and hormone replacement (see sections 4.2 and 4.4 of the SmPC).

Immune mediated type 1 diabetes mellitus, which can first present as diabetic ketoacidosis that can be fatal if not detected early, occurred in patients receiving tremelimumab in combination with durvalumab and chemotherapy. Patients should be monitored for clinical signs and symptoms of type 1 diabetes mellitus. For symptomatic type 1 diabetes mellitus, patients should be managed via treatment with insulin as clinically indicated (see sections 4.2, 4.4 and 4.8 of the SmPC).

Patients should be monitored for clinical signs and symptoms of hypophysitis or hypopituitarism. For symptomatic hypophysitis or hypopituitarism, patients should be managed as recommended through dose interruption and corticosteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Given the mechanism of action of tremelimumab in combination with durvalumab, other potential immune mediated adverse reactions may occur. The following immune-related adverse reactions have been observed in patients treated with tremelimumab in combination with durvalumab: myasthenia gravis, myositis, polymyositis, meningitis, encephalitis, Guillain-BarrÃ© syndrome, immune thrombocytopenia and cystitis noninfective. Patients should be monitored for signs and symptoms and managed through dose interruption, treatment discontinuation and/or corticosteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Although the rate of imAEs with the T300+D is considered high, these are considered generally clinically manageable.

<div style=\"page-break-after: always\"></div>

Patients should also be monitored for signs and symptoms of IRRs. IRRs should be managed through dose interruption, treatment discontinuation, prophylaxis and appropriate treatment (see sections 4.2 and 4.4 of the SmPC).

Serious adverse events (SAEs) were very common in the T300+D arm vs the S arm in Himalaya study (40.5% vs 29.7%) and it is noted that 10% less SAEs were observed with durvalumab monotherapy, suggesting that the addition of the single dose of 300 mg tremelimumab significantly adds toxicity. The most frequent SAEs in the T300+D arm vs the S arm were diarrhoea (2.3% vs 1.6%), sepsis (2.1% vs 0), and pneumonia (1.8% vs 2.1%). Overall, the high level of SAEs with T300+D is worrisome although the targeted patient population is previously untreated patients and this may influence the tolerability in the general patient population in the first-line setting. Of note, diarrhoea and colitis are important identified risks of the anti-CTLA-4 agent ipilimumab, which has a similar mechanism of action as tremelimumab. Moreover, the targeted patient population from the 2L+ setting is expected to have even more serious toxicity.

AEs leading to death occurred in 34 patients (7.4%) in the HCC T300+D pool and 30 patients (7.7%) in the T300+D arm of the Himalaya study.

The overall discontinuation rate due to AEs in the HCC pool was 13.6%, while it was 13.7% of the patients in the pivotal Himalaya study. Most commonly the patients discontinued treatment due to AST increased and diarrhoea, which reflects the safety profile of T300+D. Dose delays were very common in the patients who had T300+D in the HCC pool (32.3%) and mostly due to diarrhoea and increased liver enzymes.

Laboratory findings showed that the changes in haematological parameters were mostly of low grade and pertaining to a decrease in lymphocytes â‰¥ grade 2 for 20% of the patients and grade 3 or 4 in 11.8%. This is in line with the findings in the pivotal Himalaya study. Laboratory shifts for clinical chemistry parameters were rare and mostly to low grade events. It is noted that increased glucose was common in the HCC pool (19.4%) and that grade 3 or 4 were observed in 14.6% of the patients. New onset diabetes mellitus was identified in 39 (8.4%) of 462 patients in the T300+D HCC pool and 30 (6.1%) of 492 patients in the D monotherapy HCC pool. Eight (1.7%) SAE reports of hyperglycaemia occurred in the T300+D HCC pool and most patients did not receive therapy for the hyperglycaemic event and the reported events were resolved in 21 (4.5%) of the patients in the T300+D HCC pool. One patient with hyperglycaemia and one patient with T2DM discontinued treatment. Liver toxicity was very often observed regarding elevated hepatic laboratory parameters in the HCC pool. Potential Hy's law cases were reported for 57 patients (12.3%) in the HCC pool and the narratives for the 4 patients, who met the Hy's law criteria in the T300+D arm of the pivotal Himalaya study are all agreed.

Increased toxicity with increasing age was observed in the HCC pool, as the incidence of ADRs were 72.1% in the patients of &lt;65 years of age vs 79.8% in patients of 65-75 years of age and 85.7% in those of â‰¥7 5 years of age. A trend towards more discontinuations with increasing age was also observed.

Safety and tolerability profiles were similar in patients with ADAs and in those without ADAs. According to the applicant, there were no new types of events or events clearly suggestive or indicative of infusion reactions or immune complex disease.

Overall, the toxicity observed in the first-line study Himalaya was significantly less than what was observed for the entire HCC pool, which is to be expected for the included study population, who was previously systemically untreated patients, who are usually more fit and able to tolerate toxicities. The toxicity observed with Sorafenib is similar to the toxicity level observed in the HCC pool and in some cases worse than what was observed for the T300+D arm of the Himalaya study. However, the toxicity

<div style=\"page-break-after: always\"></div>

profiles of T300+D and Sorafenib differs due to different mechanisms of action mainly between immune checkpoint inhibition and a tyrosine kinase inhibitor (TKI).

## 2.6.10. Conclusions on the clinical safety

The toxicity of the proposed dosing regimen of T300+D is considerable, since approximately half of the patients experience grade 3 or 4 adverse events and 40% of the patients have serious adverse events, mostly pertaining to diarrhoea and immune-mediated adverse events. The discontinuation rate is however relatively low (~13%) and most of the toxicity observed is clinically manageable and the toxicity profile of T300+D is not considered significantly worse than that of Sorafenib, the current standard of care.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

The applicant proposed the following summary of safety concerns in the RMP:

Table 90: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns        |
|------------------------------|-----------------------------------|
| Important identified risks   | Immune-mediated adverse reactions |
| Important potential risks    | None                              |
| Missing information          | None                              |

## 2.7.2. Pharmacovigilance plan

The PRAC Rapporteur, having considered the data submitted, is of the opinion that routine pharmacovigilance is sufficient to identify and characterise the risks of the product.

## 2.7.3. Risk minimisation measures

Table 91: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                    | Risk minimisation measures                                                                                                                                                     | Pharmacovigilance activities                                                                                                                           |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks        | Important Identified Risks                                                                                                                                                     | Important Identified Risks                                                                                                                             |
| Immune-mediated adverse reactions | Routine risk minimisation measures: â€¢ SmPC Sections 4.2, 4.2, and 4.8 â€¢ PL Sections 2 and 4 â€¢ Prescription-only medicine Additional risk minimisation measures: â€¢ Patient card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: â€¢ None. Additional pharmacovigilance activities: â€¢ None. |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 2 is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 21.10.2022. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

A justification to consider the package leaflet user testing report for the POSEIDON MAA (EMEA/H/C/004650) as relevant for this application has been provided. This is considered acceptable on the basis of the similarities in the text of both package

## 2.9.2. Labelling exemptions

A request to use minimum particulars on the labelling as per Art.63.3 of Directive 2001/83/EC has been submitted by the applicant and has been found acceptable by the QRD Group. However the QRD Group would like the applicant to take note of the following remarks:

- Vial label: The short pharmaceutical form can be used as proposed on the multilingual label. However on the single language labels the full pharmaceutical form should be used. If not possible, 'after dilution' should be added next to the route of administration, i.e. 'IV after dilution'.
- Outer carton: The statement 'Keep out of the sight and reach of children' can be grey-shaded in Annex IIIA, and there is no need to print it on the actual carton as the product will be handled by healthcare professionals only. This will leave more space on the carton to improve readability of the rest of information.

## 2.9.3. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Imjudo (tremelimumab) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU;

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of

<div style=\"page-break-after: always\"></div>

new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The approved therapeutic indication is:

IMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

The aim of the applied dosing regimen of tremelimumab plus durvalumab (T300+D) in comparison to Sorafenib (SOC) in the targeted population is to prolong overall survival (OS).

## 3.1.2. Available therapies and unmet medical need

The first-line treatment of uHCC includes sorafenib (a tyrosine-kinase inhibitor - TKI) based on OS benefit when compared to placebo (10.7 vs 7.9 months) and lenvatinib, another TKI, which is noninferior when compared to sorafenib (median OS 13.6 vs 12.3 months). Atezolizumab (a PD-L1 inhibitor) in combination with bevacizumab (a vascular endothelial growth factor receptor inhibitor) has also been approved in the first-line setting, based on the Phase III IMbrave150 study showing improvements of OS and PFS compared to sorafenib i.e. the median OS was 19.2 months with atezolizumab + bevacizumab vs 13.4 months with Sorafenib (HR, 0.66 [95%CI: 0.52, 0.85]), while the PFS by blinded review was 6.9 vs. 4.3 months (HR 0.65 [95%CI: 0.53, 0.81]).

Despite recent advances in treatment options, patients with uHCC continue to have a short life expectancy and the underlying liver disease and portal vein hypertension increase the risk of gastrointestinal bleeding, which can be potentially life-threatening. Currently available therapies provide only a modest improvement in survival with safety profiles that require management due to adverse events such as diarrhoea, hypertension, and palmar-plantar erythrodysaesthesia (PPE). Treatment with atezolizumab plus bevacizumab also carries a higher incidence of bleeding, including fatal bleeding, despite attempts to exclude patients at risk for gastrointestinal bleeding from the pivotal study. Moreover, the underlying liver cirrhosis may result in moderate liver dysfunction, which may exacerbate the toxicity of systemic therapies such as TKIs. Hence, additional therapeutic options are needed, including options for patients with uHCC, who are at higher risk of bleeding events, so there exist an unmet medical need for better and more tolerable treatment options for patients with uHCC.

## 3.1.3. Main clinical studies

The pivotal study Himalaya is a randomised, open-label, multicentre Phase III study in patients with unresectable HCC not eligible for locoregional therapy, which compared tremelimumab + durvalumab (T300+D) to standard of care, sorafenib, in the first-line setting. The primary endpoint was OS in the ITT population.

Additional supportive evidence of clinical efficacy was provided from Study 22, a randomised, phase I/II, open-label study conducted in the 2L+ setting, comparing the efficacy of T300+D and durvalumab monotherapy.

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

The primary endpoint for the Himalaya study was met as treatment with T300+D showed a statistically significant improvement in overall survival (OS) compared to standard of care, Sorafenib.

- At data cutoff 27 August 2021 and after ~33 months of follow up, 66.7% OS events had occurred in the T300+D arm versus 75.3% OS events in the Sorafenib arm, treatment with T300+D showed a statistically significant survival benefit as compared with SoC: Median OS was improved from 13.77 months to 16.43 months, HR 0.78 (96.02% CI: 0.65, 0.93).
- The secondary endpoint of ORR by investigator was 20.1% for the T300+D arm compared to 5.1% in the sorafenib arm, and the median duration of response was 22.34 months in the T300+D arm vs 18.43 months in the sorafenib arm.
- The PFS analyses were not controlled for multiplicity. PFS by investigator was not significantly improved, since the median PFS was 3.78 months in the T300+D arm versus 4.07 months in the S arm; HR 0.90 (95%CI: 0.77, 1.05). The event rates were 85.2% and 84.1% in the T300+D and S arms, respectively.
- Relevant subgroup analyses of the primary endpoint of OS show that the benefit of T300+D vs S is maintained across important subgroups of age of less than or â‰¥ 65 years, HBV or other reasons for liver disease, ECOG performance status, macrovascular invasion (MVI), AFP at baseline and BCLB score C.

## 3.3. Uncertainties and limitations about favourable effects

None.

## 3.4. Unfavourable effects

The safety populations of interest are the 388 patients from the pivotal Himalaya study and the patients included in the HCC pool (n=462), which also contains patients from the supportive study 22. The median treatment duration in the Himalaya study were 5.5 months, while the median treatment duration was 4.1 months in the Sorafenib arm (n=374).

Almost all of the patients in the HCC pool, who received T300+D, experienced at least one adverse event (AE) (97.6%), and 51.9% experienced a grade 3 or 4 AE. For the Himalaya study, a similar pattern was observed.

Adverse drug reactions (ADRs) in the T300+D arm of the pivotal Himalaya study were rash , pruritus , diarrhoea , and hypothyroidism. In comparison, common ADRs in the Sorafenib arm were diarrhoea, palmar-plantar erythrodysaesthesia (PPE), hypertension, and fatigue. The most common grade 3 or 4 ADRs in the T300+D arm were increased lipase, diarrhoea, amylase increased and ASAT increased. Common grade 3 or 4 ADRs in the S arm were PPE, hypertension, and diarrhoea.

Adverse events of special interest for T300+D include immune-mediated AEs (imAEs) and as expected, the occurrence of imAEs are much more common in the HCC pool vs the Sorafenib arm (36.1% vs 7.5%), and these were of grade 3 or 4 in 13.4% vs 2.4% of the patients, respectively. Serious imAEs were observed in 10.2% vs 1.1% and 6 patients (1.3%) died from these.

The most common serious adverse reactions in the T300+D HCC pool are colitis (2.6%), diarrhoea (2.4%), pneumonia (2.2%), and hepatitis (1.7%).

<div style=\"page-break-after: always\"></div>

In the pivotal Himalaya study, 6.1% of the patients in the T300+D arm died from an adverse event , while it was 7.4% in the HCC pool.

The overall discontinuation rate due to ADRs was 6.5%. Most commonly the patients discontinued treatment due to ADRs of hepatitis (1.5%) and aspartate aminotransferase increased/alanine aminotransferase increased (1.3%).

Laboratory findings showed that the changes in haematological parameters and clinical chemistry were mostly to low grade events. It is noted that increased glucose was common in the HCC pool (19.4%) and that grade 3 or 4 were observed in 14.6% of the patients. Liver toxicity was often observed regarding elevated hepatic laboratory parameters in the HCC pool and potential Hy's law cases were reported for 57 patients (12.3%) in the HCC pool.

## 3.5. Uncertainties and limitations about unfavourable effects

There are very limited safety data on elderly aged 75 years and older (see section 4.8 of the SmPC).

## 3.6. Effects Table

Table 92: Effects table for T300+D in the treatment of uHCC for the Himalaya Study (data cut-off: 27 August 2021)

| Effect               | Short Description                | Unit                 | Treatment            | Control              | Control              | Uncertainties/ Strength of evidence                                                                          | Ref                  |
|----------------------|----------------------------------|----------------------|----------------------|----------------------|----------------------|--------------------------------------------------------------------------------------------------------------|----------------------|
|                      |                                  |                      | T300+D               | Sorafenib            | Durvalumab           |                                                                                                              |                      |
| Favourable Effects   | Favourable Effects               | Favourable Effects   | N=393                | N=389                | N=389                |                                                                                                              |                      |
| OS                   | Median overall survival          | Months 95%CI         | 16.43 14.16; 19.58   | 13.77 12.25; 16.13   | 16.56 14.06; 19.12   | At 71% events, HR for T300+D vs S 0.78 (96.02%CI: 0.65; 0.93) P=0.0035                                       |                      |
| PFS by INV           | Progression- free survival       | Months 95%CI         | 3.78 3.68; 5.32      | 4.07 3.75; 5.49      | 3.65 3.19, 3.75      | Comparison was not formally tested; no BICR assessment                                                       |                      |
| ORR                  | Overall response rate            | %                    | 20.1                 | 5.1                  | 17.0                 |                                                                                                              |                      |
| DoR                  | Duration of response             | Months               | 22.34                | 18.43                | 16.82                |                                                                                                              |                      |
| Unfavourable Effects | Unfavourable Effects             | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                         | Unfavourable Effects |
| Any AE               | Any adverse event                | %                    | 97.4                 | 95.5                 | 90.0                 | Incidences from the Himalaya study, except for the Durvalumab monotherapy arm; which are from the HCC D pool |                      |
| Grade 3 or 4 AEs     | High-grade AEs                   | %                    | 50.5                 | 52.4                 | 38.2                 | Incidences from the Himalaya study, except for the Durvalumab monotherapy arm; which are from the HCC D pool |                      |
| Grade 5 AEs          | AEs leading to death             | %                    | 7.7                  | 7.2                  | 6.1                  |                                                                                                              |                      |
| SAEs                 | Serious AEs                      | %                    | 40.5                 | 29.7                 | 32.7                 |                                                                                                              |                      |
| AEs disc.            | AEs leading to dis- continuation | %                    | 13.7                 | 16.8                 | 9.6                  |                                                                                                              |                      |
| ImAEs                | Immune- mediated AEs             | %                    | 36.1                 | 7.5                  | 16.5                 | Incidences from the HCC pool for T300+D group                                                                |                      |

<div style=\"page-break-after: always\"></div>

| Effect   | Short Description   | Unit   |   Treatment T300+D | Control Sorafenib   |   Control Durvalumab | Uncertainties/ Strength of evidence   | Ref   |
|----------|---------------------|--------|--------------------|---------------------|----------------------|---------------------------------------|-------|
|          | Hepatic events      | %      |                7.4 | NA                  |                  1.6 |                                       |       |
|          | Diarrhoea/ colitis  | %      |                6.5 | NA                  |                  1.4 |                                       |       |

Abbreviations: OS: Overall survival; PFS: Progression free survival; INV: Investigator; ORR: Objective response rate; DoR: Duration of response; AE: Adverse event; SAE: Serious adverse event; ImAEs: Immune-mediated adverse events; HCC: hepatocellular

carcinoma; BICR: Blinded independent central review.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The proposed dosing regimen of tremelimumab + durvalumab provides a statistically significant and clinically meaningful survival benefit compared to the current standard of care, sorafenib, in a head-tohead comparison from the pivotal Himalaya study, in a population of patients with unresectable hepatocellular carcinoma, who had not received prior systemic treatment. The ORR was also significantly improved; however, the magnitude of patients who had an objective response with T300+D is still low (~20%). The few objective responses were durable (~22 months), which is considered clinically significant. Hence, the efficacy of T300+D in the first-line setting could be considered shown.  Supportive evidence for the application comes from Study 22, which compared T300+D to durvalumab monotherapy in the 2L+ setting.

The safety profiles of T300+D versus sorafenib are distinct as they have different mechanisms of action (immune checkpoint inhibition vs TKI) and the toxicity does not seem worse than sorafenib regarding grade 3 or 4 AEs (50.5% vs 52.4%), AEs leading to discontinuation (13.7% vs 16.8%), and AEs leading to death (7.7% vs 7.2%) as reported in the pivotal Himalaya study. The safety profile of tremelimumab in combination with durvalumab in the HCC setting is serious and has to be weighed against the seriousness of palliative setting and individual patient (ECOG status, age, comorbidities). This is of particular importance since a significant proportion of the immune-mediated adverse events observed with the T300+D regimen were serious (e.g. diarrhoea/colitis, pancreatitis and pneumonitis), expected to be less manageable and often require hospitalisation. Immune-mediated AEs have therefore been included as important identified risks in the list of safety concerns for tremelimumab.

## 3.7.2. Balance of benefits and risks

The shown overall survival benefit and the fact that the safety profile of T300+D is not worse than that of standard of care, sorafenib, support a positive benefit-risk balance in the first-line treatment setting of advanced, unresectable HCC.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall benefit /risk balance of tremelimumab + durvalumab in the first line treatment of uHCC is positive, subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Imjudo is favourable in the following indication(s):

Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Â· Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Â· Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Â· Additional risk minimisation measures

Prior to the launch of Imjudo in each Member State the MAH will agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority. The additional risk miniminsation measure is aimed at increasing awareness and providing information concerning the symptoms of immune-mediated adverse reactions.

<div style=\"page-break-after: always\"></div>

The MAH shall ensure that in each Member State where Imjudo is marketed, all physicians who are expected to use Imjudo have access to/are provided with the following to provide to their patients:

## Patient card

Key messages of the Patient Card include:

- A warning that immune-mediated adverse reactions (in lay terms) may occur and that they can be serious.
- A description of the symptoms of immune-mediated adverse reactions.
- A reminder to contact a healthcare professional provider immediately to discuss signs and symptoms.
- Space for contact details of the prescriber.
- A reminder to carry the card at all times.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that tremelimumab is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.